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ABSTRACT 
Campylobacter jejuni is a leading cause of human bacterial enteritis 
worldwide. Consumption of contaminated poultry meat is considered a major 
source of infection. The use of virulent bacteriophages as a form of biocontrol 
to specifically reduce this pathogen in poultry (phage therapy) is a promising 
intervention that does not rely on antimicrobials and therefore circumvents the 
emergence of antibiotic-resistant Campylobacter strains. In order to achieve 
this, a better understanding of the mechanisms involved in phage-host 
interactions at the molecular level would assist in the development of the 
strategy and the selection of bacteriophages. The main objective of this study 
was to therefore examine such interactions between Campylobacter and its 
virulent phages. To achieve this, the transcriptional response of C. jejuni to 
phage infection was investigated, along with the role of a Type II restriction-
modification system during phage infection of Campylobacter. These studies 
were conducted using the highly phage-sensitive Campylobacter strain, C. 
jejuni PT14, in conjunction with a number of group II and III bacteriophages 
(Eucampyvirinae). 
Transcriptome studies (RNA-Seq) revealed a phage-induced host 
response that included a demand for iron and oxygen. This was highlighted by 
the up-regulation of several siderophore-based iron acquisition genes and 
down-regulation of genes associated with a number of anaerobic electron 
transport pathways that utilise alternative electron acceptors to oxygen. In 
addition, the pattern of gene regulation also suggested apo-Fur regulation of 
the iron-responsive and flagellar biogenesis genes. This host response has been 
proposed to occur as a consequence of the reduction of ribonucleotides to form 
deoxyribonucleotides during phage DNA replication. This process is catalysed 
by the enzyme ribonucleotide reductase and requires iron and oxygen during 
the formation of a reactive di-iron centre within the ȕ-subunit of the enzyme. 
Unusually knock-out mutants of a Type II restriction-modification 
system had a negative impact on phage replication. The A911_00150 mutant 
displayed pleiotropic changes in motility, cell based invasion and the ability to 
colonise chickens. Transcriptome analysis highlighted down-regulation of the 
genes required for the synthesis of the bacterial flagellum. 
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1.1 CAMPYLOBACTER 
1.1.1 Overview of early history  
Campylobacters were originally classified in the genus Vibrio. Early literature 
referred to WKH LVRODWLRQ RI ³Vibrio fetus´ IURP WKH VWRPDFK FRQWHQWV RI DQ
aborted lamb (McFadyean & Stockman 1913)³V. jejuni´IURPWKHMHMXQXPRI
calves (Jones et al. 1931) DQGODWHU³V. coli´IURPSLJV(Doyle 1944). The first 
ZHOO GRFXPHQWHG ³vibrio-UHODWHG´ FDVH RI KXPDQ LQIHFWLRQ RFFXUUHG GXULQJ D
diarrhoeal outbreak caused by contaminated milk (Levy 1946) where 
organisms rHVHPEOLQJ ³V. jejuni´ ZHUH LVRODWHG Kist (1985) however later 
argued that these organisms were in fact Campylobacter spp. He also 
highlighted the work of Escherich (1886) who had earlier described a spiral 
form of non-culturable bacteria isolated from stool specimens and mucous 
from the large intestine of infants who had died from ³FKROHUDLQIDQWXP´King 
(1957) was the first to successfully culture microaerophilic isolates of V. fetus 
at 42°C. However, this temperature was higher than the optimal growth 
temperature of traditional vibrios and she provisionally referred to her isolates 
DV ³UHODWHG YLEULR´ ,Q  WKH JHQXV Vibrio underwent a major taxonomic 
revision and the new genus Campylobacter *UHHN IRU ³FXUYHG URG´ ZDV
introduced (Sebald & Véron 1963). The atypical vibrios, V. fetus and V. 
bubulus, were placed into this new genus because of their low G+C DNA 
content, microaerophilic growth requirements and their inability to ferment 
glucose. Campylobacter was finally recognised as a human pathogen after 
successful isolation from human faeces in 1972 (Dekeyser et al. 1972) and the 
subsequent development of selective media allowed for routine isolation of 
campylobacters (Skirrow 1977). 
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1.1.2 Taxonomy 
Following the introduction of the genus Campylobacter by Sebald and Véron 
(1963), there has been extensive revision of this taxon, with many organisms 
once thought to be campylobacters or Campylobacter-like being reclassified 
(Goodwin et al. 1989; Vandamme, P. et al. 1991; Vandamme et al. 1992). For 
instance, C. pylori and C. mustelae were reassigned to the genus Helicobacter 
because they exhibited multiple sheathed flagella, showed differences in their 
cellular fatty acid composition and were phylogenetically different based on 
16S rRNA sequencing (Goodwin et al. 1989). Similarly, several aerotolerant 
Campylobacter-like organisms were re-classified to the genus Arcobacter 
(Vandamme et al. 1992). The Campylobacteraceae family includes the genera 
Campylobacter, Arcobacter and Sulfurospirillum (Vandamme 2000). Figure 1-
1 shows the members of this family along with their phylogenetic relationship 
based on 16S rRNA homology. The genus Campylobacter has been 
determined to be a member of the epsilon subdivision of the class 
Proteobacteria by partial 23S rRNA gene analysis (Trust et al. 1994) and 
presently contains 17 species and 6 sub-species (Debruyne et al. 2008) with the 
type species being C. fetus. Many of the campylobacters have been implicated 
in human disease, however, the two species C. jejuni and C. coli are 
recognised as the major causative agents of human Campylobacter infections. 
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Figure 1-1 Phylogenetic relationship of the Campylobacteraceae family 
based on 16S rRNA sequencing.  
(Reproduced from Debruyne et al., 2008) 
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1.1.3 Physiology  
Campylobacters are Gram-negative nonspore-formers that possess a low G+C 
content (27-47%) and require temperatures ranging from 30-37°C for optimal 
growth. Campylobacter cells are typically curved, S-shaped or spiral rods (0.2 
to 0.8 µm wide and 0.5 to 5 µm long) (Vandamme 2000) but some species, 
such as C. showae, produce cells with less curved rods and occasionally C. 
jejuni strains may also produce cells with straight rods (Wassenaar & Newell 
2006). Campylobacter cells may change to spherical or coccoid forms on 
entering the late stationary phase of their life cycle or when exposed to 
environmentally stressful conditions (Ng et al. 1985; Griffiths 1993). 
Campylobacter cells typically display corkscrew-like motility through the use 
of a single, polar non-sheathed flagellum at one or both ends (Vandamme 
2000). However, C. gracilis lacks flagella and is therefore non-motile while C. 
showae possesses multiple unipolar flagella (Vandamme & De Ley 1991; 
Vandamme 2000). C. jejuni and C. coli are also known to produce spontaneous 
non-motile variants, especially following frequent subculturing. In C. jejuni 
81-176, this phenotype has recently been linked to a motA gene mutation, 
which encodes a flagellar motor protein that allows energy to be transmitted to 
the flagellum (Mohawk et al. 2014).  
 
1.1.4 Growth requirements and biochemical characteristics 
Campylobacters generally thrive in microaerophilic environments, requiring 
low concentrations of oxygen (5-10%) and elevated levels of carbon dioxide 
(3-5%) for optimal growth. Some species, such as C. gracilis and C. showae, 
are capable of growing under anaerobic conditions and they also require H2 
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and sometimes formate or fumarate for growth (Wassenaar & Newell 2006). 
Members of the Campylobacter genus are oxidase-positive, with the exception 
of C. gracilis, indole-negative and able to reduce nitrate, except for C. jejuni 
subsp. doylei. They are also unable to hydrolyze hippurate, except C. jejuni 
which is known to possess the hippurate hydrolase gene, hipO. 
Campylobacters produce energy through respiration, and because they do not 
ferment or oxidise carbohydrates, they utilise amino acids and intermediates 
from the tricarboxylic acid cycle as substrates (Mohammed et al. 2004).  
 
1.1.5 Reservoirs 
Campylobacters readily inhabit the intestinal mucosa of many warm-blooded 
animals (Fhogartaigh & Edgeworth 2009). For instance, C. coli, C. mucosalis 
and C. hyointestinalis are known to colonise the intestines of pigs (Schultheiss 
et al. 1989; Young et al. 2000b) while C. upsaliensis and C. helveticus can be 
isolated from the intestines of cats and dogs (Mandrell et al. 2005). 
Campylobacters have also been found to inhabit cold-blooded animals as the 
strain C. fetus was previously isolated from reptiles such as snakes, turtles and 
lizards (Wang et al. 2013). C. jejuni primarily colonises the intestinal mucosa 
of avian species and appears to have evolved to optimally grow at their internal 
body temperature of 42°C. C. jejuni, C. coli and C. lari are all recognised as 
thermophilic Campylobacter species because they optimally grow at such a 
temperature. Campylobacters are considered pathogens when they colonise the 
intestinal mucosa of mammals (Newell 2001) but in comparison C. jejuni and 
C. coli typically behave as commensals in the avian gut (Waldenstrom et al. 
2002), with a few strain-specific exceptions (Knudsen et al. 2006) and the 
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exception of ostriches, where outbreaks of enteritis and avian hepatitis have 
been reported following infection (van Der Walt et al. 1996; Stephens et al. 
1998). More recently, it was also reported that a fast-growing commercial 
breed of broiler chickens exhibited a strong inflammatory response to C. jejuni 
infection (Humphrey et al. 2014). This response led to intestinal mucosal 
damage and diarrhoea, which in turn led to subsequent damage of the feet and 
legs of the chickens as a result of standing on wet litter. It was determined that 
the disease occurred as a consequence of poor regulation of the inflammatory 
immune response because the affected chickens failed to express the regulatory 
cytokine, interleukin-10, which controls inflammation (Humphrey et al. 2014).   
 
1.2 PREVALENCE OF CAMPYLOBACTER IN POULTRY  
Campylobacters have been readily isolated from broiler carcasses and poultry 
meat (Newell et al. 2001; Cui et al. 2005; Moran et al. 2009; Ridley et al. 
2011). Within this genus, C. jejuni and C. coli are the main species posing 
major problems for food safety (Adak et al. 2005; Fhogartaigh & Edgeworth 
2009). In 2001, a study in the United States looked at 32 broiler flocks on 8 
different farms over a one year period (Stern et al. 2001). Up to 87.5% of the 
flocks were found to be Campylobacter-positive, while only 4 flocks (12.5%) 
remained free of the pathogen throughout the six to eight week rearing period. 
Similarly, a survey was conducted in Europe from January to December 2008 
to investigate the prevalence of Campylobacter in broiler flocks and on broiler 
carcasses immediately following slaughter (EFSA 2010a). A total of 10,132 
broiler batches were sampled from 561 slaughterhouses within 26 European 
Union Member States as well as Norway and Switzerland. Campylobacter was 
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isolated from the pooled caecal contents of 71.2% of the slaughtered broilers 
and on 75.8% of broiler carcasses, with such samples being collected from the 
neck and breast skin immediately after chilling (EFSA 2010a). A high 
prevalence of Campylobacter has also been generally associated with non-
conventional broiler production, such as in free-range and organic broiler 
rearing systems (Kazwala et al. 1993; Rivoal et al. 1999; Heuer et al. 2001; 
Colles et al. 2008; Colles et al. 2011). A study in France found that 85.7% of 
faecal samples taken from a batch of broiler chickens raised in a free-range 
system were Campylobacter-positive (Rivoal et al. 1999) while another study 
in Denmark isolated Campylobacter spp. from 100% of organic broiler flocks 
(Heuer et al. 2001). Rivoal et al. (1999) also investigated the molecular 
diversity of Campylobacter isolates collected during rearing and slaughter of 
free-range broiler chickens and found that poultry carcasses were contaminated 
with the same Campylobacter strains that were present in the caeca of the 
broilers. The prevalence of antimicrobial resistant Campylobacter spp. from 
conventional and organic production systems was also investigated and it was 
found that a large number of isolates from the conventional system were 
resistant to the nine antimicrobial substances tested compared to the 
organically raised poultry (Luangtongkum et al. 2006). However, El-Shibiny et 
al. (2005) reported that although organic flocks in the UK contained largely 
antibiotic-sensitive campylobacters, multiply resistant Campylobacter isolates 
were recovered from free-range flocks which was of concern since use of 
antimicrobials as growth promoters had been banned in the European Union 
since 1998. 
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In temperate countries, Campylobacter colonisation of poultry flocks has 
generally been reported to vary by season and geographical location, with 
higher infection rates being reported in the summer and autumn months as 
compared to the winter (Kapperud et al. 1993; Wallace et al. 1997; Refrégier-
Petton et al. 2001; Kovats et al. 2005; Rushton et al. 2009). A study in Great 
Britain investigated the influence of season and geography on the prevalence 
of Campylobacter subtypes in housed broiler flocks between 2004 and 2006 
(Jorgensen et al. 2011). They found that prevalence of positive batches was 
significantly higher in the northern part of Great Britain compared to southern 
and central areas (p < 0.001), and was significantly higher in July (p = 0.01), 
August (p = 0.005) and September (p < 0.001) compared to other times of the 
year, being more pronounced in the southern areas. Some countries in the 
Europe Union showed a similar seasonal pattern of Campylobacter prevalence 
as well, with the highest levels of infection also being experienced during the 
months of July to September (EFSA 2010b).  
 
Commercial broiler flocks, reared under controlled conditions, have been 
found to show an age dependent increased risk of Campylobacter colonisation. 
Broiler flocks do not generally become colonised until 2-3 weeks of age 
(Shane 2000; Evans & Sayers 2000) 7KLV SHULRG KDV EHHQ WHUPHG WKH ³ODJ
SKDVH´DQGXQGHU ILHOGFRQGLWLRQVYHU\ \RXQJ ELUGV do not appear to become 
colonised. Protective mechanisms have been considered to explain this 
observation, which include the presence of maternal antibodies (Sahin et al. 
2001), the use of antibiotic feed additives and competition among gut flora 
(Newell & Wagenaar 2000). It also appears that intact egg shells may be 
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permeable to Campylobacter since it has been possible to experimentally infect 
eggs by immersion in a suspension of the organism (Neill et al. 1985; Allen & 
Griffiths 2001). This suggests that contact with faecal material on the outer 
shell could result in penetration. Earlier studies have also revealed that C. 
jejuni could be isolated from the inner shell and membrane of eggs but not the 
egg contents (Doyle 1984; Neill et al. 1985). On this basis, vertical 
transmission of Campylobacter from parent flock to progeny has been 
proposed (Cox et al. 2012) but was previously thought to be a very rare event 
(Sahin et al. 2003; Fonseca et al. 2006) and remains a highly controversial 
issue amongst researchers (Newell & Fearnley 2003). On the other hand, the 
role that horizontal transmission plays in the spread of Campylobacter within 
flocks has been demonstrated. Once a flock becomes colonised, bird to bird 
transmission rapidly occurs and up to 100% of the flock can be colonised 
within a few days (Shreeve et al. 2000; van Gerwe et al. 2009).  
 
Various transmission routes have been suggested within the environment of the 
broiler house. These include aerosols caused by poor air-ventilation systems 
that circulate air from potentially contaminated areas as well as transmission 
from wildlife that occupy the surroundings of the broiler house such as 
rodents, insects, livestock and domestic pets (Moreno et al. 1993; Newell & 
Fearnley 2003; Bull et al. 2006). However, commercial broilers within the 
confined space of the broiler house are also coprophagic and therefore the 
faecal-oral route is probably the main route of transmission within an already 
infected flock. Nevertheless, once colonised, it is unclear the actual length of 
time broiler flocks remain colonised and how long they are capable of 
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shedding Campylobacter in their faeces; but it is thought to last for the 
duration of their lifespan, which is typically less than 47 days (Newell & 
Fearnley 2003).  
 
1.3 HUMAN CAMPYLOBACTER INFECTIONS 
1.3.1 Clinical manifestations of infection 
Campylobacter is generally recognised as the leading cause of human bacterial 
gastroenteritis worldwide (Fhogartaigh & Edgeworth 2009), with C. jejuni and 
C. coli representing the main sources of infection (Adak et al. 2005; 
Fhogartaigh & Edgeworth 2009). Infectious doses of C. jejuni as low as 500-
800 bacteria have been reported to be sufficient to cause illness in healthy 
adults (Robinson 1981; Black et al. 1988). The mean incubation period 
following infection in humans is estimated to range from 1 to 7 days (Blaser & 
Engberg 2008), although this depends on the infectious dose as well as the 
immune status of the individual. Clinical manifestations of Campylobacter 
infections vary throughout the world, with individuals from industrialized 
nations usually exhibiting more severe symptoms than those from the 
developing world, where high rates of asymptomatic carriage are observed 
(Oberhelman & Taylor 2000). In industrialized countries, symptoms vary from 
slightly loose stools to more severe mucoid diarrhoea, which may last for three 
to five days and is sometimes accompanied by blood, along with abdominal 
pain, cramps and fever (Wassenaar & Blaser 1999). At the peak of the illness, 
individuals may experience 8 to 10 bowel movements a day (Blaser et al. 
1983). In most non-immune individuals, symptoms are usually accompanied 
by an acute inflammatory response which results in leukocytes and 
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erythrocytes being recovered from stools (Blaser et al. 1979), even when loose 
and not exceptionally bloody (Wassenaar & Blaser 1999).  
 
Although most Campylobacter infections are self-limiting and last only a few 
days, complications may arise due to direct spread from the gastrointestinal 
tract which may lead to local infections such as cholecystitis, pancreatitis, 
peritonitis as well as gastrointestinal haemorrhaging (Allos 2001). 
Extraintestinal manifestations of Campylobacter infection have also been 
reported and include toxic hepatitis and myocardial injury (Braun et al. 2008). 
In addition, bacteraemia is usually detected in less than 1% of patients 
suffering from campylobacteriosis, which predominantly affects the young, old 
and immunocompromised (Allos 2001; Nielsen et al. 2009). Severe systemic 
illness is rare but may lead to sepsis and even death (Allos 2001). In Europe, 
mortality due to infection was recorded for 2012 at 0.03% of the 111,464 
confirmed campylobacteriosis cases, with a total of 20 deaths being reported 
for the United Kingdom (EFSA 2014b). 
 
A number of post-infectious complications, which are auto-immune in nature, 
are associated with Campylobacter infections including reactive arthritis, 
Miller Fisher syndrome and most importantly, Guillain-Barré syndrome 
(GBS). GBS is an acute disorder of the peripheral nervous system and is 
characterised by progressive motor weakness in more than one limb, which is 
usually symmetrical and accompanied by the loss of some tendon reflexes 
(Asbury & Cornblath 1990). The disease is generally self-limiting and patients 
usually regain their muscle strength within two to three weeks, with partial or 
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complete recovery taking place over a few months. However, 15-20% of GBS 
patients may be left with severe long term neurological defects (Nachamkin et 
al. 1998). C. jejuni is a major antecedent infectious agent in GBS development, 
where evidence from Japanese patients with GBS showed that the infecting C. 
jejuni strains belonged predominately to the O serotype O:19 (Kuroki et al. 
1993). Although the risk of developing GBS may increase following exposure 
to C. jejuni type O:19, it has been estimated that if 20% of GBS-associated C. 
jejuni isolates are serotype O:19 then there is a 1 in 158 chance of developing 
GBS following infection with this particular serotype (Nachamkin et al. 1998). 
A number of other O serotypes have also been associated with C. jejuni strains 
from GBS patients from other parts of the world, such as the O:41 C. jejuni 
strains in South Africa (Lastovica et al. 1997). It was previously estimated that 
the chance of developing GBS following a C. jejuni infection was 
approximately 1 in 1000 infections (Nachamkin et al. 1998). 
 
Production of serum anti-ganglioside antibodies is frequently triggered as a 
result of this infection (Ho et al. 1998). Gangliosides contain one or more sialic 
acid (N-acylneuraminic) residues linked to an oligosaccharide core and are 
generally classified by letters according to the number of residues present. For 
instance, M (-mono), D (-di), T (-tri) and Q (-quad). The ganglioside GM1 is 
found in peripheral nerve tissue and a previous study found that almost 38% of 
GBS patients had high titres of anti-GM1antibiodies, which was linked with a 
poor clinical outcome at 6 and 12 months following the development of GBS 
(Ilyas et al. 1992). Miller Fisher syndrome, on the other hand, is usually 
associated with the presence of anti-GQ1b antibodies :LOOLVRQ 	 2¶+DQORQ
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1999). Pathogenesis of Campylobacter-mediated GBS is thought to involve 
molecular mimicry between the lipooligosaccharide (LOS) of C. jejuni and 
peripheral nerve gangliosides as a result of the presence of sialic acid in the 
LOS of C. jejuni (Xiang et al. 2006).  
 
1.3.2 Epidemiology 
Surveillance of Campylobacter infections has shown an increasing trend in 
reported cases over the past 30 years, with initial increases most likely linked 
to improved diagnosis. In England and Wales between 1989 and 2011 there 
were 1,109,406 confirmed cases, with 64,582 of them reported in 2011 alone 
(Nichols et al. 2012). Within the European Union, Campylobacter was also the 
most commonly reported zoonosis between 2005-2012 with 214,268 
confirmed cases in 2012 and an incidence rate of 55.49 cases per 100,000 
population (EFSA 2014a). These figures included 72,578 confirmed cases 
from the United Kingdom for 2012. In addition, two studies conducted within 
the UK (IID1 in 1993-1996 and IID2 in 2008-2009) that looked at the 
incidence and etiology of infectious intestinal disease (IID) (Wheeler et al. 
1999; Tam et al. 2012), found Campylobacter to be the most common bacterial 
pathogen amongst general practice cases. Similarly, there has been an 
increased incidence of Campylobacter infections within the United States since 
2008 with the Foodborne Diseases Active Surveillence Network (FoodNet) 
reporting an incidence of 14.3 confirmed cases per 100,000 population for 
2012, resulting in approximately 1.5 million cases for that year (CDC 2013). 
This figure remains below the national health objective for 2020 which is 
aiming for no more than 8.5 cases per 100,000 population. Campylobacter 
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infections exhibited the second highest incidence rate of all pathogens reported 
to FoodNet after Salmonella (16.42 per 100,000). In comparison, Salmonella 
was the second highest zoonotic agent to be reported in the EU with 22.2 cases 
per 100,000 population (EFSA 2014a). This may be linked to the success of 
control measures for Salmonella, including programmes to control Salmonella 
in domestic fowl (Gallus gallus) populations which has resulted in the reduced 
occurrence of this pathogen in eggs (EFSA 2014a). Ultimately the incidence of 
occurrence of Campylobacter infections as well as other zoonoses is generally 
linked to the number of laboratory-confirmed cases, however under-reporting 
and under-ascertainment of infections is a major issue for most countries 
(Gibbons et al. 2014). The true incidence of infection may actually be up to 7-8 
times higher than documented case numbers.  
 
The first documented case of a campylobacteriosis outbreak directly linked to 
consumption of chicken meat was amongst a group of soldiers in the 
Netherlands, where 72% of 123 soldiers were infected (Brouwer et al. 1979). 
Symptoms included fever, vomiting, abdominal cramps and diarrhoea, which 
were accompanied with blood in four of the cases. A number of recent 
Campylobacter outbreaks associated with different food sources have been 
documented (Black et al. 2006; Inns et al. 2010; Gardner et al. 2011). However 
the majority of human campylobacteriosis cases are not part of recognised 
outbreaks and exhibit different epidemiological features (Tauxe 1992). For 
instance, in temperate countries there is a strong seasonal trend of 
Campylobacter infections, with outbreaks usually occurring during spring and 
autumn months (Tauxe 1992) while sporadic cases are typically seen during 
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the summer (Altekruse et al. 1999). Over the past three decades, several case-
control studies have been conducted throughout many developed countries to 
identify risk factors associated with sporadic illnesses. The findings of such 
studies were generally consistent, indicating a major source of infection was 
either the handling of raw poultry (Hopkins & Scott 1983) or consumption of 
undercooked poultry and poultry products (Kapperud et al. 1992; Eberhart-
Phillips et al. 1997; Neimann et al. 2003; Friedman et al. 2004). Other 
important risk factors included consumption of raw or unpasteurised milk 
(Hopkins et al. 1984; Neimann et al. 2003), foreign travel (Norkrans & 
Svedhem 1982; Schorr et al. 1994; Eberhart-Phillips et al. 1997; Neimann et 
al. 2003) and transmission from pets and domestic animals (Norkrans & 
Svedhem 1982; Hopkins et al. 1984; Eberhart-Phillips et al. 1997; Neimann et 
al. 2003; Friedman et al. 2004). However, the population attributable fraction 
determined for all of these variables combined typically does exceed more than 
50%. 
 
1.3.3 Treatment of C. jejuni infections 
Initial treatment of symptoms of campylobacteriosis generally includes 
rehydration and electrolyte replacement. Primarily, an oral glucose or starch-
based electrolyte solution would be recommended, however if the patient is 
comatose or severely dehydrated then fluids would be administered 
intravenously (Guerrant et al. 2001; Thielman & Guerrant 2004). Although 
Campylobacter infections are usually self-limiting, some patients may exhibit 
high fever or bloody diarrhoea, may experience more than 8 bowel movements 
in 24 hours or their symptoms may persist for more than 1 week following 
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diagnosis. In such cases, as with cases with immunocompromised individuals, 
antimicrobial treatment has been shown to reduce the duration of the illness 
and shedding of Campylobacter in the faeces (Ternhag et al. 2007). 
Erythromycin has been found to be particularly effective against the disease in 
children if administered early in the course of illness (Anders et al. 1982; Pai et 
al. 1983; Salazar-Lindo et al. 1986) while other macrolide antibiotics as well as 
quinolones such as ciprofloxacin are usually prescribed for adults (Dryden et 
al. 1996). 
 
1.3.4 Antimicrobial resistance  
A major problem associated with using antibiotics to treat illness is the 
development of resistant bacterial strains. The emergence of quinolone-
resistant and, to a lesser extent, macrolide-resistant Campylobacter strains in 
the food chain has become a major concern worldwide as these strains impact 
on clinical management of campylobacteriosis (Engberg et al. 2001). High 
rates of resistance of Campylobacter to antibiotics such as tetracycline, 
amoxicillin, ampicillin, metronidazole and the cephalosporins have previously 
been observed, while resistance to erythromycin has been low despite several 
years of use (Allos 2001). Patients infected with antibiotic-resistant strains 
have been found to experience prolonged illness (Smith et al. 1999) and this 
may present adverse implications for immunocompromised individuals. In 
Europe, quinolone resistance was observed DVHDUO\DVWKH¶VZKHQEndtz 
et al. (1991) suggested that the emergence of quinolone-resistant C. jejuni and 
C. coli human isolates coincided with the increasing use of fluoroquinolones, 
such as ciprofloxacin and enrofloxacin, in human and veterinary medicine. 
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They screened human and poultry Campylobacter isolates from 1982-1989 for 
quinolone resistance and found that prevalence of resistant strains increased 
over time from both sources. The presence of fluoroquinolone-resistant 
Campylobacter strains in food animals is now recognised as an important 
public health issue (Nelson et al. 2007), especially in developing countries 
where antibiotic use may not be as strictly monitored. Campylobacter 
fluoroquinolone resistance often occurs due to mutations in the genes encoding 
DNA gyrase (gyrA) at positions Thr-86, Asp-90 and Ala-70 (Griggs et al. 
2005).   
 
Antimicrobial resistance in Campylobacter isolates from human, animals and 
food was evaluated in the EU for 2012, with data submitted from 26 EU 
member states (EFSA 2014b). High levels of resistance to ampicillin, 
ciprofloxacin, nalidixic acid and tetracyclines were observed for 
Campylobacter isolates of human origin. However, resistance to erythromycin 
in human C. jejuni isolates was generally low but moderately high for isolates 
of C. coli. Very high levels of resistance to ciprofloxacin were also observed in 
human Campylobacter isolates, with co-resistance to ciprofloxacin and 
erythromycin being reported for almost one in six C. coli isolates.  The 
prevalence of resistance to ciprofloxacin, erythromycin, gentamicin, nalidixic 
acid and tetracyclines was also evaluated for Campylobacter isolates from 
poultry and poultry meat. In general, relatively high levels of resistance to 
ciprofloxacin, nalidixic acid and the tetracyclines was observed in 
Campylobacter isolates from poultry and poultry meat, whilst low levels were 
reported for erythromycin and gentamicin. 
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In 2005, the US Food and Drug Administration (FDA) banned the use of 
enrofloxacin in poultry production (FDA 2005). Studies were later carried out 
to evaluate the post-ban Campylobacter resistance to fluoroquinolones in 
poultry products. One such study was a year-long project carried out in 
Louisiana, which started in October 2006 and compared Campylobacter 
isolates from retail conventionally raised and organic chickens (Han et al. 
2009). They looked at resistance to the four antibiotics tetracycline, 
erythromycin, ciprofloxacin and gentamicin. Tetracycline was the antibiotic 
most isolates were resistant to (31.5%), followed by erythromycin (20%). 
Significantly higher rates of resistance to erythromycin were observed in 
conventional chicken isolates compared to those from organic chickens. 
However, the results generally showed low resistance rates to ciprofloxacin, 
with all isolates from organic chickens being susceptible to this antibiotic 
compared to 8.5% of isolates from the conventional chickens being resistant. 
No isolates were found to be co-resistant to both ciprofloxacin and 
erythromycin. In comparison, another study in Maryland looked at the 
prevalence of fluoroquinolone-resistant campylobacters in poultry products 
from two conventional producers who announced they had stopped using 
fluoroquinolones from 2002 (Price et al. 2007). The results however showed 
no significant change in the amount of fluoroquinolone-resistant 
Campylobacter isolates from the two producers throughout the duration of the 
study. They also compared the rates of fluoroquinolone-resistance of 
Campylobacter spp. isolated from the conventional poultry products compared 
to those from antibiotic-free producers. They found that the isolates from the 
two conventional producers were significantly more likely to be resistant to 
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fluoroquinolones than the antibiotic-free isolates. Although these two US 
studies had different outcomes, they give an idea of fluoroquinolone-resistance 
rates of Campylobacter spp. immediately following the ban in 2005. However, 
the long-term effects of ceasing the use of fluoroquinolones in US poultry 
production will have to be determined over time. 
 
1.4 PATHOGENESIS OF C. JEJUNI 
The pathogenic mechanisms by which C. jejuni infections occur in humans 
remain poorly understood despite the availability of a wealth of genomic 
information from several different Campylobacter strains. A major reason for 
this is the lack of appropriate animal disease models which efficiently mimic 
infection in humans (Newell 2001). However, experimental Campylobacter 
infection of primates has been found to very closely simulate the disease and 
immune response of humans (Fitzgeorge et al. 1981; Russell et al. 1989; 
Russell et al. 1993; Islam et al. 2006), particularly the New World monkey 
Aotus nancymae (Jones et al. 2006). Despite this, the cost of such 
experimentation is quite excessive, making it unavailable to most research 
institutions and there have always been ethical concerns surrounding such 
types of research. Nevertheless, using the available animal models, such as 
Toll-like receptor (TLR)-deficient mice, ferrets and wax moth larvae, several 
putative virulence factors involved in pathogenesis of human 
campylobacteriosis have been previously described (Ketley 1997; van Vliet & 
Ketley 2001; Konkel et al. 2001; Young et al. 2007; Dasti et al. 2010). In 
addition, the complete genome sequence of C. jejuni NCTC 11168 (Parkhill et 
al. 2000) earlier revealed that many classical virulence factors, known to be 
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key for other enteropathogens, were not present. For instance, no virulence-
associated pathogenicity island was found in NCTC 11168 (Parkhill et al. 
2000). However several genes with homopolymeric G-tracts, which can be 
prone to phase variation through slipped-strand mispairing, were identified. In 
spite of this, the role that phase variation plays in pathogenesis of 
Campylobacter has yet to be determined. 
 
Following exposure to C. jejuni, the lower intestinal tract of the gut (ileum, 
jejunum and colon) becomes colonised.  Expression of a  number of putative 
virulence determinants are predicted to be necessary for intestinal colonisation 
(see Figure 1-2), including those for chemotaxis and motility (Ketley 1997). 
Once colonisation occurs, other potential factors needed for virulence, 
including adhesion and invasion of host epithelial cells, toxin production, iron 
acquisition as well as oxidative, nitrosative and thermal stress defence 
mechanisms are necessary (Ketley 1997; van Vliet & Ketley 2001).  
 
1.4.1 Chemotaxis and motility 
Chemotaxis and flagellar motility are important for effective colonisation of 
the intestines as it is first necessary to penetrate the mucus layer of the 
intestinal cells. Chemotaxis is the ability of motile bacteria to sense and 
respond to specific chemical attractants. Several chemoattractants have been 
determined for C. jejuni including many constituents of mucin, which is a key 
component of mucus, such as L-fucose, L-glutamate, L-serine, pyruvate and 
succinate while many bile acids were found to act as chemorepellents 
(Hugdahl et al. 1988). The importance of chemotaxis in colonisation has been  
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Figure 1-2. The different phases of Campylobacter intestinal colonisation.  
The numbers represent putative C. jejuni virulence determinants and the 
different phase (s) where each is thought to be expressed; 1 ± motility, 2 ± 
chemotaxis, 3 ± oxidative stress defence, 4 ± adhesion, 5 ± invasion, 6 ± toxin 
production, 7 ± iron acquisition, 8 ± heat stress response and 9 ± coccoid 
dormant stage. 
 
Legend:  - epithelial cell, - viable Campylobacter cell, - dormant 
coccoid Campylobacter cell. Reproduced from van Vliet & Ketley (2001). 
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Proven with non-chemotactic C. jejuni mutants isolated by chemical 
mutagenesis, which failed to colonise the intestinal tract of suckling mice 
(Takata et al. 1992).  
 
Orthologues of the chemotaxis genes cheA, cheW, cheV, cheY, cheB and cheR 
have been identified in the genome sequence of C. jejuni (Parkhill et al. 2000) 
but their roles in chemotaxis, with the exception of cheY, cheB and cheR, have 
not been characterised. It has been reported that C. jejuni strains that lacked or 
over-expressed CheY, which is a response regulator that controls the direction 
of flagellar rotation when phosphorylated by CheA (Marchant et al. 2002), 
resulted in decreased virulence in a ferret disease model (Yao et al. 1997). The 
cheA and cheV genes also encode polypeptides that contain response regulator 
domains. The cheB and cheR genes, which respectively encode a 
methylesterase and methyltransferase, were determined to be arranged in an 
operon and have a putative role in the adaptation of C. jejuni to changes in the 
chemical gradient of their swimming environment (Kanungpean et al. 2011). 
Motility swarming assays were conducted to examine the chemotactic 
behaviour of deletion mutants of cheB, cheR and cheBR. The results showed 
significantly decreased swarm sizes compared to the wild-type, which 
suggested that the CheB and CheR proteins influence, but are not essential, for 
chemotaxis to occur in C. jejuni (Kanungpean et al. 2011). In addition, in vitro 
analyses using human intestinal INT-407 cell cultures revealed that a cheR 
deletion mutant was hyperadherent and hyperinvasive to these cells while a 
cheB mutation resulted in a non-adherent and non-invasive phenotype. In vivo 
experiments furthermore revealed that CheB and CheR are required for 
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colonisation of chickens as a cheBR mutant showed a reduced ability to 
colonise the caecum of 1-day old chicks compared to the wild-type strain. 
 
C. jejuni also possesses ten putative chemoreceptors (designated Transducer-
like proteins, Tlps), some of which show homology to the methyl-accepting 
chemotaxis proteins (MCPs) in E. coli. They are responsible for sensing 
chemoattractants in the environment and C. jejuni mutants lacking two of 
them, either cj0019c (DocB) or cj0262c, showed decreased colonisation of the 
gastrointestinal tract of 1-day old chickens, but the chemoattractants were 
unknown (Hendrixson & DiRita 2004). More recently, the C. jejuni group A 
Tlp receptor, Tlp3 (cj1564), was found to be a multi-ligand binding 
chemoreceptor that has several functions including recognition of the 
chemoattractants isoleucine, purine, malic acid and fumaric acid as well as the 
chemorepellants lysine, glucosamine, succinic acid, arginine and thiamine 
(Rahman et al. 2014). An isogenic mutant of cj1564 showed altered 
morphology, reduced chemotactic motility but increased autoagglutination and 
biofilm formation (Rahman et al. 2014). In addition, the tlp3 mutation reduced 
the ability of C. jejuni to adhere to and invade human intestinal Caco-2 cells 
but caused no change in its ability to colonise one day old chickens (Rahman et 
al. 2014). 
 
Campylobacters are motile through the presence of a single flagellum, at one 
or both cellular poles, which provides their typical corkscrew-like morphology. 
The importance of the flagella in colonisation has been demonstrated using 
flagellar mutants which were unable to colonise the gut of chickens 
  Chapter 1 
25 
 
(Nachamkin et al. 1993; Wassenaar et al. 1993), mice (Morooka et al. 1985; 
Newell & Mcbride 1985), rabbits (Caldwell et al. 1985; Pavlovskis et al. 1991) 
and hamsters (Aguero-Rosenfeld et al. 1990). Flagellar motility was also found 
to be important in causing disease in humans (Black et al. 1988). Furthermore, 
the importance of flagella in adhesion and invasion of host cells in vitro has 
been shown for flagellar mutants of C. jejuni 81176 that lost their ability to 
adhere to and invade human INT 407 cells (Wassenaar et al. 1991; Yao et al. 
1994). The flagellum of C. jejuni is unsheathed and is composed mainly of 
flagellins, which are encoded by the genes flaA and flaB (Nuijten et al. 1990). 
The two flagellin genes show 95% sequence similarity but are expressed 
independently from their own promoters.  The flaA gene is expressed at much 
greater levels than flaB and is regulated by ı28 (fliA), whilst ı54 (rpoN) controls 
expression of flaB (Guerry et al. 1991; Hendrixson et al. 2001; Jagannathan et 
al. 2001; Hendrixson & Dirita 2003; Carrillo et al. 2004). Inactivation of the 
flagellin genes has been found to affect motility in different ways. A flaA- 
flaB+ mutant resulted in formation of a truncated flagellum which led to a non-
motile phenotype while a flaA+ flaB- mutant possessed full-length flagella and 
remained motile (Guerry et al. 1991; Wassenaar et al. 1991; Wassenaar et al. 
1994). 
 
1.4.2 Adhesion and invasion 
Adherence and invasion of eukaryotic cells is an important feature of C. jejuni 
pathogenesis. In order to colonise hosts, microorganisms generally require 
adhesion and binding factors, including surface appendages such as pili which 
are found on the surfaces of many Gram-negative and Gram-positive bacteria. 
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However, the genome of C. jejuni does not appear to possess genes encoding 
homologues for obvious pilus-like structures and the organism has been shown 
not to produce such structures (Gaynor et al. 2001; Wiesner et al. 2003). 
Nevertheless, components of type II secretion systems which function in pilus 
biogenesis and assembly have been identified and are similar to systems used 
in assembly of type IV pili in organisms such as Vibrio cholera and Neisseria 
gonorrhoeae (Wiesner et al. 2003). Such components have been found to play 
a role in natural transformation of C. jejuni (Wiesner et al. 2003). 
 
In order to characterise the interaction of C. jejuni with eukaryotic cells, a 
number of studies have used models with human cells; for example human 
laryngeal carcinoma (HEp-2), human cervical cancer (HeLa) and human 
epithelial kidney (HEK-293) cell lines. However, cell lines that mimic the 
conditions expected to be encountered in vivo, such as human intestinal 
epithelial (INT 407) and human colon (Caco2 or HCA-7) cells, have been 
more extensively used. As a result, a number of putative adhesion and binding 
factors have been found despite the absence of identifiable pili or pilus-like 
organelles in C. jejuni.  These include CadF (Konkel et al. 1997), JlpA (Jin et 
al. 2001) and PEB1 (Pei & Blaser 1993). CadF is an outer membrane protein 
which facilitates binding of Campylobacter to fibronectin, a component of the 
extracellular matrix. Studies have shown that CadF is required for maximal 
adherence and invasion of INT 407 cells in vitro (Monteville et al. 2003) as 
well as for the efficient colonisation of infant leghorn chickens (Ziprin et al. 
1999). JlpA is a surface-exposed liproprotein which has been found to be 
important in binding of C. jejuni to HEp-2 epithelial cells in vitro as adherence 
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of insertion and deletion jlpA mutants to HEp-2 cells was reduced compared to 
the wild-type strain (Jin et al. 2001).  The periplasmic cell-binding protein 
PEB1 plays a role in C. jejuni adherence to HeLa cells in vitro (Kervella et al. 
1993; Pei et al. 1998). A mouse challenge study also found that peb1 mutants 
showed significantly reduced rates and duration of intestinal colonisation of 
mice compared to the wild-type (Pei et al. 1998).  
 
The invasive ability of C. jejuni has been demonstrated in vitro using various 
human cell lines (Wassenaar et al. 1991; Grant et al. 1993; Szymanski et al. 
1995; Pei et al. 1998) as well as in vivo using animal models of Campylobacter 
enteritis. Some of the experimentally challenged animals used were infant 
chickens (Ruiz-Palacios et al. 1981; Sanyal et al. 1984; Welkos 1984), infant 
mice (Newell & Pearson 1984; Yanagawa et al. 1994), newborn piglets 
(Babakhani et al. 1993) and infant monkeys (Russell et al. 1993). In addition, 
there is strong evidence to suggest that Campylobacter invades intestinal 
epithelial cells of humans as intracellular bacteria have been recovered from 
patients with colitis (van Spreeuwel et al. 1985). Another study found that 
there was a significant difference in the level of invasion between isolates from 
patients with Campylobacter colitis compared to those with non-inflammatory 
diarrhoea (Everest et al. 1992). Eighty-six percent of the colitis strains were 
also able to translocate across Caco-2 cell monolayers compared to 48% of 
isolates from patients with non-inflammatory diarrhoea.  
 
A previous study found that during co-cultivation with INT 407 cells or in an 
INT 407 cell-conditioned medium, C. jejuni secreted at least eight proteins into 
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the culture medium (Konkel et al. 1999). These secreted proteins are 
collectively known as Campylobacter invasion antigens (Cia), and include the 
73-kDa protein CiaB. Their precise role in the invasion process is still to be 
determined. However, mutation of the ciaB gene in C. jejuni significantly 
reduced the number of cells which were internalised, compared to the wild-
type, and resulted in failure to secrete the other proteins (Konkel et al. 1999). It 
was earlier suggested that CiaB may belong to a type III secretion system 
(Konkel et al. 1999) but no type III system has been found in the C. jejuni 
genome. Nevertheless, it was later demonstrated that CiaB and other secreted 
proteins require a functional flagellar export apparatus for their secretion 
(Konkel et al. 2004). More recently, a functional type VI secretion system was 
identified in C. jejuni but the genes encoding this system were only found to be 
present in 10% of the C. jejuni isolates tested, all of which contained the CJIE3 
integrative element (Bleumink-Pluym et al. 2013).  
  
1.4.3 Toxin production 
Toxins have been proposed as important virulence factors but their role in 
pathogenesis of Campylobacter enteritis remains unclear. Many cytotoxins and 
enterotoxins in campylobacters have been described (Wassenaar 1997) but to 
date cytolethal distending toxin (CDT) is the only toxin to be well 
characterised (Pickett et al. 1996; Whitehouse et al. 1998). CDT is produced 
by many Campylobacter species, including C. jejuni, C. coli, C. lari, C fetus 
and C. upsaliensis  and was found to be cytolethal to CHO (Chinese hamster 
ovary), Vero, HeLa, HEp-2 and Caco2 cell lines (Johnson & Lior 1988; 
Whitehouse et al. 1998). The toxic effect on sensitive cells was characterised 
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by progressive cell elongation, swelling and eventual death. It was however 
found that not all cell types were sensitive to CDT since mouse Y-1 adrenal 
cells were unaffected (Johnson & Lior 1988). This toxin can cause a variety of 
mammalian cells to become irreversibly blocked in the G2 phase of the cell 
cycle due to failure to activate CDC2 kinase, which is required for transition 
into mitosis (Whitehouse et al. 1998). CDT is also produced by a number of 
other bacterial species including E. coli (Johnson & Lior 1987; Scott & Kaper 
1994), Shigella spp. (Okuda et al. 1997), Haemopilus ducreyi (Gelfanova et al. 
1999) and Helicobacter hepaticus (Young et al. 2000a). In C. jejuni and other 
Gram-negative bacteria, toxin delivery can be mediated by outer membrane 
vesicles (OMVs), which have been found to aid in the release of CDT into the 
surrounding environment by C. jejuni 81-176 (Lindmark et al. 2009). 
 
The function of three structural genes, cdtA, cdtB and cdtC, is necessary for 
CDT cytotoxicity (Pickett et al. 1996; Pickett & Whitehouse 1999). It has been 
determined that CdtB is the enzymatically active subunit of the toxin (Pickett 
& Whitehouse 1999). The functions of CdtA and CdtC are still unclear but it 
has been demonstrated that when invidual Cdt components were purified and 
applied to cells, no toxic activity was observed (Lara-Tejero & Galan 2001). 
However when applied together they interacted to form a fully active tripartite 
complex (Lara-Tejero & Galan 2001). It was therefore proposed that CdtA and 
CdtC act as a heterodimeric B subunit and may be involved in the delivery of 
CdtB into eukaryotic cells (Lara-Tejero & Galan 2001). The role of CDT in C. 
jejuni pathogenesis was also tested using isogenic cdtB mutants (Purdy et al. 
2000). HeLa cytoxicity assays showed that CDT activity was either greatly 
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reduced or not detected in the mutants whilst their colonisation ability during 
an intragastric challenge of adult severe combined immunodeficient (SCID) 
mice was unaffected by the mutation (Purdy et al. 2000). However, the results 
also showed that the C. jejuni cdtB mutants invaded blood, spleen and liver 
tissue of the SCID mice less readily than wild-type bacteria, therefore 
suggesting a potential role for CDT in invasion of host tissues. 
 
1.4.4 Iron acquisition 
The ability of campylobacters to acquire iron within their animal host is known 
to be a key step for infection. Free iron usually has very limited availability as 
it is complexed with iron-binding and transport proteins such as haemoglobin, 
transferrin (in serum) and lactoferrin (in mucosal secretions) (Andrews et al. 
2003). This iron limited environment acts as a non-specific host defence 
mechanism against pathogenic bacteria, where a free iron concentration of 
around 10-18 M is maintained, whilst at least 10-7 to 10-5 M is generally 
required for optimal bacterial growth (Andrews et al. 2003). In order to 
overcome this limitation, many bacterial pathogens have evolved a number of 
mechanisms to enable them to scavenge iron from their extracellular 
environment, including the use of small iron-chelating compounds known as 
siderophores. However, siderophore biosynthesis genes have not yet been 
identified within genome sequences of Campylobacter strains (Parkhill et al. 
2000; Chaudhuri & Pallen 2006). Although, Field et al. (1986) found that 7 of 
26 C. jejuni human isolates tested produced detectable amounts of 
siderophores when grown under iron-limited conditions and that three of the 
strains were also able to utilize exogenously supplied enterochelin and 
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ferrichrome, which are known to be produced by E. coli and certain soil fungi 
respectively. C. jejuni was also found to be able to utilize haem-containing 
compounds (Pickett et al. 1992). Genes encoding enterochelin (ceuBCDE) 
(Richardson & Park 1995), ferrichrome (cfhuABD) (Galindo et al. 2001) and 
haemin/haemoglobin (chuABCDZ) (Rock et al. 1999) have been characterised 
in Campylobacter and were demonstrated to be involved in iron acquisition.  
 
Iron can exist in either ferrous (Fe2+) or ferric (Fe3+) states, and depending on 
the pH and redox conditions of the surrounding environment, soluble ferrous 
iron can be rapidly oxidised to the insoluble ferric iron. Iron in the ferrous state 
can easily diffuse through outer-membrane porins (size limit ~600 Da) but 
Fe3+-siderophore complexes are too large to pass through. Therefore the ferric 
iron acquisition system of Gram-negative bacteria is generally comprised of an 
outer-membrane (OM) receptor protein, which specifically binds to cognate 
ferri-siderophore or free iron and transports it through the OM to a periplasmic 
binding protein and subsequently to a cytoplasmic membrane (CM) ABC 
transporter, consisting of a permease and an ATP-binding protein. Transport of 
ferri-siderophores through OM receptors relies on energy transduced through 
the TonB-ExbB-ExbD protein complex, while ATP is hydrolysed to provide 
energy for transport across the IM into the cytoplasm (Braun et al. 1998). 
 
C. jejuni typically acquires iron from ferri-enterochelin through the CfrA OM 
receptor, which shows high homology to a number of other ferric siderophore 
receptors (Palyada et al. 2004). The cfrA gene was previously found to be iron 
regulated (Guerry et al. 1997) and mutation of this gene in C. jejuni NCTC 
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11168 prevented growth when ferri-enterochelin was provided as the only 
source of iron (Palyada et al. 2004). Another ferri-enterochelin receptor, 
designated CfrB, was identified and characterised in Campylobacter (Xu et al. 
2010). It is a homolog of the Cj0444 protein in C. jejuni NCTC 11168 
(annotated as a pseudogene) and was found to be important in colonisation of 
chickens by both C. jejuni and C. coli (Xu et al. 2010). Most strains of C. 
jejuni that produced the CfrB receptor protein did not produce CfrA, whilst C. 
coli strains were found to widely produce both CfrA and CfrB but not CfrB 
alone (Xu et al. 2010). 
 
The enterochelin transport system encoded by ceuBCDE is similar in C. jejuni 
and C. coli, with ceuB and ceuC encoding integral membrane proteins, ceuD 
an ATPase-binding protein and ceuE a periplasmic-binding lipoprotein 
(Parkhill et al. 2000; Palyada et al. 2004). The importance of enterochelin 
uptake in gut colonisation was demonstrated in vivo as cfrA and ceuE mutants 
of C. jejuni NCTC 11168 were unable to colonise the gastrointestinal tract of 
chickens (Palyada et al. 2004).  
 
A ferrichrome uptake operon was identified in C. jejuni strain M129, encoding 
proteins with homology to the ferrichrome uptake systems of E. coli and 
Pseudomonas aeruginosa (Galindo et al. 2001). The operon is comprised of 
the genes cfhuABD and has not been identified so far in any of the sequenced 
Campylobacter genomes (Chaudhuri & Pallen 2006). In E. coli the fhuA gene 
encodes an outer membrane receptor, fhuB a permease and fhuD a periplasmic 
binding protein. CfhuA was found not to be uniformly present in eleven C. 
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jejuni strains tested as Southern blot analysis showed that only six of them 
carried the fhuA homologue (Galindo et al. 2001). Under iron-limited 
conditions, C. jejuni strain M129 grew best when ferrichrome was used as an 
iron source compared to other sources (Galindo et al. 2001). However, the role 
of CfhuA in ferrichrome uptake is still unclear, along with the role of cfhuABD 
in C. jejuni pathogenesis. 
 
The cj1658-cj1663 locus of the C. jejuni NCTC 11168 genome is involved in 
iron uptake associated with rhodotorulic acid, which is a fungal hydroxamate 
siderophore that was previously isolated and characterised (Atkin & Neilands 
1968). A 19-kDa periplasmic protein (cj1659) of C. jejuni designated p19 was 
previously determined to be iron regulated (van Vliet et al. 1998). The gene 
directly upstream of p19, cj1658, encodes a putative membrane-associated 
protein but does not resemble a Ton-B dependent receptor. However, the genes 
cj1661-cj1663 appear to encode an IM ABC transporter system and 
homologues of cj1658 and p19 can be found in a Yersinia pestis iron-uptake 
pathogenicity island (Carniel 2001). Mutation of cj1658 and p19 in C. jejuni 
NCTC 11168 affected the ability of this strain to utilize ferri-rhodotorulic acid 
for growth (Stintzi et al. 2008). 
 
In the Enterobacteriaceae, uptake of ferrous iron is mediated by the Feo 
transport system and is quite different to siderophore-dependent systems. The 
system is comprised of the two proteins FeoA and FeoB, which lie in an 
operon with the putative [Fe-S] transcriptional repressor FeoC (Cartron et al. 
2006). The function of FeoA is unknown but FeoB appears to encode an IM 
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protein. Homologues of the E. coli feoB and feoA genes have been identified in 
the C. jejuni NCTC 11168 genome sequence but a feoC homologue was not 
found (Parkhill et al. 2000). Raphael and Joens (2003) reported that FeoB was 
not required for uptake of ferrous iron in C. jejuni and site-directed mutations 
in feoB resulted in no change in 55Fe2+ uptake. It was subsequently determined 
that the feoB and feoA genes form an operon in C. jejuni and the role of FeoB 
in iron acquisition, gut colonisation and intracellular survival in C. jejuni was 
examined (Naikare et al. 2006). It was found that feoB C. jejuni mutants were 
significantly affected in their ability to transport Fe2+ and that intracellular iron 
accumulated within the periplasm compared to the cytoplasm for the wild-
type. The feoB mutant was also out-competed by the wild-type during 
colonisation and survival studies using the rabbit ileal loop model as well as 
during chicken colonisation studies. Infection of the intestinal tract of 
colostrum-deprived piglets was also significantly reduced in the mutant 
compared to the wild-type (Naikare et al. 2006). In contrast to the findings of 
Raphael and Joens (2003), these results therefore not only suggest a role for 
FeoB in iron acquisition but also in colonisation and pathogenesis. 
 
1.4.5 Oxidative stress defence 
Although bacteria need to secure iron for growth and survival within the host, 
it is necessary for them to ensure that the intracellular supply is safe and non-
toxic. However, incomplete reduction of oxygen can generate a mixture of 
highly reactive intermediates of varying toxicity known as reactive oxygen 
species (ROS), which include super anions (O2-) and peroxides (RO2). 
Increased exposure to these intermediates can cause oxidative stress, which 
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leads to lethal damage of cell membranes, proteins and nucleic acids. Super 
anions can destroy enzymes containing [4Fe-4S] clusters, causing the release 
of iron and subsequent inactivation of the enzyme (Fridovich 1995). Released 
iron can then react with ROS to generate hydroxyl radicals (OH) through the 
Haber-Weiss and Fenton reactions (Miller & Britigan 1997) as shown in the 
equations below: 
 
O2- + Fe3+           Fe2+ + O2   Iron reduction (eq. 1) 
Fe2+ +H2O2          Fe3+ OH- + HO  Fenton reaction (eq. 2) 
O2- + H2O2           HO + OH- +O2  Haber-Weiss reaction (eq. 3) 
 
Campylobacters possess oxidative stress defence systems mainly against stress 
from superoxides and peroxides (van Vliet & Ketley 2001). Superoxide 
dismutases (SODs) catalyse the breakdown of superoxide molecules to 
hydrogen peroxide and dioxygen (Fridovich 1995). A single iron cofactored 
SOD, encoded by the sodB gene, is expressed by Campylobacter and is the key 
component of stress defence against superoxides (Pesci et al. 1994; Purdy & 
Park 1994). It was found that sodB C. jejuni mutants were significantly less 
able to invade INT 407 cells in vitro (Pesci et al. 1994) while C. coli sodB 
mutants showed decreased colonisation ability during experimental infection 
of 1-day old chicks (Purdy et al. 1999). Absence of the sodB gene also 
previously affected the ability of Campylobacter to survive for prolonged 
periods in milk and on chicken skin (Purdy et al. 1999) and mutants were also 
more sensitive to freeze-thaw stress (Stead & Park 2000). It has also been 
shown that sodB mutants have increased sensitivity upon exposure to paraquat, 
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which is a strong oxidising agent (Garénaux et al. 2008). All of these results 
therefore suggest that the SodB protein plays an important role in infection, 
oxidative stress defence and survival of Campylobacter in different foods.  
 
Mechanisms for peroxide stress defence mainly rely on the enzymes catalase 
(KatA) and alkyl hydroperoxide reductase (AhpC) (Grant & Park 1995; 
Baillon et al. 1999). Catalase catalyses the conversion of hydrogen peroxide to 
hydrogen and water and can therefore assist in removal of the hydrogen 
peroxide produced by SOD and other metabolic reactions. Catalase-deficient 
mutants were found to be more sensitive to exposure to H2O2 than the parental 
strain and had a reduced ability to detoxifying this molecule, as more than 60% 
of the H2O2 remained for the duration of the experiment compared to wild-type 
cells which reduced the concentration to undetectable levels within 5 minutes 
(Grant & Park 1995). Interestingly, it was later found that the ability of katA 
mutants to grow and survive in aerobic conditions as well as to colonise an 
animal model were unaffected by the mutation (Purdy et al. 1999). This may 
therefore suggest that katA is not an important determinant in aerobic survival 
and optimal colonisation ability of Campylobacter. Catalase expression in C. 
jejuni is regulated by the PerR protein and is repressed by iron but induced by 
H2O2 exposure (Park 1999; van Vliet et al. 1999).  
 
Alkyl hydroperoxide reductase, also referred to as thiol-specific antioxidant 
(Tsa or TsaA), reduces alkyl hydroperoxides to alcohols. C. jejuni expresses a 
homologue of the catalytic AhpC protein but does not contain the flavoprotein 
AhpF, found in E. coli and several other bacteria (Poole et al. 2000). The 
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importance of AhpC in aerobic survival of C. jejuni was demonstrated as an 
ahpC mutant showed significantly reduced aerotolerance compared to the 
wild-type and was more sensitive to an inducer of oxidative stress (Baillon et 
al. 1999). However, the ahpC mutant was not sensitive to H2O2 exposure 
(Baillon et al. 1999). 
 
The genome of C. jejuni contains a number of other peroxidases that may have 
roles in oxidative stress defence. These include thiol peroxidase (Tpx) and the 
bacterioferritin comigratory protein (Bcp), both of which are represented by 
homologues in C. jejuni and are encoded in C. jejuni NCTC 11168 by cj0779 
and cj0271 respectively. It was found that Tpx and Bcp are cytoplasmic 
enzymes, which together play important roles in oxidative and nitrosative 
stress defence as a tpx/bcp double mutant was hypersensitive to exposure to 
hydrogen peroxide, organic peroxides, superoxide and nitrosative stress agents 
compared to the wild-type and single mutants (Atack et al. 2008). 
 
1.4.6 Nitrosative stress response 
During human infection and pathogenesis, campylobacters encounter elevated 
levels of nitric oxide (NO) and other agents that cause nitrosative stress. This 
has previously been demonstrated in patients with infective gastroenteritis, 
including individuals suffering from campylobacteriosis (Forte et al. 1999; 
Enocksson et al. 2004). The main sources of NO in human hosts are NO 
synthases (particularly inducible NO synthase), dietary nitrate, which is 
reduced to nitrite and then to NO by bacteria, and salivary nitrite, which is 
reduced to NO through the action of stomach acid (Lundberg et al. 2004). In 
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response to this form of stress, C. jejuni expresses a single-domain 
haemoglobin (Cgb), which functions in the scavenging and detoxification of 
NO (Elvers et al. 2004; Lu et al. 2007b). A Cgb-deficient mutant showed 
increased sensitivity to NO and nitrosative stress as it was hypersensitive to the 
nitrosating agents S-nitrosoglutathione (GSNO) and sodium nitroprusside, and 
to the nitric oxide±releasing compound spermine NONOate (Elvers et al. 
2004). The NO-sensing regulator NssR (nitrosative stress sensing regulator, 
cj0466), which is a member of the Crp-Fnr superfamily of transcription 
factors, was found to regulate NO-responsive expression of cgb (Elvers et al. 
2005). C. jejuni also expresses a second globin (Ctb), which is a truncated 
haemoglobin that has also been found to be under the control of NssR (Elvers 
et al. 2005). The function of Ctb has not been fully established but it has an 
extremely high affinity for oxygen and has been implicated in oxygen 
metabolism (Wainwright et al. 2005; Wainwright et al. 2008) and in 
performing a role in cytochrome c peroxidase or cytochrome P450-like oxygen 
chemistry (Lu et al. 2007a).  
 
1.4.7 Thermal stress response 
Campylobacters are exposed to a range of temperatures including 37°C within 
human and animal hosts, 42°C within avian reservoirs and around 4°C within 
food products (water, milk or on poultry meat). The optimal temperature range 
for growth is between 37-42°C, where temperatures above this trigger a 
thermal stress response in C. jejuni and result in the synthesis of heat shock 
proteins (HSPs). HSPs are a group of highly conserved proteins that are co-
regulated and play an important role in thermotolerance as well as in response 
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to other environmental stresses. They also participate in normal cell function 
by acting as chaperones to allow the correct folding of many cellular proteins 
and the proteolysis of misfolded proteins, which can be deleterious if allowed 
to accumulate. A number of HSPs have been identified in C. jejuni including 
the proteins GroEL, GroES, DnaJ, DnaK and ClpB (Konkel et al. 1998; Thies 
et al. 1999a; Thies et al. 1999b; Thies et al. 1999c). However, only DnaJ has 
been shown to play a role in C. jejuni pathogenesis as a dnaJ null mutant was 
unable to colonise newly hatched Leghorn chickens (Konkel et al. 1998). The 
dnaJ mutant also exhibited impaired growth at 46°C, implying the chaperone 
has a role in thermotolerance (Konkel et al. 1998). Konkel et al. (1998) 
demonstrated a heat shock response for C. jejuni immediately following 
exposure to temperatures above the optimal range (43°C), and found that the 
synthesis of at least 24 proteins increased in response to this thermal stress. 
Similarly, another study looked at the global transcriptional response of C. 
jejuni to a temperature increase from 37 to 42°C and found that approximately 
20% of the genes in the genome were either significantly up- or down-
regulated over a 50 minute period following the temperature increase (Stintzi 
2003). Genes encoding chaperones, chaperonins and HSPs, including groEL, 
groES, dnaK, dnaJ, hspR, hcrA and clpB, showed increased levels of 
expression. The RacRS regulon, which is a two-component regulatory system, 
has been found to be involved in differential expression of proteins at 37 and 
42°C in C. jejuni (Brás et al. 1999). Inactivation of the response regulator gene 
in C. jejuni, encoded by racR, also resulted in a reduced ability to colonise the 
intestinal tract of chickens (Brás et al. 1999). 
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1.5 REGULATION OF CAMPYLOBACTER VIRULENCE  
1.5.1 Iron-responsive regulation  
Iron is an absolute requirement for life but in the presence of oxygen, it is 
capable of generating toxic and potentially harmful metabolites (see section 
1.4.5). Iron acquisition, metabolism and storage are therefore strictly regulated 
to allow iron homestasis to be carefully balanced. In C. jejuni and other Gram-
negative bacteria, iron-regulated gene expression is under the control of the 
transcriptional regulator Fur (ferric uptake regulator). When the intracellular 
ferrous ion concentration exceeds a threshold level, Fur binds to Fe2+ ions and 
forms a dimeric Fe2+-Fur complex (holo-Fur). This complex recognises 
specific consensus sequences (Fur box) in promoter regions upstream of iron-
regulated genes and represses their transcription by blocking entry of RNA 
polymerase (Figure 1-3) (Andrews et al. 2003; Butcher et al. 2012). However, 
when the concentration of intracellular iron becomes low, the Fur complex 
dissociates (apo-Fur) and no longer binds to the recognition sequences, thus 
de-repressesing transcription of iron-regulated genes (Figure 1-3) (Andrews et 
al. 2003; Butcher et al. 2012). The structure of the Fur protein in C. jejuni was 
recently determined and differences were observed in the orientation of the 
apo-Fur DNA-binding domain compared to other structurally characterised Fur 
and Fur-like homologues (Butcher et al. 2012). It was found that the C. jejuni 
apo-Fur protein retains a canonical V-shape dimer conformation, and in doing 
so re-positions the DNA-binding domain to enable DNA interactions that can 
be modulated by the binding of iron (Butcher et al. 2012). 
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Figure 1-3. Schematic diagram of Fur regulation of iron-regulated genes. 
Fur represses transcription of iron-responsive genes once it forms a complex 
with its co-repressor Fe2+, but causes de-repression in the absence of Fe2+. 
(Reproduced from Andrews et al., 2003) 
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The C. jejuni Fur protein has been previously found to control transcription of 
at least 60 genes related to iron acquisition, oxidative stress defence, flagellar 
biogenesis and energy metabolism (Palyada et al. 2004; Holmes et al. 2005). 
Binding of purified Fur to the promoters upstream of p19, cfrA, ceuBCDE, 
chuABCD and cj1613 (putative haem oxygenase) has also been demonstrated 
(Holmes et al. 2005; Ridley et al. 2006). More recently, a chromatin 
immunoprecipitation and microarray analysis assay (ChIP-chip) was used to 
define the role of Fur in C. jejuni and 95 genomic loci were identified that 
were bound by Fur regardless of the fold change (Butcher et al. 2012). These 
Fur binding sites were found to include some in the vicinity of genes encoding  
proteins involved in metal homeostasis, flagellar biogenesis, energy production 
and conversation, and stress response (Butcher et al. 2012). 
 
It was previously found that a C. jejuni fur mutant was unable to regulate 
expression of iron acquisition genes, but there was still iron-responsive gene 
regulation (van Vliet et al. 1998). This suggested the presence of a second iron-
response regulator, which was found to be the peroxide stress regulator PerR 
protein. Fur is known to regulate the genes katA and ahpC, which are also 
regulated by PerR (van Vliet et al. 1999). A perR mutation in C. jejuni caused 
hyper-resistance to peroxide stress as the aphC and katA promoters were de-
repressed under these conditions, leading to high levels of expression of these 
genes (van Vliet et al. 1999). In addition, iron-responsive regulation of aphC 
and katA completely ceased in a C. jejuni perR fur double mutant (van Vliet et 
al. 1999). 
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1.5.2 Two-component regulatory systems 
Two-component systems (TCSs) provide a stimulus-response mechanism that 
allows organisms to sense and respond to changes within their environment, 
mainly through changes in gene expression. TCSs are usually comprised of a 
membrane-located sensory histidine protein kinase and a cytoplasmic response 
regulator protein. The histidine kinase senses extracellular stimuli and transfers 
a phosphoryl group to a conserved aspartate residue on the N-terminal domain 
of the response regulator, which then interacts with the promoters of target 
genes and regulates their expression. The genome of C. jejuni is regulated by 
at least 37 putative transcription factors, including 10 response regulators 
(Wösten et al. 2008). Examples of two-component transduction systems in C. 
jejuni are: FlgS-FlgR which regulates the fla regulon and is essential for 
flagella biogenesis (Wösten et al. 2004); PhosS-PhosR which is activated by 
phosphate limitation and regulates the pho regulon (Wösten et al. 2006); RacR-
RacS which is responsive to temperature and is important for colonisation of 
chickens (Brás et al. 1999); DccR-DccS which is activated in the late 
stationary phase of bacterial growth and is required for optimal in vivo 
colonisation (MacKichan et al. 2004) and CprR-CprS which is essential for 
expression of factors that are needed for biofilm formation, planktonic growth 
and optimal colonisation of chickens (Svensson et al. 2009).  
 
1.6 GENOME SEQUENCE OF C. JEJUNI NCTC 11168 
The C. jejuni NCTC 11168 genome has 1,641,481 base pairs (bp) arranged as 
a circular chromosome, with a G+C content of 30.6% and the presence of 
1,643 putative coding sequences (CDS), including 19 probable pseudogenes 
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(Parkhill et al. 2000; Gundogdu et al. 2007). The genome generally lacks 
repetitive DNA sequences, with only four repeated sequences being identified 
throughout the entire genome, one of them being the ribosomal RNA operon. 
There are no inserted sequence (IS) elements, transposons, retrons or 
prophage-associated genes present. Shotgun assembly of the genome 
illustrated the presence of homopolymeric G:C tracts exhibiting length 
variations amongst identical clone (Parkhill et al. 2000). Variation in length of 
poly G:C tracts may be due to slipped-strand mispairing during chromosomal 
replication (Levinson & Gutman 1987) and is known to mediate phase 
variation of surface molecules in pathogenic bacteria such as Haemophilus 
influenzae (Hood et al. 1996). Hypervariable sequences were identified in gene 
clusters mainly responsible for lipooligosaccharide (LOS) biosynthesis 
(cj1131c-cj1152), capsular polysaccharide (CPS) biosynthesis (cj1413c-
cj1448c) and flagellar modification (cj1293-cj1342). 
 
Following publication of the genome sequence of C. jejuni NCTC 11168, the 
sequenced clone (11168-GS) was found to be non-motile, displaying a straight, 
rod-shaped morphology that invaded and translocated poorly through tissue 
culture cells, and was a poor coloniser of 1 day old chickens (Ahmed et al. 
2002; Gaynor et al. 2004). However, variants exist with more typical 
phenotypes (Carrillo et al. 2004; Gaynor et al. 2004; Revez et al. 2012). 
Transcriptional analysis of the sequenced variant compared to the original 
isolate (11168-O) revealed differences in expression of genes relating to 
respiration and metabolism, suggesting that adaptation to different oxygen 
tensions may have contributed to the differences in phenotype  (Gaynor et al. 
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2004). Another study with two variants of NCTC 11168 found differences in 
their virulence properties, including motility, and suggested these were largely 
due to changes in expression of ı28 and ı54-regulated genes (Carrillo et al. 
2004). More recently, Campylobacter isolates that were recovered from a 
diarrheic human and identified as strain NCTC 11168-GSv (American Type 
Culture Collection (ATCC) genome sequence reference strain) exhibited major 
genetic changes compared to NCTC 11168-GS (Thomas et al. 2014). These 
changes were found at 15 loci within the genome of NCTC 11168-GSv and 
included several insertion/deletion (indel) mutations in genes carrying 
homopolymeric regions as well as point mutations in two loci. On inoculation 
of interleukin-10 knockout mice with an isolate of NCTC 11168-GSv from the 
infected individual, the isolate was found to undergo further genetic variations, 
with specific mutations occurring at nine loci. These findings therefore 
illustrate that C. jejuni is capable of exhibiting host-specific genetic adaptation. 
 
1.7 BACTERIOPHAGE 
Bacteriophages (commonly referred to as phages) are bacterial viruses that 
infect, replicate and ultimately kill susceptible hosts. An estimated 1031 
individual virus particles (mostly tailed phage) are thought to be in existence, 
making them the most abundant biological entities present on the planet 
(Hendrix et al. 1999). Bacteriophages are ubiquitous and can be found in most 
environments that support bacterial growth such as seawater, soil and within 
animal intestines; typically with a phage-to-bacterium ratio of 10:1 or greater. 
An early study reported on the high abundance of viruses present in marine 
environments (Bergh et al. 1989) where phage concentrations of up to 2.5 x 
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108 particles/ml have been detected in lake Plussee, Germany and 
approximately 107 phage particles/ml compared to 106 cells/ml of bacteria 
were present in marine samples. These concentrations were found to vary 
according to the season and geographical location. 
 
1.7.1 Classification 
Bacteriophages are classified by the International Committee on Taxonomy of 
Viruses (ICTV) primarily according to their morphology and nucleic acid 
content (whether they contain single- or double-stranded RNA or DNA), but 
host range and antigenic properties are also taken into account. For 
classification, the ICTV requires that capsid morphology be determined by 
visualising phage particles using an electron microscope. However, this 
procedure is not usually routinely performed by researchers, resulting in many 
of the completely sequenced bacteriophages in GenBank (Benson et al. 2002) 
remaining unclassified by the ICTV system. As of July 2013, bacteriophages 
were classified into the order Caudovirales (ICTV 2014), which consists of 3 
families based on tail morphology (Figure 1-4): Myoviridae with long 
contractile tails, Siphoviridae with long non-contractile tails and Podoviridae 
with extremely short tails (Hendrix & Casjens 2005). A further 10 families 
also exist but are currently not assigned to an order (ICTV 2014). The viruses 
that typically represent bacteriophages are the tailed phages that contain linear 
double-stranded DNA and genome sizes ranging from 17 to 500 kb.  
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Figure 1-4. Viruses classified in the order Caudovirales. 
Electron micrographs illustrating a T4-like myovirus (panel a), an Escherichia 
coli siphovirus HK97 (panel b) and a Salmonella typhimurium podovirus P22 
(panel c). Each phage shows the characteristic tail morphology associated with 
its classification. The scale bar is 50 nm. Images reproduced from Krupovic et 
al. (2011). 
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1.7.2 Lifecycle 
Apart from being classified on the basis of morphology, phages can also be 
grouped according to their lifecycle. Phages are generally either virulent (lytic) 
or lysogenic (Adams 1959) but alternative lifecycles also exist, including 
pseudolysogeny and the carrier state life cycle (Abedon 2009). An overview of 
the different lifecycles is discussed next. 
 
1.7.2.1 Virulent bacteriophage 
Virulent bacteriophages redirect host metabolism in order to produce new 
phage particles, which are finally released on lysis of the host cells (example 
bacteriophage T4).  The mechanisms associated with the lifecycle of virulent 
phages were first investigated in vitro by Ellis and Delbrück (1939) with their 
one-step growth experiment (Figure 1-5). They were able to determine the 
minimum latent period needed for intra-cellular virus growth as well as the 
average burst size. The latent period represents the time which elapses between 
adsorption of phage to the host cell and lysis, while the burst size is the mean 
yield of phage particles per infected host cell. The main stages of the lytic 
lifecycle are (1) adsorption, (2) infection, (3) replication and (4) release of 
virions. Bacteriophages adsorb to bacterial host cell receptors such as flagella, 
pili or capsule. Some phages also require adsorption cofactors, for example 
coliphage T4 reversibly lost its ability to adsorb to its host cells in the absence 
of tryptophan (Anderson 1948). 
 
Following adsorption the phage injects its DNA into the bacterial cytoplasm, 
signalling the beginning of the eclipse and latent periods. The DNA is then  
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Figure 1-5. The bacteriophage one-step growth curve of Ellis and 
Delbrück (1939). 
The bacteriophages are mixed with a specific bacterial host and incubated for a 
short period of time to allow phage adsorption. The mixture is diluted 1 in 
1000 to prevent any further rounds of replication by reducing the number of 
available bacteria. The curve begins with the latent period, which represents 
the time that elapses between phage adsorption and bacterial cell lysis. The 
latent period also spans the eclipse phase where the bacteriophages are 
replicating and mature phage virions are accumulating within host cells (red 
line). As these mature virus particles are released into the extra-cellular 
environment, the curve enters the rise period. This can be used to calculate the 
burst size, which refers to the number of phage virions produced per infected 
host cell, for this single round of phage replication. 
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replicated to create multiple copies that are packaged into the capsid, which is 
constructed in the very late stages of phage infection. Assembly of the phage 
progeny is completed by attachment of tail fibres onto the DNA-filled heads 
and the eclipse phase comes to an end as the number of mature intra-cellular 
viruses accumulates. These mature phage virions are then released into the 
extra-cellular environment, which marks the end of the latent period. 
 
1.7.2.2 Temperate bacteriophage 
Temperate or lysogenic bacteriophages (lysogens) integrate phage DNA into 
the genome of the bacterial host cell, where replication occurs alongside the 
host DNA. The phage generally remains dormant, causing no cell lysis and 
producing no progeny (example bacteriophage Ȝ). Lysogeny however means 
³SURGXFWLRQRI O\VLV´DQGUHIHUV WRWKHhabit of some infected bacterial strains 
producing phage capable of lysing sensitive bacterial strains. This is possible 
because lysogenic phages can recommence the lytic life cycle either 
spontaneously or in response to environmental factors to produce infective 
phage progeny. In contrast, bacterial lysogens are generally resistant to super-
infection by phages that are genetically related to their integrated prophage.  
 
1.7.2.3 Pseudolysogeny and carrier state life cycle 
Pseudolysogeny (false lysogeny) and the carrier state life cycle (CSLC) are 
two alternative bacteriophage lifecycles (Lwoff 1953; Adams 1959) that have 
previously been reported for either lytic or lysogenic phages (Miller & Ripp 
2002). Pseudolysogeny describes an unstable condition where the viral DNA 
of the infecting phage fails to establish a long-term, stable relationship with the 
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host (lysogeny) or does not cause cell lysis, but is instead maintained within 
the cell in a non-active state (Ripp & Miller 1997). Such a situation may arise 
during nutrient limited conditions where the pseudoprophage can survive for 
extended periods. As nutrients are replenished, the unstable pseudolysogens 
can either be converted to true lysogens or elicit a lytic response (Miller & 
Ripp 2002). On the other hand, the CSLC refers to a mixture of bacteria and 
bacteriophages which exist in a stable equilibrium (Lwoff 1953). The majority 
of the bacteria are resistant but some sensitive variants are also present and 
these can be infected by the phage to allow multiplication. Bacteriophages are 
therefore constantly generated at the expense of the sensitive population 
(Siringan et al. 2014). 
 
1.7.3 Bacteriophage therapy 
1.7.3.1 History and early phage therapy trials 
Bacteriophages were diVFRYHUHG LQGHSHQGHQWO\ LQ WKH HDUO\ ¶V E\
)UHGHULFN7ZRUWLQ(QJODQGDQG)HOL[G¶+HUHOOHLQ)UDQFHZKR
both described a phenomenon where bacterial cell lysis was taking place on 
VROLG PHGLD )HOL[ G¶+HUHOOH LQWURGXFHG WKH WHUP EDFWHULRSKage, meaning 
µEDFWHULD HDWHU¶ attributed to their bactericidal ability and was the first to 
formally propose the use of bacteriophages as therapeutic agents against 
bacterial infections. In 1919, he isolated phages from chicken faeces and used 
them to successfully control an epidemic of avian typhosis and subsequently 
went on to use this approach as a therapy to treat dysentery in human patients 
(Summers 2001). Bacteriophages were also used in 1921 by Richard 
Bruynoghe and Joseph Maisinto, who successfully treated staphylococcal skin 
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disease by injecting phages into and around surgically opened lesions, with 
regression of the disease occurring within 24-48 hours of administration 
(Bruynoghe & Maisin 1921). Dr. d¶+HUHOOH¶VODERUDWRU\LQ3DULVFRPPHUFLDOO\
produced phage preparations against a number of bacterial infections, which 
included the products Bacté-coli-phage, Bacté-intesti-phage and Bacté-pyo-
phage, which were marketed by what later became /¶2UHDO Ln France. In the 
¶VFRPPHUcial phage products for human use were also produced by Eli 
Lilly Co. in the United States which targeted bacterial pathogens such as 
Staphylococcus, Streptococcus and E. coli. However, with the discovery and 
introduction of antibiotics, commercial production of bacteriophage 
preparations was discontinued in most of the Western world. On the other 
hand, the therapeutic use of bacteriophages still continued in Eastern Europe 
and the Russian Federation, in conjunction with or instead of antibiotics 
(Sulakvelidze et al. 2001). 
 
1.7.3.2 Rediscovery and recent advances 
Phage therapy trials ceased for some time after World War II, but the research 
of Smith and colleagues in the United Kingdom LQ WKH HDUO\ ¶V EHJDQ D 
promising era of rediscovery (Smith & Huggins 1982). Their work focused on 
an E. coli strain which was a known pathogen of calves and they selected 
phages that utilised the K1 capsular antigen as a receptor for surface 
attachment. By doing this, they were able to successfully treat experimental E. 
coli infections in mice and found that a single-dose phage treatment was more 
effective than several doses of antibiotics including tetracycline, ampicillin and 
chloramphenicol (Smith & Huggins 1982). Anti-K1 phages were also used to 
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successfully treat experimentally induced E.coli diarrhoea in calves, lambs and 
piglets (Smith & Huggins 1983; Smith et al. 1987a; Smith et al 1987b). A 
decade later Barrow et al. (1998) extended these results by using anti-K1 
phages for treatment of E. coli septicaemia and meningitis in chickens and 
calves.  
 
Further experimental studies using animal models have been generally 
successful in treating bacterial pathogens including Lactococcus garvieae in 
yellowtail fish (Nakai et al. 1999), Pseudomonas plecoglossicida in Japanese 
sweetfish (Park et al. 2000), Staphylococcus aureus in mice and rabbits 
(Matsuzaki et al. 2003; Wills et al. 2005) and P. aeruginosa in mice (Watanabe 
et al. 2007). A number of studies have also evaluated the potential of using 
virulent phages to reduce bacterial loads on foods including Listeria 
monocytogenes on fresh-cut produce (Leverentz et al. 2003), C. jejuni on 
chicken skin (Atterbury et al. 2003b; Goode et al. 2003) and L. monocytogenes 
on soft cheeses (Carlton et al. 2005). In addition, some trials have used a 
mixture of two or more phages as a cocktail to cover a broader host range and 
reduce the bacterial load of contaminated food products (Pao et al. 2004; 
Abuladze et al. 2008).  In recent times, commercial bacteriophage-derived 
products have become available for use in the food and agricultural industry. 
However, before such products are deemed safe for human consumption they 
have to meet certain safety standards. For instance, ListShield (Intralytix Inc, 
USA) and Listex P-0LFUHRV1HWKHUODQGVhave been granted µJHQHUDOO\
UHJDUGHGDVVDIH¶*5$6VWDWXVby the US Food and Drug Administration and 
are now available in the United States to treat L. monocytogenes 
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contamination. With the continued rise of multi-drug resistant bacterial 
pathogens, there has been re-newed interest in the use of bacteriophage therapy 
as an alternative to target infectious bacteria. 
 
1.7.4 Campylobacter phages 
1.7.4.1 Characteristics 
The majority of Campylobacter bacteriophages are members of the Myoviridae 
family with long contractile tails, double-stranded DNA and icosahedral heads 
(Atterbury et al. 2003a; Loc Carrillo et al. 2005; Timms et al. 2010). Figure 1-
6 shows an electron micrograph of Campylobacter phages. The sixteen 
virulent phages comprising the phage typing scheme of Frost et al. (1999) were 
characterised by  Sails et al. (1998) and these could be subdivided into three 
groups based on their genome size and head diameter. Group I included two 
phages with head diameters of 140.6 and 143.8 nm and large genomes, 320 kb 
in size. Five phages with average head diameters of 99 nm and average 
genome sizes of 184 kb were classified into group II. Group III was comprised 
of nine phages with an average head size of 100 nm and average genome sizes 
of 138 kb. The sixteen phages were later classified into four groups according 
to their pattern of activity against spontaneous, transposon and defined mutants 
of C. jejuni (Coward et al. 2006). In addition, bacteriophage genomic DNA is 
usually resistant to restriction endonuclease digestion, however the DNA of 
group III phages is digestible with HhaI, making this a useful means of 
discriminating these Campylobacter phages (Sails et al. 1998). Several group 
III phages have been isolated from poultry (El-Shibiny et al. 2005; Loc 
Carrillo et al. 2005, 2007). The recent availability of the published genome  
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Figure 1-6. Transmission electron micrograph of Campylobacter phages. 
The phage particles have icosahedral heads and long contractile tails, making 
them members of the Myoviridae family. The phages have been artificially 
coloured. Image was produced courtesy of Dr. Catherine Loc Carrillo.  
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sequences of virulent Campylobacter phages has also made it possible for 
further classification (Javed et al. 2014). Based on whole genome homology 
and protein sequence similarities it was proposed to introduce two new genera, 
WKH ³&SOLNHYLUXV´ DQG ³&SXQDOLNHYLUXV´ ZLWKLQ WKH SURSRVHG VXEIDPLO\
³(XFDPS\YLULQDH´ (Javed et al. 2014). 
 
1.7.4.2 Sources of Campylobacter phages  
Campylobacter bacteriophages have been isolated from multiple sources 
including the faeces of pigs, cattle and sheep (Bryner et al. 1970; Bryner et al. 
1973; Firehammer & Border 1968) as well as abattoir effluent, sewage, manure 
and the faeces of chickens (Grajewski et al. 1985; Salama et al. 1989; Khakhria 
& Lior 1992; Sails et al. 1998; Connerton et al. 2004; Atterbury et al. 2005; El-
Shibiny et al. 2005; Loc Carrillo et al. 2007). Campylobacter-specific phages 
have also been isolated from retail chicken samples (Atterbury et al. 2003a; 
Tsuei et al. 2007), therefore illustrating that these phages can still remain 
viable after processing and survive under commercial storage conditions. 
 
1.7.4.3 Campylobacter prophages 
As genome sequence data became available, the presence of lysogenic 
bacteriophages within C. jejuni was revealed in some strains. Notably, a Mu-
like phage sequence (CJIE1/CLMP1) and other integrated prophages (CJIE2 
and CJIE4) were identified within C. jejuni RM1221 (Fouts et al. 2005). A 
comparative genome analysis using PCR and a multistrain C. jejuni DNA 
microarray later demonstrated that these prophage sequences were also present 
in other Campylobacter strains (Parker et al. 2006). Similarly, a number of 
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studies have also reported the presence of Mu-like prophages integrated within 
the chromosomes of Campylobacter isolates (Barton et al. 2007; Scott et al. 
2007b; Clark & Ng 2008). Furthermore, a C. jejuni strain originally isolated 
from the caecal contents of commercially reared broiler chickens, displayed 
genomic rearrangements that were found to be associated with intra-genomic 
recombination between multiple Mu-like phage sequences (Scott et al. 2007b). 
These variants showed resistance to infection by virulent phages, failed to 
colonise the intestine of broiler chickens and spontaneously produced 
infectious bacteriophage CampMu virions. However, reintroduction of these 
strains into chickens without bacteriophages present resulted in a reversion to a 
bacteriophage sensitive and colonisation proficient phenotype, by further 
recombination between the Mu-like phage sequences. These results illustrate a 
mechanism that enables the host to survive bacteriophage predation while 
influencing the Campylobacter population that colonises broiler chickens. 
 
1.7.4.4 Application of Campylobacter bacteriophages 
A quantitative risk assessment in Europe has predicted that a 3 log10 reduction 
in the number of Campylobacter in the chicken gut at slaughter would result in 
at least a 90% reduction in the risk to public health (EFSA 2011). It has also 
been predicted that a 1 log10 reduction in the number of Campylobacter 
contaminating chicken carcasses would be associated with a 50-90% reduced 
risk to public health, while reductions of more than 2 log10 units would reduce 
the risk to public health by more than 90% (EFSA 2011). To this end, targeting 
such Campylobacter reduction rates with phage therapy would be beneficial to 
the consumer. Initial bacteriophage therapy studies involving live birds used 
  Chapter 1 
58 
 
group III phages only. Wagenaar et al. (2005) were the first to report on the use 
of bacteriophages to reduce C. jejuni colonisation of broiler chickens. They 
compared the effects of phage therapy as either a therapeutic or preventive 
measure of treating broiler chickens by using two of the phages 
(NCTC12669/phage 69 and NCTC 12671/phage 71) used in the phage typing 
scheme of Frost et al. (1999). A 3 log10 CFU/g decline in C. jejuni numbers 
was initially observed in the therapeutic group but after 5 days bacterial counts 
stabilised at a level 1 log10 CFU/g below the non-phage-treated controls. 
Preventative phage treatment resulted in a delay but not prevention of 
colonisation, with results reaching comparable levels to the therapeutic group 
after 1 week. In a similar investigation, Loc Carrillo et al. (2005) used broad 
lytic spectrum bacteriophages (CP8 and CP34) and C. jejuni host strains 
isolated from broiler chickens. This treatment successfully reduced 
Campylobacter levels by between 0.5 and 5 log10 CFU/g of caecal content as 
compared to the untreated chicks. Group II bacteriophages (CP220, 
phiCcolBB35, phiCcolBB37, phiCcolBB12) were also used in phage therapy 
trials and reduction levels of up to 2 log10 CFU/g were achieved (El-Shibiny et 
al. 2009; Carvalho et al. 2010) with these phages exhibiting an ability to infect 
both C. jejuni and C. coli strains.  
 
Bacteriophages have also been used to reduce Campylobacter contamination 
levels on the surface of chicken carcasses artificially contaminated following 
slaughter (Goode et al. 2003; Atterbury et al. 2003b). The group III phages 
NCTC 12673 and NCTC 12674 were used in these studies and reduction levels 
of 1-2 log10 cm-2 were achieved. However, a greater reduction was observed 
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when bacteriophage application was combined with freezing (Atterbury et al. 
2003b). Another study looked at the effects of using a lytic bacteriophage 
isolated from chicken faeces (phage Cj6) as a biocontrol agent against 
Campylobacter on cooked and raw beef (Bigwood et al. 2008). Phages were 
applied to the food at refrigerated and room temperatures (5 and 24°C) at high 
and low MOI (10 to 104) to either low or high host densities (<100 or 104 host 
cells cm-2). The greatest reductions were observed at high host cell density and 
high MOI, with the degree of Campylobacter inactivation increasing with 
incubation time. After 24 hours incubation, reductions in excess of 2 log10 cm-2 
were achieved on the raw and cooked beef at both temperatures.  
 
1.7.4.5 Bacteriophage resistance 
The development of bacteriophage resistant Campylobacter strains following 
phage therapy has always been perceived as a potential problem. However, 
experimentally these resistant types comprised a minor part of the overall 
population in vivo and appeared to be less virulent than the wild-type strains 
(Loc Carrillo et al. 2005; Scott et al. 2007a; Scott et al. 2007b). Loc Carrillo et 
al. (2005) found that the incidence of phage-resistant isolates recovered from 
the intestines of phage-treated bird was <4%. These resistant types were 
compromised in their ability to colonise new chickens and immediately 
reverted to a phage-sensitive phenotype in vivo. The phage-resistant phenotype 
therefore did not become the dominant population in these phage-treated 
chickens despite their continued presence and predation upon the sensitive 
population (Loc Carrillo et al. 2005).  
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Phage-resistance has been found to be overcome by using multiple 
EDFWHULRSKDJHVLQDµFRFNWDLO¶WKDWDUHFDSDEOHRIWDUJHWLQJGLIIHUHQWFHOOVXUIDce 
receptors of the host. However, bacteria are capable of modifying their 
receptors as a means of avoiding bacteriophage infection. Coward et al. (2006) 
reported that resistance to some bacteriophages was associated with motility 
and capsular polysaccharide defects in C. jejuni. Similarly, Sørensen et al. 
(2011) found a novel phage receptor in C. jejuni and determined that a NCTC 
11168-phage F336 resistant mutant, generated in vitro, had lost the phase 
variable O-methyl phosphoramidate (MeOPN) moiety attached to a GalfNAc 
(N-acetylgalactosamine in furanose configuration) residue of the CPS. It was 
later determined that coinfection of chickens with C. jejuni NCTC 11168 and 
phage F336 resulted in the selection of resistant types in vivo as all isolates 
from phage-infected chickens were resistant to subsequent phage F336 
infection  (Sørensen et al. 2012). 
 
1.7.4.6 Genome sequences 
Highly purified, high titre suspensions are required for DNA sequencing of 
bacteriophages. However, due to the refractory nature of many Campylobacter 
bacteriophage genomes to restriction enzyme digestion as well as the 
difficulties associated with amplifying their DNA using Taq polymerase, 
sequencing phage genomes has proven problematic. To date, complete genome 
sequences are available for eight Campylobacter phages and a further 
incomplete sequence composed of 5 contigs has also been published (Table 1-
1). The available genome sequences represent group II and III phages but no  
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Table 1-1. Published sequences of virulent Campylobacter phages to date 
Phage  
Accession 
number Group Length Reference 
CP220 FN667788 II 177,534 Timms et al. 2010 
CPt10 FN667789 II 175,720 Timms et al. 2010 
NCTC12673 GU296433 III 135,041 Kropinski et al. 2011 
vB_CcoM-IBB_35 Contig 1 HM246720 II 53,237 Carvalho et al. 2012 
vB_CcoM-IBB_35 Contig 2 HM246721 II 51,534 Carvalho et al. 2012 
vB_CcoM-IBB_35 Contig 3 HM246722 II 27,985 Carvalho et al. 2012 
vB_CcoM-IBB_35 Contig 4 HM246723 II 14,701 Carvalho et al. 2012 
vB_CcoM-IBB_35 Contig 5 HM246724 II 24,608 Carvalho et al. 2012 
CP81 FR823450 III 132,454 Hammerl et al. 2011 
CP21 HE815464 II 182,833 Hammerl et al. 2012 
CP30A JX569801 III 133,572 - 
CPX JN132397 III 132,662 - 
CP8  KF14816 III 132,667 - 
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group I sequence has yet been deposited. Group II phages CP220 and CPt10 
were isolated at least fourteen years apart but interestingly showed very high 
levels of sequence conservation (Timms et al. 2010). Both genomes contained 
numerous copies of radical S-adenosylmethionine genes, which were 
suggested to be involved in enhancing host metabolism during bacteriophage 
infection. The other group II phages, CP21 and vB_CcoM-IBB_35, showed 
sequence homology with CP220 and CPt10, however the genomic organisation 
of CP21 is divergent (Hammerl et al. 2012). Group III phage CP81 was also 
found to display a relationship with phages CP220 and CPt10 as well as T4-
like phages, with similarities being seen with proteins associated with capsid 
structure, DNA replication and recombination (Hammerl et al. 2011). 
However, some genes encoding membrane proteins, transposases and 
metabolic enzymes in CP220 and CPt10 were not present in CP81. 
Bacteriophage NCTC 12673 (Kropinski et al. 2011) was found to show closest 
homology to T4-related cyanophages, sharing very limited homology to CP220 
and CPt10 at the nucleotide level and only 36.6% and 36.7% at the protein 
level respectively. What all of the phage genomes (groups II and III) appear to 
share in common however, is the presence of homing endonucleases related to 
Hef which are absent in the sequenced Campylobacter genomes. 
 
1.8 OBJECTIVES OF STUDY 
The main objective of this study was to examine phage-host interactions 
between Campylobacter and virulent phages. This was performed by observing 
the transcriptional response of C. jejuni to bacteriophage infection and 
determining the viral mechanisms necessary for redirection of normal host 
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metabolic functions to enable production of new phage progeny. The 
restriction-modification system of a phage-sensitive C jejuni strain and the role 
lack of phase variation plays in its restrictive ability were also examined.  
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2.1 PREPARATION OF GROWTH AND STORAGE MEDIA 
Unless otherwise stated, all growth and storage media were prepared using 
reverse osmosis (RO) water and was sterilised by autoclaving at 121°C and 15 
psi for 15 minutes on a liquid cycle. For agar media, molten agar was firstly 
tempered 45-50°C before adding any supplements or antibiotics. Plates were 
prepared inside a laminar flow cabinet. On setting, the agar plates were stored 
at 4°C for up to four weeks. All other chemicals were stored at room 
temperature after autoclaving and cooling, unless otherwise indicated. 
 
2.1.1 Blood agar (BA)  
Blood agar base No. 2 (Oxoid Ltd., Basingstoke, UK: CM0271; proteose 
peptone 15.0 g/l, liver digest 2.5 g/l, yeast extract 5.0 g/l, sodium chloride 5.0 
g/l, agar 12.0 g/l) was prepared by suspending 40 g into 1 litre of RO water. 
After autoclaving, it was cooled to 45-50°C and defibrinated horse blood (TCS 
Biosciences, Buckingham, UK) was added to a final concentration of 5% (v/v).  
 
2.1.2 Campylobacter blood-free selective agar (modified CCDA-
Preston)  
Campylobacter blood-free selective agar (Oxoid: CM0739; nutrient broth No.2 
25.0 g/l, bacteriological charcoal 4.0 g/l, casein hydrolysate 3.0 g/l, sodium 
desoxycholate 1.0 g/l, ferrous sulphate 0.25 g/l,  sodium pyruvate 0.25 g/l, agar 
12.0 g/l) was prepared by suspending 45.5 g into 1 litre of RO water. However, 
an additional 2% (w/v) of bacteriological agar No. 1 (Oxoid) was occasionally 
added during preparation in order to prevent swarming of Campylobacter. To 
isolate Campylobacter from samples other than pure cultures, 1 vial of CCDA 
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selective supplement (SR 155E; 16 mg of cefoperazone and 5 mg of 
amphotericin B) was reconstituted in sterile RO water and was aseptically 
added to 500 ml of sterilised CCDA after tempering.  
 
2.1.3 New Zealand Casamino Yeast Medium (NZCYM) basal 
agar  
New Zealand Casamino Yeast Medium broth (Difco, Oxford, UK: 240410; 
pancreatic digest of casein 10.0 g/l, casamino acids 1.0 g/l, yeast extract 5.0 
g/l, sodium chloride 5.0 g/l, magnesium sulphate, anhydrous 0.98 g/l) was 
prepared by adding 22 g of NZCYM broth to 1 litre of RO water. NZCYM 
basal agar was then made by adding 15 g of bacteriological agar No. 1 (Oxoid) 
to the broth to a final agar concentration of 1.5% (w/v). 
 
2.1.4. NZCYM overlay agar 
1=&<0 EURWK 'LIFR ZDV SUHSDUHG DFFRUGLQJ WR WKH PDQXIDFWXUHU¶V
instructions. NZCYM overlay agar was then made by adding bacteriological 
agar No. 1 (Oxoid) to the broth to a final agar concentration of 0.6% (w/v). 
Following sterilisation, 5 ml volumes were aseptically aliquoted into sterile 
glass universal bottles and were allowed to temper in a 50-55°C water bath 
until ready for use.  
 
2.1.5 Nutrient broth No.2  
1XWULHQWEURWK1R2[RLG&0µ/DE-/HPFR¶SRZGHUJOSHStone 
10.0 g/l, sodium chloride 5.0 g/l) was prepared by suspending 25 g into 1 litre 
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of RO water. After sterilisation, it was stored at room temperature for up to 
eight weeks. 
 
2.1.6 Mueller-Hinton (MH) broth  
Mueller-Hinton broth (Oxoid: CM0405; dehydrated beef infusion 300 g/l, 
casein hydrolysate 17.5 g/l, starch 1.5 g/l, Ca2+ 3.854 mg/l, Mg2 5.072 mg/l) 
was prepared by suspending 21 g into 1 litre of RO water. After sterilisation, it 
was stored at room temperature for up to eight weeks.  
 
2.1.7 Mueller-Hinton (MH) agar  
Mueller-Hinton agar was prepared by adding bacteriological agar No. 1 
(Oxoid) to MH broth (2.1.6) to a final agar concentration of 1.5% (w/v). 
 
2.1.8 Campylobacter MH motility agar 
MH motility agar was prepared as previously described for MH agar (2.1.7) 
but instead the bacteriological agar was added to a final concentration of 0.4% 
(w/v). 
 
2.1.9 Modified Semi-solid Rappaport Vassiliadis (MSRV) agar 
(ISO)  
Modified Semi-solid Rappaport Vassiliadis agar (Oxoid: CM1112; enzymatic 
digest of animal and plant tissue 4.6 g/l, acid hydrolyate of casein 4.6 g/l, 
sodium chloride 7.3 g/l, potassium dihydrogen phosphate 1.5 g/l, magnesium 
chloride anhydrous 10.9 g/l, malachite green oxalate 0.04 g/l, agar 2.7 g/l) was 
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prepared by suspending 31.6 g of MSRV (ISO) agar base into 1 litre of RO 
water. After boiling and without autoclaving, the medium was cooled to 50°C. 
One vial of novobiocin supplement (SR0181; novobiocin 10 mg) was 
reconstituted in RO water and was then aseptically added. The medium was 
mixed well and poured into sterile petri dishes. Due to the semi-solid nature of 
the medium care was taken after the agar was set and the petri dishes were also 
not inverted. 
 
2.1.10 Xylose Lysine Desoxycholate (XLD) agar 
Xylose Lysine Desoxycholate agar (Oxoid: CM0469; yeast extract 3.0 g/l, L-
Lysine HCl 5.0 g/l, xylose 3.75 g/l, lactose 7.5 g/l, sucrose 7.5 g/l, sodium 
desoxycholate 1.0 g/l, sodium chloride 5.0 g/l, sodium thiosulphate 6.8 g/l, 
ferric ammonium citrate 0.8 g/l, phenol red 0.08 g/l, agar 12.5 g/l) was 
prepared by suspending 53 g into 1 litre of RO water. The medium was boiled 
with frequent agitation but was not autoclaved.  
 
2.1.11 Buffered Peptone Water (BPW)  
Buffered Peptone Water (Oxoid: CM0590; peptone 10 g/l, sodium chloride 5.0 
g/l, disodium phosphate 3.5 g/l, potassium dihydrogen phosphate 1.5 g/l) was 
prepared by suspending 20 g into 1 litre of RO water. It was aliquoted into 10 
ml volumes prior to autoclaving and was stored at room temperature until 
ready for use. 
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2.1.12 Phosphate Buffered Saline (PBS) 
Phosphate buffered saline (Oxoid: BR0014) was prepared according to the 
PDQXIDFWXUHU¶VLQVWUXFWLRQVWRDS+RI±0.2 at 25°C. The final composition 
was 0.8% (w/v) NaCl, 0.02% (w/v) KCl, 0.115% (w/v) Na2HPO4 and 0.02% 
(w/v) KH2PO4. Following sterilisation, the PBS was stored at room 
temperature until ready for use. 
 
2.1.13 Maximum Recovery Diluent (MRD) 
Maximum recovery diluent (Oxoid: CM0733; peptone 1.0 g/l, sodium chloride 
8.5 g/l) was prepared by suspending 9.5 g into 1 litre of RO water. It was 
stored at room temperature following sterilisation until ready for use. 
 
2.1.14 Salt Magnesium (SM) buffer 
Salt Magnesium buffer was prepared by combining NaCl (Fisher Scientific, 
Loughborough, UK) to a final concentration of 0.1 M, MgSO4.7H2O (Fisher 
Scientific) to a final concentration of 10 mM, gelatine (Sigma-Aldrich, Dorset, 
UK) to a final concentration of 0.01% and Tris (Sigma-Aldrich) to a final 
concentration of 50 mM. The solution was adjusted to pH 7.5 with 
concentrated HCl (Acros Organics, Loughborough, UK) and was then made up 
to a final volume of 1 litre with RO water. After sterilising, the buffer was 
stored at room temperature until ready for use. 
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2.1.15 Bacteriological storage medium 
Nutrient broth No.2 (2.1.5) was prepared accoUGLQJ WR WKH PDQXIDFWXUHU¶V
instructions but was supplemented with 20% (v/v) glycerol (Fisher Scientific). 
After sterilisation, it was stored at room temperature until ready for use. 
 
2.1.16 Antibiotics 
Stock solutions were prepared by dissolving the desiccated antibiotic in their 
appropriate solvents and then filter sterilising through a Minisart 0.2 µm filter 
(Sartorius Stedim Biotech, Goettingen, Germany). These were stored at 4°C 
until ready for use. Table 2-1 shows the stock and working concentrations for 
the antibiotics used in this thesis. 
 
Table 2-1. Antibiotics used within this thesis.  
Antibiotic Solvent Stock 
Concentration 
Working 
Concentration 
Kanamycin RO water 50 mg ml-1 50 µg ml-1 
Chloramphenicol Ethanol 50 mg ml-1 30 µg ml-1 
  
2.1.17 Iron chelator 
¶¶-dipyridyl (DIP) (Fisher Scientific), was dissolved in ethanol to give a 10 
mM stock solution. This was then added to the appropriate nutrient media to 
give a final concentration of 20 µM.  
 
2.2 CAMPYLOBACTER 
2.2.1 Strains 
The Campylobacter strains used in this thesis are detailed in Table 2-2.
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Table 2-2.  Campylobacter strains used within this thesis. 
C. jejuni strain or 
genotype 
Description Source Reference 
PT14 Clinical isolate previously used to propagate 
bacteriophages in the UK phage typing scheme. 
Dr. J. Richardson, HPA, 
Colindale, UK 
Brathwaite et al. 
2013 
NCTC 11168 Wild-type human isolate. NCTC, PHLS, Colindale, UK Parkhill et al. 2000 
NCTC 11168H Hypermotile variant of NCTC 11168. Dr. M. Jones, University of 
Nottingham, UK 
 Jones et al. 2004 
HPC5 Isolated from broiler chickens within the UK. C. Loc Carrillo PhD thesis, 
University of Nottingham 
  
PT14CP30ACS Stable carrier strain life cycle (CSLC) isolate obtained 
from phage treatment of biofilms. 
P. Siringan PhD thesis, University 
of Nottingham 
 
PT14CP8CS Stable CSLC isolate obtained from phage treatment of 
biofilms. 
P. Siringan PhD thesis  
1&7&¨NDQ Transformed by electroporation with plasmid DNA 
from pUC-¨FM1::kan. This plasmid contained 
a 700-ESUHJLRQRIWKH¶HQGRIcj0031 (flanked by PstI 
and BamHI sites) which was ligated to a 600-bp region 
of cj0032 (flanked by EcoRI and BamHI sites). A 
kanamycin resistance cassette derived from pJMK30 
was inserted into the BamHI site. 
Dr. C. Bayliss, University of 
Leicester, UK 
  
NCTC 11168ON Variant of NCTC 11168 with cj0031 gene phased on. Dr. C. Bayliss   
CH11168ON Chicken isolate with cj0031 gene phased on. Dr. C. Bayliss   
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Table 2-2 continued 
C. jejuni strain or 
genotype 
Description Source Reference 
&+¨FMNDQ Chicken isolate naturally transformed with 
FKURPRVRPDO'1$IURP1&7&¨FM0031::kan. 
Dr. C. Bayliss,   
37¨NDQ Naturally transformed with chromosomal DNA from 
1&7&¨FMNDQ 
This thesis   
37ǻ::kan, 
00230::00150cam 
The complementation vector PCfdxA:PerR was used to 
replace the ferredoxin promoter and perR gene with the 
cj0031-ON promoter and gene fragment of NCTC 
11168. The vector was then amplified in E. coli and was 
used to transform and complement the 
PT14ǻ00150::kan mutant. 
This thesis  
11168 cgb::Kanr The gene encoding cgb (cj1586) in C. jejuni NCTC 
11168 was disrupted by insertion of a kanamycin 
resistance cassette using the suicide plasmid pKE18. 
Prof. R. Poole, University of 
Sheffield 
 Elvers et al. 2004 
11168 ctb::Kanr The gene encoding ctb (cj0465c) in C. jejuni NCTC 
11168 was disrupted by insertion of a kanamycin 
resistance cassette using the suicide plasmid pKE29. 
Prof. R Poole  Wainwright et al. 
2005 
PT14 cgb::Kanr Naturally transformed with chromosomal DNA 
from11168 cgb::Kanr 
This thesis   
PT14 ctb::Kanr Naturally transformed with chromosomal DNA from 
11168 ctb::Kanr 
This thesis   
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2.2.2 Growth conditions 
Campylobacter strains were subcultured on BA (2.1.1) and incubated in 3.5L 
anerobic gas jars (Oxoid) without catalyst unless otherwise stated. Prior to 
incubation, the internal atmospheric pressure of the jar was reduced to -22 psi 
and was restored using a gas mixture containing 85% (v/v) N2, 10% (v/v) CO2 
and 5% (v/v) H2 (BOC Limited, Surrey, UK). This resulted in microaerobic 
growth conditions of approximately 83% (v/v) N2, 7.3% (v/v) CO2, 3.6% (v/v) 
H2 and 5.6% (v/v) O2. Alternatively, Campylobacter was grown in a Modular 
Atmospheric Controlled System (MACS) cabinet (Don Whitley Scientific, 
Shipley, UK) containing a gas mixture of 88% (v/v) N2, 5% (v/v) CO2, 2% 
(v/v) H2 and 5% (v/v) O2 (BOC Limited). Incubation in either the gas jars or 
MACS cabinet was for 18-24 hours at 42°C unless otherwise specified. 
 
2.2.3 Storage 
2.2.3.1 Long-term storage 
For long-term storage, Campylobacter strains were firstly grown overnight on 
BA (2.1.1). A sterile cotton swab was then used to harvest growth from the 
plates and dispersed into 1 ml aliquots of bacteriological storage medium 
(2.1.15). These were stored at -80°C until ready for use.  
 
2.2.3.2 Short-term storage 
Long-term stocks were revived monthly by quickly thawing an aliquot, 
spreading 40µl onto a BA plate (2.1.1) and incubating at 42°C for 18-24 hours 
under microaerobic conditions (2.2.2). Plates with overnight growth were then 
stored microaerobically (2.2.2) at 4°C for up to one month. This provided an 
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immediate source of cells without having to continuously thaw and re-freeze 
the long-term stocks. The plates were used to sub-culture growth by placing an 
inoculum onto a fresh BA plate (2.1.1) and incubating under microaerobic 
conditions (2.2.2) at 42°C for 18-24 hours. 
 
2.2.4 Enumeration 
Enumeration of Campylobacter was performed using a modification of the 
Miles and Misra (1938) technique. Serial ten-fold dilutions of the cell 
suspension to be enumerated were firstly prepared in PBS (2.1.12).  Five 10 µ l 
aliquots of each dilution were then spotted onto pre-dried modified CCDA-
Preston plates (2.1.2). The spots were allowed to dry with the help of a Bunsen 
flame and the plates were incubated in a MACS cabinet (Don Whitley 
Scientific) at 42°C for 48 hours. Dilutions with counts of 3-30 colonies were 
counted and the average of the five spots was determined. The number of 
colony forming units per ml (CFU ml-1) was then calculated by multiplying the 
average number of colonies by the inverse of the dilution factor and by 100. 
 
2.2.5 Confirmatory tests 
2.2.5.1 Gram stain 
*UDP VWDLQ UHDJHQWV ZHUH ILUVWO\ SUHSDUHG DFFRUGLQJ WR WKH PDQXIDFWXUHU¶V
instructions immediately prior to use. Smears of colonies to be tested were 
then prepared aseptically on a glass microscope slide (BDH Lab Supplies, 
Leicestershire, UK) in PBS (2.1.12) using a sterile 1 µl plastic loop and sterile 
water. The Gram staining procedure was followed after air drying and heat 
fixing of the smears. Slides were placed in crystal violet solution (Pro-lab 
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Diagnostics, Bromborough, Wirral, UK) for 1 minute, with the excess rinsed 
RIIZLWK52ZDWHU1H[WWKHVOLGHVZHUHLPPHUVHGLQ/XJRO¶V LRGLQH3UR-lab 
Diagnostics) for 30 seconds, again rinsing the excess with RO water. The 
stained smears were then decolourised by placing the slides into ethanol 
(Fisher Scientific) for 1 minute, followed by counterstaining with carbol 
fuschin solution (Pro-lab Diagnostics) for 30 seconds followed by rinsing with 
RO water. Slides were air dried and viewed under oil immersion at 100 x 
magnification using a light microscope.  
 
2.2.5.2 Oxidase test 
111¶1¶-tetramethyl-p-phenylenediamine dihydrochloride (Acros Organics) 
was dissolved in RO water to give a final concentration of 0.01 g ml-1 
immediately before use. A sterile swab, moistened with the solution, was then 
used to harvest cells from overnight growth from the surface of BA plate 
(2.1.1). The appearance of a deep blue colour within 10 seconds indicated a 
positive result while a light blue colour or no colour change was considered to 
be negative.  
 
2.2.5.3 Hippurate test 
Sodium hippurate (Sigma-Aldrich) was dissolved in RO water to give a final 
concentration of 5% (w/v). The solution was filter sterilised and dispensed into 
500 µl aliquots. These were stored at -20°C until ready for use. Hippurate 
activity was tested by inoculating overnight growth from a BA plate (2.1.1) 
into the thawed solution. This was then incubated at 37°C for 2 hours under 
aerobic conditions followed by addition of 100 µl of freshly prepared 7% (w/v) 
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1,2,3-triketohydrindene monohydrate (ninhydrin reagent) and a further 
incubation period of 10 minutes. A positive result was seen by a deep violet 
colour while a light purple colour or no colour change was considered a 
negative result. 
 
2.3 MOTILITY ASSAY 
Using a sterile 1 µl loop, an inoculum of overnight Campylobacter growth was 
stabbed into the centre of a MH motility agar plate (2.1.8), avoiding stabbing 
through the agar onto the base of the petri dish. The plates were incubated 
upright at 42°C for 24-48 hours under microaerobic conditions (2.2.2). The 
diameter of the motility zone was subsequently measured. 
 
2.4 NATURAL TRANSFORMATION OF CAMPYLOBACTER 
Cells from an overnight BA plate (2.1.1) were resuspended in 10 ml of MH 
broth (2.1.6.) and the OD600 was adjusted to 0.5. Next, 0.5 ml of the 
Campylobacter suspension was added to a 15 ml Falcon tube (Fisher 
Scientific) containing 1 ml of MH agar (2.1.7). This was incubated for 5 hours 
under microaerobic conditions in the MACS (2.2.2). Five micrograms of DNA 
containing the marker to be transformed was then added to the cells followed 
by a further overnight incubation in the MACS (2.2.2). The culture was 
collected from the Falcon tube and was centrifuged at 13,000 g for 15 minutes 
in order to concentrate the cells. The resulting pellet was resuspended in 100 µ l 
of MH broth (2.1.6) and spread onto the appropriate selective medium and 
incubated for 2-3 days in the MACS. Seven to eight transformed colonies were 
individually collected and spread onto selective agar to produce confluent 
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growth.  The growth was harvested with a sterile cotton swab and was 
dispersed into 1 ml aliquots of bacteriological storage medium (2.1.15) and 
stored at -80°C until ready for use. 
 
2.5 BACTERIOPHAGE 
2.5.1 Strains 
The bacteriophages used within this thesis, along with their propagating strains 
are listed in Table 2-3. Propagation of the phages is described in section 2.5.2. 
 
2.5.2 Propagation, harvesting and storage of bacteriophage 
The propagating strains of Campylobacter were cultured on BA (2.1.1) under 
microaerobic conditions (2.2.2) at 42°C for 18-24 hours. The overnight growth 
was then harvested into 10 ml of 10 mM MgSO4 using a sterile cotton swab to 
give an approximate final cell density of 8 log10 CFU ml-1. One hundred 
microlitres of bacteriophage stock at 8 log10 PFU ml-1 was then added to the 
cell suspension and this was incubated for 20-30 minutes in the MACS cabinet 
(Don Whitley Scientific) at 42°C. During this time, 5 ml aliquots of NZCYM 
overlay agar (2.1.4) were heated in a microwave and were allowed to temper in 
a 55°C water bath. Five hundred microlitres of the Campylobacter-
bacteriophage suspension was then transferred to the cooled overlay agar and 
mixed. This was poured onto pre-dried NZCYM plates (2.1.3) which were 
allowed to set prior to incubation under microaerobic conditions (2.2.2) at 
42°C for 18-24 hours. The bacteriophage was harvested from the plates by 
dispensing 5 ml of SM buffer (2.1.14) onto the surface of the agar followed by  
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Table 2-3. Bacteriophages used within this thesis and their propagating 
strains.  
Bacteriophage Propagating strains Source 
CP8 
  
  
  
C. jejuni PT14 C. Loc Carrillo PhD thesis, 
University of Nottingham 
 
 
 
C. jejuni HPC5 
C. jejuni NCTC 11168 
C. jejuni NCTC 11168H 
CP30 
  
  
  
C. jejuni PT14 Dr. P. Connerton, University of 
Nottingham 
  
  
  
C. jejuni HPC5 
C. jejuni NCTC 11168 
C. jejuni NCTC 11168H 
CP220 
  
C. jejuni PT14 A. Scott PhD thesis, University 
of Nottingham 
  
C. jejuni HPC5 
A14 C. jejuni PT14 Dr. P. Connerton 
A1B C. jejuni PT14 Dr. P. Connerton 
CP20 C. jejuni PT14 C. Loc Carrillo PhD thesis 
CP25 C. jejuni PT14 C. Loc Carrillo PhD thesis 
CP28 C. jejuni PT14 C. Loc Carrillo PhD thesis 
CP32 C. jejuni PT14 C. Loc Carrillo PhD thesis 
CP34 C. jejuni PT14 C. Loc Carrillo PhD thesis 
CP51 C. jejuni PT14 C. Loc Carrillo PhD thesis 
CPX C. jejuni PT14 S. Al-Kandari PhD thesis, 
University of Nottingham 
E5 C. jejuni PT14 Dr. P. Connerton 
G1 C. jejuni PT14 Dr. P. Connerton 
G3 C. jejuni PT14 Dr. P. Connerton 
G4 C. jejuni PT14 Dr. P. Connerton 
G5 C. jejuni PT14 Dr. P. Connerton 
G6 C. jejuni PT14 Dr. P. Connerton 
G7 C. jejuni PT14 Dr. P. Connerton 
G8 C. jejuni PT14 Dr. P. Connerton 
mc1a C. jejuni PT14 Dr. P. Connerton 
X3 C. jejuni PT14 Dr. P. Connerton 
NQ1 C. jejuni PT14 Dr. P. Connerton 
4B C. jejuni PT14 Dr. P. Connerton 
7 C. jejuni PT14 Dr. P. Connerton 
9 C. jejuni PT14 Dr. P. Connerton 
10b C. jejuni PT14 Dr. P. Connerton 
11 C. jejuni PT14 Dr. P. Connerton 
18b C. jejuni PT14 Dr. P. Connerton 
19 C. jejuni PT14 Dr. P. Connerton 
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Table 2-3 continued 
Bacteriophage Propagating strain Source 
19b C. jejuni PT14 Dr. P. Connerton 
NCTC 12669 C. jejuni PT14 NCTC, PHLS, Colindale, UK 
NCTC 12670 C. jejuni PT14 NCTC 
NCTC 12671 C. jejuni PT14 NCTC 
NCTC 12672 C. jejuni PT14 NCTC 
NCTC 12673 C. jejuni PT14 NCTC 
NCTC 12674 C. jejuni PT14 NCTC 
NCTC 12675 C. jejuni PT14 NCTC 
NCTC 12676 C. jejuni PT14 NCTC 
NCTC 12677 C. jejuni PT14 NCTC 
NCTC 12678 C. jejuni PT14 NCTC 
NCTC 12679 C. jejuni PT14 NCTC 
NCTC 12680 C. jejuni PT14 NCTC 
NCTC 12681 C. jejuni PT14 NCTC 
NCTC 12682 C. jejuni PT14 NCTC 
NCTC 12683 C. jejuni PT14 NCTC 
NCTC 12684 C. jejuni PT14 NCTC 
PT14CP30ACS C. jejuni PT14 P. Siringan PhD thesis, 
University of Nottingham 
PT14CP8CS C. jejuni PT14 P. Siringan PhD thesis 
HPC5CP30ACS C. jejuni HPC5 P. Siringan PhD thesis 
HPC5CP8CS C. jejuni HPC5 P. Siringan PhD thesis 
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shaking at 60 rpm aerobically overnight at 4°C. The SM buffer was recovered 
with a syringe and was filtered through a 0.2 µm filter to remove the remaining 
Campylobacter cells and any cell debris present. The recovered phage was 
stored indefinitely at 4°C in glass McCartney bottles. The stocks were 
routinely filter-sterilised if there was any sign of contamination. 
 
2.5.3 Titration of bacteriophage 
Bacteriophage titration was performed using the appropriate propagating host 
strain. Briefly, an overnight culture of the desired host strain was prepared on a 
BA plate (2.1.1) and the cells were harvested into 10 ml of 10 mM MgSO4 
using a sterile cotton swab to give an approximate final cell density of 8 log10 
CFU ml-1. This suspension was incubated in the MACS cabinet (Don Whitley 
Scientific) for 15-20 minutes to allow recovery of the bacterial cells. During 
this time, 5 ml aliquots of NZCYM overlay agar (2.1.4) were heated in a 
microwave and cooled in a 55°C water bath. Five hundred microlitres of the 
Campylobacter suspension was then transferred to the cooled overlay agar, 
mixed and poured onto pre-dried NZCYM basal plates (2.1.3) with gentle 
swirling to form an even lawn. The plates were allowed to dry prior to 
incubation in the MACS cabinet (Don Whitley Scientific) for 10-15 minutes. 
Serial ten-fold dilutions of the bacteriophage to be enumerated were prepared 
in PBS (2.1.7). Five 10 µl aliquots of each dilution were then spotted onto the 
bacterial lawns and the spots allowed to dry. The plates were incubated for 18-
24 hours under microaerobic conditions (2.2.2) at 42°C. Dilutions resulting in 
the appearance of 3-30 plaques were counted and the average of the five spots 
was determined. The number of plaque forming units per ml (PFU ml-1) was 
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then calculated by multiplying the average number of plaques by the inverse of 
the dilution factor and by 100. 
 
2.5.4 Bacteriophage lytic spectra 
Bacterial lawns for each Campylobacter strain were prepared as previously 
described (2.5.3). The bacteriophages of interest were diluted to the routine test 
dilution of approximately 6 log10 PFU ml-1 and 10 µl aliquots were spotted onto 
the surface of the lawns, with a maximum of 16 spots per plate. The spots were 
allowed to dry with the help of a Bunsen flame prior to microaerobic 
incubation (2.2.2) at 42°C for 18-24 hours. The lytic ability of each phage was 
scored according to the nomenclature used by Frost et al. (1999) in the UK 
phage typing scheme.  
 
2.5.5 Efficiency of plating 
In order to determine the susceptibility of various test strains of 
Campylobacter to phage infection, the efficiency of plating (EOP) was 
calculated. This was done by determining plaque formation on one strain and 
comparing it to that on another strain. For instance, in the case of wild-type 
and mutant strains, EOP values were calculated by dividing the PFU ml-1 of 
the phage grown on the mutant by the PFU ml-1 of the phage grown on the 
wild-type. 
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2.6 IN VITRO GROWTH EXPERIMENTS  
2.6.1 Bacteriophage infection of C. jejuni 
Three independent cultures of the appropriate Campylobacter strain were 
grown overnight on BA plates (2.1.1) under microaerobic conditions (2.2.2) at 
42°C. Campylobacter from each plate was suspended into individual 10 ml 
volumes of PBS (2.1.12) using sterile cotton swabs. OD600 readings were taken 
using the Pharmacia Biotech Ultrospec 2000 UV/Visible spectrophotometer 
with PBS used as the control. The estimated bacterial concentration was then 
calculated using an empirical formula based on optical density (eq. 4) which 
was derived from a standard Campylobacter dilution series, previously carried 
out by Dr. A. Scott. 
 
Campylobacter titre (CFU ml-1) = (OD600 x 2 x 109) ± 6 x 106  (eq. 4) 
 
Three biological replicates were prepared by adding the suspensions to 250 ml 
conical flasks containing 150 ml of nutrient broth No. 2 (2.1.5) to give final 
estimated concentrations of 7 log10 CFU ml-1 of culture. Three biological 
replicates were also prepared for non-bacteriophage infected cultures. One 
millilitre aliquots were taken at 0 h for actual enumeration of the initial 
concentration of Campylobacter cells (2.2.4). The flasks were then placed into 
anaerobic gas jars (Oxoid) and were incubated under microaerobic conditions 
at 42°C (2.2.2) with shaking at 100 rpm in an IS-971R Lab Companion 
shaking incubator (Fisher Scientific). After 2 hours, the appropriate 
bacteriophage was added to the broth to generate an effective multiplicity of 
infection (MOI) of >1. Aliquots were again taken for enumeration of 
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Campylobacter (2.2.4) and for the bacteriophages (2.5.3). The latter samples 
were filtered through a Minisart 0.2 µm filter (Sartorius Stedim Biotech) in 
order to remove bacterial cells. Microaerobic incubation at 42°C (2.2.2) with 
shaking was then resumed. Aliquots for enumeration of C. jejuni and to titre 
bacteriophages were taken at hourly intervals.  
 
2.6.2 Bacteriophage infection of C. jejuni for transcriptome 
analysis experiments 
The desired Campylobacter strain was grown and infected with the appropriate 
bacteriophage as previously described (2.6.1) until the phage reached the 
eclipse phase of growth. Cells were harvested from three biological replicates 
at the time point confirmed by enumerations to have occurred directly before 
cell lysis (population crash) in order to capture Campylobacter cells that were 
under phage infection. 
 
2.6.3 Determination of bacteriophage resistance 
A 50 µl aliquot of the bacteriophage of interest at a concentration of 7 log10 
PFU ml-1 was pipetted evenly down the centre of a MH agar plate (2.1.7) in a 
single line and allowed to dry. Twenty individual Campylobacter colonies 
from the in vitro growth experiment (2.6.1) were chosen at random to represent 
the time points of interest. Each of these colonies was streaked perpendicularly 
across the phage line using a single streak. Phage resistance was determined by 
the presence of growth across the phage line.  
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2.7 IRON-DEPLETION GROWTH EXPERIMENT 
Independent cultures of C. jejuni PT14 were grown overnight on MH agar 
(2.1.7) under microaerobic conditions (2.2.2) at 42°C. Cells were harvested 
and cultures were grown and infected with bacteriophages as previously 
described (2.6.1), however MH broth (2.1.6) was used instead of NB No. 2 
(2.1.5). All glassware was previously treated with 8 M HCl and then rinsed 
three times with RO water to remove residual iron from their surfaces. In order 
to induce iron-limited conditions, ¶¶-dipyridyl (DIP) (2.1.17) was added to 
the broths at a final concentration of 20 µM prior to their inoculation. 
 
2.8 ISOLATION OF GENOMIC DNA 
Campylobacter genomic DNA was isolated using the GenElute Bacterial 
Genomic DNA Kit (Sigma-$OGULFKIROORZLQJWKHPDQXIDFWXUHU¶VLQVWUXFWLRQV
Cells were harvested from a quarter of an overnight BA plate (2.1.1) into 1.5 
ml of PBS (2.1.9). The suspension was then centrifuged at 12,000 x g for 2 
minutes at room temperature using a Heraeus Pico 17 bench-top centrifuge. 
The pellet was then resuspended in 180 µl of Lysis Solution T (BB6678: 
composition confidential) and 20 µl of RNase A solution (R6148: composition 
confidential) was added followed by incubation at room temperature for 2 
minutes. 20 µl of 20 mg ml-1 Proteinase K (Sigma-Aldrich) was then added 
and the mixture was incubated for 30 minutes at 55°C. Afterwards, 200 µl of 
Lysis Solution C (B8803: composition confidential) was added and the mixture 
was thoroughly vortexed for 15 seconds to achieve a homogenised mixture 
followed by a further incubation at 55°C for 10 minutes. During this time, a 
column was prepared by adding 500 µl of Column Preparation Solution 
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(C2112: composition confidential) and centrifuging at 12,000 x g for 1 minute 
using a Heraeus Pico 17 bench-top centrifuge. The eluate was then discarded. 
After incubation, 200 µl of absolute ethanol (Fisher Scientific) was added to 
the lysate and this was homogenised thoroughly by vortexing for 5-10 seconds.  
This mixture was then loaded onto the prepared column and was centrifuged at 
6,500 x g for 1 minute using a Heraeus Pico 17 bench-top centrifuge. The 
eluate and collection tube were both discarded and the column was placed into 
a new 2 ml collection tube. 500 µl of Wash Solution 1 (W0263: composition 
confidential ) was added to the column and this was again centrifuged for 1 
minute at 6,500 g using a Heraeus Pico 17 bench-top centrifuge. Next the 
collection tube was discarded and replaced and 500 µl of Wash Solution 1 
Concentrate (B6553: composition confidential) was added to the column for a 
second wash. The column was centrifuged in a Heraeus Pico 17 bench-top 
centrifuge at maximum speed for 3 minutes to dry the column. The collection 
tube was discarded and replaced. 200 µl of Elution Solution (B6803: 10 mM 
Tris-HCl, 0.5 mM EDTA, pH 9.0) was added directly to the centre of the 
column. The tube was then centrifuged at 6,500 g for 1 minute in a Heraeus 
Pico 17 bench-top centrifuge in order for the DNA to elute. The genomic DNA 
was stored at 4°C for short-term storage and more immediate use and at -20°C 
for long-term storage. 
 
2.9 POLYMERASE CHAIN REACTION (PCR) 
2.9.1 Primer design 
The primers used within this thesis are listed in Table 2-4. The Cgb and Ctb 
forward and reverse primers were designed based on the gene homologues in  
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Table 2-4. Primers used within this thesis.  
 
Note: 3ULPHUVHTXHQFHVDUHJLYHQLQWKH¶WR¶GLUHFWLRQ 
Tm - melting temperature  
F and R represent the forward and reverse gene directions respectively. 
 
  
  
Primer 
name 
3ULPHUVHTXHQFH¶ĺ¶ Tm
/°C 
Source Amplicon 
size (bp) 
Cgb-F GGAGAGGATTTAACCAATGAG 60 This 
thesis 
1711 
Cgb-R CCATAAGCAACTTCCCAAGC 60 This 
thesis 
Ctb-F ACAATTAATCAAGAAAGCATAGC 60 This 
thesis 
1797 
Ctb-R GCTATCATTTGTGCACGCTG 60 This 
thesis 
PT14-
00150F 
GTTTAACCCCAACGATGC 54 This 
thesis 
2856 
PT14-
00150R 
GCTTTTAAAATTTCATCGAC 52 This 
thesis 
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C. jejuni PT14 to cj1586 (cgb) and cj0465c (ctb) in NCTC11168. The PT14-
00150 primers were designed to amplify a fragment of the A911_00150 gene 
in PT14.  This was done with the help of the RNA-seq mapping data for the 
PT14ǻ00150::kan mutant using PT14 as the reference genome. Sequence 
reads for C. jejuni NCTC11168 and PT14 were both available, which made it 
possible to design primers that could amplify DNA from either source. 
 
Primers were designed in such a way that the difference in melting temperature 
between the two primers did not exceed 5°C. An optimal GC content of 40-
60% was strived for and where possible, the primer was terminated with a  
guaninHRUF\WRVLQHUHVLGXHDWWKH¶-end. Primers were designed so that they 
were shorter than 25 nucleotides and their melting temperatures were estimated 
using the equation below (eq. 5): 
 
Tm = 4 (G+C) + 2 (A+T)   (eq. 5) 
 
All primers were synthesised by Eurofins MWG Operon (Ebersberg, 
Germany). 
 
2.9.2 PCR conditions 
PCR was carried out using Fermentas DreamTaq Green PCR Master Mix (2x) 
(Fisher Scientific) containing 2 U DreamTaq DNA polymerase, 2x DreamTaq 
Green buffer, 0.4mM of each dNTP and 4mM of MgCl2, along with two dyes 
(blue/yellow) to monitor electrophoresis progress. Reactions (1x) were carried 
out in 0.5 ml thin-walled PCR tubes (Fisher Scientific) in 50 µl volumes with 
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100 ng of template DNA. Amplification of PCR products was conducted using 
the BIOER XP thermal cycler (Alpha Laboratories, Hampshire, UK). Initial 
denaturation of the template DNA and enzyme activation was done at 95°C for 
3 minutes. This was followed by 35 cycles each of denaturation at 95°C for 30 
seconds, annealing of the primers at 45-55°C for 30 seconds and extension at 
72°C for 1-3 minutes.  The length of the extension step was based on the size 
of the expected PCR product, with 1 minute extension per kb for products up 
to 2 kb being deemed sufficient. A final extension step was also done at 72°C 
for 5-15 minutes.  
 
2.10 AGAROSE GEL ELECTROPHORESIS 
Routine analysis of DNA was performed using agarose gel electrophoresis. 
Molecular Biology grade agarose (Melford Laboratories, Suffolk, UK) was 
melted in a microwave in 1x TAE buffer (40 mM tris-acetate adjusted with 
glacial acetic acid to pH 8.3, 1 mM disodium ethylenediaminetetraacetic acid) 
to give a 1% (w/v) solution. After cooling, ethidium bromide was added to the 
solution to a final concentration of 0.4 µg ml-1 prior to pouring into a gel 
casting tray with an appropriately sized comb. The gel was allowed to set at 
room temperature followed by removal of the comb. DNA markers used were 
100-bp DNA ladders (New England Biolabs, Ipswich,UK) and 1 kb ladders 
(Promega).  Samples were run for 1-2 hours at 5-7 V/cm in 1 x TAE buffer. 
Gels were subsequently visualised under UV using the Gel Doc XR system 
(BIO-RAD) with the Quantity One basic software, version 4.6.5 (BIO-RAD). 
 
  Chapter 2 
89 
 
2.11 GENOME ANALYSIS AND SEQUENCING 
2.11.1 Genome sequencing of C. jejuni PT14 and phages CP30 
and CPX 
Genomic DNAs from C. jejuni PT14 and bacteriophage CP30 were previously 
isolated by Dr. P. Siringan and genomic DNA from bacteriophage CPX was 
isolated by Dr. S. Alkandari. Sequencing was performed by Deep Seq 
(University of Nottingham) using the 454 GS FLX platform (Roche 
Diagnostics, Indiana, USA). Raw data consisting of a total of 257,645, 26,922 
and 37,429 reads for C. jejuni PT14, CP30 and CPX respectively was 
generated, with an average read length of 352, 324 and 321 bases respectively. 
Initial processing of the raw data was done by Deep Seq using Newbler 
Assembly software (454 Life Science, Connecticut, USA) and a single contig 
was produced for CPX. This was however not the case for the other genomes. 
 
2.11.2 Phage sequence accession numbers 
No further processing needed to be done for CPX, therefore the complete 
genome was annotated and deposited into GenBank by Dr. A. Timms under 
the accession number JN132397. The CP30 genome was de novo assembled by 
Prof. I. Connerton using CLC Genomics Workbench software (CLC Bio, 
Swansea, UK). The genome was found to have multiple sequence 
configurations, which were separated and annotated. One of the configurations, 
designated CP30A, was annotated in Artemis and was deposited in GenBank 
under accession number JX569801. CP30A is the only configuration that will 
be referred to in this thesis. 
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2.11.3 Genome assembly of C. jejuni PT14 
The C. jejuni PT14 454 reads (2.11.1) were de novo assembled using CLC 
Genomics Workbench v6.0 software. The sequence was subsequently 
compared and confirmed with 5 million 50-bp reads generated using MiSeq 
technology operating in paired-end mode (Illumina). 
 
2.11.4 Annotation of C. jejuni PT14 
The complete genome of C. jejuni PT14 was sent to NCBI for annotation using 
their Prokaryotic Genomes Automatic Annotation Pipeline (PGAAP) 
(Angiuoli et al. 2008). Frameshifts or any errors in the sequence assembly 
were confirmed using a combination of translated Basic Local Alignment 
Search Tool (BLAST) (Camacho et al. 2009), to observe protein translations 
for each nucleotide sequence and Artemis (Rutherford et al. 2000), to examine 
the six reading frames and determine which bases were responsible for the 
frameshifts. Once all potential frameshifts were confirmed the complete 
genome of C. jejuni PT14 was deposited in GenBank under the accession 
number CP003871.  
 
2.11.5 Genome analysis  
The complete annotated genome of C. jejuni PT14 was analysed using CLC 
Genomics Workbench software to identify the major genetic features. Genome 
comparisons were also made between C. jejuni PT14 and other Campylobacter 
strains using the genome database Biocyc (Caspi et al. 2014) as well as the 
online version of Artemis Comparison Tool (WebACT) (Abbott et al. 2005). 
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2.12 TRANSCRIPTOME ANALYSIS 
2.12.1 RNA isolation and purification 
C. jejuni PT14 cultures were grown and infected with phage as previously 
described (2.6.2). Cells were harvested by centrifuging the samples for 15 
minutes at 10,000 x g with a J2-21 centrifuge (Beckman Coulter, High 
Wycombe, UK) using a JA14 rotor. Cell pellets were transferred to 1.5 ml 
microcentrifuge tubes and were washed three times in 1 ml of PBS (2.1.12) to 
get rid of the growth medium. This was done in an Eppendorf 5415R benchtop 
centrifuge (Fisher Scientific) at 10,000 x g for 15 minutes each at 4°C. Total 
RNA was then extracted from the cell pellets using the Trizol Max Bacterial 
Isolation kit with Max Bacterial Enhancement Reagent (Invitrogen, Paisley, 
UK). The RNA was ethanol-precipitated and an on-column DNase treatment 
was performed using an RNase-free DNase set (Qiagen). The RNA was 
subsequently purified using an RNeasy Mini kit (Qiagen, Crawley, UK). 
Briefly, the sample volume was adjusted to 200 µl with RNase-free water and 
700 µl of Buffer RLT (cat. no. 79216: composition confidential but contains 
high concentration of guanidine isothiocycanate) was added. Five hundred 
microlitres of absolute ethanol was added to the diluted sample and this was 
mixed well by pipetting action. The sample was transferred to an RNeasy Mini 
spin column placed in a collection tube and was centrifuged for 15 seconds at 
8,000 x g in a Heraeus Pico 17 bench-top centrifuge. The flow-through was 
discarded and 500 µl of Buffer RPE (cat. no. 101813: ethanol added but 
composition confidential) was added and the sample centrifuged for 15 
seconds at 8,000 x g in a Heraeus Pico 17 bench-top centrifuge  to wash the 
spin column. A second wash was carried out using Buffer RPE but with a spin 
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of 2 minutes at 8,000 x g. The column was then placed into a new collection 
tube and was centrifuged at full speed for 1 minute. The spin column was 
transferred to a new 1.5 ml collection tube and 30-50 µl of RNase-free water 
was added directly to the column membrane. The RNA was then eluted by 
centrifuging the column for 1 minute at 8,000 x g. The total RNA was 
quantified using a NanoDrop ND-1000 spectrophotometer (NanoDrop 
Technologies) and the integrity was assessed with a bioanalyzer 2100 (Agilent 
Technologies Inc., South Queensferry, UK) using the Prokaryote Total RNA 
Nano assay. Total RNA samples with RIN values of at least 7.0 were selected 
for cDNA library preparation.  
 
2.12.2 Depletion of rRNA and library construction  
Depletion of 23S, 16S and 5S rRNA from samples was achieved using the 
Ribo-Zero rRNA removal kit for Gram-negative bacteria (Epicentre 
Biotechnologies, Madison, :LVFRQVLQ DFFRUGLQJ WR WKH PDQXIDFWXUHU¶V
instructions. Depletion of the rRNA was confirmed using a bioanalyzer 2100 
(Agilent). Library preparation and sequencing were carried out at either Source 
BioScience (Nottingham, UK) or Ark Genomics (University of Edinburgh, 
Scotland, UK). To prepare the cDNA libraries, the ScriptSeq mRNA-Seq 
library preparation kit (Epicentre Biotechnologies) and the ScriptSeq v2 RNA-
Seq library preparation kit (Epicentre Biotechnologies) were used respectively 
according to the mDQXIDFWXUHU¶V LQVWUXFWLRQV%ULHIO\JRI U51$-depleted 
RNA was chemically fragmented by using the RNA fragmentation component 
of each kit (composition confidential) and incubating for 5 minutes at either 85 
or 94°C. The fragmentation reaction was stopped by placing the mixture on 
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ice. Fragments of approximately 300-350 bp were reverse transcribed to cDNA 
using random-sequence primers containing DWDJJLQJVHTXHQFHDWWKHLU¶HQGV. 
The RNA was then digested and the ¶ HQGV RI WKH F'1$ ZHUH UDQGRPO\
tagged XVLQJ WKH 7HUPLQDO 7DJJLQJ 2OLJR 772 ZKLFK FRQWDLQHG D ¶-
EORFNLQJJURXSRQWKH¶-terminal nucleotide to prevent extension of the TTO. 
The TTO was hydrolysed and the cDNA produced was tagged at both ends. 
The libraries were then individually indexed with a unique identification 
adapter sequence (TruSeq adapter index sequences) and the second strand of 
the cDNA was generated during a PCR amplification step of at least 15 cycles. 
At Source BioScience, the libraries were validated using the Shimadzu 
MultiNA and were normalised to approximately 10 nM while Ark Genomics 
used qPCR to quantify the libraries prior to sequencing and checked their 
quality using a bioanalyser 2100 (Agilent). 
 
2.12.3 RNA-seq analysis 
Paired-end, directional sequencing was carried out using the Illumina HiSeq 
2000 sequencer. The indexed libraries were pooled and loaded onto a single 
lane of a HiSeq 2000 flowcell at a concentration of 8 pM. Cluster formation, 
primer hybridisation as well as 50-bp, 36 cycle sequencing at Source 
BioScience and 100-bp, 36 cycle sequencing at Ark Genomics were performed 
according to the Illumina standard protocol. On completion of the run, the raw 
sequence data were extracted, sorted according to index and converted to the 
FASTQ format using the sequencing analysis software Real Time Analysis 
(RTA) v1.10 and CASAVA v1.8. 
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2.12.4 Processing of the RNA-seq data 
All processing of the RNA-seq data was carried out on a 64 bit desktop 
computer with 24 GB RAM and an Intel core i7 3.20 GHz processor. Three 
main steps were involved in the processing. The first was a quality control step 
where filtering of the raw reads was done, this was followed by mapping all 
reads against a reference genome and finally analysis of differential gene 
expression was carried out.  
 
2.12.4.1 Filtering of the raw reads 
The raw sequence reads were imported into the CLC Genomics Workbench 
v6.0 package and were filtered to remove low quality reads and the TruSeq 
adapter indexes. A duplicate read removal tool was also downloaded into the 
Workbench in order to filter any duplicated reads generated during PCR 
amplification. 
 
2.12.4.2 Mapping filtered reads to reference genomes  
The filtered reads were analysed using the RNA-Seq feature of CLC Genomics 
Workbench. Ignoring non-specific matches, reads were mapped to the C. jejuni 
PT14 genome sequence (GenBank accession number CP003871), and 
bacteriophages CP30A (GenBank accession number JX569801) and CPX 
(GenBank accession number JN132397).  
 
2.12.4.3 Analysis of differential gene expression 
The filtered reads were analysed using the RNA-seq Analysis tool of the CLC 
Genomics Workbench v6.0 package in order to identify differential gene 
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expression. This was achieved using the prokaryote setting under the exon 
identification and discovery section. Expression values were determined using 
reads per kilobase of transcript per million mapped reads (RPKM) (Mortazavi 
et al. 2008). Significant differential gene expression was assessed using the 
%DJJHUO\¶V VWDWLVWLFDO WHVW RQ H[SUHVVLRQ SURSRUWLRQV ZKLFK DVVXPHV D %HWD-
Binomial distribution and tests for RPKM differences between replicate 
samples (Baggerly et al. 2003). To correct for multiple hypothesis testing, p-
values were calculated from the original p-values for the test statistic with a 
confidence rate of 0.05 by applying the false discovery rate controlling method 
of Benjamini and Hochberg (1995). 
 
2.13 CAMPYLOBACTER COLONISATION OF BROILER 
CHICKENS 
2.13.1 Pre-trial rearing of Campylobacter-free broilers 
Commercial male Ross 308 broiler chickens were obtained from PD Hook 
(Oxfordshire, UK) as hatchlings. The Campylobacter-free day old chicks were 
group housed in a Home Office designated chicken house at Sutton Bonington 
Campus (Loughborough, UK) in accordance with the UK Home Office 
Regulations: Animal (Scientific Procedures) Act, 1986.  The initial 
temperature of the house was 35°C but this was reduced on a daily basis by 
1°C until it reached 21°C. All broilers were kept in full sight of other cohort 
members and in keeping with normal commercial rearing practices, they were 
provided with 23 hours of daylight and 1 hour of darkness every day. They 
were given food and water ad libitum DQGZHUHIHGDµFKLFNHQVWDUWHU¶PL[WXUH
containing 18% protein and supplemented with 105 mg/kg lasalocid sodium to 
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prevent coccidiosis. The birds were also checked twice a day for any changes 
in their appearance or behaviour. On reaching 16 days of age, they were 
weighed and randomly assigned to 12 caged groups of 7 birds. To ensure that 
they were still free of naturally occurring infection, the chicks were tested for 
the presence of Campylobacter by direct plating of cloacal swabs onto CCDA 
agar (2.1.2); and for Salmonella by pre-enrichment in BPW (2.1.11), selective 
isolation on MSRV agar (2.1.9) and confirmation of presence on XLD agar 
(2.1.10). 
 
2.13.2 Preparation of bacterial suspensions 
Two of the strains that were administered during the trials were C. jejuni PT14 
and PT14¨00150::kan mutant. The strains were grown on blood agar (2.1.1) 
incubated at 42°C for 24 hours under microaerobic conditions (2.2.2) and was 
supplemented with kanamycin (2.1.16) for the mutant strains. Three 
suspensions of each strain were prepared from the overnight growth to give 
approximate concentrations of 7 log10 CFU ml-1, 5 log10 CFU ml-1 and 3 log10 
CFU ml-1. These concentrations were determined by OD600 measurements but 
the actual dose administered was confirmed by enumeration on CCDA (2.1.2).  
 
2.13.3 Administration of C. jejuni strains 
On day 22, three groups of 7 birds were dosed with 1 ml of C. jejuni PT14 and 
another three groups were dosed with PT1¨00150::kan. For both strains, each 
individual group of 7 birds was dosed with either 7 log10 CFU ml-1, 5 log10 
CFU ml-1 or 3 log10 CFU ml-1 of Campylobacter (Table 2-5), which was 
administered by oral gavage. 
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Table 2-5. Dosing schedule for chicken colonisation trial 
Bird 
ID 
Strain Dose  
(CFU 
ml-1) 
Bird 
ID 
Strain Dose 
(CFU 
ml-1) 
10-1 C. jejuni PT14 WT 10-3 7-1 37ǻNDQ 10-3 
10-2 C. jejuni PT14 WT 10-3 7-2 37ǻNDQ 10-3 
10-3 C. jejuni PT14 WT 10-3 7-3 37ǻNDQ 10-3 
10-4 C. jejuni PT14 WT 10-3 7-4 37ǻNDQ 10-3 
10-5 C. jejuni PT14 WT 10-3 7-5 37ǻNDQ 10-3 
10-6 C. jejuni PT14 WT 10-3 7-6 37ǻNDQ 10-3 
10-7 C. jejuni PT14 WT 10-3 7-7 37ǻNDQ 10-3 
11-1 C. jejuni PT14 WT 10-5 8-1 37ǻNDQ 10-5 
11-2 C. jejuni PT14 WT 10-5 8-2 37ǻNDQ 10-5 
11-3 C. jejuni PT14 WT 10-5 8-3 37ǻNDQ 10-5 
11-4 C. jejuni PT14 WT 10-5 8-4 37ǻNDQ 10-5 
11-5 C. jejuni PT14 WT 10-5 8-5 37ǻNDQ 10-5 
11-6 C. jejuni PT14 WT 10-5 8-6 37ǻNDQ 10-5 
11-7 C. jejuni PT14 WT 10-5 8-7 37ǻNDQ 10-5 
12-1 C. jejuni PT14 WT 10-7 9-1 37ǻkan 10-7 
12-2 C. jejuni PT14 WT 10-7 9-2 37ǻNDQ 10-7 
12-3 C. jejuni PT14 WT 10-7 9-3 37ǻNDQ 10-7 
12-4 C. jejuni PT14 WT 10-7 9-4 37ǻNDQ 10-7 
12-5 C. jejuni PT14 WT 10-7 9-5 37ǻNDQ 10-7 
12-6 C. jejuni PT14 WT 10-7 9-6 37ǻNDQ 10-7 
12-7 C. jejuni PT14 WT 10-7 9-7 37ǻNDQ 10-7 
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2.13.4 Enumeration of caecal contents 
The broiler chickens were sacrificed on day 23 according to the Home Office 
Humane Killing of Animals Schedule 1 code of practice. The birds were 
rendered unconscious via CO2 asphyxiation and their necks were dislocated to 
confirm death. The birds were dissected using aseptic technique. With the 
breast facing upward, an incision was carefully made with a sterilised scalpel 
from the middle of the bird towards the vent. The breast muscle was then 
exposed by pulling the skin back, followed by carefully exposing the intestines 
by cutting and removing all surrounding tissue. The intestines were pulled 
away to expose the two caeca, which were cut using scissors and their contents 
squeezed into a pre-weighed Falcon tube. The weight of the caecal contents 
was then determined and a 1 in 10 (w/v) dilution was prepared using sterile 
MRD (2.1.13). This was vortexed vigorously to mix the sample as thoroughly 
as possible and further ten-fold dilutions were performed. Campylobacter 
enumerations were carried out on CCDA (2.1.2). 
 
2.14 CONSTRUCTION OF CJ0031 COMPLEMENTATION 
CONSTRUCT  
2.14.1 Complementation vector 
The PCfdxA:PerR complementation shuttle vector was kindly provided by 
Bruce Pearson (Institute of Food Research, Norwich, UK). It contains the 
ferredoxin promoter fdxA (van Vliet et al. 2001), a perR (van Vliet et al. 1999) 
gene fragment, a chloramphenicol resistance cassette and two fragments of the 
cj0046 pseudogene, which allow recombination into this gene locus in the 
NCTC 11168 genome following transformation. 
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2.14.2 Amplification of target gene 
Primers were designed that could amplify the cj0031 gene in NCTC 11168 and 
the upstream promoter region. (Primers-: Cj0031-IZ¶-
ATCGTCTCCAGGAAGCATATATAAAGGTATT-¶ &M-UY¶-
TATCGGCCGTTTCCCTTCAATGATTTTTATTTC-¶ The forward primer 
contained a BsmBI (Esp3I) restriction site while the reverse primer contained 
BsiEI, EaeI and Eco52I restriction sites. The desired fragment (3700-bp) was 
amplified using Q5 polymerase (New England Biolabs) and the PCR product 
was cleaned up with the Qiaquick PCR purification kit (Qiagen). The fragment 
was then subcloned into a pCR2.1 TOPO vector (Invitrogen). 
 
2.14.3 Ligation of vector and amplified cj0031 fragment 
The amplified cj0031 product was digested with BsmBI and Eco52I and the 
PCfdxA:PerR complementation vector was linearised by digesting it with 
BsmBI. The fragment was then ligated into the vector, where the fdxA 
promoter and perR gene were replaced by the cj0031 promoter and gene 
fragment. 
 
2.14.4 Recombination of the complementation construct into 
the C. jejuni PT14 genome 
The vector was amplified in E. coli. Genomic DNA was then used to naturally 
WUDQVIRUPDQGFRPSOHPHQWWKH37ǻNDQGHOHWLRQPXWDQW 
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2.15 C. JEJUNI INFECTION OF CULTURED HUMAN 
EPITHELIAL CELL LINES 
2.15.1 Maintenance of cell cultures 
Human colonic epithelial HCA-7 cells (Kirkland 1985) were grown as 
monolayer cultures in 24-well SODWHVLQ'XOEHFFR¶V0RGLILHG(DJOH¶V0HGLXP
(D-MEM) supplemented with foetal calf serum (FCS) at a final concentration 
of 10% (v/v) (Invitrogen) at 37°C in 5% (v/v) CO2. Cells were stained with 
0.4% (v/v) Trypan Blue (Invitrogen) and their viability was monitored by 
microscopic examination. 
 
2.15.2 Adhesion and invasion assay 
Adhesion and invasion assays were performed as previously described by Al-
Sayeqh et al. (2010). Duplicate cell monolayers at 70% confluence were 
covered with cells of the Campylobacter strain of interest. This was done at an 
approximate multiplicity of infection of 100 in D-MEM supplemented with 
10% FCS and incubated at 37°C for 3 h in 5% CO2. Both monolayer plates 
were washed three times with PBS (2.1.12) but one was also treated with 1 ml 
of fresh D-0(0VXSSOHPHQWHGZLWKȝJJHQWDPLFLQPOí1 and incubated for 
a further 2 hours in order to kill extracellular bacteria. The cell monolayers 
were lysed by adding 0.1% (vol/vol) Triton X-100 in PBS to release 
internalized bacteria and cells were enumerated on CCDA plates (2.1.2). The 
number of adherent bacteria was calculated by subtracting the number of 
internalized bacteria from the total number of adherent and invaded cells and 
then expressing this value as a percentage of the inoculum. The invasion 
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efficiency was expressed as the percentage of the inoculum that survived 
gentamicin treatment.  
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3.1 INTRODUCTION 
Campylobacter jejuni strain PT14 is a clinical isolate which was previously 
used to propagate bacteriophages in the United Kingdom phage typing scheme 
(Frost et al. 1999). It has proven useful in the isolation of Campylobacter 
bacteriophages from several sources and has successfully colonised chickens 
during experimental infection trials (Atterbury et al. 2003a; Atterbury et al. 
2003b; Atterbury et al. 2005; Connerton et al. 2004; El-Shibiny et al. 2005; 
Loc Carrillo et al. 2005). The strain is available from the Public Health 
England Board as NCTC 12662 (www.phe-culturecollections.org.uk).  
 
Over the last decade, a large number of Campylobacter genomes have either 
been partially or completely sequenced. Publication of the first complete 
Campylobacter genome sequence, that of C. jejuni NCTC 11168 (Parkhill et 
al. 2000; Gundogdu et al. 2007), provided an ideal reference genome for a 
number of comparative genome studies which examined genetic variability 
within the genus (Pearson et al. 2003; Taboada et al. 2004; Parker et al. 2006). 
Prophage-related DNA sequences were notably absent from the genome of C. 
jejuni NCTC 11168. In constrast, the chicken isolates C. jejuni RM1221 (Fouts 
et al. 2005) and C. jejuni S3 (Cooper et al. 2011) were found to possess 
Campylobacter jejuni integrated elements (CJIEs), one of which was identified 
as a Mu-like prophage. It has been reported that the Mu-like prophage 
sequences are substrates for recombination adding to the diversity of 
Campylobacter. Genomic rearrangements observed in C. jejuni HPC5 occurred 
as a result of intra-genomic inversions between Mu-like prophage DNA 
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sequences provoked by exposure to virulent bacteriophages, which resulted in 
the activation of dormant Mu-like prophages (Scott et al. 2007a).  
 
Bacteria have evolved a number of defence mechanisms to help protect them 
from invading foreign nucleic acids, such as those of bacteriophages and 
plasmids. One such system in many bacterial species, including C. jejuni, is the 
presence of the clustered regularly interspaced short palindromic repeats 
(CRISPR) and associated (cas) genes. CRISPR-cas loci are comprised of an 
array of multiple DNA repeats that generally vary between 21 and 48 bp in 
length, separated by non-repetitive sequences called spacers that are 
approximately 26-72 bp in length (Grissa et al. 2007). Cas proteins, ranging 
from 4 to 20 in number (Haft et al. 2005), are usually present in the vicinity of 
the CRISPR array and an AT-rich sequence known as the leader is also located 
directly upstream of this locus. 
 
The CRISPR-cas system was firstly identified in 1987 in E. coli K12 (Ishino et 
al. 1987), followed by identification of CRIPSR arrays in a number of other 
bacterial and archeal species in the early 2000s, including Streptococcus 
pyogenes (Hoe et al. 1999), Haloferax mediterranei (Mojica et al. 1995), 
Anabaena sp. PCC 7120 (Masepohl et al. 1996) and Mycobacterium 
tuberculosis (Groenen et al. 1993). It was later determined that the spacer 
sequences of the CRISPR-cas system were actually capable of providing 
resistance against bacteriophages and plasmids (Barrangou et al. 2007; 
Marraffini & Sontheimer 2008; Horvath & Barrangou 2010).  Barrangou and 
colleagues (2007) looked at the CRISPR sequences of numerous 
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bacteriophage-sensitive Streptococcus thermophilus strains and found that 
after a viral challenge, the bacteria had integrated new spacers derived from the 
DNA of the infecting phage (protospacer). Acquisition of this new protospacer 
resulted in resistance to subsequent infection by phages carrying the same 
sequence in their genome. The protospacer sequence was found to be 
integrated adjacent to the leader sequence of the CRISPR array.  
 
The CRISPR locus is generally transcribed as a large single RNA transcript 
(precursor CRISPR RNA or pre-crRNA), which is processed by Cas proteins 
to generate small antisense RNA molecules (CRISPR RNA or crRNA). These 
cRNAs contain a single spacer that is flanked by direct repeat fragments, 
which then target and cleave the invading DNA during subsequent reinfection 
(Brouns et al. 2008). Spacer acquisition as well as target recognition and 
cleavage are usually mediated by recognition of a short protospacer adjacent 
motif (PAM), which is located adjacent to either end of the protospacer (Shah 
et al. 2013). There are three major types of CRISPR-cas systems (Type I, II 
and III), all of which contain the highly conserved Cas proteins, Cas1 (DNA 
endonuclease) and Cas2 (RNA endonuclease). Each system is characterised by 
the specific Cas proteins involved in maturation of crRNAs, nucleic acid 
targeting and cleavage of the invading DNA element (Makarova et al. 2011). 
Type II CRISPR-cas is considered to be the minimal CRISPR-cas system and 
typically contains genes encoding various configurations of Cas1, Cas2, Cas4 
or Csn2/Csn2-like and Cas9 (Makarova et al. 2011; Chylinski et al. 2014). It is 
predominately associated with pathogenic bacteria such as C. jejuni, which 
possesses a type II-C system that lacks a Cas4 or Csn2/Csn2-like protein 
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(Figure 3-1). The crRNA maturation step that takes place within type II 
systems is characterised by a requirement for a trans-activating CRISPR RNA 
molecule (tracrRNA), host RNase III and Cas9 (Deltcheva et al. 2011; Jinek et 
al. 2012). It has previously been demonstrated that the mature crRNA can be 
complementary base-paired to the tracrRNA in the presence of Cas9 to form an 
RNA duplex, which subsequently guides the Cas9 protein to cleave the target 
DNA at sites that are complementary to the crRNA (Jinek et al. 2012). This 
step is referred to as CRISPR interference.  
 
Another important bacterial defence system that utilises a self/non-self DNA 
recognition mechanism is the use of restriction-modification (R-M) systems 
that degrade unmethylated or unmodified incoming DNA. R-M systems 
typically consist of a methyltransferase that catalyses methylation of a specific 
host DNA sequence and a restriction enzyme which cleaves or restricts foreign 
DNA lacking that specific methylation. Approximately 90% of bacterial 
genomes were found to contain at least one R-M system and approximately 
80% contain multiple R-M systems (Vasu & Nagaraja 2013). In general, a 
relationship exists between the number of R-M systems present in a genome 
and the genome size of a bacterial strain, (Vasu & Nagaraja 2013). However 
the reason for the presence of multiple R-M systems in a single host is not 
clearly understood. R-M systems are classified into four main groups (Types I, 
II, III and IV) based primarily on enzyme subunit composition, cofactor 
requirements, symmetry of the recognition sequence and positioning of the 
DNA cleavage site (Boyer 1971; Roberts et al. 2003; Yuan 1981). Each group 
can be divided into sub-categories, especially the Type II.  
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Figure 3-1. Typical type II-C CRISPR-cas systems. 
The CRISPR repeats are represented by black boxes and the spacers by green 
diamonds. Each spacer is capable of independent expression due to the 
presence of transcriptional start sites within their sequences (black arrows). 
The tracrRNA sequence is illustrated by a red box and it can either be located 
upstream or downstream of the genes encoding the CRISPR-associated Cas 
proteins cas2, cas1 and cas9 (blue arrows). Adapted from Dugar et al. 2013. 
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Type I R-M systems are comprised of a multisubunit complex which functions 
as both a methyltransferase and a restriction endonuclease. It usually contains 
two R subunits (restriction), two M subunits (modification) and one S subunit 
(specificity) (Dryden et al. 2001). Sequence recognition is determined by two 
target recognition domains (TRDs) in the S subunit. The genes present in Type 
I systems are hsdR, hsdM and hsdS and the proteins encoded by the latter two 
are sufficient for methyltransferase activity, but all three are required for 
restriction activity. Type I restriction enzymes require ATP, S-
adenosylmethionine (AdoMet) and Mg2+ during cleavage of unmethylated 
substrates, which occurs at a variable distance from the recognition sequence 
following DNA translocation. However, if the enzyme complex targets a 
hemimethylated substrate, where only one strand is methylated, it can act as a 
methyltranferase to methylate the other strand and requires AdoMet to donate 
the methyl group. Methylation with a Type I system produces N6-
methyladenine (m6A) and the recognition sequence is asymmetrical and 
bipartite. Type I systems are currently divided into five sub-categories (A, B, 
C, D and E) based on genetic complementation, where subunits from different 
enzymes associate to produce a single functional enzyme; DNA sequence 
similarity and immunological cross-reactivity (Titheradge et al. 2001; Chin et 
al. 2004).  
 
Type II R-M systems are the simplest and most commonly known. They are 
comprised of separate subunits for restriction and modification but some 
classes are known to produce a single bifunctional protein due to fusion of the 
R and M genes. The endonuclease component of the system requires Mg2+ ions 
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as a cofactor and the methyltransferase requires AdoMet as a methyl group 
donor to produce N4-methylcytosine (m4C), 5-methylcytosine (m5C) or m6A. 
The Type II enzymes generally recognise a 4-8 bp palindromic sequence and 
DNA cleavage occurs symmetrically on both strands at a defined position at or 
close to the recognition site. Type II restriction enzymes have been subdivided 
into 11 different classes according to their enzymatic behaviour and sequence 
cleaving nature (A, B, C, E, F, G, H, M, P, S and T) and some enzymes can 
belong to more than one subcategory (Roberts et al. 2003).  
 
The Type III R-M systems comprise of two genes, mod and res, which encode 
protein subunits M (recognition and modification) and R (restriction). The M 
subunit can act independently as a methyltransferase but both M and R 
subunits are required for restriction activity (Janscak et al. 2001; Mucke et al. 
2001). Methylation requires AdoMet while cleavage requires ATP in the 
presence of AdoMet. For successful cleavage, Type III enzymes recognise two 
copies of a non-palindromic 5-6 bp sequence which are oppositely positioned 
within the DNA substrate. Cleavage occurs in a similar fashion to Type I 
enzymes where the DNA is cleaved at a distinct location from one copy of the 
recognition sequence following ATP-dependent DNA translocation. 
Methylation takes place primarily on one strand but cleavage will only occur if 
both strands are unmodified. The product of methylation is hemimethylated 
m6A. 
 
Type IV R-M systems have been re-classified to include modification-
dependent restriction enzymes that specifically recognise methylated DNA 
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sites (Roberts et al. 2003). These systems possess no associated 
methyltransferase activity. Foreign DNA is therefore targeted if it contains 
methylated bases in a particular recognition sequence. One well defined Type 
IV system is that of McrBC in E. coli (Raleigh & Wilson 1986; Stewart et al. 
2000), which generally targets two variably spaced dinucleotides in the form 
RmC (m4C or m5C), and cleaves approximately 30-bp away from one of these 
recognition elements with a GTP requirement for translocation of the DNA. 
The RmC recognition site can be found on both strands or may only be present 
on one. 
 
C. jejuni strains are known to possess many hypervariable homopolymeric 
repeats within genes related to the assembly of their capsule, 
lipooligosaccharides (LOS) and flagella structures (Parkhill et al. 2000). The 
presence of these repeats makes the genes prone to slipped-strand mispairing 
during chromosomal replication leading to phase variation (Parkhill et al. 
2000). Surface capsular polysaccharide (CPS) structures and flagella of C. 
jejuni have been recognised as important factors in the binding of 
bacteriophages (Coward et al. 2006). However, phase variation of such genes 
can alter cell surfaces, which in turn can affect phage propagation by 
restricting access to cell surface recognition sites. The cps locus of C. jejuni is 
known to contain conserved as well as variable genes (Karlyshev et al. 2005). 
The gene cluster responsible for the biosynthesis of heptosyl residues (Hep), 
including hddC, gmhA2 and hddA, is highly variable while the transport related 
kps genes flanking the Hep residues are conserved among strains (Karlyshev et 
al. 2005).  
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In this chapter the genome sequence of C. jejuni PT14 was characterised and 
an attempt was made to determine what genetic factors may be contributing to 
the phage-sensitive nature of this strain.  
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3.2 RESULTS 
3.2.1 Genome analysis 
The circular genome of C. jejuni PT14 was found to be 1,635,252-bp in length 
with 1607 putative open reading frames (ORFs) and an average G+C content 
of 30.5%. The genome sequence contains 3 copies of the ribosomal RNA 
operon and 41 tRNA genes covering all amino acids, with arginine being 
represented most frequently followed by alanine and leucine. The genome was 
automatically annotated using the NCBI programme PGAAP (Angiuoli et al. 
2008) (2.11.4), from which it was possible to assign functional information to 
80.9% of the 1607 ORFs on the basis of what was available in the database. 
Figure 3-1 shows a genome map of C. jejuni PT14 with annotation related to 
as CDS, pseudogenes and conserved hypothetical proteins illustrated. There is 
no evidence for the presence of any prophage-associated genes or plasmids 
within this genome.  
 
C. jejuni PT14 contains 26 probable pseudogenes, with many in common with 
those in other C. jejuni genomes. Table 3-1 shows a comparison of the 
pseudogenes present in the PT14 genome with their gene homologues in the 
NCTC 11168 genome. The majority of these are also probable pseudogenes in 
NCTC 11168 and have been highlighted in yellow. However, twelve 
pseudogenes present in PT14 remain intact within NCTC 11168.  Similarly, on 
examination of the NCTC 11168 genome, there are three annotated 
pseudogenes that are intact within the PT14 genome. These are cj0501 
(A911_02450), cj1064 (A911_05150) and cj1470c (A911_07080). 
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Figure 3-2. Circular representation of the C. jejuni PT14 genome.  
The annotation types are colour coded according to the key. Colour coded are 
1607 CDS, 1657 genes, 26 pseudogenes, 42 conserved hypotheticals, 9 rRNAs 
and 41 tRNAs. 
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Table 3-1. Probable pseudogenes within the C. jejuni PT14 genome.  
 
Gene ID Product Gene ID Product
A911_00225
A911_00230
A911_00235
A911_00240
A911_00245
A911_00335
A911_00340
3 A911_00820 Methyl transferase Cj0170 Methyl transferase
A911_01045
A911_01050
A911_01055
A911_01060
5 A911_01405 Glycerol-3-phosphate transporter Cj0292c Putative glycerol-3-phosphate transporter
A911_02170
A911_02175
7 A911_02370 MFS transport protein Cj0484 Putative MFS transport protein
8 A911_02550 Na+/Pi cotransporter protein Cj0522 Putative Na+/Pi cotransporter protein
A911_02750
A911_02755
10 A911_03205 Di-/tripeptide transporter Cj0654 Putative transmembrane transport protein
NCTC 11168PT14
9 Hypothetical protein Cj0565 Hypothetical protein
4 Serine protease eatA precursor Cj0223 Putative IgA protease family protein
6 TonB-dependent receptor Cj0444 Putative TonB-dependent outer membrane 
receptor
2 Hemerythrin family non-heme iron protein Cj0072c Putative iron-binding protein
No.
1 C4-dicarboxylate transporter Putative sodium sulfate transmembrane 
transport protein
Cj0046
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Table 3-1 continued 
 
Gene ID Product Gene ID Product
A911_03280
A911_03285
12 A911_03300 Potassium-transporting ATPase, subunit C Cj0678 Potassium-transporting ATPase C chain
13 A911_03365 Restriction/modification enzyme Cj0690c Putative restriction/modification enzyme
14 A911_03610 Flamentous hemagglutinin domain protein Cj0738-Cj0740 Hypothetical proteins
A911_03630
A911_03635
A911_03645
A911_03650
A911_04205
A911_04210
A911_04215
A911_04220
A911_04225
A911_04680
A911_04685
19 A911_04765 MFS transport protein Cj0987 Putative MFS transport protein
20 A911_05030 Putative transmembrane transport protein Cj1040 Putative MFS transport protein
A911_06755
A911_06760
21 Cryptic C4-dicarboxylate transporter, DcuD Cj1389 Putative C4-dicarboxylate anaerobic carrier
17 Arylsulfotransferase Cj0866 Arylsulfatase
18 Putative periplasmic protein Cj0969 Putative periplasmic protein
15 Putative outer membrane protein Cj0742 Putative outer membrane protein
16 ISCco1, transposase orfB IS element transposaseCj0752
11 Potassium-transporting ATPase,  subunit A Cj0676 Potassium-transporting ATPase A chain
No. PT14 NCTC 11168
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 Table 3-1 continued 
 
Note: Predicted pseudogenes shared between the C. jejuni NCTC 11168 and PT14 genomes have been highlighted in yellow in the NCTC 11168 
genome. Genes that remain intact within C. jejuni NCTC 11168 compared to those in the PT14 genome have not been highlighted. 
Gene ID Product Gene ID Product
22 A911_06780 Adenylosuccinate lyase Cj1395 Putative MmgE/PrpD family protein
23 A911_06985 Integral membrane protein Cj1452 Putative integral membrane protein
24 A911_07015 Periplasmic protein Cj1456 Putative periplasmic protein
A911_07345 C4-dicarboxylate anaerobic carrier, putative
A911_07350 C4-dicarboxylate anaerobic carrier, putative
A911_07355 Cryptic C4-dicarboxylate transporter, DcuD
A911_07485
A911_07490
No. PT14 NCTC 11168
26 Putative permease Cj1560 Putative permease
25 Cj1528 Putative C4-dicarboxylate anaerobic carrier
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C. jejuni PT14 was found to contain 27 homopolymeric G:C tracts (defined as 
FRQWDLQLQJ  FRQVHFXWLYH *& UHVLGXHV ZKLFK EHDUs comparison to 29 
reported for NCTC 11168 (Parkhill et al. 2000; Gundogdu et al. 2007), 25 for 
RM1221 (Parker et al. 2006) and 23 for CG8486 (Poly et al. 2007). The 
locations of homopolymeric tracts are generally conserved between C. jejuni 
strains. Within the C. jejuni PT14 genome, there are five tracts residing in 
intergenic regions, two in probable pseudogenes and nine within genes of 
unknown function (Table 3-2). Variation in the length of the G:C tracts within 
genes results in phase variable expression. Five of the tracts identified in C. 
jejuni PT14 show phase variation at the sequence level. These are genes 
encoding two putative methyltransferases, one of unknown function, an 
DPLQRJO\FRVLGDVH 1¶-acetyltransferase and the invasion protein CipA. C. 
jejuni PT14 also contains a phase variable A:T region within the gene 
A911_06060 encoding a GMP synthase. 
 
3.2.2 Nucleotide sequence statistics 
The nucleotide distribution displayed in Figure 3-3 is typical of an AT-rich 
Campylobacter genome. The average G+C content of the C. jejuni PT14 
genome is 30.5% and this percentage is similar to that observed for other 
strains including NCTC 11168 (30.6%) (Parkhill et al. 2000; Gundogdu et al. 
2011), CG8486 (30.4%) (Poly et al. 2007) and 81-176 (30.6%) (Hofreuter et 
al. 2006). Table 3-VKRZV WKH QXFOHRWLGH IUHTXHQF\ LQ FRGRQSRVLWLRQV ³$´
residues are observed most frequently in the first and second position whilst 
³7´UHVLGXHVare most frequent LQWKHWKLUGSRVLWLRQ³&´UHVLGXHVZHUHWKHOHDVW
IUHTXHQWO\RFFXUULQJQXFOHRWLGHLQWKHILUVWDQGWKLUGSRVLWLRQZKLOH³*´ 
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Table 3-2. Listing and location of homopolymeric repeats within the C. jejuni PT14 genome 
 
 
 
No Position Homopolymeric 
G/C tract
Gene ID/Region 
affected
Putative function Note
1 37029-37038 C (10) Intergenic N/A N/A
2 66340-66349 C (10) A911_00220 Hemerythrin-like iron -binding protein N/A
3 167095-167103 G (9) A911_00820 Methyl transferase Pseudogene
4 527148-527157 G (10) Intergenic N/A N/A
5 577352-577361 G (10) A911_03015 Unknown N/A
6 588134-588143 G (10) A911_03065 Lipoprotein N/A
7 629763-629772 G (10) A911_03285 Potassium transporting ATPase, A-subunit Pseudogene
8 640595-640603 G (9) A911_03335 Invasion protein CipA Phase variable
9 697531-697541 C (11) Intergenic N/A N/A
10 1074514-1074524 C (11) A911_05520 Beta-1,3 galactosyltransferase N/A
11 1080064-1080070 C (7) A911_05550 Unknown N/A
12 1227262-1227270 G (9) A911_06290 Unknown Phase variable
13 1228732-1228741 G (10) A911_06295 Aminoglycosidase N3'-acetyltransferase Phase variable
14 1235061-1235069 C (9) A911_06340 Unknown N/A
15 1236300-1236308 C (9) A911_06345 Unknown N/A
16 1240439-1240447 C (9) A911_06365 Unknown N/A
17 1241666-1241674 C (9) A911_06370 Unknown N/A
18 1250228-1250237 G (10) Intergenic N/A N/A
   
 
 
119
 
Table 3-2 continued 
 
 
Note: Homopolymeric G:C tracts are GHILQHGDVFRQWDLQLQJFRQVHFXWLYH*&UHVLGXHV. The relative chromosomal position within the PT14 
genome is indicated with respect to the nucleotide sequence beginning at dnaA, along with the gene or intergenic regions where the G:C tracts 
occur. Genes that are observed to be phase variable at sequence level are noted. 
No Position Homopolymeric 
G/C tract
Gene ID/Region 
affected
Putative function Note
19 1253090-1253098 G (9) A911_06440 Methyltransferase Phase variable
20 1263087-1263095 G (9) A911_06490 Motility accessory factor N/A
21 1274781-1274789 C (9) A911_06515 Unknown N/A
22 1353164-1353172 C (9) A911_06906 SAM-dependent methyltransferase Phase variable
23 1355346-1355354 C (9) A911_06907 Sugar transferase N/A
24 1364471-1364479 C (9) Intergenic N/A N/A
25 1366633-1366640 C (9) A911_06918 Unknown N/A
26 1385824-1385832 G (9) A911_07000 Sugar transferase N/A
27 1591849-1591858 G (10) A911_08080 Lipoprotein N/A
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Figure 3-3. Nucleotide distribution histogram for the C. jejuni PT14 
genome. 
The occurrence of each nucleotide within the genome is illustrated. The 
average G+C content of the genome is shown to be 30.5%. 
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Table 3-3. Frequency of nucleotide codon positioning for C. jejuni PT14 
genome. 
 
Codon 
position 
Nucleotide frequency in codon position (%) 
A C G T 
1st position 36 13 30 21 
2nd position 37 17 14 33 
3rd position 36 9 10 45 
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residues were the least in the second position. The reduced frequency of G and 
C residues is consistent with their low distribution within the genome. The 
FRGRQ³$$$´HQFRGLQJWKHDPLQRDFLGO\VLQHRFFXUUHGWLPHVDQGZDV
WKH PRVW DEXQGDQW FRGRQ +RZHYHU ³&**´ HQFRGLQJ Drginine was the least 
frequent, occurring only 58 times. 
 
3.2.3 Phylogenetic relation to other C. jejuni strains 
Figure 3-4 illustrates the relationship between C. jejuni PT14 and its nearest 
neighbours based on genomic BLAST comparisons. The dendogram shows 
that although there is strong synteny with NCTC 11168, the genome with the 
most genetic similarity is that of C. jejuni IA3902. This is quite interesting 
because PT14 and NCTC 11168 are both human C. jejuni isolates while 
IA3902 was originally isolated from an aborted ovine fetus and is a highly 
abortifacient strain (Burrough et al. 2009). It is also notable that the two strains 
known to contain prophage-associated elements, C. jejuni RM1221 and C. 
jejuni S3, are clustered furthest away from PT14 since this genome does not 
appear to contain any such integrated elements. 
 
 
 
 
  Chapter 3 
123 
 
 
Figure 3-4. Phylogenetic comparison of C.jejuni PT14 with its closest 
relatives.  
The comparisons are based on genomic BLAST searches. The PT14 genome is 
clustered furthest away from the two genomes known to contain 
Campylobacter jejuni integrated elements (CJIEs), RM1221 and C. jejuni S3. 
The dendogram was calculated using the Genome feature of the NCBI website. 
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3.2.4 CRISPR-cas system of C. jejuni PT14 
The CRISPR-cas system within the genome of C. jejuni PT14 was identified 
and found to be intact. PT14 contains a minimal type II-C CRISPR array, with 
four 36-bp direct repeats (start position of first repeat: 1448528, end position 
of last repeat: 1448761) flanking three 30-bp spacer sequences (start position 
of first spacer: 1448564, end position of last spacer: 1448725). Interestingly, 
WKH ILUVW GLUHFW UHSHDW VHTXHQFH LV PLVVLQJ WKH LQLWLDO ³*´ UHVLGXH ZKLFK LV
present in the other three repeats. A putative transcriptional -VWDUWVLWH¶-
TAAAAT-¶ was identified 123-bp upstream of the initial direct repeat. The 
genes encoding three CRISPR-associated Cas proteins, cas2 (A911_07325) 
(position: 1448906-1449337), cas1 (A911_07330) (position: 1449330-
1450220) and cas9 (A911_07335) (position: 1450217-1453180) were also 
identified, beginning 145-bp downstream of the terminal direct repeat 
sequence. A tracrRNA sequence was also determined that could potentially 
base-pair with the repeat sequence. The CRISPR array sequences can be found 
in Table 3-4. 
 
BLAST searches revealed that for each spacer sequence of the C. jejuni PT14 
CRISPR array, there were no obvious matches to phage or plasmid DNA but 
instead nucleotide sequences were found that mapped to the PT14 
chromosome. The first spacer sequence mapped to the gene encoding the 
peptidoglycan-associated lipoprotein Omp18 (A911_00540) while the second 
spacer mapped to the genes encoding apolipoprotein N-acyltransferase 
(A911_05300) and isoleucyl-tRNA ligase (A911_05135). BLAST searches 
also found matches to other C. jejuni strains, with the first and third spacer  
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Table 3-4. CRISPR array sequences for C. jejuni PT14 
 
CRISPR feature Sequence (5'ĺ3') 
Direct repeat  GTTTTAGTCCCTTTTTAAATTTCTTTATGGTAAAAT 
Spacer 1 ATAATTTCTAATTTCATTTATAACCTTTCA 
Spacer 2 TAGTAGCTAAGAATAAAATAAGAAACACTG 
Spacer 3 GTTGGAATGCTTAAGCAGGGGTGGAGTGAA 
tracrRNA AAGAAAUUUAAAAAGGGACUAAAA 
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sequences displaying 100% sequence identity to spacer sequences of three 
other C. jejuni strains for the full length of the sequence. The second spacer 
showed 100% identity to spacer sequences of five other strains, with two of 
them matching 100% for the full sequence length. A BLAST search of the 
direct repeat sequence displayed 100% nucleotide sequence identity to those of 
at least 99 other C. jejuni strains. The CRISPR element of C. jejuni PT14 has a 
G+C content of 28.4%, which is lower than the average G+C content of the 
rest of the genome. 
 
3.2.5 The cps gene locus of C. jejuni PT14 
The C. jejuni PT14 cps gene locus extends from A911_06875 to A911_06960 
and has a G+C content of 27%. On comparing the genomes of PT14 to NCTC 
11168, the capsular polysaccharide loci were found to have variable regions. 
However, both genomes contained kps orthologs with seven genes that make 
up two clusters and flank the polysaccharide biosynthesis genes. The first 
cluster contains the genes kpsS and kpsC (A911_06875 and A911_06880) 
while kpsF, kpsD, kpsE, kpsT and kpsM (A911_06940, A911_06945, 
A911_06950, A911_06955 and A911_06960) make up the second cluster 
(Figure 3-5). The Kps proteins allow translocation of the capsular 
polysaccharide to the bacterial surface. Within the PT14 genome, twenty-two 
polysaccharide biosynthetic genes were identified but none appear to encode 
proteins that are responsible for biosynthesis of Hep residues as observed 
within NCTC 11168 (Parkhill et al. 2000). However, the capsular 
polysaccharide locus in C. jejuni PT14 was found to be identical to that of C. 
jejuni IA3902, which also contained no genes for biosynthesis of Hep residues. 
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An insertion of six genes as well as a gene substitution of fourteen genes has 
occurred within NCTC 11168 compared to PT14 (A911_06908 to 
A911_06935, excluding A911_06918) and IA3902 (CJSA_1353 to 
CJSA_1367 excluding CJSA_1363). This occurs between cj1422 and cj1442c 
within the NCTC 11168 genome. In addition, within the cps locus of PT14 
there are three genes containing homopolymeric G:C tract repeats and two of 
them appear phase variable at sequence level. These are A911_06906 and 
A911_06907, which encode a SAM-dependent methyltransferase and a 
putative sugar transferase respectively while the hypothetical gene represented 
by A911_06918 does not appear to be phase variable. The nearest homologues 
to A911_06906, A911_06907 and A911_06918 within C. jejuni NCTC 11168 
are cj1420c, cj1421c and cj1422c respectively, which are all phase variable 
within that genome. Figure 3-5 shows an alignment of the capsular 
polysaccharide loci between C. jejuni PT14, NCTC 11168 and IA3902. These 
two genomes were chosen for the alignment because of their close 
phylogenetic relationship with PT14 based on genomic BLAST searches 
(3.2.3). The gene arrangement within this locus is identical between PT14 and 
IA3902. The gene substitutions in the NCTC 11168 genome are also clearly 
illustrated in Figure 3-5. 
 
3.2.6 The lipooligosaccharide biosynthesis locus of C. jejuni 
PT14 
The C. jejuni PT14 LOS locus extends from A911_05480 (galE) to 
A911_05580 (gmhB) (Figure 3-6) and has a G+C content of 27.8%. Genes 
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Figure 3-5. Alignment of the capsular polysaccharide loci of C. jejuni PT14, NCTC 11168 and IA3902.  
Gene names are shown on or above each ORF and the direction of transcription is indicated by an arrow. Corresponding homologous genes are 
assigned the same colour and the kps genes clusters are indicated for each genome. In PT14, this locus extends from the first gene shown, kpsS, 
until the kpsM gene (A911_06875 to A911_06960). Gene substitutions occur in NCTC 11168 compared to the other two genomes directly after 
cj1422c until cj1442c. In NCTC 11168 this region includes genes responsible for heptosyl biosynthesis but not in C. jejuni PT14 and C. jejuni 
IA390. The alignment was performed using the Biocyc databases (Caspi et al. 2014). 
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Figure 3-6. Alignment of the LOS biosynthesis loci of C. jejuni PT14, 
NCTC 11168, RM1221, 81-176 and IA3902. 
Gene names are shown on or above each ORF and the direction of 
transcription is indicated by an arrow. Corresponding homologous genes are 
assigned the same colour and white shading accompanied by an X represents a 
pseudogene. The LOS locus in PT14 extends from galE (A911_05480) to 
gmhB (A911_05580) and genes involved in LOS heptose biosynthesis pathway 
are present. The neuBCA gene operon and cstIII gene, which are involved in 
sialic acid biosynthesis are present in all of the aligned genomes, with the 
exception of RM1221. The alignment was performed using the Biocyc 
databases (Caspi et al. 2014). 
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involved in the LOS heptose biosynthesis pathway are present such as waaC 
(A911_05490) encoding heptosyltransferase I, gmhA (A911_05565) encoding 
phosphoheptose isomerase and hldD (A911_05575) encoding ADP-L-glycero-
D-manno-heptose-6-epimerase. Three glycosyltransferases (A911_05505, 
A911_05510 and A911_05515) were identified as well as the neuBCA gene 
operon (A911_05530, A911_05535 and A911_05540), which is required for 
sialic acid biosynthesis. The cstIII gene (A911_05525) encoding Į-2,3 
sialyltransferase is also present. These genes are known to be involved in 
biosynthesis of sialylated LOS structures with the potential for human 
ganglioside mimicry (Gilbert et al. 2002). Figure 3-6 shows an alignment of 
the LOS biosynthesis loci of C. jejuni PT14, NCTC 11168, RM1221, 81-176 
and IA3902. As seen with other loci, the gene arrangement is identical for 
PT14 and IA3902. 
 
3.2.7 The flagellar modification locus in C. jejuni PT14 
In C. jejuni PT14, the flagellar modification locus extends from A911_6280 
(pseB) to A911_06515 (hypothetical protein) and has a G+C content of 30.2%. 
Within this locus, nine genes and an integenic region contain homopolymeric 
G:C tracts. These genes encode a number of hypothetical proteins as well as 
known motility accessory factors7ZRRIWKHJHQHVDQDPLQRJO\FRVLGDVH1¶-
acetyltransferase (A911_06295) and a methyltransferase (A911_06440), are 
observed to be phase variable at sequence level. 
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 3.2.8 Restriction and modification systems in C. jejuni PT14 
C. jejuni PT14 possesses multiple R-M systems. A type I R-M system was 
identified containing the genes hsdR, hsdS and hsdM (A911_07460, 
A911_07470 and A911_07480). The genome also contains a type IIs system 
(A911_00150), with the nearest homologue in NCTC 11168 being 
cj0031/cj0032. Adenine-specific (A911_01010), site-specific (A911_07040) 
and methionine-dependent (A911_03525) DNA methyltransferases were also 
identified as well as two putative R-M enzymes (A911_03365 (pseudogene) 
and A911_05085).  
 
3.2.9 Lytic profiles 
Bacteriophage-sensitivity of C. jejuni PT14 was tested against the activity of 
60 selected lytic phages (Figure 3-7), including the 16 UK typing phages 
(Frost et al. 1999). All phage were initially propagated using C. jejuni PT14, 
with the exception of those on plate 4 where the propagating strain is indicated. 
For example, CP8/11168 refers to initial propagation of phage CP8 with C. 
jejuni NCTC 11168 as the propagating host strain. The bacteriophages of 
interest were diluted to the routine test dilution of approximately 6 log10 PFU 
ml-1 and 10 µl aliquots were spotted onto the surface of the PT14 lawns (2.5.4). 
The plaque forming ability of each phage was observed and 35 phages 
displayed either confluent or semi-confluent lysis, while only 9 phages (E5, 
10b, 9, NCTC 12671, NCTC 12677, NCTC 12672, NCTC 12675, NCTC 
12683 and CP220/PT14) showed no lytic ability. 
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3.2.10 In vitro growth curves 
After examining the activity of lytic bacteriophages against C. jejuni PT14 
(3.2.9), two were selected to perform in vitro growth experiments. 
Campylobacter phages CP30A and CPX were selected on the basis of their 
ability to produce confluent lysis on C. jejuni PT14 and that genome sequence 
data were available, identifying them as group III Campylobacter 
bacteriophages and representatives of the CP8unalikevirus genera (Javed et al. 
2014). A decision not to use the group II Campylobacter phage CP220 for the 
in vitro experiments was made, despite also being a sequenced strain, because 
of its inability to lyse PT14 cells as noted by the lack of plaques on the PT14 
lawns (Figure 3-7).  
 
It was necessary to conduct in vitro growth experiments in order to evaluate 
growth and infection conditions during phage infection of PT14 as well as to 
develop appropriate modelling parameters to allow a measurable output of 
phage-infected cells to be generated for subsequent transcriptomic analysis 
(see Chapter 4). The experiment was conducted in 50 ml volumes of nutrient 
broth no.2 over 24 hours using the procedure described in section 2.6.2. Figure 
3-8 shows the two growth curves for infection of C. jejuni PT14 with CP30A 
(A) and CPX (B). An initial density of 7.45 log10 ± 0.09 CFU ml-1 and 7.20 
log10 ± 0.06 CFU ml-1 of C. jejuni PT14 was grown for two hours and was then 
infected with 5.91 log10 ± 0.09 PFU ml-1 of phage CP30A and 6.02 log10 ± 0.05 
PFU ml-1 of phage CPX respectively. These concentrations and the ratio of 
bacteria to phage were chosen to take into consideration the results of in vitro 
growth experiments previously conducted by Cairns et al. (2009). Figure 3-8  
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Figure 3-7. Sensitivity of C. jejuni PT14 to selected bacteriophages.  
The phages were diluted to the routine test dilution of 6 log10 PFU ml-1 and 
were spotted onto PT14 lawns The phages tested include the 16 typing phages 
(Frost et al. 1999), the sequenced group II phage CP220 (Timms et al. 2010) 
and the sequenced group III phages CP30A and CP8. The plaque forming 
ability of each phage was observed. Confluent lysis was exhibited by phages 
A14, A32, CP8, A1B, G6, 18b, CP28, NQ1, NCTC 12670, NCTC 12673, 
NCTC 12674, NCTC 12678, CP8/11168, CP8/HPC5, CP8/PT14, 
CP30A/11168H, CP30A/11168, CP30A/HPC5, CP30A/PT14, CP30A/PT14PL 
and CP8HPC5CS, semi-confluent lysis by phages CP51, CP25, CP30A, 4b, 
X3, CP34, G5, 19b, NCTC 12679, NCTC 12680, CP8/11168H, 
CP30AHPC5CS, CP8PT14CS and CP220/HPC5 and opaque lysis by phages 
CP220, CP20, 7, G1, G4, G3, 11, mc1a, G8, G7, NCTC 12669, NCTC 12681, 
NCTC 12682, NCTC 12684. No lysis was exhibited by phages E5, 10b, 9, 
NCTC 12671, NCTC 12677, NCTC 12672, NCTC 12675, NCTC 12683 and 
CP220/PT14. Lytic activity was scored according to the nomenclature used 
during the UK phage typing scheme (Frost et al. 1999).  
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shows uninfected C. jejuni PT14 in blue, phage-infected C. jejuni PT14 in 
brown and bacteriophage growth in green.  
 
Infection with CP30A resulted in an immediate drop in bacterial numbers by at 
least 3 logs on addition of the phage at the second hour. However, a similar 
drop in the host population in response to CPX infection was not observed 
until two hours post-infection. Following the fall in the host viable count, the 
CP30A-infected and CPX-infected Campylobacter populations began to 
increase in growth from the 6th and 8th hour respectively until the final 
sampling point at the 24th hour. Although growth of the phage-infected host 
appeared to be relatively constant in both cases, a slight drop was observed for 
the CP30A-infected population at the 18th hour which occurred with a 
simultaneous rise in CP30A. This is indicative of further lysis of phage-
sensitive C. jejuni cells. Statistical analysis showed that there was no 
VLJQLILFDQW GLIIHUHQFH 6WXGHQW¶V W-Test, >0.05, n=3) between the post-crash 
growth rate of the CP30A-infected population compared to the CPX-infected 
SRSXODWLRQ7KHUHZDVDOVRQRVLJQLILFDQWGLIIHUHQFH 6WXGHQW¶V W-Test, >0.05, 
n=3) in the phage yields generated from cell lysis of these two populations. 
Mean burst sizes of 5.0 and 5.2 (infectious virions per cell) could be estimated 
from the phage yields with respect to the synchronous fall in the bacterial 
populations for CP30A and CPX respectively.  
 
In order to establish whether the host population during the resurgence in 
growth contained a mixed population of phage-sensitive and resistant cells, 
that were both capable of growing following the crash, samples were collected 
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at the 6th, 8th, 18th and 24th hour and phage resistance was determined with the 
assistance of Dr. A. Timms as described in section 2.6.3. The results confirm 
that subsequent to the bacterial crash at the 8th hour, a high percentage of the 
isolates were indeed resistant to CP30A (65-85%) and CPX (84-90%) infection 
(Table 3-5). However, there was a decline in the frequency of phage resistance 
by the 24th hour. The results also illustrate that the percentage of isolates that 
were sensitive to CP30A infection at the 18th hour was quite low, suggesting a 
reason for the small drop in host numbers observed at that time point compared 
to the large drop previously encountered at the 2nd hour.  
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Figure 3-8. In vitro growth curves of C. jejuni PT14 infected with 
bacteriophages CP30A (A) and CPX (B).  
Uninfected C. jejuni PT14 are indicated by the blue lines, phage-infected by 
the brown and bacteriophage growth by the green lines. The phages were 
added at the second hour of growth, at which point the host population infected 
with CP30A crashed, while a reduction in the CPX-infected cell numbers 
occurred 2 hours post-infection. A simultaneous rise in phage titre occurred at 
these times. Following the crash, the C. jejuni PT14 population steadily 
increased in growth until the final sampling point.  
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Table 3-5. Frequency of phage-resistant C. jejuni PT14 isolates during infection with phages CP30A and CPX 
 
Phage resistance to CP30A Phage resistance to CPX 
Time/hours Culture Culture 
1 2 3 4 5 6 7 8 9 1 2 3 4 5 6 7 8 9 
6 ND ND ND 0.10 0.05 0.15 ND ND ND ND ND ND ND ND ND ND ND ND 
8 ND ND ND 0.70 0.65 0.85 ND ND ND ND ND ND ND ND ND 0.84 0.90 0.85 
18 ND ND ND 0.73 0.75 0.82 ND ND ND ND ND ND ND ND ND 0.60 0.67 0.73 
24 0.00 0.00 0.05 0.60 0.53 0.50 ND ND ND 0.05 0.10 0.10 ND ND ND 0.44 0.29 0.67 
 
Key - 
Cultures 1-3: Uninfected C. jejuni PT14 replicates 1-3 
Cutures 4-6: CP30A-infected C. jejuni PT14 replicates 4-6 
Cultures 7-9: CPX-infected C. jejuni PT14 replicates 7-9 
ND: Not determined 
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3.3 DISCUSSION 
Analysis of the C. jejuni PT14 genome has identified features such as an intact 
CRISPR-cas system (3.2.4), multiple R-M systems (3.2.8) as well as the 
presence of homopolymeric tract repeats with phase variable regions within 
genes that have the potential to impact on bacteriophage replication (Table 3-
2). These features are all related to bacterial defence and therefore suggest that 
although this strain is highly phage-sensitive, mechanisms are still in place to 
enable potential escape from bacteriophage predation.  
 
3.3.1 Phage-derived protospacers not detected in PT14 CRISPR 
array 
The CRISPR direct repeat sequence of C. jejuni PT14 is highly conserved with 
other members of the species. BLAST searches for each spacer repeat 
sequence of the C. jejuni PT14 CRISPR array did not reveal any phage-
associated or plasmid DNA sequence matches but instead identified nucleotide 
matches to the PT14 chromosome and other C. jejuni strains (3.2.4). This 
finding was not surprising as PT14 was not resistant to many of the 
bacteriophages examined in this study, which may be a consequence of the 
strain not previously integrating phage-derived proto-spacers into its CRISPR 
region. However, the BLAST searches also showed that none of the spacer 
sequences were unique to PT14, with other C. jejuni strains carrying identical 
spacers.  
 
CRISPR spacers that target chromosomal genes have previously been 
examined by Stern et al. (2010), who found that amongst 23,550 spacers from 
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330 CRISPR-encoding prokaryotic organisms, one in every 250 spacers were 
self-targeting. As a result, they initially hypothesised that the CRISPR system 
may be involved in gene regulation and therefore sought to determine 
conservation amongst self-targeting spacers. However, no conserved sequences 
were identified and this hypothesis was dismissed. It was noted that 37% of the 
self-targeting spacer sequences were found to be located close to the leader 
sequence, either in the first or second position of the array. Generally, spacers 
are integrated into the array towards the leader end and this finding may 
suggest that acquisition of self-targeting spacers is a recent event that could 
possibly have deleterious effects. A similar finding was observed for PT14 
with both the first and second spacers containing nucleotide sequences that can 
be aligned to chromosomal genes. Stern et al. (2010) also found that the two 
direct repeats flanking the self-targeting spacer sequence were twice as likely 
to contain mutations compared to those flanking the other spacers. This could 
therefore affect crRNA maturation of the self-targeting spacer whilst allowing 
the rest of the CRISPR array to remain functional. It was finally suggested that 
targeting of chromosomal genes by the CRISPR system may have been 
accidental and this may therefore be a form of autoimmunity which could 
eventually lead to a negative fitness cost to the organism (Stern et al. 2010). 
 
3.3.2 Gene encoding specific phage target not phase variable in 
PT14  
Three genes within the CPS locus of C. jejuni PT14 were found to contain 
homopolymeric tract repeats. However, one of these genes, A911_06918, does 
not appear to be phase variable at sequence level. Its nearest homologue within 
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the NCTC 11168 genome is cj1421 and this gene is phase variable. It encodes 
a MeOPN transferase, which allows attachment of MeOPN to a GalfNAc (N-
acetylgalactosamine in furanose configuration) residue of the CPS. It has been 
identified in other C. jejuni strains (Karlyshev et al. 2005) and has also been 
determined to be a specific target for bacteriophage F336 (Sørensen et al. 
2011). It was found that a phage F336 resistant NCTC 11168 variant selected 
in vitro had in fact lost the MeOPN as a result of having an additional G 
residue in cj1421, thus causing the gene to be in a non-functional phase 
(Sørensen et al. 2011). Later, Sørensen and colleagues (2012) tested whether 
C. jejuni NCTC 11168 could become resistant to bacteriophage F336 in vivo 
during chicken colonisation whilst observing the MeOPN transferase status of 
any resistant variants. They found that the phage-sensitive isolates expressed 9 
G residues in the cj1421 gene whereas phage-resistant isolates contained either 
8 or 10 G residues, which would FDXVHWKHJHQHWRVZLWFKWRWKH³RII´SKDVH. 
Phase variable disruption of cj1421 of C. jejuni NCTC 11168 therefore 
prevents MeOPN attachment to GalfNac of capsular polysaccharide, which 
leads to non-infection by bacteriophage F336 (Sørensen et al. 2011) and allows 
bacteriophage evasion during chicken colonisation (Sørensen et al. 2012). In 
contrast, the cj1421 homologue identified in C. jejuni PT14 (A911_06918) 
does not appear in a syntenic region and as it is not phase variable, 
bacteriophage targeting the MeOPN capsular modification are unlikely to be 
hindered by such a mechanism in C. jejuni PT14.  
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3.3.3 C. jejuni PT14 appears to possess a class C LOS locus 
Comparative genome analyses have shown that the LOS biosynthesis locus of 
C. jejuni is a highly variable region within the genome (Gilbert et al. 2002; 
Leonard II et al. 2003; Leonard II et al. 2004; Parker et al. 2005). These 
variations are responsible for the differences observed in LOS structures 
amongst C. jejuni strains. Five classes (A-E) of the LOS locus have been 
identified within C. jejuni based on the general organisation of the LOS 
biosynthetic genes (Gilbert et al. 2002; Godschalk et al. 2004). Godschalk et al 
(2004) examined the correlation between expression of ganglioside-like 
structures and the class of LOS locus assigned as well as the prevalence of the 
different classes amongst GBS-associated C. jejuni strains. They found that 
classes A, B and C contained genes involved in biosynthesis and transfer of 
sialic acid while classes D and E lacked such genes. Classes A and B loci were 
also previously found to contain the cstII gene encoding the bi-functional 
Į2,3/Į2,8-sialyltransferase which catalyses transfer of sialic acid molecules to 
sugar structures at the cell envelope (Gilbert et al. 2002; Chiu et al. 2004). 
However, class C was reported to carry the cstIII variant encoding the mono-
functional Į2,3-sialyltransferase (Gilbert et al. 2002). Likewise, the LOS locus 
of C. jejuni PT14 contains the sialic acid biosynthesis genes as well as Į-
sialyltransferase (cstIII), which suggests that this strain has a class C LOS 
locus. In addition, Godschalk et al. (2004) further reported that class A was 
specifically associated with GBS and the expression of GM1 ganglioside-like 
structures whereas class B was linked to MFS and the production of GQ1b-like 
structures. No significant results were achieved for classes C, D or E but some 
class C isolates were found to produce GM1 structures in their LOS as well. 
  Chapter 3 
143 
 
3.3.4 Phage-sensitivity determined by ganglioside-like LOS 
structures  
Louwen et al. (2013) examined the link between bacteriophage resistance in C. 
jejuni as a consequence of the expression of ganglioside-like LOS structures 
and the association with preservation of the CRISPR-cas system. Their 
findings suggest possible reasons for the phage-sensitivity of C. jejuni PT14 to 
many phages. Firstly, Louwen et al. (2013) found that isolates producing GM1 
and GD1 ganglioside-like structures (classes A and B) were significantly more 
phage-resistant compared to isolates that did not express these structures. They 
also tested the involvement of the sialyltransferase gene cstII and the cas gene 
csn1 in bacteriophage-resistance. They found that cstII mutants were more 
susceptible to phage infection than wild-type isolates and that cstII-positive 
csn1 mutants were less susceptible to bacteriophage infection than cstII-
negative csn1 mutant. This therefore suggests that cstIII isolates require the 
CRISPR-cas system for defence against bacteriophages. Further analysis also 
showed that strains containing the cstII gene and therefore expressing GM1 or 
GD1 ganglioside-like structures, possessed mutations or frameshifts within 
their cas genes or contained short repeats (1-3) or no CRISPR element at all. 
There was no mention of integration of proto-spacer sequences into the 
CRISPR elements of the strains tested. All of these findings therefore suggest 
that C. jejuni PT14, which possesses a cstIII sialyltransferase gene, would not 
be as resistant to bacteriophage infection as the cstII-positive isolates used 
within their study. Based on these results, an assumption can also be made that 
C. jejuni PT14 retains a functional CRISPR-cas system as a bacterial defence 
mechanism against bacteriophage infection. 
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3.3.5 Genome analysis does not provide clear rational for the 
phage-sensitivity of C. jejuni PT14 
The genome of C. jejuni PT14 has considerable synteny with the genomes of 
C. jejuni IA3902 and NCTC 11168, containing no prophage-associated 
elements or genomic islands. No obvious features were identified via the 
genome analysis that could explain the bacteriophage-sensitive nature of C. 
jejuni PT14 over any other strain. Nevertheless, continued exposure to 
bacteriophages may cause C. jejuni PT14 to evolve over time or may even 
force this strain to make better use of its host defence mechanisms in order to 
overcome phage predation. 
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4.1 INTRODUCTION 
Bacteriophages rely on their bacterial host during reproduction as a means of 
providing the appropriate substrates and metabolic machinery to allow efficient 
production of progeny. Usually this involves redirecting the host cellular 
metabolism for viral production and thus allows the phages to regulate host 
macromolecular synthesis. Earlier studies have shown that in some instances, 
such as with the T-even bacteriophages (T2, T4 and T6) of E. coli, there is 
extensive shutdown of host DNA synthesis within a few minutes of infection 
(reviewed by Koerner & Snustad 1979). On the other hand, transcription of 
host DNA has been found to continue late into the phage lytic cycle during 
infection with phages like ĭ29 of Bacillus subtilis (Schachtele et al. 1972).  
 
Active bacteriophage replication is a density-dependent process whereby a 
threshold density of host bacteria must be present in order for phage numbers 
to increase (Wiggins & Alexander 1985; Payne et al. 2000; Payne & Jansen 
2001). Wiggins and Alexander (1985) investigated the existence of critical 
thresholds that may be required for phage replication to take place. Using a 
number of different hosts they found that a minimum concentration of about 4 
log10 CFU ml-1 was required for phage numbers to increase. This host density 
threshold value was later referred to by Payne and Jansen (2001) as the 
proliferation threshold, which refers to the minimum concentration of bacteria 
required for there to be an increase in the phage population. Payne and Jansen 
(2001) also introduced another term, the viral inundation threshold, which 
refers to the concentration of bacteriophage required to cause a decrease in the 
host population. 
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Cairns et al. (2009) investigated phage-bacteria interactions using the 
Campylobacter bacteriophage CP8 and the minimally passaged broiler chicken 
isolate C. jejuni strain GIIC8 (Loc Carrillo et al. 2005). Their models took into 
account the proliferation and inundations thresholds hypothesised by Payne 
and Jansen (2001). The results revealed a proliferation threshold of around 5-6 
log10 CFU ml-1 for their chosen strain of phage and bacterium. The minimum 
concentration of bacteriophage before a decrease in Campylobacter occurred, 
or the inundation threshold, was around 7 log10 PFU ml-1. These interaction 
experiments therefore illustrated that there was no net increase in the 
bacteriophage population until the host concentration reached the proliferation 
threshold. 
 
To date, only a few studies have examined global changes in host gene 
expression during infection by lytic bacteriophages (Karlsson et al. 2005; 
Poranen et al. 2006; Ravantti et al. 2008; Fallico et al. 2011; Ainsworth et al. 
2013). These studies have all used microarray technology validated by 
quantitative real-time PCR to profile the bacterial transcriptome under phage 
infection. Cells were generally harvested from samples with the aim to span 
the entire phage replication cycle. A consistent feature arising from these 
studies, was that the majority of changes in host gene expression only occurred 
during the later stages of phage infection, after virion components had already 
been synthesised (Poranen et al. 2006; Ravantti et al. 2008; Ainsworth et al. 
2013). However, the results thus far do not suggest a universal host 
transcriptional response to phage infection. For instance, changes in E. coli 
gene expression in response to bacteriophage PRD1 infection showed that 
  Chapter 4 
148 
 
some of the most highly up-regulated genes included chaperonins, proteases 
and other stress-related genes of the heat shock regulon as well as components 
of the phage shock regulon and several genes related to synthesis of 
exopolysaccharides of the cell surface (Poranen et al. 2006). However, 
investigating the transcriptional response of Pseudomonas aeruginosa to 
infection with phage PRR1, which uses a similar cell surface receptor complex 
to that of phage PRD1 and as a result shares the same broad host range, 
resulted in. differential expression of genes encoding products whose functions 
were mostly linked to transport, energy production and protein synthesis 
(Ravantti et al. 2008). In addition, host gene changes during phage c2 infection 
of Lactococcus lactis subspecies lactis IL1403 were mostly associated with 
cell envelope processes, regulatory functions and carbohydrate metabolism, 
with up-regulation of genes encoding proteins involved in membrane stress, D-
alanylation of cell wall lipoteichoic acids, maintenance of the proton motive 
force and energy conservation (Fallico et al. 2011). However, infection of L. 
lactis UC509.9 with phages c2 and Tuc 2009 resulted in more phage-specific 
host responses, although there were only a few shared differentially transcribed 
genes between cells infected by the two phages (Ainsworth et al. 2013). The 
shared host response, which showed similarities to that observed by Fallico et 
al. (2011), involved differential expression of genes related to catabolic flux 
and energy production, cell wall modification and the conversion of 
ribonucleotides to deoxyribonucleotides.  
  
A number of studies have opted to monitor expression of phage-specific 
transcripts over an infection cycle instead of characterising host transcription 
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using either solely quantitative real-time PCR (Clokie et al. 2006) or 
microarray technology validated by quantitative real-time PCR (Luke et al. 
2002; Duplessis et al. 2005; Liu & Zhang 2008; Berdygulova et al. 2011; 
Pavlova et al. 2012). Phage gene expression was generally regulated in a 
temporal manner by identification of early, middle and late transcriptional gene 
classes. However, temporal assignments varied amongst the different studies, 
which were either based on the initial appearance of a transcript (Luke et al. 
2002), the time interval during which the greatest change in transcript 
abundance occurred (Duplessis et al. 2005; Sevostyanova et al. 2007) or the 
time interval during which transcript abundance peaked (Clokie et al. 2006; 
Berdygulova et al. 2011; Pavlova et al. 2012). Many of the early genes 
encoded products of no known function as well as proteins involved in 
transcriptional regulation. The middle genes encoded proteins predicted to be 
involved in DNA replication, recombination and nucleotide metabolism, 
whereas the late genes mostly encoded proteins related to capsid and tail 
morphogenesis, DNA packaging and host cell lysis.  
 
Using bioinformatic and biochemical approaches, it was also possible to 
identify early, middle and late phage promoters (Sevostyanova et al. 2007; 
Berdygulova et al. 2011; Pavlova et al. 2012). These promoters were 
recognised by the host RNA polymerase enzyme, which typically catalyses 
bacterial transcription. RNA polymerase is composed of four catalytic subunits 
(Į, ȕ, ȕ¶DQGȦ) and a regulatory subunit (sigma factor). Bacterial transcription 
is initiated when the catalytic core of the RNA polymerase binds to a sigma 
factor and recognises a specific consensus sequence of the promoter, which is 
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located around positions -35 and -10 relative to the transcriptional start site at 
+1. Some bacteriophages, such as phage T4, do not encode their own RNA 
polymerase or associated sigma factors but instead utilise those of the host in 
order to transcribe their genes. Previously, two phage-encoded proteins were 
identified that bind to RNA polymerase in vitro and prevented recognition of 
the consensus sequence (Berdygulova et al. 2011; Pavlova et al. 2012). This 
therefore inhibited transcription from host promoters but however allowed 
transcription from the middle or late phage promoters (Berdygulova et al. 
2011; Pavlova et al. 2012). These proteins may therefore be involved in 
shutting off host transcription and causing the shift from host to viral 
transcription. Such studies have provided a better understanding of the 
temporal regulation of gene expression in bacteriophages. 
 
With the introduction of direct cDNA sequencing (RNA-seq) for whole-
transcriptome analysis, some of the limitations associated with previous high-
throughput approaches, such as microarray technology, were clearly 
highlighted. For instance, microarrays are usually designed based on known 
transcripts and may therefore cause gene expression to be viewed in a biased 
manner. In fact, this technique lacks the ability to detect novel transcripts and 
also has the potential for non-specific or cross-hybridisations to occur. 
Microarrays also rely on indirect measurements of the hybridisation intensity 
of labelled cDNA to oligonucleotide probes whilst the RNA-seq approach 
allows direct mapping of sequence data to a sequenced reference genome. In 
addition, RNA-seq has provided many advantages over hybridisation-based 
techniques including greater sensitivity, a larger dynamic range, less 
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background noise and the ability to detect transcripts in an annotation-
independent manner. Thus, early studies revealed RNA-seq as a revolutionary 
tool for investigating the transcriptome of prokaryotic organisms as these 
studies were able to identify rare or novel transcripts, accurately define 
operons, discover expression of putative noncoding RNAs (ncRNAs) and 
correct existing gene annotations (Yoder-Himes et al. 2009; Passalacqua et al. 
2009; Perkins et al. 2009; Parkhomchuk et al. 2009; Sharma et al. 2010; 
Filiatrault et al. 2010). However, it has been more challenging to examine the 
bacterial transcriptome compared to that of eukaryotes. This has mainly been 
due to the fact that total RNA of bacterial cells is typically comprised of less 
than 5% of messenger RNA (mRNA). In addition, the lack of polyadenylation 
DW WKH ¶-end, which occurs with mature mRNA in eukaryotes, prevents 
specific targeting of bacterial mRNA. To overcome this, mRNA enrichment 
protocols have been used to increase mRNA recovery, including the removal 
of ribosomal RNA (rRNA) by hybridisation to complementary oligonucleotide 
sequences that target specific regions of the 5S, 16S and 23S rRNAs (Chen & 
Duan 2011; Giannoukos et al. 2012; Peano et al. 2013). 
 
Two key factors to be considered when carrying out a transcriptome analysis 
using sequencing are read lengths and the number of reads obtainable in a 
sequencing reaction. It has previously been reported that short read lengths 
may cause reads to align to multiple locations of the reference genome (Bloom 
et al. 2009; Passalacqua et al. 2009). As a result, such ambiguously mapped 
reads may influence subsequent analyses to determine gene expression levels, 
and may be better excluded (Passalacqua et al. 2009). In addition, the bacterial 
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transcriptome generally consists of coding RNA (mRNA) and small ncRNAs 
(rRNA, tRNA and regulatory RNAs). However, if transcripts of ncRNAs are 
highly abundant and therefore more frequently sequenced, this can reduce the 
number of reads available for low abundance mRNA transcripts (Bloom et al. 
2009).  Bloom et al. (2009) separated their reads into unique sequences which 
mapped to either an ORF, a rRNA gene or a tRNA gene and compared them to 
reads which mapped to multiple locations. They found that most unique reads 
originated from ORFs but that a large number of the multiple-mapping reads 
were derived from highly abundant rRNA genes despite including a rRNA 
depletion step prior to their cDNA library preparation.  
 
A potential shortcoming of RNA-seq is the inability of standard cDNA 
libraries to preserve information on the direction of transcription. 
Directionality is especially crucial in cases where transcripts may be generated 
from both strands and would therefore influence determination of gene 
expression levels. Several protocols have been developed to allow strand-
specific RNA-seq, including modification of the RNA molecule prior to 
reverse transcription E\OLJDWLRQRID¶51$OLQNHU(Passalacqua et al. 2012), 
or chemical modification during second strand cDNA synthesis by adding 
VSHFLILF UHVLGXHV WR WKH ¶-end, followed by subsequent degradation of the 
unmarked strand (Parkhomchuk et al. 2009; Levin et al. 2010). Another very 
useful feature of RNA-seq is the ability to discriminate between primary and 
processed transcripts (van Vliet 2010). Primary transcripts, including mRNAs 
DQGQF51$VFDUU\D¶WULSKRVSKDWHHQG¶333ZKLOHSURFHVVHGWUDQVFULSWV
including rRNAs and tRNAs, carry a ¶ PRQRSKRVSKDWH ¶3. A sequencing 
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approach known as differential RNA-seq (dRNA-seq) allows selective 
sequencing of primary transcripts without prior rRNA removal (reviewed by 
Sharma & Vogel 2014) and can be used for annotation of transcriptional start 
sites (TSSs). The dRNA-seq libraries are prepared by splitting the RNA 
VDPSOH LQWR WZR DQG OHDYLQJ RQH XQWUHDWHG WR FDSWXUH ERWK ¶333 DQG ¶3
RNAs. For the second sample, processed RNAs are depleted by treatment with 
¶3-GHSHQGHQWWHUPLQDWRUH[RQXFOHDVH7(;ZKLFKGHJUDGHVWKH¶351$V 
Directionality is also maintained with this method. The dRNA-seq method was 
first used to describe the primary transcriptome of H. pylori under five 
different growth conditions and was successful in identification of at least 
1,900 TSSs and assignment of antisense TSSs to 46% of the genes (Sharma et 
al. 2010). 
 
A number of  studies have examined the transcriptome of C. jejuni using RNA-
seq technology (Chaudhuri et al. 2011; Dugar et al. 2013; Taveirne et al. 2013; 
Porcelli et al. 2013; Butcher & Stintzi 2013). In some instances, dRNA-seq 
was used to enable selection of unprocessed RNA species and allowed the 
primary transcriptome of C. jejuni to be determined (Dugar et al. 2013; 
Porcelli et al. 2013), along with identification of a novel type-II CRISPR/Cas 
system amongst multiple Campylobacter strains (Dugar et al. 2013). 
Variations of strand-specific sequencing were utilised in other cases to 
determine ncRNAs and antisense transcription (Chaudhuri et al. 2011; 
Taveirne et al. 2013; Butcher & Stintzi 2013). The earliest RNA-seq study of 
the C. jejuni transcriptome characterised the regulon of the sigma factor RpoN 
(ı54), which regulates expression of genes involved in flagellar biosynthesis, 
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and expression data was compared to previous microarray data (Chaudhuri et 
al. 2011). A proteome study was also conducted to supplement the 
transcriptome data (Chaudhuri et al. 2011). RNA-seq technology has also been 
used to examine the transcriptome of Campylobacter during colonisation of the 
chicken caecum and 250 genes were identified that were differentially 
expressed in vivo (Taveirne et al. 2013). More recently, the transcriptional 
response of C. jejuni to iron limitation was reported (Butcher & Stintzi 2013) 
and a more extensive examination of the transcriptome under these conditions 
was provided compared to previous work utilising microarray technology 
(Palyada et al. 2004; Holmes et al. 2005). 
 
In this chapter, the transcriptome of C. jejuni PT14 was examined during 
phage infection with group III phages CP30A and CPX in order to characterise 
differential expression patterns. Thus far, there are no published studies 
reporting host or phage transcription during bacteriophage infection of 
Campylobacter with virulent phages.  
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4.2 RESULTS 
4.2.1 In vitro growth curves for RNA isolation and protein 
extraction 
Growth experiments were conducted to harvest cells for RNA isolation and 
protein extraction as described in section 2.6.1. Briefly, three independent 
cultures of C. jejuni PT14 were grown for 6 hours in 150 ml of nutrient broth 
No. 2 (2.1.5) under microaerobic conditions (2.2.2) with shaking at 100 rpm. 
In order to determine the response of C. jejuni to bacteriophage infection, 
samples for RNA isolation were taken during the eclipse phase of 
bacteriophage growth (2.6.2). This would therefore allow Campylobacter cells 
that were most likely under bacteriophage infection to be captured. This 
approach was adopted taking into account the findings of previous studies 
where major changes in the host transcriptional response to phage infection 
occurred only during the later stages of infection (Poranen et al. 2006; Ravantti 
et al. 2008; Ainsworth et al. 2013). 
 
In order to generate an infectable host population that could achieve a 
synchronous fall and provide sufficient cells to be harvested for RNA isolation 
purposes, appropriate infection conditions were sought. A number of growth 
experiments were performed with the aim of determining suitable host and 
viral concentrations that would encourage phage to potentially infect at a rate 
of 1 phage per 1 bacterial cell. An effective MOI of 1 was found to achieve a 
synchronous infection and fall in the Campylobacter population. The initial 
Campylobacter concentration was chosen to take into account the finding of 
Cairns et al. (2009), who observed that an increase in bacteriophage growth 
  Chapter 4 
156 
 
was observed after their Campylobacter population had reached 5-6 log10 CFU 
ml-1. Therefore initial C. jejuni densities of at least 6.0 log10 CFU ml-1 were 
selected. However, it was determined that a bacterial density of 7.0 log10 CFU 
ml-1 for CP30A-infected cells was required to enable the harvesting of 
sufficient phage-infected cells for RNA isolation over a 6 hour period. Viable 
counts of triplicate cultures were performed and the RNA preparations selected 
post-hoc for RNA-seq analysis represented infected cell populations directly 
before synchronous lysis. For CPX-infected C. jejuni PT14 populations, 
synchronous lysis occurred when the bacterial density reached close to 7.0 
log10 CFU ml-1 (Figure 4-1). Therefore to achieve exponentially growing C. 
jejuni PT14 cultures at 7.0 log10 CFU ml-1, initial inoculums of 6.0 log10 CFU 
ml-1 were prepared in order that similar eclipse phase phage-infected cell 
populations to that of the CP30-infected cells could be harvested prior to lysis.  
 
Figure 4-1 illustrates growth of C. jejuni PT14 in the absence and presence of 
CP30A (A) and CPX (B) following optimisation of the infection conditions. 
Bacteriophages were added at the second hour of bacterial growth and an 
approximate 1-log decrease in the CP30A- and CPX-infected C. jejuni PT14 
population was observed at 3 and 4 hours post-infection respectively. This 
population decline occurred when the concentration of Campylobacter cells 
infected with CP30A and CPX had reached approximately 7.7 log10 CFU ml-1 
and 7.1 log10 CFU ml-1 respectively. These concentrations are in excess of the 
bacteriophage proliferation threshold. Although bacteriophage growth is not 
illustrated in Figure 4-1, the phages were titrated at intervals throughout the 
experiment and the phage progeny produced following the decrease in  
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Figure 4-1. In vitro growth curves of C. jejuni PT14 in the presence and 
absence of bacteriophages CP30A (A) and CPX (B). 
Cultures were grown in 150 ml of NB no. 2 and initial C. jejuni densities were 
chosen to enable harvesting of sufficient phage-infected cells for RNA 
isolation. The red arrows indicate the time point where CP30A and CPX were 
added. Samples were collected for total RNA isolation at the time points prior 
to host cell lysis (2 and 3 hours post-infection respectively) and at the 
equivalent time points for phage-uninfected cultures (green arrows). Values for 
bacterial growth (CFU ml-1) are generated from 3 independent cultures ± SD 
and plotted as a function of time. Bacteriophages were titrated at intervals 
throughout the experiment to confirm their replication and effective MOI (data 
not shown). 
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C. jejuni population was verified (2.5.3). Cells were harvested from the three 
biological replicates for RNA isolation at 2 and 3 hours post-infection for the 
CP30A and CPX-infected cultures repectively. These time points represent the 
points directly before the decrease in C. jejuni PT14 numbers was observed 
and should also correspond to the esclipse period of phage growth. In Figure 4-
1, these are illustrated by the green arrows and bacterial concentrations were 
verified by Campylobacter enumerations (2.2.4). 
 
4.2.2 Transcriptome analysis of C. jejuni during phage infection 
Total RNA was isolated from the uninfected and phage-infected cells using the 
Trizol Max Bacterial Isolation kit (Invitrogen) according to section 2.12.1 and 
was purified using an RNeasy Mini kit (Qiagen). The RNA was quantified 
using a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies) and 
the integrity was measured using a Bioanalyser 2100 (Agilent Technologies 
Inc.). All samples selected for cDNA library preparations had RIN numbers of 
at least 7.0. Ribosomal RNA was depleted from the total RNA according to 
section 12.2.2 using the Ribo-Zero rRNA removal kit for Gram negative 
bacteria (Epicentre Biotechnologies). Two µg of the rRNA depleted RNA was 
then used to prepare cDNA libraries using the ScriptSeq mRNA-Seq library 
preparation kit (Epicentre Biotechnologies). The libraries were individually 
indexed, pooled and then sequenced using an Illumina HiSeq 2000 sequencing 
system. 
 
The RNA-sequencing generated an average of approximately 28 million reads 
per sample (Table 4-1), each of which was 50 nucleotides in length and from 
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paired-ends. CLC Genomics Workbench version 6.0 software was used to 
remove the adapter indexes and filter the raw reads (section 2.12.4.1). Principle 
component analysis of the datasets demonstrated the replicates clustered 
according to their origin (Figure 4-2). The filtered reads were mapped against 
the C. jejuni PT14 reference genome (Brathwaite et al. 2013) according to 
section 2.12.4.2. Table 4-1 provides a summary of the number of reads attained 
after filtering as well as illustrates the number of reads that aligned uniquely to 
the reference genome. Figures 4-3 to 4-6 illustrate how the mapped reads were 
distributed over specific genes and displayed within the CLC Genomics 
Workbench. All unmapped reads were collected and BLAST searches 
confirmed some of them were of bacteriophage origin. 
 
4.2.3 Differential host gene expression during bacteriophage 
infection of C. jejuni 
In order to identify genes that were regulated in response to bacteriophage 
infection, reads that mapped uniquely to the C. jejuni PT14 genome were 
firstly normalized for transcript length and the total number of reads by 
calculating the reads per kilobase of transcript per million mapped reads 
(RPKM) (Mortazavi et al. 2008). This was done using the CLC Genomics 
Workbench 6.0 package and generated expression values that allowed for 
comparisons between genes and infection conditions. Significant differential 
JHQH H[SUHVVLRQ ZDV DVVHVVHG XVLQJ WKH %DJJHUO\¶V VWDWLVWLFDO test on 
expression proportions (Baggerly et al. 2003). To correct for multiple 
hypothesis testing, p-values were adjusted by applying the false discovery rate 
controlling method of Benjamini and Hochberg (1995). 
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Figure 4-2. Principle component analysis of RNA-seq reads for C. jejuni 
under bacteriophage infection. 
The uninfected C. jejuni PT14 replicates are illustrated in red while the 
CP30A-infected and CPX-infected replicates are shown in green and blue 
respectively. Each condition is displayed as a distinct group, with patterns of 
similarity being exhibited in each case. 
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Table 4-1. Analysis of RNA-seq data for reads mapped against the C. jejuni PT14 genome. 
Condition Original read count Number of reads after trimming Number of uniquely mapped reads  
Uninfected C. jejuni PT14 replicate 1 47,972,332 22,793,829 18,326,585 
Uninfected C. jejuni PT14 replicate 2 37,012,236 17,115,514 12,893,941 
Uninfected C. jejuni PT14 replicate 3 24,676,752 13,051,011 10,660,977 
CP30A-infected C. jejuni replicate 1 25,744,022 11,585,083 6,603,483 
CP30A-infected C. jejuni replicate 2 25,935,970 15,119,809 10,237,483 
CP30A-infected C. jejuni replicate 3 23,851,478 14,041,695 10,596,450 
CPX-infected C. jejuni replicate 1 22,349,820 14,512,973 10,790,373 
CPX-infected C. jejuni replicate 2 20,865,460 13,067,709 9,149,500 
CPX-infected C. jejuni replicate 3 23,071,418 15,172,122 10,545,329 
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Figure 4-3. RNA-seq data mapped against the C. jejuni PT14 genome, 
showing read distribution for the cgb gene (A911_07630).   
Data are shown for uninfected (top panel) and CP30-infected PT14 (bottom 
panel). Reads are illustrated by horizontal green (forward orientation) and red 
(reverse orientation) lines. After 30 rows of reads, an overflow graph following 
the same colour scheme is displayed below the reads. Mismatches between the 
reference sequence and the mapping data are highlighted in red (A), blue (C), 
green (T) and yellow (G). Coverage is displayed relative to the total number of 
reads and is shown above the reads. The cgb gene is up-regulated in the CP30-
infected PT14 sample. The RNA-seq data have been visualised using CLC 
Genomics Workbench. 
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Figure 4-4. RNA-seq data mapped against the C. jejuni PT14 genome, 
showing read distribution for the flaC gene (A911_03515).   
Data are shown for uninfected (top panel) and CP30-infected PT14 (bottom 
panel). Reads are illustrated by horizontal green (forward orientation) and red 
(reverse orientation) lines. After 30 rows of reads, an overflow graph following 
the same colour scheme is displayed below the reads. Mismatches between the 
reference sequence and the mapping data are highlighted in red (A), blue (C), 
green (T) and yellow (G). Coverage is displayed relative to the total number of 
reads and is shown above the reads. The flaC gene is down-regulated in the 
CP30-infected PT14 sample. The RNA-seq data have been visualised using 
CLC Genomics Workbench. 
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Figure 4-5. RNA-seq data mapped against the C. jejuni PT14 genome, 
showing read distribution for the iron uptake genes A911_07990-
A911_08015 (cj1658-cj1663).   
Data are shown for uninfected (top panel) and CPX-infected PT14 (bottom 
panel). Reads are illustrated by horizontal green (forward orientation) and red 
(reverse orientation) lines. After 34-35 rows of reads, an overflow graph 
following the same colour scheme is displayed below the reads. Mismatches 
between the reference sequence and the mapping data are highlighted in red 
(A), blue (C), green (T) and yellow (G). Coverage is displayed relative to the 
total number of reads and is shown above the reads. Genes A911_07990, 
A911_07995, A911_08000, A911_08005, A911_08010 and A911_08015 are 
all up-regulated in the CPX-infected PT14 sample. The RNA-seq data have 
been visualised using CLC Genomics Workbench.  
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Figure 4-6. RNA-seq data mapped against the C. jejuni PT14 genome, 
showing read distribution for the nrfA gene (A911_06595).   
Data are shown for uninfected (top panel) and CPX-infected PT14 (bottom 
panel). Reads are illustrated by horizontal green (forward orientation) and red 
(reverse orientation) lines. After 30 rows of reads, an overflow graph following 
the same colour scheme is displayed below the reads. Mismatches between the 
reference sequence and the mapping data are highlighted in red (A), blue (C), 
green (T) and yellow (G). Coverage is displayed relative to the total number of 
reads and is shown above the reads. The nrfA gene is down-regulated in the 
CPX-infected PT14 sample. The RNA-seq data have been visualised using 
CLC Genomics Workbench. 
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Infection of C. jejuni PT14 with CP30A produced differential regulated 
H[SUHVVLRQ-fold, padj<0.05) of 100 genes compared to uninfected control 
cultures, which may be compared to differential regulation of expression of 
466 genes in response to CPX infection. These values represent 6.2% and 
28.7% of the overall host genetic makeup, suggesting that CPX had more of a 
measurable effect on the host genes than CP30A. A total of 68 genes were 
identified that showed common transcriptional responses to infection by 
bacteriophages CP30A and CPX. In addition, there was quite an even 
distribution between up- and down-regulated genes following CP30 infection 
as just under half of the genes showed increased abundance (49 out of 100). 
However, the distribution of regulated genes in response to CPX infection was 
less evenly spread with more than three quarters of the CPX-regulated genes 
(360 out of 466) showing up-regulation. Figure 4-7 provides a summary of the 
distribution of the regulated genes in response to infection with either phage 
and the number of common genes exhibiting similar behaviour in response to 
infection by either phage. In addition, Figure 4-8 illustrates the log2(RPKM+1) 
values obtained for uninfected PT14 plotted against the equivalent values for 
CP30A and CPX-infected PT14 respectively. Up- and down-regulated genes 
are colour-coded in yellow and red respectively. 
 
Genes displaying significant differential expression were classified into 
functional categories, according to the scheme originally used by the Sanger 
Centre for the C. jejuni genome database (Parkhill et al. 2000). Figure 4-9 
shows Circos diagrams (Krzywinski et al. 2009) depicting these classifications. 
Genes from the two datasets show similarities in the functional profiles of the  
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Figure 4-7. Distribution of differentially expressed genes in response to 
bacteriophage infection.  
The distribution of genes significantly differentially expressed in response to 
phage CP30A infection is represented by the red circle, while the blue circle 
shows those for the CPX infection. Between the two conditions, there were 32 
genes in common that were activated in response to bacteriophage infection 
while 35 common genes were found to be repressed. 
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Figure 4-8. Differential gene expression in C. jejuni PT14 in response to 
infection with bacteriophages CP30A(A) and CPX(B). 
The average log2(RPKM+1) value for each gene in the PT14 genome was 
calculated and plotted for the uninfected and phage-infected PT14 isolates 
using RPKM values for 3 biological replicates.  Significantly differentially 
expressed genes (1.5-fold, *padj<0.05) are highlighted in yellow (up-
regulated) and red (down-regulated).  
*padj<0.05 ± corrected p-value representing a false discovery rate of <5% 
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Figure 4-9. C. jejuni PT14 genes differentially expressed in response to 
phage infection ordered by functional category. 
Individual genes that were found to be greater than 1.5 fold differentially 
expressed in response to CP30 phage infection (A) or CPX phage infection (B), 
compared to uninfected bacteria, are represented using Circos diagrams 
(Krzywinski et al. 2009) with each gene represented and colour-coded according 
to functional class (Parkhill et al. 2000; Gundogdu et al. 2007) as follows: 1A 
Degradation; 1B Energy metabolism; 1C Central intermediary metabolism; 1D 
Amino acid biosynthesis; 1E Polyamine synthesis; 1F Purines, pyrimidines, 
nucleosides and nucleotides; 1G Biosynthesis of cofactors, prosthetic groups and 
carriers; 2 Broad regulatory functions and signal transduction; 3A Synthesis and 
modification of macromolecules; 3B Degradation of macromolecules; 3C Cell 
envelope; 4A Transport/binding proteins; 4B Chaperones, chaperonins, heat 
shock; 4C Cell division; 4D Chemotaxis and mobility; 4E Protein and peptide 
secretion; 4G Detoxification; 4I Pathogenicity; 5A IS elements; 5D 
Drug/analogue sensitivity; 5G Antibiotic resistance; 5H Conserved hypothetical 
proteins; 5I Unknown; 6A Miscellaneous. Histograms in the central rings 
represent the fold change with increased expression on infection represented by 
red bars and reduced expression represented by black bars. Asterisk in A 
indicates a greater than 5 fold change in expression. Each gene is labelled 
individually in A whilst only genes that are differentially expressed in both data 
sets, are labelled in B to avoid congestion.  
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differentially regulated genes, with the CP30A-infected regulated genes being 
assigned to 17 categories while the CPX-infected regulated genes were 
classified into 24 categories. A high number of up-regulated genes in response 
to both infection conditions were related to cell envelope and transport or 
binding protein functions, while those regulated in response to CPX infection 
were also involved in synthesis of macromolecules. Several down-regulated 
genes for both infection conditions were associated with energy metabolism 
and cell envelope functions. 
 
Among the genes that were up-regulated in response to infection of C. jejuni 
PT14 by phages CP30A or CPX, were a substantial number classified in 
transport or binding protein functions that encode products involved in iron 
acquisition. For infection with either phage, these include the gene loci 
associated with the transport of rhodotorulic acid (A911_07990/cj1658, 
A911_07995/p19, A911_08000, A911_08005, A911_08010 and 
A911_08015/cj1660-cj1663). With the exception of the p19 gene, this operon 
represents the top five most highly expressed genes in response to CPX 
infection of C. jejuni PT14, with A911_08005 being the most up-regulated at 
9.5-fold higher than the uninfected samples. There were also several other iron 
acquisition genes that showed increased abundance in the CPX-infected 
samples, including most of those involved in the ferric enterochelin uptake 
system (cfrA, ceuBDE), haemin uptake system (chuABC) and the ferri-
transferrin uptake system (cfbpBC). Many components of the three TonB 
energy transduction systems (exbB1 (both phages), exbB2 (both phages)-
exbD2-tonB2 and exbD3-tonB3) also showed elevated levels of transcription in 
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response to CPX infection. In addition, some genes known to be associated 
with oxidative stress defence in C. jejuni were also up-regulated in response to 
infection with CPX, including katA, sodB, perR, A911_06735/cj1386, 
A911_08020/cj1664 (CP30A and CPX), A911_08025/cj1665 and 
A911_02725/cj0559.  
 
The genes exhibiting the greatest differential expression in response to CP30A 
infection of C. jejuni PT14 were cgb (+63.97-fold) and ctb (+7.92-fold), which 
encode a single domain haemoglobin and a truncated haemoglobin 
respectively, and are known to be involved in nitrosative stress defence. The 
cgb gene was also up-regulated (+1.98-fold) in response to CPX-infection, but 
although ctb was also up-regulated by this phage, it fell below the 1.5 fold cut-
off (+1.18-fold). Two other nitrosative stress responsive genes of unknown 
function were also up-regulated in response to CP30A infection, these are 
A911_03685/cj0761 (CPX also) and A911_04025/cj0830. In addition, CP30A 
increased expression of genes encoding a ribosomal protein (rplR), a subunit of 
RNA polymerase (rpoC) and the tryptophan biosynthesis gene locus 
(trpABFDE). The trpA and trpF genes were also up-regulated by CPX. 
 
Genes coding for proteins involved in cell envelope functions related to surface 
polysaccharides, lipopolysaccharide and antigens (kpsS, neuB2, neuC2, 
A911_06918/cj1421c) also showed increased expression in response to phage 
infection. Interestingly, cj1421c was previously reported to encode a product 
that was identified as a specific target for bacteriophage F336 (Sørensen et al., 
2011). A considerable number of genes co-regulated by CPX were also related 
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to synthesis and modification of macromolecules including several that 
encoded proteins involved in DNA replication, restriction/modification and 
repair (dnaA, dnaX, nth, mutY, polA, ruvB, ruvC, topA, ung, uvrC and xerD).   
 
Four genes encoding products related to the host defence system were up-
regulated in response to CPX infection. These were the genes encoding a 
CRISPR-associated Cas protein, cas2 (A911_07325), the gene encoding a 
member of the Type I R-M system of PT14, hsdS (A911_07470) as well as 
genes encoding an adenine specific (A911_01010) and site-specific DNA 
methyltransferase. 
 
Genes encoding products involved in respiration (hypD and hypF) and in 
particular, aerobic respiration (nuoA and nuoB), were found to be up-regulated 
by CPX. Other notable genes that showed elevated levels of transcription for 
the phage-infected samples included those predicted to encode proteins 
associated with aerobic transport of C4-dicarboxylates (A911_00230/cj0046), 
transport of phosphates (pstSCAB)  and phosphate-containing molecules (peb3) 
as well as transport [cstA, A911_00990/cj0204 (CPX only), 
A911_07600/cj1580c (CPX only)] and secretion of peptides [secY (CP30 
only)].  
 
The RNA-seq data indicated that in response to infection by either 
bacteriophage, there was an increase in expression of the gene 
A911_00180/cj0037c which encodes a cytochrome c. This was an interesting 
finding because other similar genes encoding products related to electron 
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transport during respiration were found to be down-regulated. The complete 
dataset of genes up-regulated in PT14 in response to infection with CP30A and 
CPX, along with their fold changes and adjusted p-values, is listed in 
appendices 1 and 3 respectively. 
 
The down-regulated genes in response to phage infection encoding products 
related to energy metabolism including some involved in glycolysis [fba, gapA 
and pyk (all CPX only)], the tricarboxylic acid cycle [sdhABC, frdABC 
(CP30A only) and acnB (CP30A only)] and electron transport during 
respiration [A911_01280/cj0265c, nrfA, nrfH, ccoN (CP30A only), ccoOPQ, 
napAGHB, petC (CP30A only) and fdxA (CPX only)]. Two notable genes that 
were down-regulated in response to infection with either phage were those 
encoding a molybdopterin oxidoreductase (A911_00025/cj0005c), which 
exhibited the greatest differential fall in response to CP30A infection (-4.33-
fold), and a hypothetical protein in C. jejuni PT14 that encodes a monohaem 
cytochrome c in NCTC 11168 (A911_00020/cj0004c). These two genes have 
been found to represent a sulphite respiration system in C. jejuni. There was 
also a reduction in transcription levels of the genes dcuA (CPX only) and dcuB, 
which encode two anaerobic C4-dicarboxylate transporters. In addition, the 
down-regulated genes encoding products related to amino acid biosynthesis 
were ilvI (CP30A only), leuA, leuB, leuC, PHW&¶, dapA and aroC (all CPX 
only) while some of those related to central intermediary metabolism functions 
include gltB, gltD, aspA and glmU (CPX only).  
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The majority of the genes down-regulated by CPX that were related to cell 
envelope functions encode products associated with flagellar biogenesis, 
including those involved in formation of the flagellar filament (flaB and flaG), 
hook (flaD, flgE, flgE2 and flgK) and rod (flgB, flgG, flgG2, flgH and flgI) as 
well as flagellar chaperones (flgD and fliK). The third flagellin gene (flaC) was 
also found to be down-regulated in response to infection by either CP30A or 
CPX. Genes related to chemotaxis and mobility (A911_01265/cj0262c and 
A911_07520/cj1564) as well as heat shock (hrcA and groES) were also down-
regulated in response to infection of PT14 with CP30A only. 
 
A striking observation was the down-regulation of the cft gene in response to 
CP30A infection and of the fdxA gene in response to CPX-infection, which are 
suggested to have roles in oxidative stress defence in Campylobacter. These 
genes encode a non-haem iron-containing ferritin and a ferredoxin protein 
respectively. This was particularly interesting because genes with similar 
function were found to be up-regulated in response to phage infection. The 
complete dataset of genes down-regulated in PT14 in response to infection 
with bacteriophages CP30A and CPX is listed in appendices 2 and 4 
respectively. 
 
4.2.4 Examination of bacteriophage transcription 
In order to have an idea of bacteriophage transcription during infection of C. 
jejuni PT14, all reads from the CP30A- and CPX-infected samples were 
mapped against the reference genomes for CP30A (GenBank accession 
number JX569801) and CPX (GenBank accession number JN132397) 
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according to section 2.12.4.2. The reads were normalized for gene length and 
the total number of reads by calculating the RPKM (Mortazavi et al. 2008). 
The average RPKM was calculated for the triplicate phage-infected samples 
and this was used as a measure of gene expression. The complete datasets 
showing the average RPKM values for the CP30A- and CPX-infected PT14 
samples during bacteriophage infection are listed in appendices 5 and 6 
respectively. The gene encoding the major capsid protein was the most highly 
expressed transcript by both bacteriophages and other genes encoding products 
that are known to be expressed late in transcription were also abundant such as 
the tail sheath protein, tail tube protein, neck protein, and putative major head 
protein II. The genes encoding the co-chaperone GroES and the prohead core 
scaffold and protease, which function in phage capsid morphogenesis, were 
also highly expressed. Genes encoding products involved in DNA synthesis 
also showed high levels of expression by both phages, including the putative 
sliding clamp DNA polymerase accessory protein, putative sliding clamp 
loader subunit, the single-stranded DNA binding protein and the ribonucleotide 
reductase subunits. 
 
4.2.5 In vitro growth of CP30A- and CPX-infected C. jejuni 
PT14 under iron-limited conditions 
Based on the RNA-seq results, it was decided to examine the requirement for 
iron during bacteriophage infection of C. jejuni PT14. This was done by 
carrying out in vitro growth experiments under iron-depleted conditions (2.7) 
to determine whether phage infection would be affected. Iron depletion was 
mediated by adding ¶¶-dipyridyl (DIP) (2.1.17) to MH broth (2.1.6) to give 
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a final concentration of 20 µM. Uninfected and phage-infected cultures were 
grown in triplicate for 5 hours under these conditions according to section 
2.6.1. Campylobacter cells were enumerated (2.2.4) every two hours and at the 
final hour. This revealed a decrease in viable bacterial density from 7.0 log10 
CFU ml-1 to 4.0 log10 CFU ml-1 for both the uninfected and phage-infected 
cultures over the 5 hours. This therefore suggested that the concentration of 
available iron was too low to support growth of the Campylobacter and 
negatively impacted its survival under these conditions, which would confound 
investigations of bacteriophage infection. 
 
4.2.6 Designing the Cgb-FR and Ctb-FR primers 
In order to further investigate the role of the haemoglobins Cgb and Ctb during 
bacteriophage infection of C. jejuni PT14, the corresponding knockout 
mutations were constructed. Prof. R. Poole (University of Sheffield, UK) 
kindly provided knockout mutant strains in which the cgb (cj1586) and ctb 
(cj0465c) genes had been disrupted in the C. jejuni NCTC 11168 genome 
(Elvers et al. 2004; Wainwright et al. 2005). The cgb mutant, 11168 cgb::Kanr 
(known as RKP1336 or CJCGB01), was constructed by introducing plasmid 
DNA from the suicide plasmid pKE18 into the NCTC 11168 genome by 
electroporation. The plasmid contained a cloning vector comprised of a 1,187-
bp DNA fragment of the cgb gene, where a BglII restriction site was 
introduced. The vector was digested with BglII and a kanamycin resistance 
(Kanr) cassette derived from pJMK30 (van Vliet et al. 1998) was inserted as a 
BamHI fragment. Similarly, the ctb mutant, 11168 ctb::Kanr (known as 
RKP1386) was constructed by introducing plasmid DNA from the suicide 
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plasmid pKE18 into the NCTC 11168 genome by electroporation. The plasmid 
contained a disruption of the ctb gene to create 11168 cgb::Kanr.  
 
The cgb and ctb genes of C. jejuni PT14 are sufficiently conserved to enable 
homologous recombination. Therefore genomic DNAs from the knockout 
mutants 11168 cgb::Kanr and 11168 ctb::Kanr, were used to introduce the 
disruption into the PT14 genome by natural transformation to generate PT14 
cgb::Kanr and PT14 ctb::Kanr (section 2.4). To determine whether the natural 
transformation had been successful, primers Cgb-F and Cgb-R as well as Ctb-F 
and Ctb-R were designed as previously described (2.9.1) to amplify 1,711-bp 
and 1,797-bp DNA fragments of cgb and ctb respectively. 
 
4.2.7 PCR confirmation of C. jejuni PT14 cgb and ctb knockout 
mutation 
Following natural transformation of C. jejuni PT14 with genomic DNAs from 
11168 cgb::Kanr and 11168 ctb::Kanr, genomic DNA was isolated from 
candidate PT14 cgb::Kanr and PT14 ctb::Kanr transformants (2.8). The DNAs 
were PCR amplified using the Cgb-FR and Ctb-FR primers (Table 2-4). 
Genomic DNA was also isolated from 11168 cgb::Kanr and 11168 ctb::Kanr to 
provide positive PCR controls, and from the parental strains, PT14 and NCTC 
11168, to provide negative controls. Figure 4-10 illustrates the agarose gel 
electrophoresis image showing successful amplification of these DNA isolates, 
generating fragments of expected amplicon size for the wild-type and mutant 
strains. 
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4.2.8 In vitro growth of Cgb- and Ctb-deficient C. jejuni PT14 
mutants under bacteriophage infection 
Due to the elevated transcription levels of the PT14 haemoglobin genes cgb 
(A911_07630) and ctb (A911_02270) during bacteriophage infection, their 
importance was further investigated by conducting in vitro growth 
experiments. The knockout mutants, PT14 cgb::Kanr and PT14 ctb::Kanr, were 
grown in triplicate in 50 ml volumes of Nutrient broth No. 2 (2.1.5) over 24 
hours according to section 2.6.1. Bacteriophages CP30A and CPX were added 
to the cultures after 2 hours of initial growth and samples were taken hourly up 
to 4 hours post infection and then every 2 hours until the 24th hour in order to 
monitor the viable count of the host and the phage titre. An initial host 
concentration of 7.0 log10 CFU ml-1 was used for the Cgb- and Ctb-deficient 
mutants. Infection with CP30A resulted in an immediate 3 log drop in bacterial 
numbers, which yielded an increased phage titre of around 2 logs (Figure 4-
11B and C). This was characteristic of what occurred with the wild-type strain 
(Figure 4-11A) and is indicative of synchronous infection, with approximately 
99.9% of the bacterial population under phage infection. The crash in host 
population following CPX infection occurred 2 hours post-infection with either 
mutant, after the bacterial numbers had reached close to 7.5 log10 CFU ml-1. 
This again exhibited an infection pattern similar to that of the wild-type strain 
(Figure 4-12A). The viable counts of the host bacteria were reduced by 
approximately 2.5 logs, which yielded increases in phage titre of around 1.4 
logs for CP30A and 2 logs for CPX (Figures 4-12B and C). However, the 
mean burst sizes calculated from triplicate globin mutant cultures were 
significantly less than those observed for wild type C. jejuni PT14 (ANOVA, 
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p<0.05, n=3). CP30A infection produced the following burst sizes: wild 
type=5.0±0.1, ǻcgb=3.7±0.3, ǻctb=2.5±0.5 pfu per cell; whilst CPX infection 
produced the burst sizes: wild type=5.2±0.2, ǻcgb=3.0±0.3, ǻctb=2.1±0.7 pfu 
per cell.  
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Figure 4-10. 1% Agarose gel of PCR products obtained using Cgb-FR and Ctb-FR primers. 
Lane 1: PT14 WT/Cgb-FR, Lane 2: PT14 WT/Ctb-FR, Lane 3: NEB 100-bp ladder, Lane 4: NCTC 11168 WT/Cgb-FR, Lane 5: NCTC 11168 
WT/Ctb-FR, Lane 6: empty, Lane 7: PT14 cgb::Kanr/Cgb-FR, Lane 8: PT14 ctb::Kanr/Ctb-FR, Lane 9: Promega 1 kb ladder, Lane 10: 11168 
cgb::Kanr/Cgb-FR, Lane 11: 11168 ctb::Kanr/Ctb-FR. The expected amplicon sizes for the fragments generated from the wildtype strains using 
Cgb-FR and Ctb-FR were approximately 311-bp and 397-bp respectively while for the mutants they were 1,711-bp and 1,797-bp respectively. 
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Figure 4-11. In vitro growth of wild-type C. jejuni PT14 (A), and Cgb- (B) 
and Ctb-deficient (C) C. jejuni PT14 mutants in the absence and presence 
of bacteriophage CP30A. 
Uninfected bacteria are represented by blue lines, phage-infected by brown 
lines and phage growth by green lines. On infection with CP30A at the second 
hour, there was an immediate approximate 3-log reduction in bacterial 
numbers. Following this, there was resurgence in growth of the host 
population, which continued until the final sampling point. The phage titre also 
remained relatively constant after the initial rise, however a second rise 
occurred between the 18-20th hour despite no clear drop in the host population 
being observed. Values for bacterial growth (CFU ml-1) and phage titre (PFU 
ml-1) are generated from 3 independent cultures ± SD and plotted as a function 
of time. The pattern of growth for the wild-type and mutants is generally 
identical, however the mean burst sizes that were calculated from the triplicate 
cultures were significantly less that that observed for the wild-type (ANOVA, 
p<0.05, n=3). 
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Figure 4-12. In vitro growth of wild-type C. jejuni PT14 (A), and Cgb- (B) 
and Ctb-deficient (C) C. jejuni PT14 mutants in the absence and presence 
of bacteriophage CPX. 
Uninfected mutants are represented by blue lines, phage-infected by brown 
lines and phage growth by green lines. Phage CPX was added at the second 
hour of bacterial growth and two hours later an approximate 2.5 log reduction 
in host numbers was observed. Following this, a resurgence in growth of the 
host population could be observed, which continued until the final sampling 
point. The phage titre remained relatively constant between the 6-24th hour 
following the burst at the 4th hour. Values for bacterial growth (CFU ml-1) and 
phage titre (PFU ml-1) are generated from 3 independent cultures ± SD and 
plotted as a function of time. The pattern of growth for the wild-type and 
mutants is generally identical, however the mean burst sizes that were 
calculated from the triplicate cultures were significantly less that that observed 
for the wild-type (ANOVA, p<0.05, n=3). 
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4.3 DISCUSSION 
The transcriptional profile of C. jejuni PT14 under infection by bacteriophages 
CP30A and CPX was characterised using RNA-seq technology. RPKM values 
were calculated and provided a measure of gene expression levels between 
uninfected and phage-infected samples.  It was also possible to determine 
measurements of gene expression for phage-specific transcripts. These results 
confirmed that RNA was isolated during the eclipse phase of phage replication 
as several genes known to be expressed late in transcription exhibited high 
expression levels, with the major capsid protein being the most abundant 
transcript expressed by both phages.  
 
4.3.1 The phage-infected host transcriptome mimics an iron-
limited environment 
The transcriptome of C. jejuni PT14 under bacteriophage infection is 
consistent with that of an iron-restricted environment since very similar genes 
were previously found to be regulated during iron limitation (Palyada et al. 
2004; Holmes et al. 2005; Butcher & Stintzi 2013). Previous studies have 
characterised gene expression of C. jejuni in response to iron limitation using 
microarray analysis (Palyada et al. 2004; Holmes et al. 2005) and RNA-seq 
technology (Butcher & Stintzi 2013). Regardless of the growth conditions 
used, a number of common genes were activated in response to the lack of 
iron. The gene products relate to different iron-acquisition systems, which 
include ferri-enterochelin (cfrA, ceuE) (Palyada et al. 2004), haem (chuABCD, 
cj1613c) (Ridley et al. 2006), transferrin (cfbpABC) (Miller et al. 2008) and 
rhodotorulic acid (cj1658/p19, cj1660-cj1663). The majority of these genes 
  Chapter 4 
188 
 
 
were also found to be activated in response to phage infection, with the 
exception of chuD and cfbpA. These both encode periplasmic binding proteins 
and although they were both up-regulated in response to infection by CP30A 
and CPX, they fell below the 1.5 fold cut-off which was selected as a 
measurable and potentially meaningful change. In addition, in response to iron-
limited conditions (Palyada et al. 2004; Holmes et al. 2005; Butcher & Stintzi 
2013), several members of the putative TonB energy transduction systems 
were also up-regulated including exbB1-exbD1-tonB1, exbB2-exbD2-tonB2 
and tonB3. In comparison to the genes up-regulated in response to phage 
infection, all of these genes were also activated with the exception of exbD1 
and tonB1. 
 
Iron-uptake systems of C. jejuni typically comprise of an outer-membrane 
(OM) receptor protein, which specifically binds to and transports ferric iron 
sources through the OM into the periplasm using energy derived from the 
ExbB-ExbD-TonB energy transduction system. The iron is then transported to  
a periplasmic iron-binding protein (highlighted in red in Figure 4-13 (A), 
which subsequently delivers it to the cytoplasmic membrane (CM) ABC 
transporter system, which consists of a permease and an ATP-binding protein. 
Figure 4-13 (A) provides a schematic of a typical iron-uptake system of C. 
jejuni and Figure 4-13 (B) illustrates the role each gene plays in the uptake of 
enterochelin, rhodotorulic acid, haemin and transferrin. The complete array of 
iron uptake  
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Figure 4-13. Schematic representation of siderophore-based iron 
acquisition systems in C. jejuni. 
(A) Ferri-siderophore complexes transport iron via outer-membrane (OM) 
receptors to the periplasmic binding protein (red), which then delivers it to the 
cytoplasmic membrane (CM) ABC transporter (comprised of a permease and 
an ATP-binding protein). Iron transport is mediated into the periplasm via the 
outer-membrane by energy derived from the ExbB-ExbD-TonB energy 
transduction system. (B) Several components that allow uptake of 
enterochelin, rhodotorulic acid, haem and ferri-transferrin in C. jejuni have 
been determined. Adapted from Andrews et al. 2003 (A) and Miller et al. 2009 
(B). 
  Chapter 4 
190 
 
 
genes that were up-regulated in response to phage infection, suggests an 
increased need for siderophore-based iron acquisition as most genes required 
for uptake of enterochelin and rhodotorulic acid were activated. On the other 
hand, since the genes encoding the periplasmic binding proteins for transport 
of haem and transferrin proteins failed to be activated, this may suggest that 
there was no increased need to transport haem and transferrin into the 
cytoplasm via the ABC transporter system, despite the genes encoding the 
permeases (chuB and cfbpB (cj0174)) and ATP-binding proteins (chuC and 
cfbpC/cj0173c) being up-regulated. Although it should be noted that the gene 
encoding the OM receptor protein for transport of transferrin 
(A911_00860/cj0178c) was up-regulated in response to infection by either 
phage, it was not significantly differentially expressed compared to the 
uninfected control. Failure of the phages to up-regulate all of the genes related 
to haem and transferrin uptake is most likely due to the lack of available 
sources to allow their acquisition under the experimental conditions.  
 
4.3.2 Regulation of iron acquisition genes in response to phage 
infection 
Bacteria generally regulate iron acquisition, metabolism and storage in 
response to iron availability and to avoid iron toxicity when excess iron 
interacts with oxygen. In C. jejuni and other Gram-negative bacteria, iron-
regulated gene expression is mediated by the Fur protein (1.5.1). Under iron-
rich conditions, the Fur protein binds to ferrous ions and forms a dimeric Fe2+-
Fur complex (holo-Fur), which recognises a specific consensus sequence 
within the promoter region of iron-regulated genes known as the Fur box and 
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represses their transcription by blocking entry of RNA polymerase. Under 
iron-limited conditions, the complex dissociates (apo-Fur) and transcription of 
iron-regulated genes is de-repressed. The expression profile of the iron 
acquisition genes regulated in response to bacteriophage infection of C. jejuni 
PT14 is therefore consistent with the model of Fur as a transcriptional 
repressor of such genes when sufficient iron is available. The findings 
therefore demonstrate that Fur appears to have derepressed transcription of 
these genes in what it perceives to be iron-limited conditions. 
 
The Fur regulon of C. jejuni was previously defined by examining the 
transcriptome of a wild-type and fur deletion mutant in the absence and 
presence of iron (Palyada et al. 2004; Holmes et al. 2005). It was demonstrated 
that that apo- and holo-Fur were both capable of activating and repressing gene 
expression (Palyada et al. 2004), with more than 60 genes encoding products 
related to iron acquisition, oxidative stress defence, flagellar biogenesis and 
energy metabolism being regulated (Palyada et al. 2004; Holmes et al. 2005). 
More recently, using a chromatin immunoprecipitation and microarray analysis 
approach (ChIP-chip), it was reported that Fur regulates 95 transcriptional 
units in C. jejuni (Butcher et al. 2012). However, the Fur regulon identified 
using this technique was significantly different to those that had previously 
been reported (Palyada et al. 2004; Holmes et al. 2005), possibly because the 
ChIP-chip identified all direct targets that were bound by Fur regardless of the 
fold change. Nevertheless, apo- and holo-Fur gene repression and activation 
was also observed (Butcher et al. 2012). Butcher et al. (2012) also determined 
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the structure of apo-Fur and suggested possible mechanisms for its regulatory 
role (discussed in section 1.5.1). 
 
4.3.3 Regulation of oxidative stress defence genes in response to 
phage infection 
A relationship exists between oxidative stress and iron metabolism as exposure 
of cellular ferrous iron to oxygen can generate the formation of reactive 
oxygen species (ROS), such as superoxide anions (O2-), peroxides (RO2) and 
hydroxyl radicals (OH), which are strong oxidants. C. jejuni has developed a 
number of defence mechanisms for protection against this type of stress 
(discussed in section 1.4.5). Genes encoding proteins with functions related to 
oxidative stress defence include ahpC, katA, perR, sodB, tpx, 
cj0559/A911_02725, cj1386/A911_06735, cj1664/A911_08020 and 
cj1665/A911_08025, which overlap with some of the genes that respond to 
iron limitation. (Palyada et al. 2004; Holmes et al. 2005; Butcher & Stintzi 
2013). All of these genes were also found to be activated in response to CPX 
infection of C. jejuni PT14, with the exception of ahpC and tpx. Although the 
peroxide stress regulator PerR has been found to control transcription of a 
number of genes encoding proteins relating to oxidative stress defence in C. 
jejuni (van Vliet et al. 1999; Holmes et al. 2005; Palyada et al. 2009), some of 
these genes are also co-regulated by Fur, including the peroxide stress genes 
aphC and katA (van Vliet et al. 1999). The genes cj1386, cj1664 and cj1665 
were also previously found to be Fur regulated (Holmes et al. 2005). In 
addition, in response to phage infection, perR was up-regulated in response to 
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CPX infection whereas expression of the fur gene remained unchanged 
between uninfected and phage-infected samples.  
 
There are other genes which have been found to contribute to oxidative stress 
defence in C. jejuni, either directly or indirectly. For instance, the ferritin 
protein, Cft, stores iron inside the ferritin cavity in an inactive but reusable 
state, and is therefore able to avoid generation of ROS. A cft-deficient mutant 
was previously found to be more sensitive to exposure to H2O2 than the 
parental strain (Wai et al. 1996). This was probably due to the inability of the 
mutant to collect and store iron from the cytoplasm and therefore resulting in 
the formation of ROS. In addition, ferritin can provide intracellular iron 
reserves during iron limitation and as would be expected, the cft gene was 
found to be up-regulated in response to iron-limited conditions (Palyada et al. 
2004; Holmes et al. 2005). However, in response to phage infection, there was 
no change in expression of this gene in response to CPX infection but 
interestingly, it was found to be 1.5-fold down-regulated in response to CP30A 
infection. Nonetheless, a similar finding was previously reported for H. pylori, 
with expression of the non-haem containing ferritin gene pfr being repressed 
by apo-Fur (Delany et al. 2001). This suggests that the cft gene may have been 
regulated by apo-Fur during CP30A infection of PT14. 
 
Another noteworthy protein is the ferredoxin FdxA, which does not appear to 
show resistance to particular peroxide stress but an fdxA-deficient mutant 
exhibited significantly reduced aerotolerance (van Vliet et al. 2001). The fdxA 
gene was also previously found to show iron-induced gene expression (van 
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Vliet et al. 2001; Palyada et al. 2004). In response to CPX infection of C. 
jejuni PT14, fdxA expression was down-regulated. However, as with the cft 
gene it has been reported that expression of fdxA was repressed by apo-Fur in 
C. jejuni (Palyada et al. 2004). This therefore suggests that the fdxA gene was 
also likely under the control of apo-Fur during CPX infection of PT14. 
 
4.3.4 Regulation of flagellar biogenesis genes in response to 
phage infection 
Transcription of flagellar genes in C. jejuni is primarily predicted to be 
controlled by the sigma factors rpoN ı54) and fliA ı28) (Guerry et al. 1991; 
Hendrixson et al. 2001; Jagannathan et al. 2001; Hendrixson & Dirita 2003; 
Carrillo et al. 2004). Nevertheless, several genes related to flagellar biogenesis 
in C. jejuni have also previously been found to be controlled either directly or 
indirectly by Fur, including flaA, flaB, flaD, flgE2, flgG2, flgH and flgI 
(Palyada et al. 2004; Butcher et al. 2012). With the exception of flaA and flaB, 
all other genes were found to be apo-Fur activated and repressed on addition of 
iron to a previously iron-limited medium, but were unusually overexpressed at 
mid-log phase under iron-rich conditions (Palyada et al. 2004). Moreover, a 
recent study reported that a large number of flagellar chaperones, regulatory 
proteins and genes involved in flagellar biogenesis were iron activated 
(Butcher & Stintzi 2013). In response to infection by CPX, several genes 
related to flagellar biogenesis were found to be down-regulated in C. jejuni 
PT14. If such genes are indeed iron-activated and PT14 is being perceived as 
experiencing iron-limited conditions during phage infection, these findings 
therefore imply that the flagellar biogenesis genes were apo-Fur repressed. 
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4.3.5 Regulation of nitrosative stress responsive genes  
The RNA-seq data indicated that in response to phage infection of C. jejuni 
PT14 there was strong up-regulation of the nitrosative stress responsive genes. 
These genes were cgb, ctb, A911_03685/cj0761 and A911_04025/cj0830, 
whose gene expression have been found to be regulated by cj0466, designated 
as NssR (Nitrosative stress sensing Regulator) (Elvers et al. 2005). The 
haemoglobin gene cgb, which was the most significantly differentially 
expressed gene in response to CP30A infection, was previously strongly and 
specifically induced following exposure to nitrosative stress, but not 
superoxide or peroxide (Elvers et al. 2004). However, the transcriptomic and 
proteomic response of C. jejuni to nitrosative stress revealed up-regulation of a 
number of genes encoding heat shock proteins as well as products related to 
oxidative stress defence and iron acquisition and transport (Monk et al. 2008). 
In addition, it was also demonstrated that Cgb and Ctb were regulated by 
oxygen availability and in particular when C. jejuni cultures were grown at 
higher rates of oxygen diffusion and then exposed to nitrosative stress. Under 
these circumstances there was increased transcription of the NssR-regulated 
genes cgb, ctb, cj0761 and cj0830 (Monk et al. 2008). These findings provide a 
rationale for the pattern of up-regulated gene expression with regards to phage 
infection of PT14 since NssR-regulated genes respond to the presence of 
oxygen prior to exposure to nitrosative stress. It is implied that there was a 
relatively strong source of nitrosative stress particularly during CP30A 
infection. Cultures of Cgb- and Ctb-deficient C. jejuni PT14 mutants could be 
infected with CP30A or CPX but infection led to reduced burst sizes compared 
to infected wild type cultures. (Figures 4-11 and 4-12). 
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4.3.6 Host response to phage infection includes a demand for 
oxygen 
The pattern of down-regulated gene expression was consistent with what 
would be expected to occur within an aerobic environment. This was evident 
by the strong repression of genes predicted to be involved in a number of 
anaerobic electron transport pathways. C. jejuni is an obligate microaerophile, 
which has an aerobic respiratory metabolism that utilises oxygen as the 
terminal electron acceptor. However, a number of reductases are present in the 
genome that have previously been shown to allow C. jejuni to carry out 
respiration with alternative electron acceptors to oxygen (Kelly 2001; Sellars et 
al. 2002; Myers & Kelly 2005b). In vitro studies have shown that C. jejuni is 
unable to grow under strictly anaerobic conditions in the presence of these 
alternative electron acceptors. However, addition of fumarate, nitrate, nitrite, 
trimethylamine-N-oxide or dimethyl sulfoxide to microaerobic cultures that 
were under severely oxygen-limited conditions resulted in increased growth 
(Sellars et al. 2002). In response to phage infection of C. jejuni PT14, genes 
encoding several of these reductases showed reduced expression levels, 
including subunits of fumarate reductase (frdCAB), nitrate reductase 
(napAGHB), nitrite reductase (nrfA and nrfH) and trimethylamine-N-oxide 
reductase (A911_01280/cj0265c). This therefore suggests that under phage 
infection, the host generates energy in an electron acceptor-dependent manner, 
with a demand for oxygen as the terminal electron acceptor. In addition, genes 
encoding anaerobic C4-dicarboxylate transporters (dcuA and dcuB) were also 
down-regulated in response to phage infection while elevated levels of 
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transcription was observed for a gene encoding a product that allows aerobic 
transport of C4-dicarboxylates (A911_00230/cj0046). 
 
C. jejuni possesses two terminal oxidases: a cytochrome bd-type quinol 
oxidase (Cyd homologues) and a cytochrome c oxidase, cb (ccb3)-type (Cco 
homologues). The latter accepts electrons from cytochrome c via a bacterial 
ubiquinol:cytochrome c oxidoreductase or bc1 complex encoded by genes from 
the petABC operon, while the previous accepts electrons directly from 
ubiquinol. The RNA-seq data show that in response to phage infection of C. 
jejuni PT14, genes encoding the cb-type cytochrome c (ccoNOPQ) and a 
subunit of the cytochrome bc1 complex (petC) were repressed, while there was 
no change in expression for the bd-type quinol oxidase. Figure 4-14 provides a 
schematic of the pathways of electron transport to oxygen and alternative 
electron acceptors in C. jejuni. All major genes that were down-regulated in 
response to bacteriophage infection of PT14 are denoted by boxes in reverse 
fields. 
 
In addition to being able to use a wide range of alternative electron acceptors 
to oxygen, C. jejuni is also capable of utilising a number of electron donors, 
including formate, hydrogen, D-lactate and succinate. Genes encoding 
products that have been predicted to allow sulphite to be used as an electron 
donor (A911_00020/cj0004c and A911_00025/cj0005c) were also down-
regulated in response to phage infection (Myers & Kelly 2005a). In C. jejuni 
NCTC 11168, cj0004c and cj0005c encode a monohaem cytochrome c and 
molydopterin oxidoreductase respectively. It was previously demonstrated that 
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Figure 4-14. Predicted electron transport pathways in C. jejuni. 
Illustrated are pathways of electron transport to oxygen and alternative electron 
acceptors, such as fumarate (frdABC), nitrate (napABGH), nitrite (nrfAH) and 
trimethylamine N-oxide reductase (A911_01280/cj0265c). The dotted lines 
represent electron transfer pathways via the menaquinone pool (MK) and the 
solid lines indicate possible electron donors for respiration or electron acceptor 
transformations. Black boxes in reverse fields show products whose gene 
expression were down-regulated at least -1.5-fold or more in response to phage 
infection of C. jejuni PT14, while the white box shows a product with no 
change in gene expression. Anaerobic transport of C4-dicarboxylate substrates 
through the cytoplasmic membrane (CM) occurs via the C4-dicarboxylate 
transporters DcuA and DcuB. The diagram is based on the findings of Woodall 
et al. (2005) and also takes into account the electron transport pathways 
described by Sellars et al. (2002) and Myers and Kelly (2005b). Adapted from 
Woodall et al. (2005). 
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a cj0004c deletion mutant was unable to utilise sulphite or metabisulphite as 
electron donors but could respire with formate (Myers & Kelly 2005a). In 
addition, formate respiration which is cytochrome bc1 complex-dependent, was 
inhibited by 50% in the presence of the bc1 inhibitor 2-heptyl-4-
hydroxyquinoline-N-oxide, while sulphite respiration was unaffected. This 
suggests that electrons donated through sulphite respiration do not rely on the 
bc1 complex to enter the respiratory chain and therefore enter at the level of 
cytochrome c (Myers & Kelly 2005a). 
 
In contrast to the transcriptional repression observed for the respiratory 
cytochromes, the gene A911_00180/cj0037c, encoding a cytochrome c, was 
up-regulated in response to phage infection of PT14. However, this gene was 
previously found to be down-regulated in response to the limited oxygen 
conditions experienced during colonisation of the chicken gut (Woodall et al. 
2005). Moreover, the vast majority of the genes associated with energy 
metabolism (TCA cycle and electron transport) that were activated at the low 
oxygen tensions of the chicken caecum, were down-regulated in response to 
phage infection of PT14. This further supports the prospect that the 
transcriptome of C. jejuni PT14 under phage infection is an aerobic 
environment and also justifies up-regulation of genes involved in oxidative 
stress defence (4.3.3). It also raises the question as to where bacteriophages 
replicate in the chicken intestine. 
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4.3.7 Possible iron- and oxygen-dependent mechanisms during 
phage infection 
Based on the changes observed in host gene expression during phage infection 
of C. jejuni PT14, there is a clear demand for iron and oxygen. A likely 
explanation for such a requirement is the existence of an iron- and oxygen-
dependent metabolic process that is important for phage replication. This 
SURFHVVLVWKHUHGXFWLRQRIULERQXFOHRWLGHVWRIRUP¶-deoxyribonucleotides for 
DNA synthesis and repair, and is solely catalysed by the iron-dependent 
enzyme ribonucleotide reductase (RNR). Following a single reduction, RNR 
receives electrons from the dithiol group of thioredoxin, which is regenerated 
through reduction of its disulphide groups by NADPH. 
 
RNRs can be classified into three distinct classes (Ia/Ib, II, III) based on their 
interaction with oxygen and the mechanism used to generate a stable tyrosyl 
radical (Nordlund & Reichard 2006). Phages CP30A and CPX both possess 
class Ia RNRs, which are comprised of two subunits: Į and ȕ. The subunits of 
class Ia enzymes of E. coli are known to associate to form a kinetically stable 
Į:ȕ complex (Minnihan et al. 2013) (Figure 4-15B). The active site of the Į2 
subunit contains a conserved cysteine residue at position 439, which is 
necessary for catalysis; as well as multiple binding sites for deoxynucleotides 
and ATP (Figure 4-15A). The ȕ2 subunit contains a di-iron tyrosyl radical 
cofactor (Y122) that requires oxygen for its formation and is needed to initiate 
the nucleotide reduction process in the ĮVXEXQLW (Figure 4-15A). The di-iron 
centre of the tyrosyl radical is flanked by a number of ligands that act as iron-
binding sites. These are aspartate (D84), three glutamates (E115, E204 and E238) 
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and two histidines (H118 and H241) (Figure 4-15A). During catalysis, the tyrosyl 
UDGLFDO LV FRQWLQXRXVO\ VKXWWOHG WR WKH Į VXEXQLW WR DOORZ R[LGDWLRQ RI WKH
cysteine residue and has been shown to involve the residues Y356, Y730 and 
Y731 (Seyedsayamdost et al. 2007; Minnihan et al. 2011). The pathway for 
electron transfer in E. coli has been proposed as: Y122ļ:48ļ<356 LQWKHȕ
subunit to Y731ļ<730ļ&439 LQWKHĮVXEXQLW(Stubbe et al. 2003; Reece et al. 
2006). 
 
Examination of the protein sequences deduced from the genomes of CP30A 
and CPX confirmed the presence of the RNR ĮDQGȕVXEXQLWVDVZHOODVWKH
location of the conserved cysteine (C440) and tyrosine residues (Y289/Y290) in 
Į (Figure 4-16). However, the C-terminus of Į is flanked beween two Hef-
like homing endonucleases and surprisingly is separated from the N-terminus 
and the ȕVXEXQLWby more than 60-kbp. The tyrosine residues were found to 
be present in the C-terminus while the cysteine was located in the N-terminus 
of the ĮVXEXQLW. Nevertheless, once these subunits are able to associate, it is 
possible that a functional and stable Į:ȕ complex could form (Minnihan et 
al. 2013). The findings obtained from the transcriptome analysis of C. jejuni 
PT14 in response to infection by CP30A and CPX are therefore consistent with 
what would be expected during the functioning of RNR. In addition, affinity of 
the di-iron centre of ȕ2 would be sufficient to displace iron from other iron-
containing proteins such as Fur. Moreover, loss of holo-Fur has been 
demonstrated to de-repress transcription of iron-regulated genes (Butcher et al. 
2012). 
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 Figure 4-15. Mechanisms of class Ia ribonucleotide reductase (RNR) in E. 
coli. 
(A) Class Ia RNRs are composed of an Į and ȕ subunit, which associate to 
form an ĮȕFRPSOH[ The Į2 subunit contains an active site cysteine residue 
(C439) which is needed for reduction of ribonucleotides to 
deoxyribonucleotides, while ȕ2 contains a stable di-iron tyrosyl radical 
cofactor (Y122). Reversible transfer of the radical electron from Y122 to C439 
takes place over a long distance and involves the residues Y356 LQȕDQG<730 
and Y731 LQĮ% A solution equilibrium exists for class Ia RNRs in E. coli 
across three inter-converting subunit states: Į  ȕ Įȕ DQG Įȕ. The 
relative distribution of these states is dependent on protein concentration and 
the identity and concentration of the nucleotides present. Taken from Minnihan 
et al. 2013.  
  
  
 
203
 
 
 
Figure 4-16. Arrangement of the ribonucleotide reductase (RNR) subunits in phages CP30A and CPX. 
The C-WHUPLQDOGRPDLQRIWKHĮVXEXQLWFRQWDLQs the two conserved tyrosine residues at positions 289 and 290. It is located between two Hef-
like homing endonucleases and is at least 60-kbp from the N-WHUPLQDOGRPDLQDQGWKHȕ2 subunit, which contains the conserved cysteine residue 
at position 440. The arrangement and positioning of the subunits appear to be different to that of the prototypical E. coli RNR. 
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Chapter 5 : Examination of a type 
II restriction-modification system 
in Campylobacter jejuni PT14 
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5.1 INTRODUCTION 
Bacterial restriction-modification (R-M) systems generally protect the host cell against 
invading foreign DNA including those of viral or plasmid origin as well as from DNA 
fragments being transferred during natural transformation (reviewed by Bickle & 
Krüger 1993; Wilson & Murray 1991). Classical R-M systems comprise of a 
modification methyltransferase, which catalyses methylation of a specific DNA 
sequence in the host genome, and a restriction enzyme which cleaves or restricts 
foreign DNA lacking that specific methylation. Methyltransferases and restriction 
endonucleases from the same system are able to recognise the same sequence of 
nucleotides. Cognate methylation can therefore prevent restriction of host DNA. On 
the other hand, some restriction enzymes exist that cleave DNA only when the target 
sequence has been modified and as such, these restriction enzymes do not coexist with 
a cognate methylation enzyme. 
 
The methyltransferase component of the R-M system catalyses transfer of a methyl 
group from S-adenosylmethionine (AdoMet) to an adenine or cytosine residue within 
each strand of the recognition sequence. In general, the same base is methylated on 
both DNA strands but it is also possible for cognate methylation of only one strand 
(hemimethylation). Methylation in bacterial genomes has been found to produce either 
N6-methyladenine (m6A) (Dunn & Smith 1958), 5-methylcytosine (m5C) (Doskocil 
& Sormova 1965) or N4-methylcytosine (m4C) (Ehrlich et al. 1987; Janulaitis et al. 
1983; Janulaitis et al. 1984). Using single molecule real-time (SMRT) sequencing, the 
complete methylation pattern of a number of bacterial genomes has been determined 
including B. cereus, H. pylori and C. jejuni (Murray et al. 2012; Krebes et al. 2013). 
Active methyltransferase genes and their recognition sequences were identified 
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including those that are part of an R-M system. For instance, C. jejuni NCTC 11168 
possesses a Type II system assigned RM.CjeNII (cj1051c), which recognises the 
sequence 5¶-GAGN5GT-¶DQGKDVEHHQVKRZQWRPHWK\ODWHWKH$UHVLGXHVRQERWK
strands (Murray et al. 2012). 
 
Preliminary studies in the earO\ ¶V (Anderson & Felix 1952; Bertani & Weigle 
1953; Luria & Human 1952; Ralston & Krueger 1952) revealed that some bacterial 
strains could inhibit the propagation of bacteriophages that were previously grown on 
different host strains.  This mechanism is known as host-controlled modification and 
allows the new host to restrict the phage DNA and prevent infection. In order to test 
the susceptibility of the bacterial strains to bacteriophage infection, the ability of the 
phages to form plaques was measured. This principle is known as the efficiency of 
plating (EOP) and it was found that propagation on a non-restricting host resulted in 
an EOP of 1 while for bacteria capable of restriction it was between 10-3 and 10-5 fold 
lower. A decade later, Arber and Dussoix (1962) looked at host-controlled 
PRGLILFDWLRQRIEDFWHULRSKDJHȜZKHQJURZQRQDSDLURI E.coli K-12 strains. Based 
on the EOP results, they concluded that the phage DNA became strain-specifically 
marked by the host during viral propagation and that subsequent host strains could 
only become infected by phage carrying that particular modification. Using 32P-
labelled phage, they observed the effects of infecting a restrictive host with 
unmodified phage DNA. Extensive breakdown of the phage DNA was observed. 
However, it had previously been observed that unmodified phages could escape 
restriction and complete the lytic stage of their life cycle, therefore passing on the 
strain-specific modification that they possess to their progeny (Bertani & Weigle 
1953; Luria & Human 1952). The resulting EOP values were close to 1 on both 
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restrictive and non-restrictive host strains. In addition, after a single passage on a non-
restrictive host, the modified progeny phage lost their ability to re-infect the restrictive 
host therefore confirming that they had not inherited the strain-specific modification 
of that host. These early experiments highlighted the use of bacterial R-M systems as a 
defence mechanism against bacteriophages. 
 
There are four major groups of R-M systems (Types I, II, III and IV) and they are 
classified primarily according to enzyme subunit composition, cofactor requirements, 
symmetry of the recognition sequence and positioning of the DNA cleavage site 
(Boyer 1971; Yuan 1981; Roberts et al. 2003) (described in detail in Chapter 3). Each 
group can be divided into sub-categories, especially the Type II, which is divided into 
11 groups (A, B, C, E, F, G, H, M, P, S and T). Of these, the Type IIS subcategory 
was the earliest to be recognised and was retained by Roberts et al. (2003) to describe 
enzymes that are capable of cleavage of at least one DNA strand outside of the 
recognition sequence, thereby suggesting shifted cleavage away from the recognition 
site (e.g. FokI and AlwI). Two further classes, Types IIP and IIA, were also introduced 
(Roberts et al. 2003). Type IIP describes enzymes, such as EcoRI and HindIII, which 
recognise palindromic sequences and cleave DNA at a defined position at or close to 
the recognition site while Type IIA refers to those that recognise asymmetrical 
sequences and can cleave DNA either close to or away from the recognition sequence. 
The Type II enzymes also include those with atypical features such as enzymes that 
cleave on both sides of the recognition sequence (e.g. BcgI [Type IIB]), which may be 
stimulated or inhibited by AdoMet (e.g. Eco57I and BsgI [Type IIG]), or can interact 
with two copies of the recognition sequence and cleave one (e.g EcoRII [Type IIE]) or 
both of them (e.g BspMI [Type IIF]) as well as may possess unusual subunit structures 
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(e.g. BbvCI [Type IIT]). The remaining enzymes are the Type IIC, which contain 
cleavage and modification functions within a single polypeptide; the Type IIH, which 
possess similar genetic structures to Type I enzymes but biochemically behave as 
Type II; and the Type IIM enzymes, which recognise a specific methylated target 
sequence and cleave at a fixed site.   
 
There is a wide distribution of R-M systems among prokaryotes, with more than 90% 
of the analysed genomes containing at least one R-M system (Roberts et al. 2010). It 
has also been found that within sequenced genomes there is generally an increase in 
the number of R-M systems with an increase in genome size (Vasu & Nagaraja 2013). 
For instance, organisms with a genome 2 to 3-Mbp in size possess a median number 
of 3 R-M systems per genome, those 3 to 4-Mbp in size have 4 R-M systems per 
genome and organisms with a genome size of 4 to 5-Mbp possess 5 R-M systems per 
genome (Vasu & Nagaraja 2013). However, the distribution of R-M systems with 
organism possessing smaller genome sizes (1 to 2-Mbp) is not as clear cut. For 
example, many Brucella species contain only 1 R-M system per genome while 
multiple R-M systems have been found amongst species of Helicobacter and 
Campylobacter. Such organisms can switch between different R-M systems when 
necessary and are therefore equipped to be naturally more competent than organisms 
with fewer systems. Miller et al. (2005) characterised the Type I R-M systems of 73 
C. jejuni strains and assigned them to Type IC as well as two additional families, 
Types IAB and IF. They found no evidence that these strains contained multiple Type 
I systems observed in H. pylori.  
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In some instances, methyltransferase genes are known to play a role in physiological 
processes, such as with the DNA adenine methyltransferase (Dam) of E. coli, which 
produces a m6A residue and functions in DNA mismatch repair, initiation of DNA 
replication and the regulation of gene expression (Boye & Løbner-Olesen 1990; 
Marinus & Casadesus 2009). In many Gram-negative bacteria such as E. coli, 
Salmonella spp., and Yersinia spp., gene regulation by a Dam methyltransferase is 
known to affect expression of a number of genes including those related to virulence 
phenotypes such as motility, adherence to and invasion of human epithelial cells and 
colonisation of the host (Low et al. 2001; Julio et al. 2001; Fälker et al. 2005; 
Balbontín et al. 2006). Transcriptional regulation can occur when genes are reversibly 
switched on-and-off (phase variation) through methylation of promoter sequences 
(Blyn et al. 1990) or via the presence of homopolymeric tract repeats in the promoter 
region of these genes (van der Ende et al. 1995). Phase variable methyltransferase mod 
genes exist in a number of bacterial Type III R-M systems, including Haemophilus 
influenzae (De Bolle et al. 2000; Srikhanta et al. 2005), H. pylori (Vries et al. 2002), 
Pasteurella haemolytica (Ryan & Lo 1999), Neisseria meningitidis (Srikhanta et al. 
2009) and Neisseria gonorrhoeae (Srikhanta et al. 2009). Altered expression of such 
methyltransferases has been reported to cause coordinated phase variation of multiple 
genes (Srikhanta et al. 2005) 7KLV QRYHO V\VWHP LV UHIHUUHG WR DV WKH µSKDVHYDULRQ¶
(phase variable regulon) and is known to regulate gene expression in H. influenzae 
(Srikhanta et al. 2005), N. meningitidis (Srikhanta et al. 2009) and N. gonorrhoeae 
(Srikhanta et al. 2009). Differential regulation of genes related to pathogenesis and 
virulence were observed within these studies and functional confirmations revealed 
the presence of phenotypically distinct populations in regards to antimicrobial 
resistance, invasion and adhesion to human cells as well
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In this chapter, C. jejuni PT14 (Brathwaite et al. 2013) was naturally transformed 
using DNA from C. jejuni NCTC ǻcj0031, which is a non-restrictive cj0031 
deletion mutant (cj0031 gene homologue: A911_00150). The restriction ability of the 
wild-type and mutant against bacteriophages previously propagated on PT14 and other 
strains was then tested. The gene structure of the mutant was examined and functional 
tests were carried out to determine whether distinct phenotypes exist between the 
wild-type and mutant. Finally, to investigate the biological role of the A911_00150 
gene in the PT14 R-M system, the effect of the A911_00150 deletion mutant on the 
transcriptional profile of PT14 was also examined. 
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5.2 RESULTS 
5.2.1 A C. jejuni PT14 putative Type II R-M system 
In C. jejuni NCTC 11168, the gene cj0031 encodes a putative Type IIS R-M system 
which is phase variable and capable of reversibly switching the expression of the 
UHDGLQJIUDPH³RQRII´E\YLUWXHRIthe sequence content of a variable polyG tract. The 
polyG tract repeat length ranges from nine to ten guanine bases in the reading frame of 
cj0031 and the adjacent gene cj0032 (Bayliss et al. 2012). A G9 tract length results in 
the fusion of cj0031 and cj0032 which places this fused gene in frame and therefore in 
WKH³RQ´FRQILJXUDWLRQZKLOVW*VHSDUDWHVWKHUHDGLQJIUDPHVDQGSURGXFHVDQ³RII´
variant. It has previously been found through SMRT sequencing that the gene is 
SUHGRPLQDWHO\ LQ WKH ³RII´ FRQIiguration and produces no active methyltransferase 
(Murray et al. 2012). This nearest homologue to this gene in C. jejuni PT14 was found 
to be A911_00150 and although it is not phase variable, a nucleotide BLAST search 
showed that there is 98% sequence identity to the N-terminal end of cj0031 in NCTC 
11168 and 90% identity to the C-terminal end. Figure 5-1 shows a comparison of 
these two genes using the Artemis Comparison Tool web-based version (WebACT) 
(Abbott et al. 2007). Regions of sequence similarity are aligned using red (same 
orientation) or blue (reverse orientation) blocks, while differences in sequences are 
illustrated with white gaps. A pairwise comparison of A911_00150 and cj0031 shows 
that the N-terminal ends of the genes display sequence homology. However, the C-
terminal ends show differences, which coincide with the position of the polymorphic 
poly-G tract within cj0031. The reading frames corresponding to cj0031 and cj0032 
are in-frame in PT14, revealing a relationship where cj0032 is replaced in all but the 
extreme C-terminal coding sequence, which is conserved along with the subsequent 
gene (A911_00155/cj0033). 
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Figure 5-1. An Artemis Comparison Tool (ACT) analysis of the cj0031 gene in NCTC 11168 and its homologue in PT14. 
The genes corresponding to PT14 are represented on the top bar (A911_00150) of the image whilst those for NCTC 11168 are on 
the bottom (cj0031). The red blocks show regions of homology and the differences are represented by white gaps. It can be 
observed that the N-terminal end of A911_00150 and cj0031 show homology but their C-terminal ends appear to be different. The 
sequence homology returns at the extreme end of cj0032. 
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5.2.2 Biofilm-derived cj0031 mutants in PT14 
Biofilms were previously prepared by Dr. P. Siringan according to the method of  
Siringan et al. (2011) by dispensing 10 µl aliquots of diluted C. jejuni PT14 culture 
into a petri dish containing glass coverslips. Once formed, the biofilms were treated 
with bacteriophages and significant (p<0.05) reductions were observed for all phages 
used. However, some viable cells recovered from the biofilm had become resistant to 
subsequent infection with the bacteriophages previously used to infect the same 
biofilm. EOP values for these isolates were lower than those of the wild-type (data not 
shown). Phase variation was one possible explanation for the frequent recovery of 
these mutants, and in particular phase variation within a restriction-modification 
system. Using the C. jejuni NCTC 11168 genome as a guide, since at this time the 
PT14 genome sequence had not been determined, PCR primers were designed to 
enable the amplification of candidate phase variable genes. DNA sequencing of 
cj0031/cj0032 amplicons revealed differences in the genome sequences of NCTC 
DQG37 ORFDWHG LQWKH¶-end of the reading frame.  DNA sequences of the 
genes amplified from the biofilm-derived mutants revealed the presence of point 
mutations towards the C-terminal coding sequence of cj0031/cj0032, where the 
sequences of NCTC 11168 and PT14 differ. Figure 5-2 shows a sequence alignment 
for a section of the cj0031 gene in NCTC 11168 and its homologue in PT14 for eight 
biofilm-derived bacteriophage escape mutants (P1-cp30, R1-30, R2-30, R4-30, R1-8, 
R2-8, R3-8 and R4-8). Some mutants occurred in locations where the sequences of 
NCTC 11168 and PT14 were identical, including mutants P1-cp30 and R4-30 where 
deletion of an adenine base has taken place at position 2418, with the adenine base of 
the start codon in cj0031 representing position 0. Other mutants have arisen at  
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PT14A911_00150   TTTGATGAAAAAGAAGCCACAAAAGAATTTGCAAATCTTAAAAAAGAATACGACAATATC 2340 
11168cj0031      TTTGATGAAAAAGAAGCCATAAAAGAATTTGCAAATCTTAAAAAAGAATACGACAATATC 2340 
******************* **************************************** 
 
PT14A911_00150   TTCAACCTAGAAAGCAATCATCCTTTTGAATGGCGTTTTGAATTCCCTGAAATTTTGGAC 2400 
11168cj0031      TTCAACCTAGAAAGCAATCATCCTTTTGAATGGCGTTTTGAATTCCCTGAAATTTTGGAC 2400 
************************************************************ 
 
PT14A911_00150   GATGATGGAAATTTCAAAGGCTTTGATCTCATCATTGGCAATCCGCCTTATATAAAAGAA 2460 
11168cj0031      GATGATGGAAATTTCAAAGGCTTTGATCTCATCATCGGCAATCCACCTTATATAAGACAA 2460 
*********************************** ******** ********** * ** 
P1-cp30                      TTGCAA-GGC 
R1-30      TCAT-TCG 
R2-30 
R3-30 
R4-30         TTGCAA-GGC 
R1-8            TCC-CCTT 
R2-8      TCATC-TT 
R3-8 
R4-8 
 
PT14A911_00150   AATGATAATAAAGATCTTTTTACCAATACAA--AAAAGTTA-AGAACTTATCAAGGAAAA 2517 
11168cj0031      GAAGAGCTTAAAGAACTCAAGCCCCATTTAGCTAAAAATTATAAGGTTTATAAAGGCACG 2520 
* **   ****** **     ** **  *   **** *** *    **** **** * 
P1-cp30 
R1-30 
R2-30    AA-GATA 
R3-30 
R4-30 
R1-8 
R2-8 
R3-8          AGG--AA 
R4-8      CA-AAAA 
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PT14A911_00150   ATGGATATTTGGTATCATTTCGTAGGGCGTGGATTTGATATACTTAAGAATAATGGA--- 2574 
11168cj0031      AGCGATATTTATACTTATTTTTATGAACTAGGATTTAATGTTTTAAAAGATAGGGGGGGG 2580 
                 *  *******    * ****    *  *  ****** ** *  * **  ***  **     
 
PT14A911_00150   --TATTTAGCATTTATCGCTACAAATAATTGGGTTACAAATTCAGGGGCTAAAAAA-CTA 2631 
11168cj0031      GGTATTGAGC-TATATCACTTCTAACAAATA---CACGCGTGCAGGATATGGGGAAGCTT 2636 
                   **** *** * **** ** * ** ** *     **   * ****   *    ** **  
 
PT14A911_00150   CGCAATATAGTTTTAG--AAGAATCTCAAATTTTAAGCCT-TGTTGATTTTAGTTCTTTT 2688 
11168cj0031      TGCG-TGAATTTTTGCTTAAAAATGTTAAGTTTTTAGAATACACTGATTTAAACGGCATA 2695 
                  **  *  * ****    ** *** * ** **** **  *    ****** *      *  
 
Figure 5-2. DNA sequence alignment of a section of the cj0031 gene in C. jejuni NCTC 11168 with its homologue in PT14. 
The alignment revealed eight bacteriophage-resistant biofilm-derived PT14 isolates (P1-cp30, R1-30, R2-30, R4-30, R1-8, R2-8, R3-8 and R4-8) 
that carry point mutations corresponding to different locations within the cj0031 gene. Some of the mutations occurred in a region where there is 
a break in sequence homology between NCTC 11168 and PT14 and close to the homopolymeric G-tract (shown in red) in NCTC 11168. These 
mutations are highlighted in yellow, while sequence identity is represented by an asterisk.  
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locations where base substitutions are visible in the PT14 sequence. For instance, 
deletion of a thymine base at position 2463 produces the R2-30 mutant in a region of 
the PT14 sequence that is different to NCTC 11168. 
 
5.2.3 Designing the PT14-00150 primers 
To further investigate the role of cj0031 in PT14, a knockout mutant was constructed 
and designated PT14ǻ00150::kan. Dr. C. Bayliss (University of Leicester, UK) kindly 
provided a knockout mutant in which the cj0031/32 locus had been disrupted in C. 
jejuni NCTC 11168 by introducing plasmid DNA into the genome from pUC-
¨cj0031::kan by electroporation. This plasmid contained a 700-bp region from 
upstream of cj0031 (flanked by PstI and BamHI sites) which was ligated to a 600-bp 
fragment downstream of cj0032 (flanked by EcoRI and BamHI sites) and the 
kanamycin resistance (Kanr) gene aphA-3, derived from pJMK30 (van Vliet et al. 
1998), was inserted into the BamHI site. Genomic DNA from the knockout mutant 
1&7& ǻcj0031::kan was used to introduce this disruption into the PT14 
genome by natural transformation (section 2.4). 
 
In order to confirm whether the natural transformation of C. jejuni PT14 had been 
successful, primers PT14-00150F and PT14-00150R were designed as previously 
described in section 2.9.1 to amplify a 2.9 kb fragment within A911_00150. Figure 5-
7 shows the RNA-seq mapping data which was used to confirm the appropriate 
sequence for designing the primers so they could amplify DNA from either the PT14 
or NCTC 11168 genome.  
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5.2.4 PCR confirmation of C. jejuni 37ǻ00150 transformation 
After naturally transforming C. jejuni PT14 with DNA from NCTC 
ǻcj0031::kan (2.4), nine transformants were selectively grown on BA agar 
(2.1.1) supplemented with kanamycin (50µg/µl) under microaerobic conditions 
(2.2.2). Confluent growth was harvested from these plates and stored in 
bacteriological storage medium (2.1.15) at -80°C until ready for used. Genomic DNA 
was extracted (2.8) from the PT14ǻ00150::kan transformants as well as NCTC 
11168ǻcj0031::kan, PT14 wild-type, NCTC 11168 wild-type and NCTC 11168WT-
ON (strains described in Table 2-2). The DNA was then PCR amplified using the 
PT14-00150FR primers (Table 2-4) and the gel electrophoresis image is presented in 
Figure 5-3. The primers successfully amplified DNA from all isolates, with the 
exception of transformants 4 and 8.  Expected band sizes were achieved for all of the 
bands visualised as indicated by Figure 5-3. The band sizes suggest successful 
disruption of A911_00150 in the mutant by the aphA-3 kanamycin resistance gene 
because bands representing the mutant isolates were 1400-bp larger than those of the 
wild-type strains, which corresponds to the approximate size of that gene. 
 
5.2.5 Bacteriophage lytic spectra 
Bacteriophage lytic reactions were scored according to the nomenclature used in 
phage typing scheme of Frost et al. (1999) (2.5.4). Campylobacter lawns were firstly 
prepared as described in section 2.5.3 and 10 µl aliquots of the bacteriophages of 
interest, diluted to the routine test dilution of approximate concentration of 6 log10 
PFU ml-1 (the routine test dilution or RTD), were then spotted onto the lawns. A 
maximum of 16 spots were pipetted onto each petri dish in duplicate. The lytic ability 
of each phage was then recorded following overnight incubation. Table 5-1 presents 
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Figure 5-3. 1% Agarose gel of PCR products obtained using PT14-00150 primers. 
Lane 1: PT14ǻ00150::kan transformant 1, Lane 2: 37ǻ00150::kan transformant 2, Lane 3: 37ǻ00150::kan transformant 3, Lane 4: 
37ǻ00150NDQ WUDQVIRUPDQW  /DQH  37ǻ00150::kan transformant 5, Lane 6: Promega 1 kb ladder /DQH  37ǻ00150::kan 
transformant 6, /DQH37ǻ00150NDQWUDQVIRUPDQW/DQH37ǻ00150NDQWUDQVIRUPDQW/DQH37ǻ00150::kan transformant 
/DQH1&7&ǻ00150::kan, Lane 12: Promega 1 kb ladder, Lane 13: PT14WT, Lane 14: NCTC 11168WT, Lane 15: NCTC 11168 
WT-ON. The approximate amplicon size for each A911_00150 mutant and wild-type strain was expected to be 4256-bp and 2856-bp 
respectively.  
 ?Ŭď  ?Ŭď  ?Ŭď 
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the scores for the propagation ability of phages from spot tests on PT14 wild-
type and PT14ǻ00150::kan lawns. Phages that displayed differences in their 
plaque forming ability are indicated in red. Twenty bacteriophages fit this 
criterion but efficiency of plating (EOP) values were only determined for those 
that formed plaques on both the wild-type and mutant strains (referred to as 
original phages in Table 5-2). EOP values were calculated by dividing the PFU 
ml-1 of each bacteriophage by the PFU ml-1 of the phages propagated on the 
wild-type strain (2.5.5). This therefore gave an EOP value of 1 for all 
bacteriophages that were propagated on the wild-type. The results indicate that 
all bacteriophages formed plaques more efficiently on the wild-type strain than 
RQ WKH 37ǻNDQ PXWDQW, and in many cases no phage could be 
recovered from the mutant. 
 
Bacteriophages that could be recovered as plaques from the mutant strain 
(referred to as recovered phages in Table 5-2) were titred against wild-type and 
37ǻNDQ PXWDQW strains to re-examine their plaque forming ability. 
The EOPs of the recovered phages are presented in Table 5-2, and with the 
exception of bacteriophage CP20, all bacteriophages continued to infect the 
wild-type strain more efficiently than on the PT14ǻ00150::kan mutant. 
Bacteriophage that replicated in the absence of the PT14ǻ00150::kan DNA 
methyltransferase appeared no less infectious to wild type PT14 and remained 
impaired in their ability to infect 37ǻNDQ. 
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Table 5-1. Bacteriophage lytic spectra on C. jejuni PT14 
 
 
Abbreviations used for scoring are as follows:  CL or OL = confluent clear or 
opaque lysis; < CL or < OL = less than confluent lysis; SCL or SOL = semi-
confluent; < SCL or < SOL = less than semi-confluent but no discrete plaques; 
µ¶   !  GLVFUHWH SODTXHV µ¶   - GLVFUHWH SODTXHV µ¶   -49 
GLVFUHWHSODTXHVµ±¶ -GLVFUHWHSODTXHVµ-µ QRSODTXHV 
 
 
 
Phage Previous 
Host
PT14WT 37ǻ$B Phage Previous 
Host
PT14WT 37ǻ$B
4b PT14 SCL SCL CP8 11168H SCL SCL
7 PT14 OL - CP8 HPC5 CL CL
9 PT14 - - CP8 PT14 CL CL
10b PT14 - - CP30 11168H CL CL
11 PT14 OL - CP30 11168 CL CL
18b PT14 CL CL CP30 HPC5 CL CL
19 PT14 <OL - CP30 PT14 CL CL
A1B PT14 CL CL NCTC 12669 PT14 OL ±
A32 PT14 CL CL NCTC 12670 PT14 CL CL
CP8 PT14 CL CL NCTC 12671 PT14 - -
CP20 PT14 OL ++ NCTC 12672 PT14 - -
CP51 PT14 SCL SCL NCTC 12673 PT14 CL ++
CP220 PT14 OL - NCTC 12674 PT14 CL CL
E5 PT14 - OL NCTC 12675 PT14 - -
G1 PT14 OL +++ NCTC 12676 PT14 ± ±
G3 PT14 OL SCL NCTC 12677 PT14 - -
G4 PT14 OL SCL NCTC 12678 PT14 CL SCL
G5 PT14 SCL SCL NCTC 12679 PT14 SCL <SCL
G8 PT14 OL - NCTC 12680 PT14 CL <SCL
mc1a PT14 OL - NCTC 12681 PT14 OL -
NQ1 PT14 CL CL NCTC 12682 PT14 OL -
X3 PT14 CL SCL NCTC 12683 PT14 - -
NCTC 12684 PT14 OL -
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Table 5-2. Relative efficiency of plating (EOP) for phages propagated on 
PT14 wild-type and PT14ǻ00150::kan mutant 
Original phagesa 
Phage 
EOP 
PT14WT 37ǻ00150 
CP20 1 3.78E-04 
E5 1 3.10E-03 
G1 1 2.03E-05 
G3 1 2.68E-03 
G4 1 3.87E-03 
NCTC12669 1 2.37E-04 
NCTC 12680 1 7.47E-04 
X3 1 6.57E-04 
Recovered phagesb 
Phage  EOP PT14WT 37ǻ00150 
CP20 1 2.7 
E5 1 7.51E-02 
G1 1 5.20E-04 
G3 1 3.42E-03 
G4 1 2.20E-03 
NCTC12669 1 2.13E-03 
NCTC 12680 1 6.47E-04 
X3 1 5.00E-03 
   
   
   
 
a ± EOP values determined for the original phages propagated on C. jejuni 
PT14 highlighted in Table 5-1 that showed differences in their plaque forming 
ability but formed plaques after propagation on both the wild-type and mutant 
strains.  
 
b ± EOP values determined for phages recovered after infection of the mutant 
strain. 
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5.2.6 Motility assay 
Swarming motility assays were performed as previously described in section 
2.3 in order to determine the functional effect of the A911_00150 deletion 
mutation on the motility phenotype of C. jejuni PT14. In Figure 5-4, there is a 
visible difference in the size of the motility zones of the two strains, illustrating 
that 37ǻ00150::kan exhibited reduced motility compared to the wild-type 
strain. Zones of motility for the wild-type and all 37ǻ00150::kan 
transformants were measured in triplicate and the average diameter of growth 
in cm for each strain is shown in Table 5-3. The transformants (T1-T9) showed 
a reduced spread of growth compared to the wild-W\SH37DQGD6WXGHQW¶VW-
Test (p<0.05) confirmed that all 37ǻ00150::kan mutants were significantly 
less motile than the wild-type. 
 
5.2.7 Complementation of the 37ǻ00150::kan mutant 
The 37ǻ00150::kan 11168cj0031 complement was constructed by PhD. 
student L. Lis (University of Nottingham) as described in section 2.14. This 
complementation strain allowed the cj0031 gene to be expressed from the C. 
jejuni fdxA promoter via the cj0046 pseudogene-based complementation 
vector, pCfdxA:PerR no7 (Bruce Pearson, IFR, Norwich). Briefly, on PCR-
amplification and pCR2.1 TOPO vector cloning of the cj0031 gene in NCTC 
11168 and its upstream promoter region, the PCR fragment was integrated into 
the complementation vector. The perR gene was replaced with the cj0031 
promoter and gene fragment. The vector was amplified in E. coli and genomic 
DNA was afterwards used to naturally transform and complement the deletion 
mutant to create PT14ǻ00150::kan, 00230::00150cam. 
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Figure 5-4. Motility assays for C. jejuni PT14 wild-type, mutant 37ǻNDQand complement. 
Motility was determined by measuring the diameter of the spread of growth in cm after 24 hours. There was a significant reduction in motility 
(p<0.05) of the 37ǻ::kan mutant compared to the wild-type. However, the wild-type phenotype was restored with the 37ǻNDQ
00230::00150cam complement. 
Wd ? ?ǻ ? ? ? ? ? P PŬĂŶ Wd ? ?ǻ ? ? ? ? ? P PŬĂŶ 
 ? ? ? ? ? P ? ? ? ? ?ĐĂŵ 
Wd ? ?ǁŝůĚƚǇƉĞ 
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Table 5-3. Average diameter of motility zones for PT14 wild-type and 
PT14ǻ00150::kan mutant strains 
Strain Average growth (cm)a 
PT14WT 4.33 ± 0.12 
37ǻ00150 T1 2.13 ± 0.05 
37ǻ00150 T2 2.07 ± 0.05 
37ǻ00150 T3 3.10 ± 0.42 
37ǻ00150 T4 2.87 ± 0.19 
37ǻ00150 T5 1.53 ± 0.39 
37ǻ00150 T6 1.30 ± 0.14 
37ǻ00150 T7 2.60 ± 0.29 
37ǻ00150 T8 1.60 ± 0.14 
37ǻ00150 T9 0.93 ± 0.17 
 
Note: aAverages of triplicate measurements are given ± standard deviation. 
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The complemented mutant strain which was found to be motile, was then used 
along with strains PT14 wild-type and 37ǻ00150::kan, to determine the 
effect of the A911_00150::kan deletion mutation of adhesion and invasion 
phenotypes.  
 
5.2.8 Adhesion and Invasion 
Adhesion and invasion assays were performed with the assistance of Prof. I. 
Connerton (University of Nottingham) as previously described by Al-Sayeqh 
et al. (2010) and as detailed in section 2.15.2. Briefly, HCA-7 cells (Kirkland 
1985) were grown as monolayer cultures in 24-well plates in D-MEM 
supplemented with FCS at a final concentration of 10% (v/v) (Invitrogen). 
Duplicate cell monolayers were individually covered with C. jejuni PT14 wild-
type, 37ǻ00150::kan and 37ǻ00150::kan, 00230::00150cam complement 
cells at an approximate multiplicity of infection of 100. Both sets of monolayer 
plates were washed three times with PBS (2.1.12) and one of them was treated 
with gentamicin. The cell monolayers were lysed to release internalized 
bacteria and cells were enumerated on CCDA plates (2.1.2). The adherent 
bacterial count was derived by subtracting the number of internalized bacteria 
from the total number and expressing this as a percentage of the inoculum. The 
invasion efficiency was expressed as the percentage of the inoculum that was 
gentamicin protected.  
 
For each experiment, means and standard deviations were derived from 
triplicate readings. Figure 5-5 illustrates that the number of bacteria that 
adhered to the HCA-7 cell monolayer was significantly reduced with 
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37ǻ00150::kan as compared to the wild-type by almost 3-fold (6WXGHQW¶VW-
Test, p<0.05). Complementation of the mutant restored the wild-type adhesion 
phenotype. Similarly, cell invasion was significantly reduced with the mutant 
compared to the wild-type by 7.5-fold (6WXGHQW¶V W-Test, p < 0.05) and the 
ability to invade the monolayer was also restored in the complemented mutant 
(Figure 5-6). 
 
5.2.9 In vivo colonisation study 
During the study, a batch of 21 chickens was divided into 3 groups of 7 and 
administered doses of either 7 log10 CFU ml-1, 5 log10 CFU ml-1 or 3 log10 CFU 
ml-1 of PT14ǻ00150::kan culture according to section 2.13.3 (Table 2-5). As a 
control a second batch of 21 chickens was infected with equivalent doses of the 
wild-type strain. For birds administered 37ǻNDQ by oral gavage, no 
Campylobacter colonies were recovered on CCDA enumeration media (2.1.2) 
from their caeca at any dose. The limit of detection was 2 log10 CFU g-1 
caecal content. On the other hand, all chickens administered the PT14 wild-
type strain were successfully colonised at a rate of >6 log10 CFU g-1 caecal 
content with any of the three doses administered. Table 5-4 presents the 
colonisation results. 
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Figure 5-5. Adherence of C. jejuni PT14 strains to HCA-7 human colonic 
cells in response to the A911_00150 knockout mutation. 
The ability of the 37ǻ::kan mutant to adhere to the HCA-7 cells was 
significantly (p<0.05) reduced compared to the wild-type and 
complementation of the mutant restored the wild-type phenotype. Results are 
derived from the mean of triplicate experiments and error bars represent the 
standard deviation.  
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Figure 5-6. Invasion of HCA-7 human colonic cells by C. jejuni PT14 
strains in response to the A911_00150 knockout mutation. 
Invasion of the HCA-7 cells by the 37ǻ00150::kan mutant was significantly 
reduced (p<0.05) compared to the wild-type and complementation restored the 
wild-type phenotype. Results are derived from the mean triplicate experiments 
and error bars represent the standard deviation.  
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Table 5-4. Chicken colonisation levels after 24 hours post-administration 
of PT14 wild-type and 37ǻNDQ mutant strains 
 
Strain Designated group Average quantity of 
recovered bacteria (CFU 
g-1)a 
37ǻNDQ group 7 (3 log10 CFU ml-1)  
  group 8 (5 log10 CFU ml-1)  
  group 9 (7 log10 CFU ml-1)  
PT14 wild-type group 10 (3 log10 CFU ml-1) 6.27 log10 ± 0.39 
  group 11 (5 log10 CFU ml-1) 6.83 log10 ± 0.40 
  group 12 (7 log10 CFU ml-1) 6.57 log10 ± 0.96 
 
Note: a Mean counts for 7 birds ± SD. 
 
  
  Chapter 5 
230 
 
5.2.10 Transcriptome analysis of C. jejuni PT14 in response to 
A911_00150 mutation 
For RNA-seq analysis of C. jejuni PT14 wild-type and the 37ǻ00150::kan 
mutant, triplicate cultures were grown and the RNAs harvested according to 
the method in section 2.12.1. Briefly, three biological replicates were grown in 
150 ml of MH broth (2.1.6) with shaking at 100 rpm under microaerobic 
conditions at 42°C (2.2.2). This was done until the cultures reached mid-log 
phase of growth, after which RNA was isolated using the Trizol Max Bacterial 
Isolation kit (Invitrogen). The RNA was purified using an RNeasy Mini kit 
(Qiagen) and only samples with a RIN number of at least 7.0 were used for 
sequencing. Ribosomal RNA was removed using the Ribo-Zero rRNA removal 
kit for Gram-negative bacteria (Epicentre Biotechnologies) and directional 
cDNA libraries were then prepared using the ScriptSeq v2 RNA-seq library 
preparation kit (Epicentre Biotechnologies) according to section 12.2.2. The 
libraries were individually indexed and their quality was verified using a 
bioanalyser 2100 (Agilent). They were quantified by qPCR and pooled prior to 
loading onto an Illumina HiSeq 2000 sequencer. Sequencing was carried out 
using the Illumina standard protocol. 
 
The RNA-sequencing generated an average of approximately 28 million reads 
per sample, each of which was 100 nucleotides in length and from paired-ends. 
CLC Genomics Workbench version 6.0 software was used to remove the 
adapter indexes and filter the raw reads (2.12.4.1). Table 5-5 provides a 
summary of the number of reads attained after filtering and also illustrates the 
number of reads that aligned uniquely to the reference genome for each 
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replicate sample. A principle components analysis was performed to validate 
the replicates (Figure 5-7) and the filtered reads were then mapped against the 
C jejuni PT14 reference genome (Brathwaite et al. 2013) according to section 
2.12.4.2. Figure 5-8 shows RNA-seq data at the A911_00150 locus for the 
PT14ǻ00150::kan mutant mapped against the PT14 genome. This data was 
also used in the design of the PT14-00150FR primers (5.2.3). Panels (a) and 
(b) show reads with faded ends, which represent the beginning and end of 
where the kanamycin resistance cassette was inserted within the 
37ǻ00150::kan genome respectively. This mapping also provided 
unequivocal confirmation that A911_00150 had been successfully disrupted by 
the aphA-3 gene. 
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Table 5-5. Analysis of the RNA-seq data 
Condition Original count Number of reads after trimming Number of uniquely mapped reads 
C. jejuni PT14 wild-type replicate 1 27,046,844 12,343,573 10,139,255 
C. jejuni PT14 wild-type replicate 2 28,227,850 13,127,628 10,552,880 
C. jejuni PT14 wild-type replicate 3 23,251,450 6,837,881 3,177,087 
37ǻ00150::kan replicate 1 34,455,968 14,792,032 10,336,677 
37ǻ00150::kan replicate 2 27,031,598 12,630,072 9,354,104 
37ǻ00150::kan replicate 3 29,370,616 12,769,998 8,674,015 
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Figure 5-7. Principle component analysis of RNA-seq reads. 
Each C. jejuni PT14 wild-type replicate and 37ǻ00150::kan mutant 
replicate are plotted on the PCA projection coordinates. The PCA successfully 
validates the reads as two distinct groups (wild-type vs mutant) regardless of 
the variation observed for the mutant reads compared to those of the wild-type 
on these two projections. 
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Figure 5-8.  C. jejuni 37ǻ00150::kan reads mapped against the PT14 
genome. 
The PT14 reference sequence is seen directly below the yellow bar to the top 
of the image and all Illumina reads mapped to this sequence are coloured in 
blue (paired reads), green (broken pairs, forward orientation) and red (broken 
pairs, reverse orientation). For all reads shown, their ends are faded because 
they do not match the reference sequence and were therefore not aligned. 
Mismatches between the reference sequence and the mapping data are 
highlighted in red (A), blue (C), green (T) and yellow (G). In this case, the 
faded read ends represent the sequence containing the A911_00150/cj0031 
knockout mutation and the nucleotide changes seen in (b) originated from the 
C. jejuni NCTC 11168 genome. Primers were designed in two regions where 
base changes did not occur and the sequence was the same for both C. jejuni 
PT14 and NCTC 11168, which would allow DNA amplification from either 
strain. The figure illustrates where the insertion of the kanamycin resistance 
gene aphA-3 begins and ends, represented by panels (a) and (b) respectively, to 
create the disruption of A911_00150. 
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5.2.11 PT14-A911_00150 regulated gene expression 
The RNA-seq data was processed using the CLC Genomics Workbench 
package (2.12.4.3). Reads that mapped uniquely to the C. jejuni PT14 genome 
were normalized by calculating the reads per kilobase of transcript per million 
mapped reads (RPKM) (Mortazavi et al. 2008) as a means of determining the 
expression level of the genes. TKH%DJJHUOH\¶VWHVWon expression proportions 
(Baggerly et al. 2003) was used to determine genes with differential expression 
between the wild-type and mutant. To account for multiple testing, p-values 
were adjusted using the false discovery rate controlling method of Benjamini 
and Hochberg (1995), A total of 65 genes displayed significant changes in 
their expression levels ( 1.5-fold, padj<0.05) in response to the A911_00150 
knockout mutation in C. jejuni PT14. Figure 5-9 shows the log2 (RPKM+1) 
values obtained for PT14WT plotted against the equivalent values for 
37ǻ00150::kan. Up- and down-regulated genes are colour-coded in yellow 
and red respectively. 
 
Twenty-nine genes were activated in response to the A911_00150 deletion 
mutation in PT14.  A substantial number of these were found to be associated 
with bacterial stress responses, including the transcriptional regulator hrcA as 
well as chaperones and chaperonins grpE, dnaK, clpB and cpbA. Although the 
heat shock proteins GroES and GroEL were found to be significantly 
regulated, they fell below the fold change cut-off of 1.5, which was selected as 
significant. A large number of genes encoding ribosomal proteins 
(rplCDFNORWX, rpsE) were also co-regulated. In addition, genes involved in 
central intermediary metabolism (gltB, gltD), amino acid biosynthesis (hisF) 
 Chapter 5 
237 
 
and protein and peptide secretion (secY) were found to be up-regulated by C. 
jejuni PT14 as well. The most activated gene in response to the mutation was 
the heat shock protein GrpE, which was just over two-fold higher in the mutant 
than in the wild-type. The complete list of up-regulated genes in response to 
the A911_00150 knockout mutation can be found in Appendix 7. 
 
Thirty-six genes were down-regulated in PT14 as a result of the mutation. 
Many were found to be associated with flagellar biogenesis, including a 
number of putative hook and basal body structural components. The gene 
encoding one of the minor flagellins, flaB, was also repressed in response to 
inactivation of A911_00150 in PT14. Genes involved in tryptophan 
biosynthesis (trpD, trpE), degradation of amino acids (putA) and fatty acid 
biosynthesis (acs) were down-regulated as well, along with a large number of 
hypothetical proteins. Three genes (A911_00155, A911_00160, A911_00170) 
which are located directly downstream of the disrupted A911_00150 gene in 
the PT14 mutant were found to be down-regulated. It is possible that the 
disruption of A911_00150 has impacted on the the expression of the following 
genes. Genes A911_00155 and A911_00160 encode hypothetical membrane 
associated proteins that contain penta peptide repeats. Gene A911_00170 
encodes amembers of the major facilitator superfamily thought to be involved 
in secondary transport functions.  The most highly repressed gene was a 
hypothetical protein (A911_00195) with a fold change of 20.6 followed by the 
flagellar hook protein FlgE which was 18-fold lower in the mutant than wild-
type. The complete list of down-regulated genes in response to the 
A911_00150 knockout mutation can be found in Appendix 8. 
 Chapter 5 
238 
 
Differentially expressed genes were functionally assigned (Figure 5-10) 
according to the Sanger Centre C. jejuni genome database. Up-regulated genes 
were placed into 11 functional categories while the down-regulated genes 
represented 8 groups. The highest number of activated genes related to 
synthesis and modification of macromolecules whilst the greatest numbers of 
down-regulated genes were involved in cell envelope functions. 
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Figure 5-9. Differential gene expression in C. jejuni PT14 in response to 
the A911_00150 mutation. 
The average log2(RPKM+1) value for each gene in the PT14 genome was 
calculated and plotted in the graph above for the PT14WT and 
PT14ǻ00150::kan isolates using RPKM values for 3 biological replicates.  
Significantly differentially expressed genes (1.5-fold, *padj<0.05) are 
highlighted in yellow (up-regulated) and red (down-regulated).  
*padj<0.05 ± corrected p-value representing a false discovery rate of <5% 
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Figure 5-10. C. jejuni PT14 genes differentially expressed in the 
37ǻ00150::kan mutant compared to wild type, ordered by functional 
category. 
Individual genes that were found to be greater than 1.5 fold differentially 
expressed, are represented using a Circos diagram (Krzywinski et al. 2009) 
with each gene represented and colour-coded according to functional class 
(Parkhill et al. 2000; Gundogdu et al. 2007) as follows: 1A, Degradation; 1C, 
Central intermediary metabolism; 1D, Amino acid biosynthesis; 1G, 
Biosynthesis of cofactors, prosthetic groups and carriers; 3A, Synthesis and 
modification of macromolecules; 3B, Degradation of macromolecules; 3C, 
Cell envelope; 4A, Transport/binding proteins; 4B, Chaperones; chaperonins, 
heat shock; 4E, Protein and peptide secretion; 5G, Antibiotic resistance; 5H, 
Conserved hypothetical proteins; 5I, Unknown; 6A, Miscellaneous;. 
Differentially expressed genes are labelled by locus-tag on the outer circle in 
UHGW\SHIRULQFUHDVHGH[SUHVVLRQLQWKH37ǻNDQPXWDQWFRPSDUHGWR
wild type PT14 or black type for decreased expression. Histograms in the 
central rings represent the fold change with increased expression in the 
37ǻNDQPXWDQWFRPSDUHGWRZLOGW\SH UHSUHVHQWHGE\UHGEDUVDQG
reduced expression represented by black bars. Scale indicated by grey circles 
with values greater than 10 fold truncated so bars touching the inner ring 
represent a fold change of greater than or equal to -10. 
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5.3 DISCUSSION 
In C. jejuni NCTC 11168, the phase variable gene cj0031 encodes a Type IIS 
R-M system. The homologue of this gene in C. jejuni PT14, A911_00150, is 
not phase variable but displays an overall 76% amino acid identity to Cj0031 
(Figure 5-1). After successful transformation to produce the 37ǻ00150::kan 
mutant, bacteriophage propagation was examined with this strain using a 
selection of group II and III Campylobacter phages. Interestingly, the EOP 
results for propagation on the wild-type was not what would be expected for a 
restricting host and contrary to findings reported for phage-host combinations 
in other species. Functional tests were carried out to assess motility, adherence 
to and invasion of human cells and colonisation ability in vivo. Phenotypic 
differences between the wild-type and mutant were observed for all tests 
performed. In addition, examination of gene regulation in PT14 revealed that 
A911_00150 plays a regulatory role within this strain and influences 
expression of key genes. These data support the phenotypic findings. 
 
5.3.1 A group of bacteriophages appears to require A911_00150 
for replication 
The plaque forming ability of a large number of the bacteriophages tested was 
reduced in the absence of A911_00150 (Table 5-1). It has previously been 
found that the efficiency of plating calculated for  phages grown on a  non-
restricting host was close to 1 whilst growth on a host containing a functional 
restriction system that recognises and restricts unmodified bacteriophage DNA 
was lower (Arber & Dussoix 1962). However, the findings of the current study 
provide a mechanism that is different to what has previously been established 
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as the EOP values for bacteriophages propagated on the wild-type, which 
should act as a restricting host if its R-M system is functional, were calculated 
to be 1 while values for those grown on the mutant, a non-restricting host, were 
lower than 1 (Table 5-2). This suggests that a class of phages replicate more 
efficiently in the presence of the type II R-M system represented by 
A911_00150 in PT14. 
 
5.3.2 Unmodified bacteriophages were not restricted by PT14 
Under normal circumstances a particular bacterial host strain will be infected 
with phages that carry the strain-specific DNA modification produced by that 
host. As the majority of the phages tested were originally propagated on C. 
jejuni PT14, they would have already been modified for the associated 
recognition sequence and were therefore equipped to escape restriction. It was 
however interesting to see that bacteriophages CP8 and CP30 that were 
previously propagated on alternative host strains, namely NCTC 11168, NCTC 
11168H and HPC5, were able to escape restriction and successfully infect and 
lyse PT14 cells, producing either confluent or semi-confluent growth on both 
the wild-type and mutant strains (Table 5-1). This may suggest that the PT14 
R-M system could be inactive against these two phages as the wild-type strain 
was unable to restrict them. This may also imply that these phages do not 
possess restriction recognition sites for A911_00150. This finding also 
illustrates that the Type I R-M system present in PT14 (3.2.8) may be also 
inactive against these unmodified phages.  
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Some bacteriophages can escape bacterial restriction by reducing or 
eliminating the number of recognition sites present in their genome or by 
changing the orientation of the recognition sequence (Labrie et al. 2010; 
Samson et al. 2013). However, Hill et al. (1991) were the first to report of a 
system where phage could escape restriction via genetic exchange between 
phage and bacterial host. They showed that phage ĭZDVDEOHWRPHWK\ODWH
its own genome and escape restriction by lactococcal strains because it 
acquired the amino domain of the type II methyltransferase, LlaI by 
recombination with the plasmid pTR2030. Similarly, a putative DNA 
methylase and a hypothetical protein noted to be similar to a putative 
methyltransferase in phage NCTC12673 have been identified in phage CP8, 
therefore making such an occurrence possible with this phage. However, 
methylase genes have not identified in phage CP30A. 
 
5.3.3 Inactivation of A911_00150 in C. jejuni PT14 leads to loss 
of motility, adhesion, invasion and colonisation ability  
Previous colonisation studies have shown that flagella play a major role in the 
ability of C. jejuni to colonise the gut of chickens (Nachamkin et al. 1993; 
Wassenaar et al. 1993), mice (Morooka et al. 1985; Newell & Mcbride 1985), 
rabbits (Caldwell et al. 1985; Pavlovskis et al. 1991) and hamsters (Aguero-
Rosenfeld et al. 1990). A study with human volunteers also found flagellar 
motility to be important in human disease (Black et al. 1988). Similarly, in 
vitro studies have suggested that flagella play a role in adherence (Newell & 
Mcbride 1985) and invasion (Wassenaar et al. 1991; Grant et al. 1993; Yao et 
al. 1994) of human epithelial cells. 
  Chapter 5 
245 
 
The A911_00150 deletion mutation in C. jejuni PT14 caused a significant 
decrease in the ability of the mutant to swarm on motility agar compared to the 
wild-type strain (Figure 5-4).  Inactivation of this gene in PT14 also caused 
hypoadherence to HCA-7 cells by almost 3-fold (Figure 5-5). However, 
complementation restored the wild-type adhesion phenotype confirming that 
the absence of this gene was responsible for the decrease in adherence to the 
HCA-7 cell monolayer. Similarly, invasion of HCA-7 cells by 
PT14ǻ00150::kan decreased by almost 8-fold compared to the wild-type and 
complementation restored wild-type invasion efficiency (Figure 5-6). This 
therefore suggests that the A911_00150 gene in PT14 is important for invasion 
of human colonic cells. The ability of the mutant to colonise chickens was also 
tested using three different concentrations of PT14ǻ00150 inoculum. The 
results showed that the mutant was unable to colonise the chicken gut while the 
wild-type was successful in doing so. Again, this illustrates that inactivation of 
this genes affects the colonisation ability of C. jejuni PT14. 
 
5.3.4 Stress-responsive and ribosomal protein synthesis genes 
were up-regulated in response to A911_00150 mutation 
A very specific set of genes were activated in response to the A911_00150 
deletion mutation in PT14. The most notable gene clusters to be up-regulated 
were the hrcA-grpE-dnaK operon, along with co-chaperones clpB and cbpA as 
well as a large number of ribosomal proteins (rplCDFNORWX, rpsE). 
Molecular chaperones within bacterial cells are known to promote efficient 
folding of newly synthesised polypeptides and allow their translocation, while 
ensuring the stability of de novo folding under conditions of stress and the re-
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folding of denatured proteins following exposure to stress (Hartl & Hayer-Hartl 
2002). Chaperone activity of ClpB in E. coli was investigated by Zolkiewski et 
al. (1999) who found that this heat shock protein worked with the DnaK-DnaJ-
GrpE system to suppress and reverse aggregation of a luciferase protein 
substrate. It was later shown that the DnaK system possessed a size-dependent 
aggregation mechanism whereby small protein aggregates could be readily 
dissolved and refolded into active proteins while large aggregates required the 
catalytic action of ClpB and ATP (Diamant et al. 2000). 
 
Many chaperones are known to be up-regulated in response to heat shock or 
any other condition that causes mis-folding of cellular proteins. It therefore 
appears that inactivation of A911_00150 in PT14 triggered protein mis-folding 
which then caused an increased need for the chaperones to function and for 
new proteins to be synthesised. As a result, up-regulation of the stress response 
genes and the ribosomal proteins occurred. 
 
5.3.5 Flagellar biogenesis genes down-regulated in response to 
A911_00150 mutation 
Several structural genes required for flagellar biogenesis in C. jejuni were 
found to be negatively regulated in response to the A911_00150 mutation in 
PT14, including those involved in formation of the filament (flaB and flaG), 
hook (flgE, flgE2, flaD and flgK) and rod (flgB, flgG, flgG2, flgH and flgI,). 
Regulation of these genes supports the findings of decreased motility of the 
mutant as well as hypoadherence to and reduced penetration of HCA-7 human 
colonic epithelial cells.  
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In C. jejuni, regulation of expression of a number of flagellar genes is known to 
be controlled by the two alternative sigma factors rpoN ı54) and fliA ı28) 
(Guerry et al. 1991; Hendrixson et al. 2001; Jagannathan et al. 2001; 
Hendrixson & Dirita 2003; Carrillo et al. 2004). However, the primary sigma 
IDFWRUı70 (Wösten et al. 1998), encoded by rpoD, plays a role in housekeeping 
functions. Flagellar structural genes are temporally transcribed in the order in 
which the proteins are required for assembly of the flagellum, ending with 
production of the structural protein, flagellin (Macnab 1992; Macnab 1996; 
Soutourina & Bertin 2003). Early genes which are needed for assembly of the 
basal body and flagellar export apparatus are FRQWUROOHG E\ ı70 promoters 
(Petersen et al. 2003).  However late genes, such as those required to complete 
DVVHPEO\RI WKHKRRNDQGEDVDOERG\FRPSOH[DUHDFWLYDWHGE\ı54 promoters 
ZKLOHH[WHQVLRQRIWKHIODJHOOXPLVFRQWUROOHGE\ı28 promoters (Hendrixson et 
al. 2001) 7KH ı54-associated transcriptional activators, FlgR and FlgS, may 
also be essential for regulation of flagellar gene expression (Jagannathan et al. 
2001; Hendrixson & Dirita 2003; Boll & Hendrixson 2013). In addition, the 
transcriptional regulator FlgM is an anti-ı IDFWRU SURWHLQ ZKLFK LQKLELWV ı28-
dependent transcription and has an important role to play as well (Wösten et al. 
2010). 
 
All of the flagellar genes that were repressed in response to the A911_00150 
deletion PXWDWLRQ LQ37ZHUHXQGHUı54 control, with the exception of flaG 
ZKLFK UHTXLUHV ı28 to initiate transcription. All three sigma factors were 
expressed at similar levels in the wild-type and mutant. The major flagellin 
encoding gene flaA, which also requiUHV D ı28 promoter, was significantly 
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down-regulated but did not meet the fold change cut-off of -1.5 fold. 
Jagannathan et al. (2001) previously found that expression of FlaA was 
UHSUHVVHGZKHQJHQHVDFWLYDWHGE\ı54 or FlgR were not expressed and this is 
similar to what was observed in the 37ǻ00150::kan mutant. On the other 
hand, Hendrixson & Dirita (2003) found that transcription of flaA remained 
unaffected in flgDE2 mutants while flaB gene expression was significantly 
UHGXFHG 7KH\ DOVR IRXQG ZHDN UHSUHVVLRQ RI ı28-dependent transcription by 
flgM.  
 
5.3.6 Possible effect of HspR transcriptional regulator 
It has previously been reported that inactivation of the negative transcriptional 
regulator for heat shock genes, hspR, resulted in increased expression of dnaK, 
grpE, clpB and hrcA along with down-regulation of many flagellar structural 
genes (flgD, flgE, flgE2, flaA and flaB) (Andersen et al. 2005). They also found 
that the hspR mutant displayed reduced motility, showed changes in 
morphology compared to the wild-type and there was a decrease in its ability to 
adhere to and invade human epithelial INT-407cells in vitro. Holmes et al. 
(2010) also obtained similar findings when they deleted both hrcA and hspR in 
C. jejuni NCTC 11168. These results overlap considerably with what has been 
seen for the PT14ǻ00150 strain. This may therefore suggest that the 
A911_00150 gene could be interacting in some way with HspR in PT14. 
However the expression level of this gene remained unchanged. 
5.3.7 The A911_00150 gene is important for pathogenesis 
Kim et al. (2008) looked at the role of the putative methyltransferase gene 
cj1461 in gene regulation and virulence in C. jejuni. They found that mutation 
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of this gene caused a significant reduction in motility and resulted in a 7-fold 
increase in adherence to but a 50-fold decrease in invasion of INT-407 human 
epithelial cells. They also found that the cj1461 mutation caused a defect in 
flagellar appearance and suggested the potential of cj1461-regulated epigenetic 
control of flagellar biosynthesis. Several studies have also demonstrated that 
inactivation of genes encoding flagellar structural components, such as flaA 
and flaB, resulted in reduced motility which led to changes in adhesion and 
invasion efficiencies (Wassenaar et al. 1991; Grant et al. 1993; Yao et al. 
1994). Wassenaar et al. (1991) found that expression of flaA but not flaB was 
necessary for motility and that non-motile C. jejuni had lost their ability to 
adhere to and invade human intestinal cells in vitro. Other studies have 
suggested that the presence of adhesins such as CadF, JlpA and PEB1 are 
important for C. jejuni adherence to and invasion of human epithelial cells and 
for intestinal colonisation (Konkel et al. 1997; Pei et al. 1998; Jin et al. 2001; 
Monteville et al. 2003). 
 
Inactivation of the A911_00150 gene in C. jejuni PT14 caused changes in 
several properties related to pathogenesis and virulence such as motility, 
colonisation and adhesion to and penetration of human epithelial cells. The 
reduced expression of the flagellar biogenesis genes is therefore likely to be 
responsible for these changes in phenotypes observed. This suggests that 
although C. jejuni PT14 does not possess a Dam methyltransferase homologue, 
there appears to be A911_00150-regulated epigenetic control of flagellar 
biogenesis.  
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6.1 GENERAL DISCUSSION 
C. jejuni is a primary cause of human bacterial gastroenteritis worldwide. 
Consumption of contaminated poultry meat is considered to be one of the main 
sources of infection. With the increasing emergence of antibiotic-resistant 
Campylobacter isolates, the use of virulent bacteriophages to reduce this 
pathogen in poultry is a potential biocontrol strategy that could limit its entry 
into the human food chain. To help achieve this, a better understanding of the 
mechanisms involved in phage-host interactions, particularly at the molecular 
level, is important. The main objective of this study was to therefore examine 
such interactions between Campylobacter and its virulent phages. This was 
achieved by investigating the transcriptional response of C. jejuni to phage 
infection as well as examining the role of a Type II R-M system during phage 
infection of Campylobacter. The highly phage-sensitive Campylobacter strain, 
C. jejuni PT14, was selected for this study along with a number of group II and 
III bacteriophages (Eucampyvirinae).  
 
The genome of C. jejuni PT14 was firstly characterised at the nucleotide level 
and examined for possible reasons to explain the susceptibility of this strain to 
phage infection based on its genome content and arrangement. However, 
despite the nature of this strain to be more vulnerable to predation by a wide 
range of Campylobacter bacteriophages compared to other C. jejuni strains, the 
genome analysis identified no obvious mechanisms that could explain this 
phenomenon. In fact, several features related to bacterial defence were found to 
be present including multiple R-M systems, an intact minimal type II-c 
CRISPR-cas system containing Cas1, Cas2 and Cas9 proteins as well as the 
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presence of homopolymeric tract repeats that constitute phase variable regions 
within genes that have the potential to impact on bacteriophage replication. 
BLAST searches of the spacer regions of the PT14 CRISPR array found no 
obvious nucleotide matches to phage or plasmid DNA, but instead identified 
matches to the PT14 chromosome and sequences of other C. jejuni strains. This 
suggests that no phage-derived protospacer sequences have yet been integrated 
into the CRISPR system of PT14. It was therefore not surprising that exposure 
of C. jejuni PT14 to 60 virulent bacteriophages as part of this study, resulted in 
only 15% of the phages being unable to form plaques, which included the 
group II phage CP220 (Timms et al. 2010) and a number of the UK typing 
phages (Frost et al. 1999). However, there was no obvious rational to explain 
the resistance of PT14 to these phages compared to the others.   
 
Examination of the transcriptional response of C. jejuni PT14 to infection by 
the group III phages CP30A and CPX enabled host-phage interactions to be 
explored immediately prior to host cell lysis. The mechanisms required by the 
phages as they redirected host metabolism for successful production of progeny 
were examined, along with the physiological state of the host. The results 
revealed coordinate changes in host gene expression in response to phage 
infection. However, despite similarities between the two phage genomes, CPX 
had more of a measurable effect on host gene transcription than CP30A as 
almost five times more genes were differentially regulated. This may have been 
solely due to the length of time the phage-infected cells were able to grow 
before cell lysis occurred because the CPX-infected PT14 population crashed 
one hour later than the CP30-infected population. 
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The phage-infected host transcriptome was consistent with that of an iron-
limited aerobic environment. In response to phage infection there was up-
regulation of several genes that were previously found to be up-regulated 
during iron limitation (Palyada et al. 2004; Holmes et al. 2005; Butcher & 
Stintzi 2013). These included genes encoding products related to siderophore-
based iron acquisition systems such as the ferri-enterochelin (cfrA, ceuBDE) 
(Palyada et al. 2004), haem (chuABC) (Ridley et al. 2006), transferrin (cfbpBC) 
(Miller et al. 2008) and rhodotorulic acid (A911_07990/cj1658, 
A911_07995/p19, A911_08000, A911_08005, A911_08010 and 
A911_08015/cj1660-cj1663) uptake systems. Up-regulation of these iron 
acquisition genes in response to bacteriophage infection of C. jejuni PT14 is 
consistent with the model of Fur as a transcriptional repressor of iron 
acquisition genes during iron-replete conditions. The results therefore suggest 
that the Fur protein, in its iron-dissociated apo-Fur form, derepressed 
transcription of the iron acquisition genes in what was perceived to be iron-
limited conditions. The up-regulation of a number of oxidative stress defence 
genes (katA, perR, sodB, A911_02725/cj0559, A911_06735/cj1386, 
A911_08020/cj1664 and A911_08025/cj1665) and down-regulation of several 
flagellar biogenesis genes (flaB, flaD, flaG, flgB, flgE, flgE2, flgG, flgG2, flgH 
flgI and flgK) in response to phage infection were also indicative of apo-Fur 
gene regulation. (Palyada et al. 2004; Holmes et al. 2005; Butcher & Stintzi 
2013) .  
 
The general pattern of down-regulated gene expression was consistent with 
what would be expected for an aerobic environment. There was strong 
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repression of genes associated with a number of anaerobic electron transport 
pathways that utilise alternative electron acceptors to oxygen. An increase in 
oxygen availability could also explain the increased transcription of the 
oxidative stress defence genes as well as up-regulation of the NO-responsive 
haemoglobins, Cgb and Ctb, which have previously been found to be up-
regulated in response to the presence of oxygen (Monk et al. 2008). The 
increased demand for iron and oxygen during phage infection of PT14 was 
thought to have occurred as a consequence of the reduction of ribonucleotides 
WR IRUP ¶-deoxyribonucleotides during phage replication. This process is 
solely catalysed by the enzyme RNR, which requires iron and oxygen during 
formation of a reactive di-iron tyrosyl radical cofactor (Y122) before initiation 
of the nucleotide reduction process. 
 
Based on the RNA-seq data, it does not appear that host defence mechanisms 
were completely disabled by either phage. Instead, up-regulation the CRISPR-
associated cas 2 gene (A911_07325), the gene encoding a member of the Type 
I R-M system of PT14, hsdS (A911_07470) as well as genes encoding an 
adenine specific (A911_01010) and site-specific DNA methyltransferase in 
response to CPX infection suggest a possible attempt by the host to defend 
itself against the incoming threat. However, in response to infection by either 
phage, there was up-regulation of the gene A911_06918/cj1421c, which was 
previously found to encode a product that was identified as a specific target for 
bacteriophage F336 (Sørensen et al., 2011). Therefore, if CP30A and CPX 
utilise this target, the phages may have counteracted the effort of the host to 
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up-regulate their defence genes by increasing the possibility of them adsorbing 
to this potential host receptor. 
 
To conclude this study, a putative type IIs R-M system in C. jejuni PT14, 
encoded by A911_00150, was examined during bacteriophage infection. The 
nearest homologue to this gene in C. jejuni NCTC 11168, cj0031, is phase 
variable and can therefore reversibly VZLWFK ³RQ´DQG ³RII´ WKH expression of 
the reading frame. However, although A911_00150 is not phase variable, a 
BLAST search showed that there is 98% sequence identity to the N-terminal 
end of cj0031 and 90% identity to its C-terminal end. An A911_00150 deletion 
mutant was constructed by naturally transforming PT14 using genomic DNA 
from the knockout mutant 1&7& ǻcj0031::kan. The plaque forming 
ability of a number of selected phages was then determined in the presence and 
absence of A911_00150. The results revealed a mechanism that is different to 
what has previously been established because the phages generally appeared to 
replicate more efficiently in the presence of this type II R-M system. The EOPs 
for bacteriophages propagated on the wild-type, which was assumed to have a 
functional R-M system that could recognise and restrict phage DNA, were 
calculated to be 1. In addition, phages that were previously propagated on 
alternative hosts and therefore should not have been modified to enable their 
escape from the R-M system, were not restricted by PT14 and instead formed 
plaques. EOPs calculated for phages propagated on the mutant were less than 
1, despite this host expected to be a non-restricting host due to deletion of the 
A911_00150 gene, which should have allowed the phages to replicate and 
therefore form plaques. EOPs previously reported for phages propagated on a 
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host containing a functional restriction system were lower than 1 whilst in the 
presence of a non-restricting host, EOPs were calculated to be close to 1 (Arber 
& Dussoix 1962). The results of the current study therefore suggest that 
A911_00150 in C. jejuni PT14 may not be functional, but the data do not 
provide a rational for the low plaque forming ability of the phages in the 
absence of this type II R-M system. Perhaps another R-M system or underlying 
mechanism was responsible for the observed outcome. 
 
Functional tests were conducted to assess the effect of the A911_00150 gene 
deletion in C. jejuni PT14. Significant changes (p<0.05) were observed 
between the wild-type and PT14ǻ00150::kan mutant in several properties 
related to pathogenesis and virulence such as motility, colonisation as well as 
adhesion and invasion of human epithelial cells. Complementation of the 
mutant was able to restore the wild-type phenotype for motility as well as 
adhesion and invasion of human cells. The transcriptional response of C. jejuni 
PT14 to inactivation of the A911_00150 gene was also investigated. It was 
found that A911_00150 plays a regulatory role within PT14 and influences 
expression of key genes involved in stress response, ribosomal protein 
synthesis and flagellar biogenesis. These data support the phenotypic findings 
and in particular, down-regulation of the flagellar biogenesis genes is 
consistent with some of the differences observed in phenotypes between the 
wild-type and mutant.  
 
In conclusion, the findings presented in this thesis provide a better 
understanding of the interactions that occur during bacteriophage infection of 
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Campylobacter. Phage infection of bacterial cells is generally known to cause 
changes in the functioning of host cells, along with modifications during 
transcription and translation.  This study identifies the regulatory mechanisms 
involved during phage infection of Campylobacter, and provides a base to 
determine how such mechanisms may impact survival or escape from phage 
predation. These findings will also contribute to the growing research involved 
in bacteriophage therapy in an effort to control this important food-borne 
pathogen. 
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6.2 FUTURE WORK 
Due to time constraints, it was not possible to complete all aspects of this work. 
Although strand-specific sequencing was applied to both of the transcriptome 
studies conducted within this thesis, the presence of novel transcripts and 
antisense transcription within C. jejuni PT14 were not extensively examined 
and were therefore not reported. In addition, subsequent to the work in this 
thesis being carried out, the transcriptomes of uninfected and phage-infected 
PT14 were reanalysed using a dRNA-seq approach to enable identification of 
host and phage-specific TSSs. Once processed, these data will likely provide 
an invaluable contribution to the current findings.   
 
Experimental validation of the expression patterns identified by the 
transcriptome data from Chapters 4 and 5 is still required. This will likely be 
performed using quantitative reverse transcription PCR (RT-qPCR) on 
remaining aliquots of the total RNA that was used for the RNA-seq analysis. 
Primers will be designed to amplify genes that displayed an increase, decrease 
or no change in gene expression levels between the uninfected and phage-
infected cultures as well as the PT14 wild-type and PT14ǻ00150::kan mutant 
strains. 
 
Finally, bacteriophage infection of a C. jejuni PT14 Fur-deficient mutant 
should be investigated since the transcriptome data suggests Fur-regulation of 
key genes that were differentially expressed between the uninfected and phage-
infected cultures. These results would supplement the findings of the current 
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study and also highlight the importance of the Fur protein during phage 
infection of Campylobacter. 
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APPENDIX 1  
Genes up-regulated in C. jejuni PT14 during bacteriophage CP30 infection 
  Gene designation Product Fold Change  padja 
1 A911_00180 (Cj0037c) cytochrome C 1.664 4.72E-02 
2 A911_00230 (Cj0046) C4-dicarboxylate transporter 2.3 7.14E-03 
3 A911_00695 (Cj0144) methyl-accepting chemotaxis signal transduction protein 1.549 3.30E-10 
4 A911_00865 (exbB1) TonB system transport protein ExbB 2.078 4.47E-02 
5 A911_01060  pathogenicity -like protein 1.829 3.46E-03 
6 A911_01395 (peb3) major antigenic peptide PEB3 1.8 3.49E-27 
7 A911_01670 (trpE) anthranilate synthase component I 1.599 2.01E-07 
8 A911_01675 (trpD) anthranilate synthase component II 1.756 4.69E-16 
9 A911_01680 (trpF) N-(5'phosphoribosyl)anthranilate isomerase 1.956 7.33E-07 
10 A911_01685 (trpB) tryptophan synthase subunit beta  1.667 4.92E-02 
11 A911_01690 (trpA) tryptophan synthase subunit alpha 1.95 9.59E-14 
12 A911_02220 (Cj0455c) hypothetical protein 1.548 3.16E-04 
13 A911_02270 (ctb) group III truncated haemoglobin  7.915 7.23E-23 
14 A911_02340 (rpoC) DNA-directed RNA polymerase subunit beta 1.549 7.66E-14 
15 A911_02730 (Cj0560) MATE efflux family protein 1.625 9.56E-06 
16 A911_02735 (Cj0561c) hypothetical protein 1.56 3.40E-08 
17 A911_02995 (pstS) phosphate ABC transporter substrate-binding protein 1.63 2.66E-05 
18 A911_03000 (pstC) phosphate ABC transporter permease 1.596 1.67E-02 
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Appendix 1 (continued) 
  Gene designation Product Fold Change   padja 
19 A911_03005 (pstA) phosphate ABC transporter permease 1.821 3.33E-05 
20 A911_03010 (pstB) phosphate ABC transporter ATP-binding protein 1.925 1.50E-07 
21 A911_03555 (Cj0728) periplasmic protein  1.701 2.59E-02 
22 A911_03560 (Cj0729) type I phosphodiesterase/nucleotide pyrophosphatase 1.756 1.82E-02 
23 A911_03565 (Cj0730) putative ABC transport system permease 1.796 1.01E-02 
24 A911_03685 (Cj0761) hypothetical protein  7.424 3.27E-150 
25 A911_04025 (Cj0830) hypothetical protein  2.842 3.45E-02 
26 A911_04030 (trmA) tRNA (uracil-5-)-methyltransferase 1.949 7.06E-05 
27 A911_04425 (Cj0916c) hypothetical protein  1.914 1.47E-14 
28 A911_04430 (cstA) carbon starvation protein A 1.608 7.98E-07 
29 A911_04885 (Cj1012c) hypothetical protein 1.501 2.91E-16 
30 A911_05610 (Cj1158c) hypothetical protein 1.628 4.63E-02 
31 A911_06295 (Cj1297) aminoglycosidase N3'-acetyltransferase 1.593 2.89E-04 
32 A911_06305 (Cj1298) putative N-acetyltransferase 1.912 1.64E-11 
33 A911_06450 (neuB2) legionaminic acid synthase 1.546 4.39E-10 
34 A911_06455 (neuC2) UDP-N-acetylglucosamine-2-epimerase 1.552 7.23E-06 
35 A911_06895 (Cj1417c) putative class I glutamine amidotransferase 1.502 2.86E-05 
36 A911_06918 (Cj1421c) hypothetical protein 1.593 3.74E-06 
37 A911_07230 (Cj1501) putative inner membrane protein 1.611 4.80E-25 
38 A911_07630 (cgb) single domain haemoglobin  63.974 6.19E-25 
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Appendix 1 (continued) 
  
Gene designation Product Fold Change  padja 
39 A911_02735 (Cj0561c) hypothetical protein 1.560 3.40E-08 
40 A911_08020 (Cj1664) putative periplasmic thioredoxin 1.555 1.70E-03 
41 A911_06455 (neuC2) UDP-N-acetylglucosamine-2-epimerase 1.552 7.23E-06 
42 A911_02340 (rpoC) DNA-directed RNA polymerase subunit beta 1.549 7.66E-14 
43 A911_00695 (Cj0144) methyl-accepting chemotaxis signal transduction protein 1.549 3.30E-10 
44 A911_02220 (Cj0455c) hypothetical protein 1.548 3.16E-04 
45 A911_06450 (neuB2) legionaminic acid synthase 1.546 4.39E-10 
46 A911_08015 (Cj1663) ABC transporter ATP-binding protein 1.541 1.56E-03 
47 rplR 50S ribosomal protein L18 1.506 9.35E-03 
48 A911_06895 (Cj1417c) putative class I glutamine amidotransferase 1.502 2.86E-05 
49 A911_04885 (Cj1012c) hypothetical protein 1.501 2.91E-16 
 
Note: The corresponding gene locus for C. jejuni NCTC11168 is illustrated within the parentheses. 
a ± padj<0.05 ± corrected p-value representing a false discovery rate of <5% 
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APPENDIX 2   
Genes down-regulated in C. jejuni PT14 during bacteriophage CP30 infection 
  Gene designation Product Fold Change   padja 
1 A911_00020 (Cj0004c) hypothetical protein -2.444 0.00E+00 
2 A911_00025 (Cj0005c) Molybdopterin oxidoreductase family protein -4.325 0.00E+00 
3 A911_00035 (gltB) glutamate synthase, large subunit -2.293 6.67E-08 
4 A911_00040 (gltD) glutamate synthase subunit beta -2.513 5.71E-10 
5 A911_00055 (rrc) rubrerythrin -1.507 1.56E-07 
6 A911_00410 (aspA) aspartate ammonia-lyase -1.502 1.05E-06 
7 A911_01265 (Cj0262c) methyl-accepting chemotaxis protein -2.344 1.78E-12 
8 A911_01275 (Cj0264c) hypothetical protein  -3.185 0.00E+00 
9 A911_01280 (Cj0265c) trimethylamine N-oxide reductase, cytochrome c-type subunit -3.038 0.00E+00 
10 A911_01735 (Cj0358) cytochrome c551 peroxidase -2.824 0.00E+00 
11 A911_01985 (frdC) fumarate reductase cytochrome b-556 subunit -1.638 7.86E-05 
12 A911_01990 (frdA) fumarate reductase flavoprotein subunit -1.865 8.83E-04 
13 A911_01995 (frdB)  fumarate reductase iron-sulfur subunit -1.502 0.00E+00 
14 A911_02130 (sdhA) succinate dehydrogenase flavoprotein subunit -2.296 1.87E-02 
15 A911_02135 (sdhB) succinate dehydrogenase, iron-sulfur protein subunit -2.669 3.85E-06 
16 A911_02140 (sdhC) succinate dehydrogenase subunit C -2.284 0.00E+00 
17 A911_02185 (Cj0448c) methyl-accepting chemotaxis protein -2.064 0.00E+00 
18 A911_02190 (Cj0449c) hypothetical protein  -1.907 0.00E+00 
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Appendix 2 (continued) 
  Gene designation Product Fold Change  padja 
19 A911_02450 (Cj0501) ammonium transporter -3.82 1.07E-03 
20 A911_02790 (ribA) bifunctional 3,4-dihydroxy-2-butanone 4-phosphate synthase/GTP 
cyclohydrolase II protein 
-1.753 1.50E-07 
21 A911_02795 (Cj0573) putative GatB/Yqey family protein -1.534 1.30E-02 
22 A911_02800 (ilvI) acetolactate synthase 3 catalytic subunit -1.522 2.77E-04 
23 A911_02950 (Cj0604) polyphosphate kinase -1.655 7.98E-07 
24 A911_02990 (cft) nonheme iron-containing ferritin -1.553 1.50E-06 
25 A911_03270 (dcuB) anaerobic C4-dicarboxylate transporter -2.834 0.00E+00 
26 A911_03515 (flaC) flagellin -1.591 6.13E-07 
27 A911_03665 (hrcA) heat-inducible transcription repressor -1.663 4.83E-06 
28 A911_03780 (napA) nitrate reductase catalytic subunit -1.634 9.41E-08 
29 A911_03785 (napG) quinol dehydrogenase periplasmic component -1.707 7.00E-05 
30 A911_03790 (napH) quinol dehydrogenase membrane component -1.676 6.66E-05 
31 A911_03795 (napB) periplasmic nitrate reductase small subunit  -1.802 1.64E-11 
32 A911_04050 (acnB) bifunctional aconitate hydratase 2/2-methylisocitrate dehydratase -1.664 3.13E-04 
33 A911_04190 (Cj0864) hypothetical protein  -1.762 1.34E-06 
34 A911_04195 (dsbB) disulfide oxidoreductase -2.343 0.00E+00 
35 A911_04390 (Cj0909) hypothetical protein  -2.032 2.04E-10 
36 A911_04395 (Cj0910) hypothetical protein -1.569 2.79E-05 
37 A911_04520 (Cj0935c) putative sodium:amino-acid symporter family protein -1.71 8.13E-05 
38 A911_04820 (Cj0999c) hypothetical protein  -2.492 0.00E+00 
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Appendix 2 (continued) 
  Gene designation Product Fold Change  padja 
39 A911_05740 (petC) ubiquinol cytochrome c oxidoreductase, cytochrome c1 subunit -1.508 7.41E-04 
40 A911_05920 (groES) co-chaperonin GroES -1.586 3.56E-09 
41 A911_06155 (hydA) Ni/Fe-hydrogenase small chain -1.516 2.37E-05 
42 A911_06590 (Cj1356c) hypothetical protein -1.751 0.00E+00 
43 A911_06595 (nrfA) Cytochrome c552   -2.194 9.94E-15 
44 A911_06600 (nrfH) putative periplasmic cytochrome C -2.365 0.00E+00 
45 A911_07155 (Cj1485c) hypothetical protein -1.788 3.37E-07 
46 A911_07160 (Cj1486c) periplasmic protein -1.774 1.47E-12 
47 A911_07165 (ccoP) cytochrome c oxidase, cbb3-type, subunit III -1.853 7.62E-10 
48 A911_07170 (ccoQ) cytochrome c oxidase, cbb3-type, subunit IV -2.187 0.00E+00 
49 A911_07175 (ccoO) cbb3-type cytochrome c oxidase subunit II -2.025 0.00E+00 
50 A911_07180 (ccoN) cbb3-type cytochrome c oxidase subunit I -1.902 4.35E-11 
51 A911_07520 (Cj1564) methyl-accepting chemotaxis signal transduction protein -1.59 5.30E-04 
 
Note: The corresponding gene locus for C. jejuni NCTC11168 is illustrated within the parentheses. 
a ± padj<0.05 ± corrected p-value representing a false discovery rate of <5% 
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APPENDIX 3 
C. jejuni PT14 genes up-regulated during bacteriophage CPX infection 
  Gene designation Product  Fold Change  padja 
     
1 A911_00005 (dnaA) chromosomal replication initiation protein 1.934 4.61E-24 
2 A911_00030 (Cj0006) histidine permease YuiF 2.73 1.88E-15 
3 A911_00060 (ilvD) dihydroxy-acid dehydratase 1.521 5.42E-09 
4 A911_00110 (purB) adenylosuccinate lyase 1.772 1.51E-14 
5 A911_00120 (Cj0025c) sodium/dicarboxylate symporter 2.077 1.74E-09 
6 A911_00155 (Cj0033) Putative integral membrane protein 1.644 5.30E-07 
7 A911_00165 (Cj0034c) periplasmic protein 1.892 9.38E-08 
8 A911_00170 (Cj0035c) Bcr/CflA subfamily drug resistance transporter 3.486 2.72E-24 
9 A911_00180 (Cj0037c) cytochrome C 5.042 6.65E-34 
10 A911_00230 (Cj0046) hypothetical protein 2.156 6.39E-03 
11 A911_00235  hypothetical protein  4.722 8.42E-03 
12 A911_00340 (Cj0072c) hemerythrin family non-heme iron protein 2.171 2.90E-05 
13 A911_00365 (cdtC) cytolethal distending toxin C 1.983 4.76E-12 
14 A911_00370 (cdtB) cytolethal distending toxin subunit CdtB 1.699 2.13E-06 
15 A911_00380 (Cj0080) C4-dicarboxylate transporter 2.156 3.93E-03 
16 A911_00405 (ung) uracil-DNA glycosylase 2.406 2.42E-13 
17 A911_00465 (fmt) methionyl-tRNA formyltransferase 2.476 1.73E-33 
18 A911_00480 (Cj0101) parB family protein 1.688 3.85E-26 
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Appendix 3 (continued) 
  Gene designation Product  Fold Change  padja 
19 A911_00525 (exbD3) exbD/tolR family transport protein 1.655 7.07E-09 
20 A911_00530 (Cj0111) periplasmic protein 1.556 4.01E-10 
21 A911_00590 (Cj0123c) transcriptional regulator 1.725 1.50E-15 
22 A911_00595 (Cj0124c) hypothetical protein 1.935 8.93E-14 
23 A911_00600 (Cj0125c) dksA-like protein 2.406 2.50E-09 
24 A911_00605 (Cj0126c) hypothetical protein  2.073 7.46E-34 
25 A911_00610 (accD) acetyl-CoA carboxylase subunit beta 1.629 9.84E-07 
26 A911_00650 (Cj0135) hypothetical protein   1.617 1.78E-16 
27 A911_00695 (Cj0144) methyl-accepting chemotaxis signal transduction protein 4.993 2.77E-12 
28 A911_00730 (Cj0151c) Putative periplasmic protein 1.5 9.97E-03 
29 A911_00745 (Cj0154c) tetrapyrrole methylase family protein 1.593 2.10E-09 
30 A911_00750 (rpmE) 50S ribosomal protein L31 1.894 2.28E-44 
31 A911_00755 (Cj0156c) 16S ribosomal RNA methyltransferase RsmE 1.68 6.75E-06 
32 A911_00775 (Cj0160c) radical SAM domain protein 1.72 7.14E-05 
33 A911_00780 (moaA) molybdenum cofactor biosynthesis protein A 1.789 3.64E-18 
34 A911_00785 (Cj0162c) hypothetical protein 1.75 1.87E-16 
35 A911_00790 (Cj0163c) hypothetical protein 1.515 1.75E-06 
36 A911_00815 (sodB) superoxide dismutase 1.615 1.56E-13 
37 A911_00835 (cfbpC) iron ABC transporter ATP binding subunit 1.524 5.02E-07 
38 A911_00840 (cfbpB) iron ABC transporter permease 1.536 2.16E-02 
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Appendix 3 (continued) 
  Gene designation Product  Fold Change  padja 
39 A911_00865 (exbB1) TonB system transport protein ExbB 2.348 3.93E-03 
40 A911_00955 (dapB) dihydrodipicolinate reductase 1.678 1.15E-15 
41 A911_00960 (Cj0198c) recombination factor protein RarA 3.351 5.12E-19 
42 A911_00965 (Cj0199c) periplasmic protein 5.022 1.07E-09 
43 A911_00985 (Cj0142c) citrate transporter 2.651 3.13E-09 
44 A911_00990 (Cj0204) OPT family oligopeptide transporter 2.174 1.83E-47 
45 A911_01000 (thrS) threonyl-tRNA ligase 1.58 4.31E-17 
46 A911_01010 (Cj0208) D12 class N6 adenine-specific DNA methyltransferase 1.526 2.34E-07 
47 A911_01080 (argC) N-acetyl-gamma-glutamyl-phosphate reductase 2.856 3.50E-47 
48 A911_01085 (Cj0225) acetyltransferase 2.651 4.75E-31 
49 A911_01090 (argB) acetylglutamate kinase 1.988 1.45E-10 
50 A911_01095 (argD) acetylornithine/succinyldiaminopimelate aminotransferase 1.798 8.85E-18 
51 A911_01100 (pcm) protein-L-isoaspartate O-methyltransferase 1.649 1.92E-06 
52 A911_01155 (Cj0239c) iron-sulfur clusteraseembly scaffold protein NifU 1.944 3.48E-49 
53 A911_01160 (iscS) cysteine desulfurase 2.249 1.35E-38 
54 A911_01165 (Cj0241c) putative iron-binding protein 3.45 3.40E-15 
55 A911_01190 (Cj0247c) hypothetical protein 2.104 4.23E-02 
56 A911_01230 (exoA) exodeoxyribonuclease III 1.626 1.17E-30 
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Appendix 3 (continued) 
  Gene designation Product  Fold Change  padja 
57 A911_01260 (Cj0261c) hypothetical protein 1.546 1.40E-07 
58 A911_01265 (Cj0262c) methyl-accepting chemotaxis protein 2.184 1.99E-06 
59 A911_01285 (Cj0266c) membrane protein 1.706 3.00E-07 
60 A911_01305 (Cj0270) 4-oxalocrotonate tautomerase 1.554 7.36E-04 
61 A911_01315 (Cj0272) hypothetical protein  1.607 1.46E-09 
62 A911_01355 (tal) transaldolase 1.647 7.59E-18 
63 A911_01380 (Cj0286c) hypothetical protein 1.7 1.73E-08 
64 A911_01385 (greA) transcription elongation factor GreA 1.692 5.14E-17 
65 A911_01395 (peb3) major antigenic peptide PEB3 1.728 2.04E-09 
66 A911_01415 (Cj0294) MoeB/ThiF family protein 1.52 2.15E-04 
67 A911_01465 (bioC) biotin biosynthesis protein BioC 1.698 1.74E-04 
68 A911_01470 (Cj0305c) hypothetical protein  2.428 4.62E-05 
69 A911_01475 (bioF) 8-amino-7-oxononanoate synthase 2.628 2.86E-35 
70 A911_01525 (pheA) chorismate mutase/prephenate dehydratase 1.689 2.91E-23 
71 A911_01555(perR) FUR family transcriptional regulator  2.143 7.53E-38 
72 A911_01635 (polA) DNA polymerase I 1.695 5.12E-14 
73 A911_01650 (Cj0341c) hypothetical protein  1.628 1.70E-08 
74 A911_01660 (Cj0343c) hypothetical protein  2.394 2.79E-46 
75 A911_01680 (trpF) N-(5'phosphoribosyl)anthranilate isomerase 1.616 4.70E-04 
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Appendix 3 (continued) 
  Gene designation Product  Fold Change  padja 
76 A911_01690 (trpA) tryptophan synthase subunit alpha 1.523 2.50E-02 
77 A911_01705 (Cj0352) transmembrane protein 1.719 4.39E-10 
78 A911_01760 (Cj0363c) coproporphyrinogen III oxidase 1.997 5.44E-15 
79 A911_01775 (cmeB) RND efflux system, inner membrane transporter CmeB 1.531 5.43E-07 
80 A911_01845 (Cj0380c) hypothetical protein 1.95 4.57E-03 
81 A911_01850 (pyrF) orotidine 5'-phosphate decarboxylase 1.717 2.97E-22 
82 A911_01870 (Cj0385c) integral membrane protein 1.842 1.07E-16 
83 A911_01915 (Cj0394c) pantothenate kinase 1.696 7.71E-11 
84 A911_02015 (Cj0414) hypothetical protein 2.499 7.06E-23 
85 A911_02020 (Cj0415) oxidoreductase 2.393 3.84E-30 
86 A911_02040 (Cj0419) histidine triad (HIT) family protein 1.557 6.07E-03 
87 A911_02100 (Cj0431) hypothetical protein 1.873 5.66E-06 
88 A911_02105 (murD) UDP-N-acetylmuramoyl-L-alanyl-D-glutamate synthetase 1.555 8.63E-06 
89 A911_02110 (mraY) phospho-N-acetylmuramoyl-pentapeptide transferase 2.775 3.22E-15 
90 A911_02215 (Cj0454c) hypothetical protein 1.806 1.51E-06 
91 A911_02220 (Cj0455c) hypothetical protein  1.726 9.44E-08 
92 A911_02250 (Cj0461c) putative MFS (Major Facilitator Superfamily) transport protein 1.787 6.50E-10 
93 A911_02345 (Cj0480c) IclR family transcriptional regulator 1.689 6.05E-05 
94 A911_02355 (uxaA) putative altronate hydrolase N-terminus 1.652 1.22E-01 
95 A911_02375 (Cj0485) short chain dehydrogenase 2.299 1.73E-12 
     
  
 
315
 
Appendix 3 (continued) 
  Gene designation Product  Fold Change  padja 
96 A911_02380 (Cj0486) L-fucose permease 1.611 3.08E-04 
97 A911_02390 (Cj0488) hypothetical protein  1.797 3.66E-05 
98 $BDOG¶ aldehyde dehydrogenase A 1.574 6.03E-06 
99 A911_02455 (hemH) ferrochelatase 1.884 7.31E-12 
100 A911_02460 (Cj0504c) Gfo/Idh/MocA family oxidoreductase 2.386 5.64E-23 
101 A911_02465 (Cj0505c) putative aminotransferase 1.949 5.63E-13 
102 A911_02485 (clpB) ATP-dependent Clp protease ATP-binding subunit 1.666 1.04E-15 
103 A911_02490 (Cj0510c) hypothetical protein  1.676 2.38E-09 
104 A911_02515 (Cj0515) periplasmic protein 1.716 8.72E-29 
105 A911_02520 (plsC) 1-acyl-sn-glycerol-3-phosphate acyltransferase 1.572 1.10E-19 
106 A911_02525 (crcB) CrcB protein 1.573 5.82E-03 
107 A911_02575 (Cj0529c) putative aminodeoxychorismate lyase family protein 1.62 5.36E-05 
108 A911_02625 (Cj0539) hypothetical protein 1.664 3.19E-13 
109 A911_02635 (Cj0541) octaprenyl-diphosphate synthase  1.523 1.91E-12 
110 A911_02705 (Cj0555) hypothetical protein  1.765 8.77E-18 
111 A911_02710 (Cj0556) putative amidohydrolase family protein 1.819 3.80E-11 
112 A911_02725 (Cj0559) Pyridine nucleotide-disulfide oxidoreductase family protein 1.548 3.68E-16 
113 A911_02735 (Cj0561c) hypothetical protein 2.519 1.51E-28 
114 A911_02770 (Cj0568) hypothetical protein 2.192 4.97E-01 
115 A911_02820 (tatC) Sec-independent protein translocase TatC 1.776 2.63E-14 
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  Gene designation Product  Fold Change  padja 
116 A911_02825 (Cj0579c) Sec-independent translocase  1.755 4.85E-45 
117 A911_02830 (Cj0580c) coproporphyrinogen III oxidase 2.296 3.45E-04 
118 A911_02895 (Cj0593c) hypothetical protein  3.177 8.22E-07 
119 A911_02900 (Cj0594c) DNA/RNA non-specific endonuclease 3.889 9.05E-31 
120 A911_02905 (nth) endonuclease III 3.672 1.37E-19 
121 A911_02975 (Cj0609c) hypothetical protein  2.923 5.55E-24 
122 A911_02980 (Cj0610c) periplasmic protein 2.503 1.32E-17 
123 A911_02985 (Cj0611c) poly(beta-D-mannuronate) O-acetylase 2.005 1.32E-16 
124 A911_02995 (pstS) phosphate ABC transporter substrate-binding protein 4.141 6.61E-09 
125 A911_03000 (pstC) phosphate ABC transporter permease 5.204 4.23E-21 
126 A911_03005 (pstA) phosphate ABC transporter permease 4.135 2.54E-40 
127 A911_03010 (pstB) phosphate ABC transporter ATP-binding protein 3.552 1.08E-16 
128 A911_03030 (Cj0621) hypothetical protein 1.509 4.69E-12 
129 A911_03035 (hypF) (NiFe) hydrogenase maturation protein HypF 1.719 7.89E-11 
130 A911_03050 (hypD) hydrogenase isoenzymes formation protein HypD 1.563 2.01E-14 
131 A911_03080 (Cj0631c) ribonuclease R 2.52 6.61E-11 
132 A911_03095 (dprA) DNA processing protein A 1.532 2.80E-05 
133 A911_03335 (cipA) invasion protein CipA 1.714 1.26E-13 
134 A911_03375 (Cj0692c) hypothetical protein  2.704 9.32E-21 
135 A911_03380 (mraW) 16S rRNA m(4)C1402 methyltransferase 1.7 3.57E-15 
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  Gene designation Product  Fold 
Change  
padja 
137 A911_03415 (Cj0700) hypothetical protein 1.549 5.28E-25 
138 A911_03420 (Cj0701) peptidase, U32 family protein 1.714 9.24E-34 
139 A911_03425 (purE) phosphoribosylaminoimidazole carboxylase catalytic subunit 1.515 2.93E-11 
140 A911_03430 (Cj0703) hypothetical protein 1.703 1.28E-24 
141 A911_03465 (rpsP) 30S ribosomal protein S16 1.57 2.93E-10 
142 A911_03555 (Cj0728) periplasmic protein 1.73 7.96E-03 
143 A911_03570 (Cj0731) ABC transporter permease 2.033 2.07E-02 
144 A911_03595 (Cj0736) hypothetical protein 1.748 2.46E-01 
145 A911_03650 (Cj0752) transposase 1.873 2.68E-02 
146 A911_03655 (tonB3) TonB transport protein 3.079 3.20E-09 
147 A911_03660 (cfrA) ferric enterobactin uptake receptor 2.011 1.57E-04 
148 A911_03680 (Cj0760) hypothetical protein  1.557 4.35E-17 
149 A911_03685 (Cj0761) hypothetical protein  1.597 3.76E-17 
150 A911_03695 (cysE) serine acetyltransferase 1.746 3.70E-07 
151 A911_03700 (speA) arginine decarboxylase 1.643 2.75E-06 
152 A911_03705 (hisS) histidyl-tRNA ligase 1.897 2.01E-17 
153 A911_03710 (tmk) thymidylate kinase 2.478 6.28E-15 
154 A911_03715 (coaD) phosphopantetheine adenylyltransferase 2.048 8.60E-23 
155 A911_03720 (Cj0768c) 3-octaprenyl-4-hydroxybenzoate carboxylase 3.155 5.10E-30 
156 A911_03725 (flgA) flagellar basal body P-ring biosynthesis protein FlgA 2.376 6.71E-26 
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  Gene designation Product  Fold Change  padja 
157 A911_03760 (Cj0776c) periplasmic protein 1.536 2.48E-23 
158 A911_03765 (Cj0777) 
ATP-dependent DNA helicase UvrD/PcrA/Rep, epsilon 
proteobacterial type1 1.933 4.00E-16 
159 A911_03815 (Cj0787) hypothetical protein  1.715 8.18E-14 
160 A911_03860 (Cj0796c) putative hydrolase 2.214 1.78E-07 
161 A911_03865 (Cj0797c) hypothetical protein 2.116 5.13E-20 
162 A911_03875 (ruvA) Holliday junction DNA helicase RuvA 1.649 2.99E-10 
163 A911_03880 (Cj0800c) putative ATPase 2.289 1.07E-17 
164 A911_03960 (glnH) putative glutamine binding periplasmic protein 1.847 1.07E-06 
165 A911_03965 (Cj0818) putative lipoprotein 2.324 9.26E-15 
166 A911_03970 (Cj0819) small hydrophobic protein 3.057 2.14E-29 
167 A911_03975 (fliP) flagellar biosynthesis protein FliP 3.17 1.36E-16 
168 A911_04030 (trmA) tRNA (uracil-5-)-methyltransferase 1.626 2.71E-14 
169 A911_04035 (Cj0832c) Na+/H+ antiporter family protein 1.548 6.53E-10 
170 A911_04080 (mobB) molybdopterin-guanine dinucleotide biosynthesis protein B 1.96 9.17E-16 
171 A911_04100 (gltX) glutamyl-tRNA ligase 1.775 5.14E-12 
172 A911_04120 (Cj0849c) hypothetical protein 1.679 8.56E-06 
173 A911_04175 (pabA) 
para-aminobenzoate synthase glutamine aminotransferase, 
component II 3.043 3.57E-03 
174 A911_04180 (pabB) 
para-aminobenzoate synthase glutamine aminotransferase, 
component I 2.647 1.96E-09 
175 A911_04185 (xerD) integrase-recombinase protein 2.262 6.79E-19 
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  Gene designation Product  Fold Change  padja 
176 A911_04270 (Cj0883c) RrF2 family protein, putative 1.606 7.65E-15 
177 A911_04280 (ftsK) putative cell division protein 1.838 5.74E-21 
178 A911_04320 (ispH) 4-hydroxy-3-methylbut-2-enyl diphosphate reductase 1.609 1.02E-19 
179 A911_04325 (aroA) 3-phosphoshikimate 1-carboxyvinyltransferase 1.591 8.49E-12 
180 A911_04355 (Cj0901) amino-acid ABC transporter permease 2.35 2.01E-18 
181 A911_04380 (Cj0906c) hypothetical protein  1.841 9.28E-26 
182 A911_04420 (Cj0915) putative acyl-CoA thioester hydrolase 1.836 3.64E-22 
183 A911_04425 (Cj0916c) hypothetical protein 2.92 5.23E-41 
184 A911_04430 (cstA) carbon starvation protein A 2.11 5.82E-13 
185 A911_04565 (Cj0944c) hypothetical protein 1.533 1.31E-07 
186 A911_04625 (Cj0957c) hypothetical protein  1.577 8.58E-08 
187 A911_04630 (Cj0958c) membrane protein insertase 1.593 2.43E-13 
188 A911_04635 (Cj0959c) hypothetical protein  1.708 3.97E-39 
189 A911_04640 (rnpA) ribonuclease P protein component 1.636 1.09E-16 
190 A911_04650 (Cj0962) GNAT family acetyltransferase 1.948 2.50E-02 
191 A911_04655 (Cj0963) hypothetical protein  2.101 8.63E-12 
192 A911_04710 (Cj0976) tRNA mo(5)U34 methyltransferase 1.768 5.32E-06 
193 A911_04735 (cjaB) transport protein CjaB 1.747 3.76E-20 
194 A911_04745 (Cj0983) surface-exposed lipoprotein JlpA 1.901 2.17E-09 
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Gene designation Product  Fold Change  padja 
195 A911_04825 (Cj1000) putative transcriptional regulator (lysR family) protein 1.625 5.20E-07 
196 A911_04875 (tgt) queuine tRNA-ribosyltransferase 1.675 9.90E-12 
197 A911_04990 (cmeF) AcrB/AcrD/AcrF family protein 1.723 3.21E-23 
198 A911_04995 (Cj1034c) adenylosuccinate lyase 1.51 2.63E-03 
199 A911_05015 (Cj1038) cell division protein FtsW 1.674 4.14E-11 
200 A911_05020 (murG) 
undecaprenyldiphospho-muramoylpentapeptide beta-N-
acetylglucosaminyltransferase 1.836 1.03E-14 
201 A911_05040 (Cj1042c) Putative transcriptional regulatory protein 1.519 2.65E-03 
202 A911_05070 (dapE) succinyl-diaminopimelate desuccinylase 1.701 1.34E-05 
203 A911_05105 (Cj1055c) putative integral membrane protein 1.71 1.74E-09 
204 A911_05210 (ctsT) transformation system protein 2.137 2.57E-06 
205 A911_05300 (lnt) apolipoprotein N-acyltransferase 1.622 1.09E-02 
206 A911_05310 (Cj1097) serine/threonine transporter SstT 2.042 8.62E-16 
207 A911_05315 (pyrB) aspartate carbamoyltransferase catalytic subunit 1.92 6.61E-12 
208 A911_05320 (Cj1099) oligoendopeptidase F 1.7 1.39E-14 
209 A911_05325 (Cj1100) hypothetical protein 1.781 6.25E-20 
210 A911_05330 (Cj1101) ATP-dependent DNA helicase UvrD/Rep family protein 1.793 3.22E-15 
211 A911_05335 (truB) tRNA pseudouridine synthase B 1.835 1.21E-09 
212 A911_05490 (waaC) lipopolysaccharide heptosyltransferase I 2.295 4.41E-22 
213 A911_05495 (htrB) lipid A biosynthesis lauroyl acyltransferase 1.923 1.26E-15 
214 A911_05500 (Cj1135) putative two-domain glucosyltransferase 1.628 2.17E-11 
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  Gene designation Product  Fold Change  padja 
215 A911_05515 (Cj1138) putative glycosyltransferase 1.792 5.79E-04 
216 A911_05600 (rho) transcription termination factor Rho 2.474 2.31E-18 
217 A911_05605 (dnaX) DNA polymerase III subunits gamma and tau 2.658 5.27E-26 
218 A911_05610 (Cj1158c) hypothetical protein  2.795 5.84E-10 
219 A911_05645 (Cj1165c) hypothetical protein  1.905 4.59E-16 
220 A911_05650 (Cj1166c) hypothetical protein  2.121 4.86E-11 
221 A911_05685 (Cj1173) SMR family multidrug efflux pump 2.518 4.24E-19 
222 A911_05690 (Cj1174) putative efflux protein 1.786 4.04E-08 
223 A911_05755 (arsB) arsenical pump membrane protein 1.526 3.05E-05 
224 A911_05765 (cetB) Signal transduction protein CetB 1.533 2.56E-13 
225 A911_05770 (cetA) bipartate energy taxis response protein CetA 1.557 1.59E-15 
226 A911_05875 (Cj1211) ComEC/Rec2 family competence protein 1.638 1.35E-02 
227 A911_05940 (Cj1224) hemerythrin-like iron-binding protein 1.78 6.70E-07 
228 A911_05975 (kefB) Sodium/hydrogen exchanger family protein 1.635 3.86E-13 
229 A911_05980 (Cj1232) hypothetical protein  2.751 3.67E-16 
230 A911_05985 (Cj1233) putative HAD-superfamily hydrolase 2.177 9.88E-20 
231 A911_05995 (Cj1235) peptidase, M23/M37 family protein 1.549 5.92E-18 
232 A911_06025 (Cj1241) transporter  1.855 1.96E-03 
233 A911_06050 (uvrC) excinuclease ABC subunit C 2.056 2.79E-20 
234 A911_06060 (guaA) GMP synthase 1.792 2.84E-33 
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  Gene designation Product  Fold Change  padja 
235 A911_06070 (Cj1249) hypothetical protein 1.786 1.57E-17 
236 A911_06085 (Cj1252) hypothetical protein  2.028 2.03E-17 
237 A911_06090 (pnp) polynucleotide phosphorylase/polyadenylase 1.638 4.79E-14 
238 A911_06095 (Cj1254) G:T/U mismatch-specific uracil/thymine DNA-glycosylase 1.678 8.57E-17 
239 A911_06110 (Cj1258) phosphotyrosine protein phosphatase 2.064 2.59E-09 
240 A911_06120 (dnaJ) chaperone protein DnaJ 1.567 3.95E-08 
241 A911_06130 (racS) two-component sensor histidine kinase 1.655 6.45E-20 
242 A911_06225 (mrdB) RodA protein 2.164 3.95E-15 
243 A911_06240 (Cj1285c) hypothetical protein  1.841 6.20E-15 
244 A911_06245 (upp) uracil phosphoribosyltransferase 1.504 2.10E-12 
245 A911_06265 (accC) biotin carboxylase 1.755 1.57E-38 
246 A911_06270 (accB) acetyl-CoA carboxylase, biotin carboxyl carrier protein 2.264 1.69E-62 
247 A911_06435 (Cj1324) hypothetical protein  1.509 2.74E-04 
248 A911_06440 (Cj1325) Putative methyl transferase 1.676 3.56E-03 
249 A911_06450 (neuB2) legionaminic acid synthase 2.138 7.63E-28 
250 A911_06455 (neuC2) UDP-N-acetylglucosamine 2-epimerase 2.078 5.37E-22 
251 A911_06460 (Cj1329) putative sugar-phosphate nucleotide transferase 2.302 2.43E-19 
252 A911_06465 (Cj1330) hypothetical protein  2.053 6.03E-22 
253 A911_06470 (ptmB) legionaminic acid cytidylytransferase 2.032 3.52E-12 
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  Gene designation Product  Fold Change  padja 
254 A911_06475 (ptmA) flagellin modification protein A 1.696 4.68E-13 
255 A911_06480 (pseD) PseD protein 1.701 1.27E-06 
256 A911_06560 (mobA) 
putative molybdopterin-guanine dinucleotide biosynthesis 
protein 2.574 5.35E-12 
257 A911_06565 (pldA) hemin uptake system outer membrane receptor 2.395 1.50E-13 
258 A911_06570 (ceuB) enterochelin ABC transporter permease protein  5.562 3.16E-14 
259 A911_06580 (ceuD) enterochelin ABC transporter, ATP-binding protein  4.475 8.74E-16 
260 A911_06585 (ceuE) 
enterochelin ABC transporter, periplasmic enterochelin-binding 
protein 3.119 3.43E-34 
261 A911_06615 (ruvB) Holliday junction DNA helicase RuvB 2.497 2.40E-12 
262 A911_06645 (Cj1368) hypothetical protein  2.09 9.38E-28 
263 A911_06650 (hydA2) xanthine/uracil permease family protein 1.887 5.25E-14 
264 A911_06655 (Cj1370) phosphoribosyltransferase 1.69 7.65E-14 
265 A911_06665 (Cj1372) putative periplasmic toluene tolerance protein 1.754 1.12E-07 
266 A911_06670 (Cj1373) putative integral membrane protein 2.14 7.80E-15 
267 A911_06675 (Cj1374c) dlTP/XTP pyrophosphatase 1.939 6.00E-20 
268 A911_06680 (Cj1375) multidrug efflux transporter 1.759 5.53E-19 
269 A911_06685 (Cj1376) hypothetical protein  1.748 1.98E-18 
270 A911_06695 (selA) selenocysteine synthase 2.501 1.19E-26 
271 A911_06700 (selB) putative selenocysteine-specific elongation factor 2.698 8.35E-13 
272 A911_06720 hypothetical protein 1.741 1.23E-01 
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  Gene designation Product  Fold Change  padja 
273 A911_06730 (katA) catalase 1.507 6.83E-03 
274 A911_06735 (Cj1386) ankyrin repeat protein 2.082 1.85E-05 
275 A911_06830 (nadD) nicotinate (nicotinamide) nucleotide adenylyltransferase 1.922 4.99E-09 
276 A911_06835 (Cj1405) hypothetical protein 1.928 4.88E-16 
277 A911_06875 (kpsS) capsule polysaccharide export protein KpsS 1.564 1.23E-14 
278 A911_06908  capsular polysaccharide biosynthesis protein 1.565 2.87E-15 
279 A911_06909  capsular polysaccharide biosynthesis protein 1.83 1.44E-05 
280 A911_06910  capsule biosynthesis phosphatase 1.614 8.13E-17 
281 A911_06918 (Cj1421c) hypothetical protein 1.646 9.88E-08 
282 A911_06965 (Cj1449c) hypothetical protein  1.916 1.89E-39 
283 A911_06990 (tilS) tRNA(Ile)-lysidine synthetase 1.695 1.89E-07 
284 A911_07000  sugar transferase 2.069 2.99E-06 
285 A911_07020 (truD) tRNA pseudouridine synthase D 1.553 1.21E-06 
286 A911_07025 (thiL) thiamine monophosphate kinase 2.316 6.58E-21 
287 A911_07035 (Cj1460) hypothetical protein 1.724 2.35E-11 
288 A911_07040 (Cj1461) site-specific DNA methyltransferase 2.022 8.20E-18 
289 A911_07075 (Cj1468) hypothetical protein  1.534 6.96E-06 
290 A911_07090 (Cj1472c) hypothetical protein 1.585 3.79E-04 
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  Gene designation Product  Fold Change  padja 
291 A911_07095 (ctsP) putative ATP/GTP-binding protein 1.696 6.34E-04 
292 A911_07100 (ctsD) general secretory pathway protein D 1.555 3.53E-08 
293 A911_07105 (ctsR) transformation system protein 1.783 1.17E-02 
294 A911_07225 (Cj1500) hypothetical protein  1.572 1.85E-03 
295 A911_07230 (Cj1501) putative inner membrane protein 1.608 1.26E-10 
296 A911_07240 (putA) bifunctional putA protein 1.825 6.81E-19 
297 A911_07290 (Cj1513c) Tat pathway signal sequence domain-containing protein 1.558 2.21E-50 
298 A911_07295 (Cj1514c) hypothetical protein 1.51 2.05E-05 
299 A911_07320 (moeA2) molybdopterin biosynthesis protein 1.752 5.89E-08 
300 A911_07325 (Cj1521c) CRISPR-associated Cas2 family protein 1.589 6.48E-17 
301 A911_07365 (coaE) dephospho-CoA kinase 2.778 2.36E-05 
302 A911_07400 (acs) acetyl-CoA synthetase 1.807 7.32E-04 
303 A911_07405 (Cj1538c) anion-uptake ABC-transport system ATP-binding protein 1.61 1.81E-02 
304 A911_07445 (Cj1546) putative transcriptional regulator 1.672 8.83E-16 
305 A911_07450 (Cj1547) Blc protein-like protein 2.806 2.73E-25 
306 A911_07470 (hsdS) putative type I restriction enzymeS protein 1.783 3.55E-08 
307 A911_07475 (mloB) hypothetical protein  1.614 1.53E-05 
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  Gene designation Product  Fold Change  padja 
308 A911_07495 (Cj1558) membrane protein 1.803 7.06E-03 
309 A911_07590 (nuoB) NADH dehydrogenase subunit B 1.566 3.79E-03 
310 A911_07595 (nuoA) NADH dehydrogenase subunit A 1.818 8.04E-08 
311 A911_07600 (Cj1580c) peptide ABC transporter ATP-binding protein 2.278 1.95E-09 
312 A911_07630 (cgb) single domain haemoglobin  1.982 1.97E-07 
313 A911_07635 (Cj1587c) 
multidrug transporter membrane component/ATP-binding 
component 1.672 6.93E-06 
314 A911_07730 (mrp) putative ATP/GTP-binding protein  1.736 5.38E-09 
315 A911_07735 (ispDF) 
bifunctional 2-C-methyl-D-erythritol 4-phosphate 
cytidyltransferase/2-C-methyl-D-erythritol 2,4-cyclodiphosphate 
synthase protein 4.044 2.94E-107 
316 A911_07740 (Cj1608) putative two-component regulator 3.02 1.99E-05 
317 A911_07745 (Cj1609) sulfate adenylyltransferase 2.449 2.16E-20 
318 A911_07750 (pgpA) putative phosphatidylglycerophosphatase 2.351 5.72E-15 
319 A911_07755 (rpsT) 30S ribosomal protein S20 1.805 4.21E-32 
320 A911_07765 (Cj1613c) heme iron utilization protein 2.08 1.46E-09 
321 A911_07770 (chuA) hemin uptake system outer membrane receptor  2.33 2.23E-02 
322 A911_07775 (chuB) putative hemin uptake system permease protein 1.991 3.04E-03 
323 A911_07780 (chuC) putative hemin uptake system ATP-binding protein 3.251 2.50E-02 
324 A911_07790 (Cj1618c) putative radical SAM domain protein 1.558 1.11E-07 
325 A911_07800 (mutY) A/G-specific adenine glycosylase 1.626 8.42E-08 
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  Gene designation Product  Fold Change  padja 
326 A911_07815 (Cj1623) hypothetical protein 1.681 1.94E-02 
327 A911_07820 (sdaA) L-serine dehydratase 1.89 5.42E-09 
328 A911_07840 (exbB2) exbB/tolQ family transport protein  4.336 9.59E-31 
329 A911_07845 (exbD2) biopolymer transport exbD protein 3.458 2.95E-12 
330 A911_07850 (tonB2) periplasmic TonB transport protein 2.614 1.70E-06 
331 A911_07865 (Cj1633) putative ATP-binding protein 2.032 3.31E-31 
332 A911_07900 (Cj1640) hypothetical protein 1.74 1.97E-04 
333 A911_07905 (murE) 
UDP-N-acetylmuramoylalanyl-D-glutamate-2,6-
diaminopimelate ligase 1.743 1.14E-22 
334 A911_07910 (Cj1642) hypothetical protein  1.582 1.62E-09 
335 A911_07915 (Cj1643) PDZ domain-containing periplasmic protein 1.563 4.84E-08 
336 A911_07920 (ispA) geranyltransterase 1.864 4.93E-17 
337 A911_07925 (tkt) transketolase 1.551 4.79E-11 
338 A911_07930 (iamB) putative ABC transport system permease 1.63 4.70E-13 
339 A911_07940 (Cj1648) ABC transporter, periplasmic substrate-binding protein, putative 1.544 1.47E-06 
340 A911_07945 (Cj1649) putative lipoprotein 1.583 1.46E-04 
341 A911_07985  hypothetical protein 4.407 1.55E-07 
342 A911_07990 (Cj1658) putative FTR1 family permease  7.183 4.32E-29 
343 A911_07995 (p19) periplasmic protein p19  5.074 5.91E-33 
344 A911_08000 (Cj1660) hypothetical protein  6.46 9.01E-62 
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  Gene designation Product  Fold Change  padja 
345 A911_08005 (Cj1661) ABC transporter permease  9.499 2.92E-29 
346 A911_08010 (Cj1662) integral membrane protein  8.947 2.76E-23 
347 A911_08015 (Cj1663) ABC transporter ATP-binding protein  5.829 5.65E-21 
348 A911_08020 (Cj1664) putative periplasmic thioredoxin 5.172 1.25E-13 
349 A911_08025 (Cj1665) putative lipoprotein thioredoxin 1.536 9.94E-05 
350 A911_08090 (Cj1679) Hypothetical protein 1.638 7.54E-08 
351 A911_08120 (topA) DNA topoisomerase I 1.73 8.73E-09 
352 A911_08240 (Cj1710c) metallo-beta-lactamase family protein 1.614 3.87E-10 
353 A911_08245 (ksgA) 16S ribosomal RNA methyltransferase KsgA/Dim1 family 
protein 
1.599 7.95E-16 
354 A911_08260  small hydrophobic protein 1.601 1.62E-05 
355 A911_08305 (Cj1725) hypothetical protein  1.704 5.33E-16 
356 A911_08325 (ruvC) Holliday junction resolvase 2.683 3.75E-40 
357 A911_t08352  1.600 1.54E-05 
358 A911_t08374  1.643 1.94E-05 
359 A911_t08376  1.618 5.38E-03 
360 A911_t08410  1.589 2.33E-03 
 
Note: The corresponding gene locus for C. jejuni NCTC11168 is illustrated within the parentheses. 
a ± padj<0.05 ± corrected p-value representing a false discovery rate of <5% 
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APPENDIX 4 
Genes down-regulated in C. jejuni PT14 during bacteriophage CPX infection 
  
Gene designation Product Fold Change  padja 
1 A911_00020 (Cj0004c) hypothetical protein -3.435 0.00E+00 
2 A911_00025 (Cj0005c) Molybdopterin oxidoreductase family protein -8.865 0.00E+00 
3 A911_00035 (gltB) glutamate synthase, large subunit -2.908 1.03E-13 
4 A911_00040 (gltD) glutamate synthase subunit beta -4.011 0.00E+00 
5 A911_00050 (Cj0011c) competence protein ComEA -1.888 0.00E+00 
6 A911_00055 (rrc) rubrerythrin -2.275 0.00E+00 
7 A911_00195 (Cj0040) hypothetical protein -2.481 1.81E-04 
8 A911_00200 (fliK) hypothetical protein  -1.863 1.09E-05 
9 A911_00205 (flgD) flagellar basal body rod modification protein -3.335 0.00E+00 
10 A911_00210 (flgE2) flagellar hook protein -2.426 7.23E-11 
11 A911_00220 (Cj0045c) Hemerythrin-like iron-binding protein -1.785 1.55E-05 
12 A911_00330 (Cj0069) hypothetical protein -2.885 2.95E-12 
13 A911_00410 (aspA) aspartate ammonia-lyase -3.054 0.00E+00 
14 A911_00415 (dcuA) anaerobic C4-dicarboxylate transporter -2.123 0.00E+00 
15 A911_00540 (pal) peptidoglycan-associated lipoprotein Omp180 -1.672 3.47E-10 
16 A911_01275 (Cj0264c) hypothetical protein  -2.116 4.47E-07 
17 A911_01280 (Cj0265c) trimethylamine N-oxide reductase, cytochrome c-type subunit -2.377 3.79E-10 
18 A911_01610 (fdxA) ferredoxin, 4Fe-4S -1.696 0.00E+00 
19 A911_01735 (Cj0358) cytochrome c551 peroxidase -4.22 0.00E+00 
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Appendix 4 (continued) 
  Gene designation Product Fold Change  padja 
20 A911_01740  hypothetical protein -2.379 1.77E-15 
21 A911_01745 (glmM) phosphoglucosamine mutase -1.761 3.81E-07 
22 A911_01800 (Cj0371) hypothetical protein -2.248 1.41E-11 
23 A911_01805 (Cj0372) glutathionylspermidine synthase -1.844 0.00E+00 
24 A911_01900 (Cj0391c) hypothetical protein -1.655 1.13E-04 
25 A911_01905 (pyk) pyruvate kinase -1.579 0.00E+00 
26 A911_02050 (Cj0421c) hypothetical protein -2.015 2.77E-05 
27 A911_02085 (Cj0428) hypothetical protein -1.613 9.21E-09 
28 A911_02130 (sdhA) succinate dehydrogenase flavoprotein subunit -12.38 1.05E-08 
29 A911_02135 (sdhB) succinate dehydrogenase, iron-sulfur protein subunit -11.668 0.00E+00 
30 A911_02140 (sdhC) succinate dehydrogenase subunit C -6.765 0.00E+00 
31 A911_02185 (Cj0448c) methyl-accepting chemotaxis protein -2.121 0.00E+00 
32 A911_02190 (Cj0449c) hypothetical protein  -2.615 0.00E+00 
33 A911_02440 (Cj0499) HIT family protein -1.702 2.81E-03 
34 A911_02445 (Cj0500) tRNA 2-selenouridine synthase -1.535 6.48E-08 
35 A911_02450 (Cj0501) ammonium transporter -7.558 1.03E-05 
36 A911_02570 (flgB) flagellar basal body rod protein FlgB -1.683 3.38E-12 
37 A911_02665 (flaG) flagellar protein FlaG -1.655 3.58E-09 
38 A911_02790 (ribA) bifunctional 3,4-dihydroxy-2-butanone 4-phosphate synthase/GTP 
cyclohydrolase II protein 
-1.817 7.02E-13 
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Appendix 4 (continued) 
  Gene designation Product Fold Change  padja 
39 A911_02795 (Cj0573) putative GatB/Yqey family protein -1.577 4.48E-05 
40 A911_02910 (peb4) major antigenic peptide PEB-cell binding factor -1.672 0.00E+00 
41 A911_02915 (fba) fructose-bisphosphate aldolase -1.741 6.74E-13 
42 A911_02950 (Cj0604) polyphosphate kinase -2.625 0.00E+00 
43 A911_02955 (Cj0605) carboxypeptidase -1.553 2.45E-04 
44 A911_03270 (dcuB) anaerobic C4-dicarboxylate transporter -3.766 0.00E+00 
45 A911_03345 (flgH) flagellar basal body L-ring protein -2.644 0.00E+00 
46 A911_03400 (flgG2) flagellar basal-body rod protein -3.462 0.00E+00 
47 A911_03405 (flgG) flagellar basal body rod protein FlgG -2.09 0.00E+00 
48 A911_03490 (Cj0715) transthyretin-like periplasmic protein -1.535 3.14E-13 
49 A911_03495 (Cj0716) phospho-2-dehydro-3-deoxyheptonate aldolase -1.606 0.00E+00 
50 A911_03510 (Cj0719c) hypothetical protein  -1.502 3.42E-15 
51 A911_03515 (flaC) flagellin -2.075 0.00E+00 
52 A911_03590 (Cj0735) periplasmic protein -1.838 7.98E-03 
53 A911_03640 (Cj0747) hypothetical protein -5.343 2.09E-10 
54 A911_03780 (napA) nitrate reductase catalytic subunit -1.74 0.00E+00 
55 A911_03785 (napG) quinol dehydrogenase periplasmic component -1.693 0.00E+00 
56 A911_03790 (napH) quinol dehydrogenase membrane component -1.581 7.56E-12 
57 A911_03795 (napB) periplasmic nitrate reductase small subunit -1.805 0.00E+00 
58 A911_03850 (Cj0794) hypothetical protein -1.884 2.65E-07 
59 A911_03910 (dapA) dihydrodipicolinate synthase -1.617 0.00E+00 
  
 
332
 
Appendix 4 (continued) 
  Gene designation Product Fold Change  padja 
60 A911_03950 (Cj0814) hypothetical protein -1.795 5.71E-05 
61 A911_03955 (Cj0815) hypothetical protein -1.825 4.39E-06 
62 A911_03980 (glmU)  bifunctional N-acetylglucosamine-1-phosphate 
uridyltransferase/glucosamine-1-phosphate acetyltransferase 
-1.839 0.00E+00 
63 A911_04190 (Cj0864) hypothetical protein  -1.84 1.88E-04 
64 A911_04195 (dsbB) disulfide oxidoreductase -2.466 0.00E+00 
65 A911_04285 (flgL) Flagellar hook-associated protein FlgL -1.824 1.20E-06 
66 A911_04345 (thiJ) 4-methyl-5(beta-hydroxyethyl)-thiazole monophosphate synthesis 
protein 
-1.502 4.79E-14 
67 A911_04350  Small hydrophobic protein -1.571 0.00E+00 
68 A911_04365 (Cj0903c) Putative amino-acid transport protein -1.507 0.00E+00 
69 A911_04390 (Cj0909) hypothetical protein  -1.544 7.21E-05 
70 A911_04665 (Cj0965c) putative acyl-CoA thioester hydrolase -1.999 0.00E+00 
71 A911_04755 (hipO) hippurate hydrolase -2.191 1.07E-08 
72 A911_04820 (Cj0999c) hypothetical protein  -4.76 0.00E+00 
73 A911_05445 (pglC) galactosyltransferase -1.511 2.17E-05 
74 A911_05480 (gne) UDP-glucose 4-epimerase -1.54 0.00E+00 
75 A911_05640 (Cj1164c) hypothetical protein  -1.507 1.37E-08 
76 A911_05810 (luxS) S-ribosylhomocysteinase -1.607 0.00E+00 
77 A911_05815 (Cj1199) 2OG-Fe(II) oxygenase -2.403 0.00E+00 
78 A911_05820 (Cj1200) putative NLPA family lipoprotein -1.544 7.72E-05 
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Appendix 4 (continued) 
  Gene designation Product Fold Change  padja 
79 A911_05960 (htrA) serine protease  -1.69 0.00E+00 
80 A911_06030 (Cj1242) hypothetical protein -2.25 0.00E+00 
81 A911_06400 (pseA) flagellin modification protein, PseA -2.003 1.72E-04 
82 A911_06500 (flaB) flagellin -2.203 1.48E-11 
83 A911_06590 (Cj1356c) hypothetical protein -3.641 0.00E+00 
84 A911_06595 (nrfA) Cytochrome c552 -5.856 0.00E+00 
85 A911_06600 (nrfH) putative periplasmic cytochrome C -5.78 0.00E+00 
86 $BPHW&¶ putative cystathionine beta-lyase, N-terminus -1.671 1.98E-02 
87 A911_06825 (gapA) glyceraldehyde 3-phosphate dehydrogenase A -1.53 1.86E-11 
88 A911_07045 (flgI) flagellar basal body P-ring protein -2.279 1.77E-15 
89 A911_07050 (flgJ) hypothetical protein -1.843 2.11E-05 
90 A911_07055 (flgM) hypothetical protein -1.608 2.36E-07 
91 A911_07060 (Cj1465) hypothetical protein -1.79 4.37E-10 
92 A911_07065 (flgK) flagellar hook-associated protein FlgK -1.606 2.67E-03 
93 A911_07155 (Cj1485c) hypothetical protein -1.737 3.20E-09 
94 A911_07160 (Cj1486c) periplasmic protein -1.752 0.00E+00 
95 A911_07165 (ccoP) cytochrome c oxidase, cbb3-type, subunit III -1.702 0.00E+00 
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Appendix 4 (continued) 
  
Gene designation Product Fold Change  padja 
96 A911_07170 (ccoQ) cytochrome c oxidase, cbb3-type, subunit IV -1.756 0.00E+00 
97 A911_07175 (ccoO) cbb3-type cytochrome c oxidase subunit II -1.599 0.00E+00 
98 A911_07810 (ribD) riboflavin-specific deaminase/reductase -1.882 6.16E-11 
99 A911_07870 (aroC) chorismate synthase -1.592 3.25E-04 
100 A911_07950 (Cj1650) hypothetical protein -1.76 3.70E-06 
101 A911_07980 (Cj1656c) hypothetical protein -1.578 3.17E-02 
102 A911_08035 (Cj1668c) hypothetical protein -1.745 0.00E+00 
103 A911_08275 (leuC) isopropylmalate isomerase large subunit -2.357 7.82E-13 
104 A911_08280 (leuB) 3-isopropylmalate dehydrogenase -2.806 2.10E-12 
105 A911_08285 (leuA) 2-isopropylmalate synthase -3.543 0.00E+00 
106 A911_08320 (flgE) flagellar hook protein FlgE -2.442 4.78E-10 
     
Note: The corresponding gene locus for C. jejuni NCTC11168 is illustrated within the parentheses. 
a ± padj<0.05 ± corrected p-value representing a false discovery rate of <5% 
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APPENDIX 5 
Bacteriophage CP30A transcription during infection of C. jejuni PT14 
 
  
Gene 
designation  
Product RPKM 
1 D302_gp001 putative homing endonuclease 4811.44 
2 D302_gp002 putative RecA-like protein 13788.2 
3 D302_gp003 hypothetical protein 5621.39 
4 D302_gp004 hypothetical protein 4012.14 
5 D302_gp005 hypothetical protein 4095.69 
6 D302_gp006 hypothetical protein 16697.2 
7 D302_gp007 DNA polymerase accessory protein 
sliding clamp loader subunit 
15376.4 
8 D302_gp008 hypothetical protein 1389.81 
9 D302_gp009 hypothetical protein 6420.72 
10 D302_gp010 putative dUTP pyrophosphatase 6122.67 
11 D302_gp011 hypothetical protein 5449.32 
12 D302_gp012 putative NAD/FAD-utilizing 
dehyrogenase 
6675.73 
13 D302_gp013 hypothetical protein 6803.97 
14 D302_gp014 hypothetical protein 4805.79 
15 D302_gp015 hypothetical protein 2757.96 
16 D302_gp016 hypothetical protein 14118.6 
17 D302_gp017 putative DNA topoisomerase 9038.05 
18 D302_gp018 putative Hef-like homing endonuclease 6926.11 
19 D302_gp019 topoisomerase II large subunit 8960.18 
20 D302_gp020 hypothetical protein 8926.36 
21 D302_gp021 hypothetical protein 5946.23 
22 D302_gp022 hypothetical protein 235.89 
23 D302_gp023 hypothetical protein 7608.72 
24 D302_gp024 hypothetical protein 2878.06 
25 D302_gp025 hypothetical protein 108.33 
26 D302_gp026 hypothetical protein 1905.03 
27 D302_gp027 hypothetical protein 1033.96 
28 D302_gp028 putative peptidase 1541.19 
29 D302_gp029 hypothetical protein 2627.29 
30 D302_gp030 hypothetical protein 4071.13 
31 D302_gp031 hypothetical protein 1763.17 
32 D302_gp032 hypothetical protein 690.95 
33 D302_gp033 hypothetical protein 952.92 
34 D302_gp034 putative baseplate hub and tail lysozyme 2080.4 
35 D302_gp035 hypothetical protein 491.4 
36 D302_gp036 hypothetical protein 6477.61 
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Appendix 5 (continued) 
  Gene 
designation  
Product RPKM 
37 D302_gp037 putative Hef-like homing endonuclease 8373.99 
38 D302_gp038 hypothetical protein 2652.81 
39 D302_gp039 hypothetical protein 4946.73 
40 D302_gp040 putative tail tube protein 8853.56 
41 D302_gp041 putative tail tube protein 6640.26 
42 D302_gp042 hypothetical protein 10177.1 
43 D302_gp043 hypothetical protein 1484 
44 D302_gp044 putative baseplate wedge subunit 2998.67 
45 D302_gp045 putative baseplate wedge subunit 3496.51 
46 D302_gp046 putative sliding clamp DNA polymerase 
accessory protein 
20782.1 
47 D302_gp047 aminidotransferase family protein 31076.5 
48 D302_gp048 DNA primase-helicase subunit 4515.99 
49 D302_gp049 hypothetical protein 281.39 
50 D302_gp050 putative tail fiber protein 2937.61 
51 D302_gp051 RNaseH ribonuclease 8851.63 
52 D302_gp052 putative clamp loader subunit 15834.8 
53 D302_gp053 putative ssDNA binding protein 52736.8 
54 D302_gp054 putative Hef-like homing endonuclease 2193.24 
55 D302_gp055 putative DNA end protector protein 2094.03 
56 D302_gp056 hypothetical protein 4691.78 
57 D302_gp057 hypothetical protein 4484.43 
58 D302_gp058 hypothetical protein 8336.65 
59 D302_gp059 thymidylate synthetase 4884.46 
60 D302_gp060 putative Hef-like homing endonuclease 2678.26 
61 D302_gp061 putative Hef-like homing endonuclease 1742.45 
62 D302_gp062 tail sheath protein 17963 
63 D302_gp063 hypothetical protein 3663.79 
64 D302_gp064 hypothetical protein 9217.55 
65 D302_gp065 DNA ligase 6095.26 
66 D302_gp066 hypothetical protein 1470.91 
67 D302_gp067 hypothetical protein 11047.3 
68 D302_gp068 hypothetical protein 13901.6 
69 D302_gp069 hypothetical protein 19142.3 
70 D302_gp070 hypothetical protein 12666.6 
71 D302_gp071 putative Hef-like homing endonuclease 823.35 
72 D302_gp072 putative Hef-like homing endonuclease 4106.93 
73 D302_gp073 ribonucleotide-diphosphate reductase 
subunit alpha 
9594.04 
74 D302_gp074 putative Hef-like homing endonuclease 6390.78 
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Appendix 5 (continued) 
  Gene 
designation  
Product RPKM 
75 D302_gp075 major capsid protein 72160.7 
76 D302_gp076 hypothetical protein 29652 
77 D302_gp077 prohead core scaffold and protease 14162.2 
78 D302_gp078 hypothetical protein 6449.2 
79 D302_gp079 portal vertex protein 3765.97 
80 D302_gp080 hypothetical protein 17412.5 
81 D302_gp081 neck protein 9324.66 
82 D302_gp082 putative phage DNA packaging protein 3876.32 
83 D302_gp083 hypothetical protein 7147.32 
84 D302_gp084 putative tail tube protein III 6250.21 
85 D302_gp085 putative Hef-like homing endonuclease 8750.53 
86 D302_gp086 phosphatidylserine decarboxylase 20784.9 
87 D302_gp087 putative co-chaperonin GroES 21107.4 
88 D302_gp088 hypothetical protein 17641.7 
89 D302_gp089 hypothetical protein 9060.75 
90 D302_gp090 putative DEAD/DEAH box helicase 1558.84 
91 D302_gp091 ATP-dependent DNA/RNA helicase 8235.29 
92 D302_gp092 hypothetical protein 10722.3 
93 D302_gp093 putative DNA repair and recombination 
protein 
2814.4 
94 D302_gp094  hypothetical protein 6030.29 
95 D302_gp095 hypothetical protein 15417.2 
96 D302_gp096 hypothetical protein 3486.23 
97 D302_gp097 RecB family exonuclease 9989.67 
98 D302_gp098 hypothetical protein 23474.7 
99 D302_gp099 hypothetical protein 10297.1 
100 D302_gp100 DNA polymerase 2225.96 
101 D302_gp101 hypothetical protein 5251.56 
102 D302_gp102 hypothetical protein 7723.93 
103 D302_gp103 thymidine kinase 5212.27 
104 D302_gp104 hypothetical protein 3412.75 
105 D302_gp105 DNA primase subunit 10198.5 
106 D302_gp106 hypothetical protein 37272.6 
107 D302_gp107 hypothetical protein 18180.4 
108 D302_gp108 tail completion and sheath stabilizer 
protein 
1447.44 
109 D302_gp109 hypothetical protein 5077.27 
110 D302_gp110 hypothetical protein 10186.3 
111 D302_gp111 hypothetical protein 18769.1 
112 D302_gp112 hypothetical protein 1691.31 
113 D302_gp113 hypothetical protein 1996.02 
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Appendix 5 (continued) 
  Gene 
designation  
Product RPKM 
114 D302_gp114 hypothetical protein 1239.57 
115 D302_gp115 hypothetical protein 6755.04 
116 D302_gp116 hypothetical protein 14523.9 
117 D302_gp117 recombination endonuclease 4234.61 
118 D302_gp118 hypothetical protein 44367.2 
119 D302_gp119 putative recombination endonuclease 
subunit 
6222.43 
120 D302_gp120 sigma factor for late transcription 5227.54 
121 D302_gp121 major head protein II 5414.88 
122 D302_gp122 putative neck protein 4188.73 
123 D302_gp123 putative Hef-like homing endonuclease 2145.02 
124 D302_gp124 tail sheath stabilizer and completion 
protein 
2708.37 
125 D302_gp125 hypothetical protein 3374.61 
126 D302_gp126 hypothetical protein 9031.61 
127 D302_gp127 hypothetical protein 3124.71 
128 D302_gp128 hypothetical protein 2711.28 
129 D302_gp129 hypothetical protein 452.67 
130 D302_gp130 hypothetical protein 2770.18 
131 D302_gp131 hypothetical protein 6061.99 
132 D302_gp132 hypothetical protein 4003.83 
133 D302_gp133 hypothetical protein 5949.08 
134 D302_gp134 hypothetical protein 5435.62 
135 D302_gp135 hypothetical protein 3367.14 
136 D302_gp136 putative exonuclease 21024.8 
137 D302_gp137 hypothetical protein 5998.39 
138 D302_gp138 hypothetical protein 3075.89 
139 D302_gp139 hypothetical protein 4986.83 
140 D302_gp140 hypothetical protein 1297.1 
141 D302_gp141 hypothetical protein 1515.38 
142 D302_gp142 hypothetical protein 1078.34 
143 D302_gp143 putative sugar-phospahte 
nucleotidyltransferase 
3340.54 
144 D302_gp144 hypothetical protein 4337.18 
145 D302_gp145 hypothetical protein 1680.82 
146 D302_gp146 hypothetical protein 6722.98 
147 D302_gp147 hypothetical protein 5499.88 
148 D302_gp148 hypothetical protein 6215.47 
149 D302_gp149 hypothetical protein 4965.93 
150 D302_gp150 head completion protein 5595.21 
151 D302_gp151 hypothetical protein 10340.9 
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Appendix 5 (continued) 
  Gene 
designation  
Product RPKM 
152 D302_gp152 hypothetical protein 5864.04 
153 D302_gp153 RNA ligase 3250.16 
154 D302_gp154 hypothetical protein 5701.31 
155 D302_gp155 hypothetical protein 6036.37 
156 D302_gp156 hypothetical protein 9963.85 
157 D302_gp157 hypothetical protein 1592.82 
158 D302_gp158 poly A polymerase 7496.6 
159 D302_gp159 ribonucleotide reductase large subunit 8499.36 
160 D302_gp160 ribonucleotide reductase small subunit 13252.5 
161 D302_gp161 hypothetical protein 5797.58 
162 D302_gp162 hypothetical protein 15357.2 
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APPENDIX 6 
Bacteriophage CPX transcription during infection of C. jejuni PT14 
  Gene designation Product RPKM 
1 CaPhCPX_gp001 putative homing endonuclease 4811.26 
2 CaPhCPX_gp002 hypothetical protein  11591.1 
3 CaPhCPX_gp003 hypothetical protein  26863.6 
4 CaPhCPX_gp004 hypothetical protein  6593.44 
5 CaPhCPX_gp005 hypothetical protein  2208.19 
6 CaPhCPX_gp006 thymidylate synthetase 4606.61 
7 CaPhCPX_gp007 putative Hef-like homing 
endonuclease  
3244.56 
8 CaPhCPX_gp008 putative Hef-like homing 
endonuclease  
1253.69 
9 CaPhCPX_gp009 gp18 tail sheath protein 27307 
10 CaPhCPX_gp010 hypothetical protein  5855.83 
11 CaPhCPX_gp011 hypothetical protein  10586.1 
12 CaPhCPX_gp012 gp30 DNA ligase 5355.69 
13 CaPhCPX_gp013 hypothetical protein  1917.43 
14 CaPhCPX_gp014 hypothetical protein  8301.72 
15 CaPhCPX_gp015 hypothetical protein  8720.23 
16 CaPhCPX_gp016 hypothetical protein  29930.6 
17 CaPhCPX_gp017 hypothetical protein  22605 
18 CaPhCPX_gp018 putative Hef-like homing 
endonuclease  
2690.91 
19 CaPhCPX_gp019 putative ribonucleotide-diphosphate 
reductase subunit alpha 
9860.65 
20 CaPhCPX_gp020 putative Hef-like homing 
endonuclease  
7754.67 
21 CaPhCPX_gp021 gp23 major capsid protein 96451.8 
22 CaPhCPX_gp022 hypothetical protein  45544.3 
23 CaPhCPX_gp023 putative gp21 prohead core scaffold 
and protease 
16957 
24 CaPhCPX_gp024 portal vertex protein 6041.46 
25 CaPhCPX_gp025 hypothetical protein  35221.6 
26 CaPhCPX_gp026 gp13 neck protein 20144.2 
27 CaPhCPX_gp027 putative phage DNA packaging 
protein (terminase) 
6609.25 
28 CaPhCPX_gp028 hypothetical protein  12952 
29 CaPhCPX_gp029 putative tail tube protein  8896.68 
30 CaPhCPX_gp030 putative Hef-like homing 
endonuclease  
6154.1 
31 CaPhCPX_gp031 phosphatidylserine decarboxylase 16341.2 
32 CaPhCPX_gp032 putative co-chaperonin GroES 18224.2 
33 CaPhCPX_gp033 hypothetical protein  22403 
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Appendix 6 (continued) 
  Gene designation Product RPKM 
34 CaPhCPX_gp034 hypothetical protein  11834.9 
35 CaPhCPX_gp035 putative helicase 487.69 
36 CaPhCPX_gp036 putative ATP-dependent DNA/RNA 
helicase (uvsW) 
2715.61 
37 CaPhCPX_gp037 putative repair and recombination 
protein 
730.64 
38 CaPhCPX_gp038 hypothetical protein  2963.83 
39 CaPhCPX_gp039 hypothetical protein  7414.31 
40 CaPhCPX_gp040 hypothetical protein  1469.49 
41 CaPhCPX_gp041 putative DNA methylase 1546.55 
42 CaPhCPX_gp042 hypothetical protein  10170.8 
43 CaPhCPX_gp043 hypothetical protein  8520.81 
44 CaPhCPX_gp044 DNA polymerase 2257.11 
45 CaPhCPX_gp045 hypothetical protein  1986.78 
46 CaPhCPX_gp046 hypothetical protein  3138.24 
47 CaPhCPX_gp047 hypothetical protein  7112.93 
48 CaPhCPX_gp048 thymidine kinase 2900.37 
49 CaPhCPX_gp049 DNA primase subunit 4904.84 
50 CaPhCPX_gp050 hypothetical protein  18730.7 
51 CaPhCPX_gp051 hypothetical protein  15585.7 
52 CaPhCPX_gp052 tail completion and sheath stabilizer 
protein 
4452.92 
53 CaPhCPX_gp053 hypothetical protein 9583.85 
54 CaPhCPX_gp054 hypothetical protein  28235.8 
55 CaPhCPX_gp055 hypothetical protein  1742.83 
56 CaPhCPX_gp056 hypothetical protein  4377.56 
57 CaPhCPX_gp057 hypothetical protein  9981.04 
58 CaPhCPX_gp058 hypothetical protein  2723.74 
59 CaPhCPX_gp059 hypothetical protein  16415.6 
60 CaPhCPX_gp060 recombination endonuclease 2854.05 
61 CaPhCPX_gp061 hypothetical protein  38990.7 
62 CaPhCPX_gp062 putative recombination endonuclease 
subunit 
3770.08 
63 CaPhCPX_gp063 putative sigma factor for late 
transcription 
4505.27 
64 CaPhCPX_gp064 putative gp23 major head protein II 13274.3 
65 CaPhCPX_gp065 putative neck protein 8288.32 
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Appendix 6 (continued) 
  Gene designation Product RPKM 
66 CaPhCPX_gp066 putative Hef-like homing endonuclease  1281.51 
67 CaPhCPX_gp067 tail sheath stabilizer and completion 
protein 
4580.52 
68 CaPhCPX_gp068 hypothetical protein  1777.08 
69 CaPhCPX_gp069 hypothetical protein  3410.45 
70 CaPhCPX_gp070 hypothetical protein  1585.38 
71 CaPhCPX_gp071 hypothetical protein  935.32 
72 CaPhCPX_gp072 hypothetical protein  3761.45 
73 CaPhCPX_gp073 hypothetical protein  643.69 
74 CaPhCPX_gp074 hypothetical protein  2870.55 
75 CaPhCPX_gp075 hypothetical protein  23347.5 
76 CaPhCPX_gp076 hypothetical protein  2946.51 
77 CaPhCPX_gp077 hypothetical protein  5485.62 
78 CaPhCPX_gp078 hypothetical protein  3334.4 
79 CaPhCPX_gp079 hypothetical protein  4779.23 
80 CaPhCPX_gp080 hypothetical protein  767.76 
81 CaPhCPX_gp081 hypothetical protein  672.78 
82 CaPhCPX_gp082 hypothetical protein  421.02 
83 CaPhCPX_gp083 hypothetical protein  603.96 
84 CaPhCPX_gp084 hypothetical protein  1601.03 
85 CaPhCPX_gp085 hypothetical protein  1258.13 
86 CaPhCPX_gp086 hypothetical protein  396.15 
87 CaPhCPX_gp087 hypothetical protein  3578.38 
88 CaPhCPX_gp088 hypothetical protein  3810.34 
89 CaPhCPX_gp089 head completion protein 5652.44 
90 CaPhCPX_gp090 hypothetical protein  13334.7 
91 CaPhCPX_gp091 hypothetical protein  5735.33 
92 CaPhCPX_gp092 RNA ligase 3628.88 
93 CaPhCPX_gp093 hypothetical protein  2716.3 
94 CaPhCPX_gp094 hypothetical protein  3864.59 
95 CaPhCPX_gp095 putative poly A polymerase 4675.57 
96 CaPhCPX_gp096 ribonucleotide reductase large subunit 6112.23 
97 CaPhCPX_gp097 ribonucleotide reductase small subunit 10508.7 
98 CaPhCPX_gp098 hypothetical protein  2679.99 
99 CaPhCPX_gp099 hypothetical protein  12396.7 
100 CaPhCPX_gp100 RecA-like recombination protein 11351.3 
101 CaPhCPX_gp101 hypothetical protein 4989.38 
102 CaPhCPX_gp102 hypothetical protein  3717.3 
103 CaPhCPX_gp103 hypothetical protein  3396.94 
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Appendix 6 (continued) 
  Gene designation Product RPKM 
104 CaPhCPX_gp104 hypothetical protein  12861.8 
105 CaPhCPX_gp105 putative DNA polymerase accessory 
factor (sliding clamp loader) 
6334.87 
106 CaPhCPX_gp106 hypothetical protein  542.68 
107 CaPhCPX_gp107 putative dUTP pyrophosphatase 6521.39 
108 CaPhCPX_gp108 hypothetical protein  3412.18 
109 CaPhCPX_gp109 putative NAD(FAD)-utilizing 
dehydrogenase 
3633.69 
110 CaPhCPX_gp110 hypothetical protein  3151.93 
111 CaPhCPX_gp111 hypothetical protein  1213.27 
112 CaPhCPX_gp112 hypothetical protein  8493.78 
113 CaPhCPX_gp113 putative DNA topoisomerase II 5374.85 
114 CaPhCPX_gp114 putative Hef-like homing endonuclease  4796.95 
115 CaPhCPX_gp115 topoisomerase II large subunit 8456.4 
116 CaPhCPX_gp116 hypothetical protein  5096.35 
117 CaPhCPX_gp117 hypothetical protein  5863.2 
118 CaPhCPX_gp118 hypothetical protein  261.18 
119 CaPhCPX_gp119 hypothetical protein  11990.2 
120 CaPhCPX_gp120 hypothetical protein  5700.71 
121 CaPhCPX_gp121 hypothetical protein  1529.77 
122 CaPhCPX_gp122 hypothetical protein  1102.38 
123 CaPhCPX_gp123 putative peptidase 2220.12 
124 CaPhCPX_gp124 hypothetical protein  3366.7 
125 CaPhCPX_gp125 hypothetical protein  7772.01 
126 CaPhCPX_gp126 hypothetical protein  4721.41 
127 CaPhCPX_gp127 hypothetical protein  1405.66 
128 CaPhCPX_gp128 hypothetical protein  2003.35 
129 CaPhCPX_gp129 putative baseplate hub subunit and tail 3831.9 
130 CaPhCPX_gp130 hypothetical protein  421.97 
131 CaPhCPX_gp131 hypothetical protein  5086.91 
132 CaPhCPX_gp132 putative Hef-like homing endonuclease  7652.2 
133 CaPhCPX_gp133 hypothetical protein  1566.19 
134 CaPhCPX_gp134 hypothetical protein  7122.74 
135 CaPhCPX_gp135 putative tail tube protein  17828.4 
136 CaPhCPX_gp136 putative tail tube protein  10268.8 
137 CaPhCPX_gp137 hypothetical protein  20861.4 
138 CaPhCPX_gp138 hypothetical protein  2031.57 
139 CaPhCPX_gp139 putative baseplate wedge protein 4600.27 
140 CaPhCPX_gp140 putative sliding clamp DNA 
polymerase accessory protein 
13716.1 
141 CaPhCPX_gp141 amidinotransferase family protein 27660.8 
142 CaPhCPX_gp142 DNA primase-helicase subunit 3230.93 
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Appendix 6 (continued) 
  Gene designation Product RPKM 
143 CaPhCPX_gp143 hypothetical protein 159.24 
144 CaPhCPX_gp144 hypothetical protein 1062.04 
145 CaPhCPX_gp145 hypothetical protein 2964.94 
146 CaPhCPX_gp146 hypothetical protein 8543.7 
147 CaPhCPX_gp147 RNaseH 5471.79 
148 CaPhCPX_gp148 hypothetical protein 8482.53 
149 CaPhCPX_gp149 putative ssDNA binding protein 41991.4 
    lysozyme   
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APPENDIX 7 
Genes up-regulated in C. jejuni PT14 LQUHVSRQVHWR37ǻ00150::kan mutation 
  Gene designation Product Fold Change  padja 
1 A911_00035 (gltB) Glutamate synthase, large subunit 1.682 8.29E-04 
2 A911_00040 (gltD) Glutamate synthase subunit beta 1.517 3.94E-05 
3 A911_01165 (Cj0241c) Putative iron-binding protein 1.637 9.63E-05 
4 A911_02485 (clp) ATP-dependent Clp protease ATP-binding subunit 1.623 1.11E-04 
5 A911_03250 (Cj0667) S4 domain-containing protein 1.877 1.26E-03 
6 A911_03255 (Cj0668) ATP/GTP-binding protein 1.824 2.12E-09 
7 A911_03260 (Cj0669) ABC transporter ATP-binding protein 1.584 5.18E-06 
8 A911_03600 (Cj0737) Putative hemagglutination activity domain containing protein 1.952 4.37E-02 
9 A911_03665 (hrcA) Heat-inducible transcription repressor 2.039 1.49E-02 
10 A911_03670 (grpE) Heat shock protein GrpE 2.381 2.31E-103 
11 A911_03675 (dnaK) Molecular chaperone DnaK 2.002 1.53E-02 
12 A911_03680 (Cj0760) Hypothetical protein 1.729 6.29E-03 
13 A911_04375 (alr) Alanine racemase 1.65 1.32E-05 
14 A911_05550 (Cj1145c) Hypothetical protein 1.633 1.05E-04 
15 A911_05665 (Cj1169c) Hypothetical protein 1.544 8.31E-20 
16 A911_05670 (omp50) Hypothetical protein 1.661 6.67E-33 
17 A911_05965 (cbpA) Co-chaperone protein DnaJ 1.756 9.75E-04 
18 A911_0771 (hisF) imidazole glycerol phosphate synthase subunit HisF 1.656 4.14E-02 
19 A911_07810 (ribD) Riboflavin-specific deaminase/reductase 1.727 2.61E-02 
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Appendix 7 (continued) 
  Gene designation Product Fold Change  padja 
20 A911_08130 (secY) Preprotein translocase subunit SecY 1.698 3.17E-08 
21 A911_08135 (rplO) 50S ribosomal protein L15 1.886 2.78E-22 
22 A911_08140 (rpsE) 30S ribosomal protein S5 1.863 6.12E-11 
23 A911_08145 (rplR) 50S ribosomal protein L18 1.641 4.18E-09 
24 A911_08150 (rplF) 50S ribosomal protein L6 1.535 6.47E-05 
25 A911_08170 (rplX) 50S ribosomal protein L24 1.632 3.91E-09 
26 A911_08175 (rplN) 50S ribosomal protein L14 1.526 1.64E-16 
27 A911_08215 (rplW) 50S ribosomal protein L23 1.639 1.17E-05 
28 A911_08220 (rplD) 50S ribosomal protein L4 1.681 1.07E-13 
29 A911_08225 (rplC) 50S ribosomal protein L3 1.644 3.06E-03 
 
Note: The corresponding gene locus for C. jejuni NCTC11168 is illustrated within the parentheses. 
a ± padj<0.05 ± corrected p-value representing a false discovery rate of <5% 
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APPENDIX 8 
Genes down-regulated in C. jejuni 37LQUHVSRQVHWR37ǻNDQPXWDWLRQ 
  Gene designation Product Fold Change  padja 
1 A911_00155 (Cj0033) Putative integral membrane protein -15.704 0.00E+00 
2 A911_00160  Hypothetical protein -8.301 0.00E+00 
3 A911_00170 (Cj0035c) Bcr/CflA subfamily drug resistance transporter -1.67 1.25E-02 
4 A911_00195 (Cj0040) Hypothetical protein -20.63 0.00E+00 
5 A911_00200 (flik) Hypothetical protein -11.498 0.00E+00 
6 A911_00205 (flgD) Flagellar basal body rod modification protein -13.954 0.00E+00 
7 A911_00210 (flgE2) Flagellar hook protein -8.821 4.46E-12 
8 A911_00220 (Cj0045c) Hemerythrin-like iron-binding protein -1.776 4.66E-03 
9 A911_01170 (Cj0243c) Hypothetical protein -2.415 3.03E-02 
10 A911_01670 (trpD) Anthranilate synthase component I -1.569 1.76E-04 
11 A911_01675 (trpE) Anthranilate synthase component II -1.587 2.22E-10 
12 A911_01900 (Cj0391c) Hypothetical protein -1.543 2.51E-04 
13 A911_02085 (Cj0428) Hypothetical protein -1.754 4.68E-09 
14 A911_02570 (flgB) Flagellar basal body rod protein FlgB -2.26 1.53E-14 
15 A911_02665 (flaG) Flagellar protein FlaG -1.51 9.37E-04 
16 A911_03190 (Cj0653c) M24 family peptidase -1.828 0.00E+00 
17 A911_03195 (Cj0654c) Di-/tripeptide transporter -1.908 0.00E+00 
18 A911_03345 (flgH) Flagellar basal body L-ring protein -4.099 1.53E-14 
19 A911_03400 (flgG2) Flagellar basal-body rod protein -2.963 5.83E-12 
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Appendix 8 continued 
  Gene designation Product Fold Change  padja 
20 A911_03405 (flgG) Flagellar basal body rod protein FlgG -2.123 0.00E+00 
21 A911_03850 (Cj0794) Hypothetical protein -2.378 4.41E-07 
22 A911_03950 (Cj0814) Hypothetical protein -2.555 1.01E-03 
23 A911_04285 (flgL) Flagellar hook-associated protein FlgL -3.836 3.30E-11 
24 A911_04425 (Cj0916c) Hypothetical protein -1.639 3.71E-06 
25 A911_04715 (Cj0977) Hypothetical protein -1.615 0.00E+00 
26 A911_06030 (Cj1242) Hypothetical protein -7.689 3.03E-04 
27 A911_06500 (flaB) Flagellin B -9.319 0.00E+00 
28 A911_06907 (Cj1422c) Putative sugar transferase -1.982 7.96E-10 
29 A911_07045 (flgI) Flagellar basal body P-ring protein -3.535 0.00E+00 
30 A911_07050 (flgJ) Hypothetical protein -3.425 2.39E-11 
31 A911_07060 (Cj1465) Hypothetical protein -1.691 1.44E-05 
32 A911_07065 (flgK) Flagellar hook-associated protein FlgK -3.082 4.16E-11 
33 A911_07240 (putA) Bifunctional putA protein -1.646 0.00E+00 
34 A911_07400 (acs) Acetyl-CoA synthetase -1.51 7.35E-04 
35 A911_07950 (Cj1650) Hypothetical protein -3.084 0.00E+00 
36 A911_08320 (flgE) Flagellar hook protein flgE -18.171 0.00E+00 
 
Note: The corresponding gene locus for C. jejuni NCTC11168 is illustrated within the parentheses. 
a ± padj<0.05 ± corrected p-value representing a false discovery rate of <5  
